object
exopolysaccharid
ep
produc
strain
geobacillu
thermodenitrifican
strain
bacillu
licheniformi
use
evalu
immunoregulatori
antivir
effect
two
strain
isol
shallow
marin
hot
spring
vulcano
island
itali
view
import
regulatori
role
antivir
defenc
play
cytokin
modul
factor
analys
effect
ep
two
marin
bacteria
cytokin
product
antivir
activ
peripher
blood
mononuclear
cell
pbmc
method
pbmc
obtain
healthi
donor
centrifug
heparinis
venou
blood
ficollhipaqu
gradient
supernat
harvest
analys
presenc
ifnc
ifna
tnfa
order
establish
ep
antivir
activ
relat
either
mark
product
cytokin
direct
interact
viru
replic
use
wish
cell
line
evalu
effect
replic
pbmc
wish
cell
line
amount
viru
product
titrat
express
pfuml
result
ep
trigger
mononuclear
phagocyt
releas
cytokin
involv
profil
ifnc
ifna
tnfa
wherea
induc
product
cytokin
furthermor
treatment
infect
pbmc
ep
downregul
viru
replic
effect
replic
seem
relat
pattern
cytokin
induc
pbmc
ep
addit
ep
wish
cell
infect
show
antivir
effect
conclus
shown
two
ep
power
stimul
cellmedi
immun
immunomodulatori
agent
could
potenti
use
therapi
immunocompromis
host
import
cytokin
cortisol
level
cerebrospin
fluid
clinic
biolog
marker
bacteri
mening
immunolog
immunotherapi
kinet
releas
nitric
oxid
tumour
necrosi
factoralpha
activ
microglia
via
tolllik
receptor
ebert
j
gerber
bader
f
hlhauser
mitchel
r
nau
goettingen
glasgow
object
microgli
cell
major
constitu
innat
immun
within
brain
express
tolllik
receptor
tlr
recognis
exogen
endogen
ligand
present
studi
aim
quantifi
activ
microgli
cell
respons
stimul
one
two
simultan
administ
specif
agonist
concentr
caus
submaximum
maximum
effect
method
primari
mous
microgli
cell
cultur
stimul
tlr
agonist
heatkil
acholeplasma
laidlawii
endotoxin
pneumolysin
oligonucleotid
contain
unmethyl
cytosinguanosin
motif
cpg
nitric
oxid
releas
quantifi
use
griess
reaction
tnfa
releas
measur
use
quantikin
mous
tnfa
immunoassay
r
system
gmbh
cell
viabil
microgli
cell
determin
use
prolifer
reagent
roch
appli
scienc
result
maximum
stimul
result
approxim
equal
amount
releas
lp
potent
stimul
microglia
concentr
caus
halfmaximum
effect
lgml
lgml
follow
pneumolysin
lgml
lgml
cpg
lgml
lgml
lgml
repres
mean
six
experi
least
triplic
measur
respect
pneumolysin
potent
activ
microgli
cell
concentr
lgml
higher
concentr
reduc
cell
viabil
cytotox
note
tlr
agonist
costimul
maximum
concentr
two
tlr
agonist
increas
releas
costimul
submaximum
concentr
addit
effect
conclus
stimul
microgli
cell
via
differ
tlr
result
rel
uniform
releas
tnfa
simultan
stimul
low
concentr
two
agonist
led
addit
effect
microbi
product
also
endogen
compound
act
agonist
tlr
system
addit
effect
stimul
one
tlr
increas
sensit
microglia
infect
yet
may
also
entail
interact
among
exogen
endogen
agonist
tlr
may
one
reason
exacerb
induct
autoimmun
diseas
infect
beran
lawrenc
albani
usa
object
human
tolllik
receptor
trl
recognis
specif
pattern
varieti
bacteri
cellwal
compon
transduc
signal
cell
earli
phase
innat
immun
respons
glucocorticoid
gc
potent
immunomodulatori
drug
although
gc
supress
mani
function
macrophag
mph
role
gc
enhanc
hostimmun
respons
particularli
effect
tlr
express
mph
remain
unknown
aim
studi
evalu
effect
dexamethason
dxm
express
cytokin
product
mph
upon
stimul
lp
salmonella
typhimurium
stm
also
determin
modul
paramet
ceftriaxon
cfx
cefalosporin
antibiot
use
treatment
bacteri
infect
method
pbmc
isol
human
buffycoat
histopaqu
sigma
usa
densiti
gradient
centrifug
monocyt
isol
adher
plastic
h
c
adher
monocyt
stimul
lp
ngml
stm
cfu
ml
h
dxm
andor
cfx
sigma
usa
use
concentr
lm
lgml
respect
cfx
ad
well
h
supernat
collect
frozen
c
quantif
elisa
pharmingen
usa
mph
harvest
stain
flowcytometr
analysi
use
mab
bectondickinson
usa
ebiosci
usa
result
express
mph
enhanc
lp
stm
ae
dxm
unlik
dxm
inhibit
lpsstimul
mph
howev
dxm
increas
product
stmstimul
mph
interestingli
mph
stimul
lp
stm
treat
cfx
show
lower
express
compar
without
cfx
associ
decreas
observ
effect
lp
stm
express
mph
conclus
result
demonstr
abil
gc
increas
express
human
mph
indic
possibl
immunostimulatori
effect
gc
howev
involv
induct
gc
subsequ
innat
specif
immun
respons
requir
studi
decreas
express
associ
lower
product
mph
treat
cfx
indic
role
immunomodulatori
effect
antibiot
r
munk
l
hareng
aulock
von
hartung
constanc
object
lipopolysaccharid
lp
gramneg
bacteria
lipoteicho
acid
lta
gramposit
bacteria
key
inflammatori
principl
differ
regard
cytokin
pattern
induc
lta
stronger
induc
chemokin
ie
gcsf
lp
stronger
induc
proinflammatori
cytokin
tnfa
shown
previous
lp
stimul
gcsf
product
increas
dbcamp
tnfa
product
decreas
describ
novel
activ
cre
gcsf
promotor
thu
investig
whether
promotor
also
activ
cre
element
might
explain
parallel
strong
induct
gcsf
lta
method
cell
transfect
mutat
wildtyp
promotor
construct
luciferas
report
bgalactosamin
cotransfect
valu
normal
activ
mrna
express
whole
blood
measur
realtim
pcr
protein
releas
whole
blood
supernat
quantifi
elisa
result
screen
promot
identifi
put
cre
tttcgtca
transfect
cell
minim
promot
contain
differ
disrupt
transcript
factor
bind
site
name
nfkb
put
cre
luciferas
report
howev
lp
lta
induc
signal
height
cell
normal
mutat
cre
indic
nonfunct
element
nfkb
confirm
essenti
element
moreov
camp
elev
human
whole
blood
led
increas
lpsinduc
releas
decreas
ltainduc
releas
indic
strong
ltainduc
releas
depend
differ
paramet
characteris
induct
close
mrna
express
peak
h
lpsstimul
whole
blood
continu
rise
h
ltastimul
blood
line
protein
level
induc
lta
becam
significantli
higher
induc
lp
time
point
h
follow
stimul
peak
h
stimuli
lgml
lp
ae
ngml
vs
lta
ae
ngml
p
n
diverg
retain
plasmafre
blood
observ
pbmc
howev
addit
erythrocyt
pbmc
reconstitut
effect
conclus
strong
induct
lta
whole
blood
appear
depend
amplif
present
factor
suppli
erythrocyt
increas
camp
level
rational
prematur
infant
particularli
suscept
infect
estim
neonat
born
week
gestat
may
suffer
clinic
sepsi
reason
complex
immatur
immun
system
suboptim
level
circul
immunoglobulin
least
partli
respons
high
mortal
morbid
associ
infect
anoth
protein
mannosebind
lectin
mbl
also
shown
low
prematur
infant
may
import
defend
prematur
infant
infect
genet
polymorph
result
defici
mbl
shown
increas
suscept
infect
especi
children
aim
current
studi
decid
role
mbl
determin
suscept
outcom
prematur
neonat
sever
sepsi
method
total
prematur
neonat
recruit
studi
serum
level
mbl
measur
enzym
immunoassay
polymorph
codon
within
exon
wild
type
variant
promot
polymorph
xy
mbl
gene
determin
pcr
heteroduplex
analysi
result
birth
weight
gestat
age
found
influenc
mbl
level
neonat
born
week
gestat
g
significantli
lower
neonat
week
g
differ
persist
p
preterm
neonat
exon
mutat
neonat
diagnos
sepsi
andor
multipl
organ
system
failur
comparison
neonat
wildtyp
allel
aa
diagnos
sepsi
mbl
level
analys
neonat
level
mbl
significantli
less
sepsi
compar
without
sepsi
mean
ngml
sd
ngml
vs
ngml
sd
ngml
p
conclus
preliminari
studi
mbl
defici
appear
associ
increas
suscept
sever
sepsi
prematur
neonat
studi
requir
elucid
true
impact
find
neonat
suscept
infect
object
studi
use
ruti
treatment
tuberculosi
infect
experiment
murin
model
ruti
vaccin
patent
pend
compos
tuberculosi
fragment
cell
wall
detoxifi
mtbfcw
liposom
method
femal
mice
week
old
infect
aerosol
use
middlebrook
devic
week
nine
postinfect
treatment
start
control
inocul
ml
empti
liposom
week
postinfect
sc
ii
chemotherapi
week
iii
chemotherapi
plu
ruti
week
iv
chemotherapi
plu
ruti
week
sc
chemotherapi
mgkg
isoniazid
first
week
rifampicin
mgkg
follow
last
week
administ
oral
gavag
daysweek
ul
ruti
contain
lg
mtbfcw
inject
everi
inocul
week
postinfect
determin
coloni
form
unit
cfu
lung
spleen
quantifi
cytokin
mrna
lung
use
realtim
pcr
level
antibodi
mtbfcw
antigen
western
blot
final
determin
area
occupi
granuloma
digit
microphotographi
process
appropri
softwar
result
signific
synergist
reduct
cfu
reveal
group
iii
iv
mice
compar
group
ii
differ
detect
mice
treatment
chemotherapi
reveal
high
effici
rel
increas
ifnc
detect
mous
strain
treat
ruti
special
inocul
group
level
tnf
kept
low
mice
elicit
strong
respons
broad
spectrum
cell
wall
antigen
increas
one
sc
inocul
enhanc
also
level
increas
high
iga
level
detect
bal
mice
sc
immunis
histometr
analysi
reveal
signific
increas
regard
area
occupi
granuloma
rutitr
mice
intranas
inocul
mice
object
improv
use
ruti
coadjuv
chemotherapi
treatment
tuberculosi
infect
mous
strain
trigger
strongest
resist
infect
method
femal
mice
balbc
week
old
infect
use
middlebrook
devic
allow
inocul
bacilli
lung
week
nine
postinfect
defin
four
differ
group
accord
intranas
inocul
ruti
balbc
mice
treat
chemotherapi
week
postinfect
inocul
week
empti
liposom
group
ruti
group
ii
mice
treat
chemotherapi
week
postinfect
inocul
week
three
dose
empti
liposom
group
iii
ruti
group
iv
chemotherapi
done
oral
gavag
day
week
mgkg
isoniazid
ruti
contain
lg
tuberculosi
fragment
cell
wall
mtbfcw
inject
everi
inocul
determin
coloni
form
unit
cfu
lung
spleen
week
group
iii
postinfect
group
iiiiv
express
cytokin
quantifi
lung
use
realtim
pcr
also
determin
ratio
area
occupi
granuloma
total
area
analys
four
consecut
lm
thick
section
two
lobe
right
lung
mous
stain
haematoxilineosin
photograph
nikon
stereoscop
microscop
imag
process
appropri
softwar
result
signific
synergist
reduct
cfu
reveal
group
ii
iv
mice
strain
signific
differ
ifnc
tnf
express
found
group
balbc
mice
besid
cytokin
significantli
low
ruti
treat
mice
week
reflect
decreas
inflammatori
respons
histometr
analysi
reveal
signific
differ
mice
strain
week
control
mice
doubl
area
compar
ruti
treat
group
week
conclus
use
ruti
coadministr
chemotherapi
inocul
intranas
demonstr
benefit
chemotherapi
treatment
even
mice
strain
abl
trigger
strongest
immunolog
respons
tuberculosi
infect
object
sinc
mortal
sever
sepsi
remain
high
aim
studi
estim
prognost
valu
certain
earli
immunolog
marker
clinic
outcom
method
thirti
patient
male
femal
mean
age
ae
year
sever
sepsi
sepsi
plu
least
one
organ
dysfunct
studi
aetiolog
sepsi
pneumonia
n
pyelonephr
n
intraabdomin
infect
n
skin
joint
infect
n
control
group
includ
healthi
subject
seven
male
seven
femal
mean
age
ae
year
percentag
monocyt
express
human
leucocyt
antigendr
determin
flow
cytometri
admiss
day
discharg
serum
cytokin
level
determin
use
elisa
quantikin
r
system
minneapoli
day
stepwis
multipl
regress
logist
regress
analysi
use
statist
analysi
result
seventeen
patient
die
day
admiss
signific
contribut
posit
outcom
detect
admiss
odd
ratio
confid
interv
ci
p
serum
level
day
ci
p
day
ci
p
found
predictor
poor
outcom
strongest
effect
level
day
attribut
day
r
p
without
contribut
cytokin
tumour
necrosi
factora
transform
growth
factorb
conclus
immunosupress
associ
low
level
monocyt
hladr
express
preced
immunosupress
correl
high
level
ii
monocyt
hladr
express
earli
prognost
marker
outcom
sever
sepsi
diagnost
tool
identifi
high
risk
patient
sepsi
common
caus
organ
dysfunct
final
multipl
organ
failur
cardiac
dysfunct
septic
patient
due
myocardi
ischaemia
endothelialleucocyt
interact
result
microcirculatori
tissu
damag
measur
cardiac
troponin
tni
provid
sensit
specif
indic
cardiac
injuri
wide
diagnost
window
aim
studi
investig
serum
troponin
correl
sever
sepsi
elderli
patient
evalu
whether
tni
might
prognost
marker
patient
subject
method
total
patient
sepsi
variou
origin
femal
male
age
ae
year
old
includ
studi
blood
sampl
collect
tni
level
measur
within
h
hospit
admiss
patient
possibl
myocardi
infarct
unstabl
angina
exclud
studi
serum
tni
determin
colorimetr
immunoassay
dadebehr
biochem
analys
result
total
patient
tni
valu
ngml
level
ngml
cpkmb
valu
elev
ecg
differ
group
patient
higher
tni
level
apach
ii
score
dic
score
criteria
intern
societi
thrombosi
haemostasi
calcul
found
higher
comparison
patient
low
tni
ae
vs
ae
p
ae
vs
ae
p
respect
student
ttest
posit
correl
tni
apach
ii
score
well
tni
ddimer
valu
also
observ
p
p
respect
stepwis
regress
analysi
conclus
serum
troponin
may
valu
recognit
clinic
unrecognis
myocardi
injuri
septic
elderli
patient
cutoff
prognost
valu
could
determin
use
mean
risk
stratif
patient
studi
abil
virus
induc
host
cytokin
chemokin
gene
express
infect
human
lung
epitheli
cell
influenza
strain
influenza
b
sendai
virus
isol
total
cellular
rna
analys
host
cell
cytokin
chemokin
mrna
express
northern
blot
rtpcr
influenza
influenza
b
viru
infect
lead
rel
weak
induct
interferon
ifnab
ifnlik
gene
express
activ
kinas
ikk
also
weakli
induc
influenza
virus
similar
experiment
condit
sendai
viru
infect
activ
express
ifna
ifnb
ikk
gene
well
similarli
sendai
viru
readili
induc
tnfa
rant
gene
express
influenza
influenza
b
virusinduc
express
gene
either
lack
tnfa
occur
rel
low
level
pretreat
cell
ifna
lead
dramat
increas
influenza
virusinduc
ifn
chemokin
gene
express
induct
correl
enhanc
express
virusactiv
signal
molecul
ikk
result
indic
human
lung
epitheli
cell
influenza
b
virus
rel
poor
induc
type
ifn
chemokin
gene
abil
induc
gene
fulli
restor
pretreat
cell
type
ifn
object
gener
monoclon
antibodi
spike
protein
neutralis
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
sarscov
infect
method
studi
code
sequenc
amino
acid
spike
glycoprotein
sarscov
clone
prokaryot
express
vector
recombin
protein
purifi
near
homogen
immunis
recombin
protein
specif
monoclon
antibodi
obtain
confirm
elisa
western
blot
immunofluoresc
assay
ifa
neutral
effect
monoclon
antibodi
recombin
spike
protein
sarscov
evalu
vero
cell
western
blot
result
result
show
monoclon
antibodi
could
effect
neutralis
infect
sarscov
dosedepend
manner
furthermor
bind
inhibit
assay
reveal
neutralis
monoclon
antibodi
sar
patient
serum
could
inhibit
sarscov
bind
vero
cell
conclus
knowledg
first
report
reveal
neutralis
monoclon
antibodi
gener
immunis
mice
prokaryot
cellexpress
recombin
spike
protein
inhibit
infect
sarscov
vero
cell
inhibit
viru
bind
cell
result
studi
facilit
descript
receptorbind
domain
target
epitop
spike
protein
sarscov
peptidebas
subunit
vaccin
well
interact
respiratori
tract
pathogen
epitheli
cell
c
kratzer
w
graning
georgopoulo
vienna
object
epitheli
cell
play
import
role
regul
local
inflammatori
immun
respons
repli
bacteri
infect
present
studi
analys
epitheli
cell
cytokin
releas
stimul
differ
strain
streptococcu
pyogen
nontyp
haemophilu
influenza
nthi
method
investig
strain
clinic
isol
patient
commun
acquir
respiratori
tract
infect
human
bronchial
epitheli
cell
line
nhbe
seed
tissu
cultur
plate
infect
group
betahaemolyt
streptococci
ga
nthi
ratio
bacteri
cell
one
bronchial
cell
differ
incub
time
within
h
invas
medium
aspir
centrifug
especi
quantifi
cell
cultur
supernat
infect
nhbe
enzymelink
immunosorb
assay
elisa
result
respons
infect
pyogen
nhbe
releas
elev
level
especi
differ
cytokin
kinet
detect
infect
clarithromycinsuscept
resist
ga
apart
one
nthi
strain
isol
patient
cystic
fibrosi
ampicillinsensit
blactamaseposit
nontyp
h
influenza
induc
similiar
cytokin
kinet
high
concentr
conclus
stimul
respiratori
tract
pathogen
nhbe
releas
increas
cytokin
level
h
influenza
induc
epitheli
cell
secret
high
concentr
test
cytokin
pyogen
caus
high
releas
addit
demonstr
differ
timedepend
nhbe
cytokin
induct
provok
clarithromycinsuscept
resist
ga
epsteinbarr
viru
ebv
human
gamma
herpesviru
infect
human
popul
usual
persist
without
harm
lifetim
host
yet
highli
transform
viru
shown
associ
number
malign
nasopharyng
carcinoma
nasal
lymphoma
preval
chines
virusspecif
cytotox
tcell
import
effect
intric
balanc
host
viru
known
howev
primari
immun
respons
regul
object
dendrit
cell
dc
potent
antigen
present
cell
investig
whether
exposur
apoptot
necrot
ebvtransform
lymphoblastoid
b
cell
line
lcl
could
mediat
neonat
dc
matur
subsequ
cell
prime
method
studi
primari
ebv
infect
sampl
fetal
cord
blood
collect
lcl
establish
infect
cord
blood
mononuclear
cell
ebv
produc
cell
line
autolog
monocytederiv
dc
cell
gener
posit
select
immunomagnet
microbead
result
found
neonat
dc
phagocytos
apoptot
necrot
lcl
effici
h
cocultur
phagocytosi
necrot
apoptot
lcl
led
lightli
upregul
hladr
compar
lp
activ
tcell
prolifer
cytotox
assay
progress
determin
capac
neonat
dc
activ
cord
blood
deriv
cell
conclus
conclus
suggest
neonat
dc
effici
phagocytos
die
cell
rel
immatur
dc
phenotyp
may
due
compromis
antigen
present
neonat
dc
object
proinflammatori
cytokin
tumour
necrosi
factor
tnf
identifi
mediat
human
cytomegaloviru
hcmv
stimul
reactiv
human
progenitor
cell
postul
tnf
may
antivir
activ
play
import
role
limit
hcmv
replic
placent
tissu
aim
studi
characteris
antivir
activ
placent
tnf
organ
cultur
oc
isol
placent
cell
system
compar
tnf
product
normal
placenta
amniot
membran
placenta
infect
hcmv
utero
method
studi
perform
organ
cultur
isol
placent
cell
cytotrophoblast
macrophag
obtain
normal
placenta
infect
hcmv
strain
vitro
neutralis
antibodi
tnfa
orand
b
use
mean
block
cytokin
activ
treatment
cell
start
immedi
hcmv
infect
cultur
h
hcmv
infect
continu
anoth
day
result
villou
cultur
infect
hcmv
utero
increas
tnf
product
found
compar
uninfect
cell
cultur
infect
decidu
tissu
hcmv
result
product
massiv
amount
tnf
treatment
organ
cultur
antitnfa
antitnfb
anibodi
result
increas
peak
level
hcmv
releas
intens
cultur
treat
antitnfa
individu
experi
treatment
antitnf
antibodi
result
increas
viru
level
increas
hcmv
replic
cytotrophoblast
macrophag
treat
antitnfa
orand
antitnfb
observ
found
enhanc
hcmv
replic
tnf
present
mainli
fetal
part
organ
conclus
obtain
result
indic
import
endogen
tnf
placent
immun
work
support
state
committe
scientif
research
grant
assess
correl
antiinflammatori
therapi
concentr
proinflammatori
cytokin
cerebrospin
fluid
csf
effect
outcom
bacteri
mening
bm
bociagajasik
garlicki
kalinowskanowak
mach
cracow
warsaw
pl
object
determin
influenc
antiinfalmmatori
therapi
dexamethason
dx
dx
pentoxifillin
px
concentr
tnfa
csf
cours
bm
method
fortytwo
patient
femal
male
bm
investig
divid
three
group
treat
antibiot
dx
treat
antibiot
dx
dx
px
treat
antibiot
dx
px
cytokin
concentr
measur
csf
elisa
day
admiss
initi
therapi
h
later
result
antiinflammatori
therapi
impact
resolut
inflamm
pleocytosi
protein
glucos
level
csf
howev
establish
adjuv
therapi
dx
px
benefici
effect
cours
bm
group
patient
recov
comparison
group
dx
group
mortal
rate
group
dx
dx
px
correl
outcom
bm
investig
group
cytokin
concentr
csf
observ
group
dx
px
patient
respond
therapi
decreas
cytokin
concentr
coeffici
variat
low
tnfa
also
group
dx
decreas
cytokin
concentr
csf
observ
howev
signific
coeffici
variat
tnfa
group
concentr
cytokin
csf
vari
coeffici
variat
high
conclus
antiinflammatori
therapi
dx
px
inhibit
releas
cytokin
cn
benefici
effect
cours
bm
ii
antiinflammatori
therapi
dx
alon
also
inhibit
cytokin
product
cn
effect
well
defin
object
invas
infect
neisseria
meningitidi
lead
meningococc
mening
fulmin
meningococc
sepsi
fm
import
caus
childhood
mortal
morbid
activ
complement
cascad
implic
pathogenesi
fm
initi
pathway
activ
complement
relat
complement
activ
activ
cytokineand
coagulatorysystem
diseas
sever
still
remain
subject
investig
method
present
studi
patient
meningococc
diseas
admit
paediatr
intens
care
unit
picu
umc
st
radboud
includ
inform
consent
obtain
parent
complement
activ
product
coagul
paramet
cytokin
measur
fix
time
interv
admiss
result
termin
complement
complex
tcc
reflect
total
complement
activ
significantli
increas
admiss
unsurpass
inflammatori
paramet
tcc
highli
correl
diseas
sever
prismscor
spearman
rank
correl
prism
tcc
r
p
r
p
tcc
also
significantli
correl
platelet
fibrinogen
consumpt
r
platelet
count
r
fibrinogen
fibrinolyt
activ
r
ddimer
addit
tcc
admiss
significantli
correl
cytokin
concentr
r
r
r
r
ifnc
first
h
admiss
tcc
slowli
declin
earli
complement
activ
caus
altern
lectin
pathway
engag
classic
pathway
activ
shown
repeat
measur
altern
classic
lectin
classic
howev
h
complex
slowli
increas
reflect
classic
pathway
activ
time
onward
conclus
data
indic
initi
activ
complement
system
meningococc
infect
highli
correl
diseas
sever
complement
activ
occur
via
altern
lectin
pathway
wherea
classic
pathway
engag
develop
h
cant
morbid
mortal
suggest
exagger
intrathec
immun
respons
play
pivot
role
diseas
pathogesi
respons
characteris
increas
intrathec
product
proinflammatori
cytokin
interleukin
il
tumour
necrosi
factor
tnf
product
cytokin
control
antiinflammatori
mediat
cortisol
aim
studi
assess
clinic
relev
cytokin
cortisol
level
cerebrospin
fluid
csf
patient
bm
method
examin
sampl
csf
bm
patient
obtain
diagnost
lumbar
punctur
perform
admiss
sampl
analys
three
colour
flow
cytometri
use
cytokin
bead
array
bd
bioscienc
san
usa
csf
cortisol
level
measur
radioimmunoassay
purchas
dsl
webster
usa
sever
ill
determin
use
apach
ii
sepsi
organ
failur
assess
sofa
score
level
unconsci
score
glasgow
coma
scale
gc
result
csf
level
cortisol
correl
posit
apach
ii
r
p
neg
gc
r
p
csf
level
correl
neg
gc
r
p
csf
level
correl
neg
sofa
r
p
moreov
level
correl
posit
csf
protein
concentr
number
neutrophil
r
p
r
p
r
p
r
p
tnfa
r
p
csf
conclus
result
indic
sever
cours
bm
associ
high
concentr
antiinflammatori
mediat
csf
furthermor
increas
level
close
connect
elev
concentr
proinflammatori
cytokin
csf
bm
find
allud
attempt
suppress
intrathec
proinflammatori
respons
thu
cortisol
level
csf
could
use
marker
diseas
sever
progress
acknowledg
studi
support
grant
ga
uk
nihfogarti
twoyear
followup
analysi
classspecif
immun
respons
infect
yersinia
pseudotuberculosi
follow
erythema
nodosum
reactiv
arthriti
case
report
w
rastawicki
jagielski
r
ski
j
buratowska
warsaw
pl
object
yersinia
enterocolitica
pseudotuberculosi
import
caus
agent
enter
infect
human
postinfecti
complic
reactiv
arthriti
erythema
nodosum
may
also
follow
infect
isol
bacteria
faec
case
achiev
consequ
diagnosi
depend
serolog
studi
result
year
serolog
investig
infect
pseudotuberculosi
follow
erythema
nodosum
reactiv
arthriti
women
describ
method
igm
igg
iga
class
antibodi
measur
nine
serum
sampl
collect
week
interv
two
elisa
use
yersinia
outer
membran
protein
yop
lipopolysaccharid
lp
extract
enterocolitica
serotyp
pseudotuberculosi
serotyp
iii
antibodi
respons
also
studi
immunoblot
western
blot
mikrogen
result
first
serum
sampl
obtain
day
onset
clinic
symptom
erythema
nodosum
arthriti
diagnos
high
level
iga
igg
igm
antibodi
yop
lp
extract
pseudotuberculosi
serotyp
immunoblot
analysi
found
antibodi
immunoglobulin
class
yopd
protein
kda
second
serum
sampl
obtain
day
observ
decreas
antibodi
titr
lp
increas
antibodi
titr
yop
obtain
result
next
seven
serum
sampl
show
antibodi
titr
measur
lp
antigen
comparison
yop
antigen
decreas
rapidli
reconvalesc
antibodi
yop
immunoglobulin
class
still
demonstr
high
level
end
followup
period
year
late
period
antibodi
lp
found
diagnost
signific
titr
conclus
result
studi
indic
infect
caus
pseudotuberculosi
complic
erythema
nodosum
reactiv
arthriti
maximum
level
specif
iga
igg
igm
antibodi
yop
reach
later
antibodi
lp
howev
antibodi
yop
comparison
antibodi
lp
persist
longer
reconvalesc
demonstr
igmclass
yersinia
antibodi
year
onset
diseas
show
class
antibodi
consid
case
good
marker
recent
acquir
infect
proinflammatori
cytokin
product
human
monocyt
respons
p
aeruginosa
infect
mainli
involv
mannos
receptor
p
xaplanteri
g
lagoumintzi
g
dimitracopoulo
f
paliogianni
patra
gr
pattern
recognit
receptor
play
import
role
protect
pathogen
link
innat
adapt
immun
p
aeruginosa
oppurtunist
pathogen
capabl
establish
chronic
acut
infect
immunocompromis
host
recent
shown
slimeglp
extracellular
product
p
aeruginosa
contain
mannos
import
stimul
tnfa
product
human
monocyt
potent
induc
transcript
activ
studi
sought
investig
role
differ
pattern
recognit
receptor
inflammatori
pathway
trigger
p
aeruginosa
end
treat
human
monocyt
p
aeruginosa
purifi
lp
lgml
slime
lgml
viabl
bacteria
bacteriamonocyt
presenc
block
antibodi
specif
lgml
lg
ml
mannos
receptor
lgml
measur
tnfa
product
h
isotyp
match
nonspecif
antibodi
use
neg
control
tnfa
induct
inhibit
presenc
antimannos
receptor
block
antibodi
wherea
block
caus
less
promin
inhibit
compar
level
inhibit
obtain
monocyt
stimul
p
aeruginosa
slimeglp
whole
viabl
bacteria
p
aeruginosa
lp
caus
weak
proinflammatori
cytokin
induct
amen
block
mannos
receptor
result
suggest
mannos
receptormedi
pathway
could
specif
target
inhibit
inflammatori
respons
trigger
p
aeruginosa
pseudomona
aeruginosa
lp
slime
glycolipoprotein
glp
differenti
activ
mitogenactiv
protein
kinas
signal
pathway
tumour
necrosi
factor
alpha
fresh
human
monocyt
g
lagoumintzi
p
xaplanteri
g
dimitracopoulo
f
paliogianni
patra
gr
tnfa
product
central
role
develop
progress
p
aeruginosa
septic
shock
previous
shown
p
aeruginosa
glp
potent
stimul
compar
homolog
lp
tnfa
product
nfkb
activ
human
monocyt
studi
use
fresh
human
monocyt
stimul
h
p
aeruginosa
lp
lgml
glp
lgml
show
secret
tnfa
induc
p
aeruginosa
glp
lp
parallel
phosphoryl
mitogenactiv
protein
kinas
mapk
stressactiv
protein
kinas
cjun
ntermin
kinas
jnk
phosphoryl
correl
increas
activ
tnfa
level
significantli
reduc
inhibitor
lm
respect
ad
cultur
h
stimul
combin
inhibitor
almost
abolish
tnfa
induct
p
aeruginosa
glp
differ
homolog
lp
regard
strength
activ
glp
lead
stronger
activ
differ
observ
level
jnk
activ
lp
glp
involv
phosphoryl
shown
employ
specif
block
antihuman
lgml
lgml
antibodi
activ
induc
p
aeruginosa
glp
dramat
reduc
presenc
antibodi
lesser
degre
presenc
wherea
lp
induc
stimul
inhibit
presenc
result
suggest
p
aeruginosa
glp
stimul
map
kinas
pathway
effect
homolog
lp
probabl
use
differ
combin
tlr
object
alreadi
shown
suscept
multidrugresist
mdr
pseudomona
aeruginosa
differ
stimulatori
effect
innat
immun
giamarellosbourbouli
et
al
clin
exp
immunol
similar
studi
perform
suscept
mdr
e
coli
method
seventeen
isol
e
coli
studi
eight
suscept
nine
mdr
pathogen
differ
case
pyelonephr
mononuclear
cell
separ
whole
blood
healthi
volunt
suspend
flask
monocyt
isol
remov
nonadher
cell
resuspend
rpmi
fb
mm
glutamin
incub
h
monocyt
trigger
log
log
inoculum
isol
tumour
necrosi
factoralpha
tnfa
measur
cultur
supernat
h
incub
enzym
immunoassay
result
given
figur
conclus
trigger
suscept
mdr
isol
e
coli
lead
differ
product
cytokin
result
might
reflect
differ
virul
campylobact
jejuni
infect
zilbauer
n
dorrel
jt
georg
pk
boughan
bajajelliott
london
uk
object
campylobact
jejuni
c
jejuni
one
commonest
caus
infect
diarrhoea
worldwid
effect
mainli
young
children
year
develop
countri
western
world
clinic
spectrum
vari
mild
wateri
bloodi
inflammatori
diarrhoea
frequent
associ
postinfecti
extraintestin
complic
syndrom
despit
seriou
health
problem
caus
bacterium
diseas
pathogenesi
remain
poorli
understood
bacteri
adhes
invas
intestin
epithelium
known
critic
featur
infect
human
beta
defensin
hbd
famili
epitheli
antimicrobi
peptid
major
compon
innat
host
defenc
other
highlight
role
peptid
gastrointestin
infect
inflamm
present
studi
investig
role
hbd
c
jejuni
infect
method
human
colon
intestin
cell
line
infect
virul
strain
nctc
c
jejuni
time
dose
depend
studi
hbd
gene
express
assess
rtpcr
bactericid
activ
recombin
wild
type
isogen
mutant
c
jejuni
evalu
brothdilut
assay
result
mark
timedepend
induct
observ
maxim
express
h
postinfect
contrast
gene
express
modest
importantli
bacterium
found
highli
suscept
antimicrobi
action
amongst
peptid
test
conclus
present
studi
provid
evid
dynam
cross
talk
bacterium
host
epitheli
innat
defenc
potent
bactericid
activ
may
contribut
selflimit
natur
infect
via
enhanc
bacteri
clearanc
healthi
host
object
present
studi
intend
understand
associ
helicobact
pylori
infect
chronic
idiopath
urticaria
method
studi
patient
chronic
idiopath
urticaria
diagnos
h
pylori
infect
urea
breath
test
use
carbon
patient
infect
receiv
tripl
erad
therapi
amoxicilin
claritromicin
omeprazol
antihistamin
loratadin
eight
noninfect
individu
receiv
antihistamin
treatment
serum
concentr
total
ige
specif
igg
h
pylori
determin
addit
standardis
elisa
detect
specif
ige
h
pylori
time
week
conclud
treatment
result
bacteria
erad
patient
infect
variabl
clinic
improv
without
clinic
sign
eight
partial
clinic
sign
patient
without
h
pylori
infect
fail
improv
treatment
conclus
present
studi
establish
statist
signific
differ
p
erad
h
pylori
infect
improv
clinic
sign
chronic
idiopath
urticaria
compar
noninfect
group
patient
moder
symptom
observ
best
treatment
respons
clinic
improv
p
statist
signific
concentr
total
ige
igg
anti
h
pylori
valu
h
pylorispecif
ige
except
patient
moder
partial
improv
h
pylorispecif
ige
significantli
diminish
p
erad
erad
h
pylori
clearli
improv
chronic
idiopath
urticaria
unknown
mechan
independ
ige
biochem
serolog
aspect
q
fever
diagnosi
k
slaba
l
skulteti
r
toman
bratislava
sk
coxiella
burnetii
oblig
intracellular
parasit
eucaryot
cell
aetiolog
agent
q
fever
diseas
widespread
zoonosi
endem
throughout
world
human
acut
form
q
fever
characteris
fluelik
ill
atyp
pneumonia
less
frequent
granulomat
hepatitit
signific
incid
neurolog
complic
persist
infect
may
lead
chronic
form
diseas
may
associ
endocard
human
infect
aquir
often
inhal
contamin
aerosol
less
frequent
drink
infect
milk
infect
skin
trauma
sexual
contact
mother
fetu
transmiss
upon
serial
laboratori
passag
embryon
hen
egg
c
burnetii
undergo
virul
phase
lowvirul
phase
ii
variat
accompani
notic
modif
composit
structur
cell
outermembran
compon
acut
q
fever
antibodi
phase
ii
antigen
detect
earlier
higher
titr
phase
antigen
contrast
titr
phase
antigen
higher
chronic
form
diseas
found
phase
antibodi
mostli
direct
ospecif
chain
c
burnetii
smoothform
lipopolysaccharid
lp
remark
decreas
serolog
activ
lp
observ
two
unusu
sugar
virenos
vir
dihydrohydroxystreptos
strep
select
remov
ospecif
chain
indic
phase
antibodi
direct
epitop
contain
termin
vir
strep
thu
result
may
suggest
vir
strep
involv
immunobiolog
diseas
mild
acid
treatment
c
burnetii
phase
cell
result
consider
degrad
lp
exposur
surfac
protein
exhibit
highimmun
respons
phase
ii
antibodi
sdspage
reveal
intens
silverstain
protein
kda
subsequ
initi
proteom
studi
identifi
latter
protein
chaperonin
kda
groel
protein
heat
shock
protein
b
protein
localis
cytoplasm
sever
bacteria
signific
fraction
also
associ
cell
envelop
like
protein
dual
associ
also
c
burnetii
immunogen
peptid
mass
fingerprint
progress
evalu
inflammatori
capac
fungal
spore
human
whole
blood
daneshian
kindung
gabrio
hartung
von
aulock
constanc
stuttgart
object
fungal
spore
clinic
relev
contamin
ubiquit
inhal
releas
mycotoxin
cell
wall
structur
glucan
mannan
seem
play
import
role
inflammatori
process
defin
structur
could
describ
respons
inflammatori
potenti
fungi
addit
wellknown
humanpathogen
fungi
like
candida
albican
facult
pathogen
eg
aspergillu
fumigatu
nonpathogen
particularli
mould
endang
human
health
immunosuppress
patient
method
differ
mould
yeast
cultur
spore
prepar
order
measur
inflammatori
capac
comparison
endotoxin
e
coli
use
standardis
whole
blood
assay
detect
pyrogen
activ
fungal
spore
basi
releas
cytokin
eg
tnfa
proinflammatori
cytokin
chemoattract
antiinflammatori
cytokin
result
detect
consider
differ
immunolog
respons
spore
differ
fungal
speci
found
differ
cytokin
induct
repres
differ
fungal
genera
member
genu
howev
strong
correl
cytokin
induct
capac
estim
total
spore
surfac
varianc
respons
individu
fungal
spore
greater
toward
endotoxin
investig
whether
structur
intact
spore
surfac
recogn
tolllik
receptor
tlr
incub
fungal
spore
bone
marrow
cell
defici
mice
found
tnf
ainduc
activ
none
test
speci
fulli
depend
tlr
recognit
speci
partial
depend
tlr
conclus
cytokin
induct
capac
seem
depend
expos
total
spore
surfac
rather
spore
count
immun
recognit
appear
central
depend
tlr
activ
studi
attempt
defin
role
differ
surfac
structur
select
fungal
spore
cytokin
induct
differenti
human
monocyt
dendrit
cell
tunabl
exploit
microorgan
modul
host
adapt
immun
respons
candida
albican
model
g
romagnoli
torosantucci
stringaro
p
chiani
mariotti
g
arancia
casson
r
nisini
rome
object
investig
whether
abil
candida
albican
convert
yeast
myceli
form
germtub
gt
format
consid
key
featur
transit
commens
virul
could
relat
abnorm
human
monocyt
differenti
dendrit
cell
dc
method
noninfect
gt
infect
monocyt
allow
differenti
dc
cultur
gmcsf
day
cultur
cell
analys
ultrastructur
phenotyp
function
result
human
monocyt
cultur
gmcsf
phagocytosi
form
differenti
dc
retain
acquir
molecul
famili
unabl
express
matur
marker
moreov
produc
tnfa
rather
abl
induc
prolifer
alloreact
memori
lymphocyt
convers
monocyt
phagocytos
gt
form
differenti
matur
dc
howev
failur
upregul
mhc
class
ii
irrespect
lp
treatment
addit
synthesis
tnfa
cell
abl
prime
cell
induc
function
polaris
effector
cell
detail
expand
lymphocyt
unabl
secret
cytokin
particular
ifnc
suggest
could
ineffect
help
macrophag
kill
microorgan
data
indic
phagocytosi
gt
form
profound
distinct
effect
differenti
pathway
monocyt
data
impli
differenti
human
monocyt
tunabl
microorgan
may
exploit
process
elud
immunesurveil
monocyt
chemotact
product
human
astrocyt
astrocytoma
cell
line
toxoplasm
infect
differenti
regul
interferongamma
f
durand
brenierpinchart
j
simon
p
march
f
berger
h
pelloux
grenobl
f
object
use
human
astrocyt
cultur
investig
cellular
respons
central
nervou
system
resid
cell
intracellular
toxoplasma
gondii
infect
object
studi
evalu
secret
express
monocyt
chemotact
measur
effect
ifnc
specif
inhibitor
phosphatidylcholinespecif
phospholipas
c
pcplc
regul
express
secret
cc
chemokin
infect
gondii
method
human
astrocyt
ex
vivo
human
astrocytoma
cell
line
ccf
infect
virul
rh
strain
parasit
multipl
penetr
measur
use
realtim
pcr
techniqu
ribonucleas
protect
assay
copi
mrna
encod
seven
chemokin
analys
h
postinfect
pi
level
determin
elisa
cultur
supernat
h
pi
ad
min
infect
cultur
medium
furthermor
effect
preincub
ifnc
iuml
studi
result
penetr
multipl
rate
gondii
higher
human
astrocytoma
cell
line
human
fibroblast
p
p
respect
parasit
infect
increas
product
astrocyt
preincub
cell
ifnc
modifi
significantli
secret
astrocytoma
cell
line
experiment
condit
nevertheless
product
astrocytoma
cell
line
treat
decreas
compar
treat
inhibitor
conclus
astrocyt
astrocytoma
cell
line
significantli
infect
gondii
fibroblast
parasit
induc
product
cell
moreov
protocol
secret
express
cc
chemokin
regul
pcplc
inhibitor
ifnc
result
suggest
upregul
may
involv
pathogenesi
toxoplasm
enceph
regul
intracellular
messeng
background
yersinia
pseudotuberculosi
colonis
gastrointestin
tract
gi
associ
lymphat
tissu
mesenter
lymph
node
mln
peyer
patch
pp
orogastr
infect
human
mice
colonis
requir
yersinia
outer
protein
yop
virul
factor
transloc
mammalian
cell
type
iii
secret
system
inhibit
cellular
function
competit
studi
mice
coinfect
wild
type
wt
yersinia
singl
yop
delet
mutant
yope
yoph
yopo
demonstr
yop
import
colon
gi
mln
pp
previou
work
demonstr
yope
yoph
yopo
antiphagocyt
activ
cultur
cell
phagocyt
earli
defenc
use
host
fight
bacteri
infect
test
whether
yope
yoph
andor
yopo
target
phagocyt
mice
method
studi
possibl
role
yop
inhibit
bactericid
effect
phagocycyt
infect
granulocytedeplet
granulocytedeplet
mice
orogastr
infect
equal
mixtur
wt
yope
yoph
yopo
mutant
strain
ratio
wt
mutant
bacteria
recov
gi
mln
pp
tissu
quantifi
compar
ratio
wt
mice
higher
number
yop
mutant
recov
defici
mice
compar
nondefici
mice
mutant
yop
strain
suscept
phagocyt
tissu
studi
henc
miss
yop
like
function
neutralis
bactericid
effect
phagocyt
result
result
show
high
recoveri
yope
mutant
strain
mln
pp
caecum
granulocytedeplet
mice
contrast
yopo
mutant
strain
recov
small
intestin
lumen
mesenter
lymph
node
mice
granulocytedeplet
mice
show
yope
yopo
rescu
tissu
studi
conclus
data
document
signific
role
yope
yopo
neutralis
phagocyt
infect
specif
yope
crucial
inhibit
granulocyt
function
yopo
target
cell
introduct
glycopeptideresist
enterococci
gre
emerg
import
nosocomi
pathogen
recent
year
part
depart
health
programm
mandatori
surveil
healthcar
associ
infect
england
surveil
scheme
gre
bacteraemia
develop
questionnair
devis
obtain
background
data
inform
develop
propos
surveil
scheme
object
establish
current
approach
detect
gre
ii
review
technic
problem
associ
detect
report
gre
iii
review
issu
relat
signific
report
gre
bacteraemia
compar
data
differ
hospit
method
questionnair
review
method
approach
test
risk
factor
gre
bacteraemia
design
nation
group
pilot
administ
laboratori
england
n
june
result
respons
rate
n
achiev
sever
questionnair
fulli
complet
thirtyfour
per
cent
n
respond
identifi
gre
bacteraemia
laboratori
n
saw
five
year
n
identifi
bacteraemia
report
via
routin
communic
diseas
report
system
n
respond
report
use
three
routin
method
gre
identif
n
identifi
isol
speci
level
n
respond
test
vancomycin
enterococci
bacteraemia
glycopeptid
suscept
test
primarili
carri
use
discdiffus
method
n
specialist
unit
bone
marrow
liver
transplant
unit
predomin
site
routin
screen
patient
faec
gre
major
respond
n
could
provid
data
indic
clinic
signific
gre
bacteraemia
conclus
major
laboratori
england
see
gre
bacteraemia
routin
report
infect
incomplet
vari
approach
identif
enterococci
blood
cultur
glycopeptidesuscept
test
observ
laboratori
could
provid
data
clinic
signific
gre
bacteraemia
standardis
procedur
guidelin
requir
robust
data
produc
part
mandatori
surveil
scheme
england
first
studi
took
place
februari
second
month
later
method
preval
studi
perform
methodolog
patient
care
highrisk
depart
includ
intens
care
unit
icu
cardiolog
intens
care
unit
cicu
renal
unit
neonat
unit
test
addit
systemat
random
sampl
process
patient
care
ward
non
highrisk
depart
also
test
faecal
sampl
rectal
swab
inocul
enterococci
broth
vancomycin
mgl
subcultur
bileesculin
azid
agar
vancomycin
mgl
enterococci
identifi
convent
method
glycopeptid
suscept
test
perform
disc
diffus
etest
mic
agar
dilut
method
character
van
genotyp
perform
multiplex
pcr
assay
use
specif
primer
vana
vanb
van
ddle
faecali
ddle
faecium
rr
gene
result
preval
rate
vre
faecal
carrier
increas
first
studi
second
studi
vana
vanb
vanc
preval
rate
first
studi
respect
second
studi
respect
first
studi
vanaharbour
isol
detect
icu
renal
unit
second
studi
reveal
dissemin
within
hospit
vre
preval
highrisk
depart
present
signific
differ
surgic
ward
increas
medic
ward
haematolog
nephrolog
orthopaed
ward
contribut
signific
number
vre
faecal
carrier
speci
distribut
first
studi
e
faecium
e
faecali
one
e
gallinarum
e
casseliflavusflavescen
six
second
studi
chang
e
faecium
e
faecali
four
e
avium
four
e
hira
one
e
gallinarum
e
casseliflavusflavescen
two
conclus
twentytwo
month
appear
vre
hospit
preval
vre
faecal
carrier
increas
especi
surgic
medic
ward
vana
isol
detect
ward
distribut
speci
nosocomi
dissemin
glycopeptideresist
enteroccocci
repres
major
problem
hospit
worldwid
brazil
dissemin
among
hospit
citi
sao
paulo
polyclon
dna
profil
previous
describ
vancomycinresist
e
faecium
object
describ
dissemin
vana
phenotyp
e
faecali
two
hospit
locat
differ
citi
state
sao
paulo
method
index
outbreak
occur
univers
hospit
citi
sao
paulo
hcusp
year
later
cluster
caus
strain
recognis
tertiari
care
hospit
locat
countri
side
cmc
may
juli
strain
e
faecali
vancomycinresist
isol
patient
hospitalis
hcusp
may
juli
three
strain
vancomycinresist
e
faecali
isol
two
patient
hospitalis
cmc
patient
colonis
vre
skin
lesion
isol
test
suscept
vancomycin
teicoplanin
use
detect
perform
pcr
method
strain
type
use
pfge
result
strain
presenc
transposon
close
relat
type
pulsedfield
gel
electrophoresi
conclus
dissemin
vana
phenotyp
e
faecali
hospit
locat
differ
citi
great
concern
monitor
measur
necessari
reduc
risk
dissemin
object
enterococcu
faecali
long
identifi
caus
endocard
bacteraemia
urinari
tract
neonat
infect
knowledg
pathogen
factor
e
faecali
still
limit
although
sever
virul
factor
describ
cytolysin
aggreg
substanc
surfac
protein
aim
work
investig
presenc
known
virul
determin
e
faecali
strain
isol
clinic
specimen
sardinia
determin
antimicrobi
resist
pattern
method
enterococcu
faecali
strain
mainli
isol
patient
urinari
tract
infect
follow
virul
gene
gele
gelatinas
esp
enterococc
surfac
protein
agg
aggreg
substanc
cylm
posttransl
modif
cytolysin
amplifi
pcr
use
publish
specif
primer
product
gelatinas
haemolysin
also
phenotyp
determin
vitro
suscept
clinic
isol
toward
antibiot
determin
vitek
method
result
strain
examin
seven
harbour
virul
determin
test
major
possess
two
three
factor
respect
carri
gene
investig
strain
present
gele
agg
determin
posit
respect
esp
cylm
detect
half
isol
sever
strain
contain
appar
silent
gele
cylm
determin
compar
genotyp
phenotyp
result
multipl
antimicrobi
resist
uncommon
major
strain
resist
two
antibiot
larg
proport
isol
resist
phosphomycin
tetracyclin
one
strain
resist
vancomycin
isol
suscept
ampicillin
teicoplanin
conclus
result
confirm
presenc
variou
virul
gene
clinic
isol
e
faecali
provid
support
evid
role
pathogenesi
worth
note
gener
low
rate
antibiot
resist
clinic
strain
examin
especi
vancomycinresist
consid
compar
data
report
countri
januari
april
postintervent
period
may
decemb
pcr
analysi
aacaaphd
gene
macrorestrict
analysi
smai
resolv
pulsedfield
gel
electrophoresi
pfge
perform
result
rate
hlgre
nosocomi
acquisit
preand
postintervent
period
respect
among
nosocomi
hlgre
strain
isol
intens
care
unit
gastroenterolog
ward
surgic
vascular
ward
hlgre
strain
harbour
aacaaphd
gene
total
pfge
type
defin
pattern
differ
dna
fragment
found
among
hlgre
strain
type
major
epidem
pfge
type
recov
patient
nosocomi
patient
communityacquir
strain
respect
type
recov
predominantli
preintervent
period
wherea
type
isol
period
conclus
type
data
show
major
shift
transmiss
predomin
hlgre
epidem
type
hospit
continu
introduct
patient
colonis
type
appear
region
endem
contact
precaut
appear
signific
impact
longterm
incid
nosocomi
acquisit
hlgre
epidemiolog
antimicrobi
pattern
multiresist
nosocomi
strain
enterococcu
faecium
isol
year
bulgarian
univers
hospit
n
hadjieva
n
hadjieva
ivanova
sofia
bg
object
enterococcu
spp
among
common
organ
associ
hospitalacquir
infect
emerg
enterococci
signific
pathogen
matter
concern
organ
inher
resist
multipl
antimicrobi
especi
enterococcu
faecium
aim
studi
examin
vitro
activ
differ
antimicrobi
agent
e
faecium
isol
collect
queen
joanna
univers
hospit
sofia
bulgaria
period
determin
preval
among
differ
ward
hospit
materi
method
novemb
decemb
total
isol
e
faecium
collect
caus
nosocomi
infect
identif
suscept
antibiot
perform
autom
system
sceptor
streptococcu
micid
becton
dickinson
micid
panel
describ
nccl
result
increas
proport
e
faecium
isol
compar
e
faecium
strain
multidrug
resist
exhibit
ampicillin
resist
highlevel
gentamicin
hlgr
quinolon
resist
strain
suscept
linezolid
glycopeptid
nine
isol
icu
abdomin
surgeri
four
neurosurgeri
medic
unit
isol
recov
surgicalsit
infect
urinarytract
infect
primari
blood
stream
infect
infect
conclus
emerg
multidrug
resist
e
faecium
dissemin
hospit
highlight
need
continu
surveil
import
problem
determin
high
frequenc
resist
ampicillin
aminoglycosid
quinolon
activ
antimicrobi
resist
found
linezolid
glycopeptid
conclud
glycopeptid
resist
yet
import
problem
enterococcu
isol
hospit
communityacquir
staphylococu
aureu
bacteraemia
risk
factor
locat
inflamm
outcom
e
kalogeropoul
l
mourgo
p
tsiodra
belechri
athen
gr
object
access
incid
recognis
risk
factor
describ
locat
specif
tissu
inflamm
along
outcom
patient
commun
acquir
nosocomi
staphylococcu
aureu
bacteraemia
sab
treat
tertiari
medic
depart
method
retrospect
studi
patient
hospitalis
medic
depart
period
januari
januari
commun
acquir
nosocomi
sab
determin
accord
posit
blood
cultur
taken
less
h
admiss
respect
categor
variabl
compar
chisquar
techniqu
result
period
male
femal
male
femal
patient
develop
commun
acquir
nosocomi
sab
correspond
incid
per
person
year
per
person
year
respect
risk
factor
develop
sab
bacteraemia
group
vs
group
b
inject
drug
use
vs
p
haemodialysisdepend
patient
seven
vs
p
ns
diabet
mellitu
vs
p
neoplasmat
diseas
five
vs
p
ns
corticosteroid
use
eight
vs
p
haematolog
disord
three
vs
p
surgeri
within
previou
day
vs
p
ns
determin
locat
septic
inflamm
feasibl
group
vs
group
b
p
ns
includ
deep
tissu
abscess
five
vs
p
ns
psoa
abscess
two
vs
p
ns
vertebr
osteomyel
four
vs
p
ns
softtissu
infect
vs
eight
p
septic
arthriti
two
vs
nine
p
ns
septic
thrombophleb
four
vs
eight
p
ns
endocard
two
vs
eight
p
ns
mening
zero
vs
eight
p
ns
infect
orthopaed
prosthet
devis
zero
vs
p
ns
mortal
three
group
group
b
respect
p
conclus
among
risk
factor
commun
acquir
sab
inject
drug
use
diabet
mellitu
nosocomi
sab
use
corticosteroid
haematolog
disord
softtissu
infect
frequent
group
communityacquir
sab
higher
mortal
rate
notic
group
nosocomi
sab
background
staphylococcu
aureu
probabl
import
pathogen
isol
intravascular
iv
catheterrel
cr
bloodstream
infect
bsi
recent
suggest
case
aureu
crbsi
complic
infect
endocard
ie
object
characteris
clinic
epidemiolog
featur
crbsi
due
aureu
institut
method
prospect
cohort
registri
start
august
consecut
adult
patient
posit
blood
cultur
bc
evalu
follow
data
demograph
microbiolog
epidemiolog
characterist
positiveblood
cultur
includ
number
durat
posit
bc
sourc
bacteraemia
presenc
type
durat
catheteris
underli
condit
type
durat
treatment
outcom
transoesophag
echocardiographi
tee
recommend
patient
perform
inform
consent
obtain
result
period
month
episod
nosocomi
aureu
bsi
primari
occur
among
patient
iv
cathet
episod
ivrel
ivassoci
haemodialysi
catheterrel
due
mrsa
nine
case
definit
hospitalacquir
ie
four
diagnos
among
episod
crbsi
tee
case
tte
five
case
perform
four
case
ie
present
least
one
find
predispos
heart
condit
clinic
sign
persist
bacteraemia
remov
cathet
would
requir
tee
episod
relaps
one
occur
among
patient
treat
day
episod
treat
antibiot
day
mean
durat
bacteraemia
significantli
longer
vancomycin
blactam
drug
day
vs
day
respect
p
overal
mortal
rate
patient
crbsi
conclus
staphylococcu
aureu
crbsi
import
caus
morbid
mortal
institut
episod
bacteraemia
treat
vancomycin
persist
significantli
longer
period
time
observ
episod
treat
blactam
antibiot
preliminari
data
show
ie
complic
aureu
crbsi
appear
less
common
previous
report
characterist
staphylococci
hip
prosthes
infect
longauerova
kotulova
l
slobodnikova
f
ruzicka
bratislava
sk
brno
cz
object
studi
virul
factor
staphylococci
isol
patient
infect
total
hip
prosthesi
method
swab
sampl
inflam
place
total
hip
prosthesi
thp
patient
depart
orthopaed
examin
standard
microbiolog
method
period
januari
june
antimicrobi
suscept
test
accord
nccl
detect
blactamas
perform
nitrocefin
method
product
measur
latex
agglutin
test
mec
gen
detect
perform
pcr
product
slime
detect
use
congo
red
agar
plate
icaa
gen
select
strain
detect
pcr
surfac
hydrophob
staphylococc
strain
evalu
method
base
bacteri
adhes
hydrocarbonxylen
haemolysin
coagulas
dnase
test
standard
microbiolog
method
result
staphylococci
repres
bacteri
isol
occurr
show
increas
tendenc
studi
period
coagulaseneg
staphylococci
con
prevail
strain
test
staphylococc
strain
vancomycin
suscept
strain
produc
blactamas
con
strain
produc
mec
gen
posit
slime
signific
virul
factor
develop
endoplastitid
produc
strain
aureu
strain
con
con
mixtur
posit
neg
slime
product
congo
red
method
icaa
gen
presenc
test
three
strain
icaa
posit
strain
aureu
produc
ahaemolysin
two
strain
dhaemolysin
deltalik
toxin
produc
strain
con
aureu
strain
produc
dnase
conclus
staphylococci
frequent
isol
bacteria
patient
thp
infect
occurr
methicillinresist
con
still
rather
high
fact
taken
account
regular
updat
antimicrobi
pre
periop
prophylaxi
thp
patient
method
retrospect
analysi
incid
sourc
outcom
aureu
bsi
carri
renal
dialysi
patient
januari
decemb
use
clinic
record
laboratori
databas
antibiot
suscept
sourc
outcom
record
isol
result
patient
episod
januari
decemb
total
blood
cultur
yield
aureu
n
resist
methicillin
comparison
bsi
isol
aureu
hospit
methicillin
resist
major
renal
patient
episod
secondari
catheterrel
sepsi
complic
document
episod
infect
endocard
common
n
patient
die
data
current
updat
conclus
staphylococcu
aureu
bsi
common
amongst
renal
dialysi
patient
infect
endocard
signific
complic
mortal
low
intervent
reduc
incid
prioriti
compromis
patient
group
antimicrobi
resist
nosocomi
strain
aureu
isol
patient
skin
soft
tissu
infect
russia
dekhnich
l
stratchounski
edelstein
object
determin
rate
antimicrobi
resist
nosocomi
strain
aureu
isol
patient
skin
soft
tissu
infect
differ
part
russia
method
total
aureu
strain
isol
patient
nosocomi
skin
soft
tissu
infect
studi
patient
hospitalis
hospit
differ
part
russia
four
central
region
two
northwest
region
three
south
region
two
volga
region
three
ural
region
three
siberia
antimicrobi
test
includ
chloramphenicol
ciprofloxacin
clindamycin
erythromycin
fusid
acid
gentamicin
levofloxacin
linezolid
lincomycin
moxifloxacin
mupirocin
oxacillin
quinupristindalfopristin
rifampicin
tetracyclin
trimethoprim
sulphamethoxazol
vancomycin
suscept
test
interpret
perform
agar
dilut
accord
nccl
guidelin
applic
result
major
strain
isol
patient
hospitalis
gener
surgic
unit
patient
hospitalis
burn
unit
traumatologyorthoped
unit
icu
neonat
unit
gener
medic
unit
result
suscept
test
present
tabl
conclus
overal
rate
methicillinresist
ii
potent
antimicrobi
linezolid
vancomycin
fusid
acid
resist
strain
found
follow
quinupristindalfopristin
mupirocin
cotrimoxazol
rate
resist
lower
iii
macrolid
blood
stream
isol
patient
epidermidi
foreign
bodi
infect
isol
casematch
control
without
foreign
bodi
infect
collect
univers
hospit
vienna
case
match
regard
hospit
placement
time
bacteraemia
isol
type
pulsedfield
electrophoresi
essay
format
biofilm
static
biofilm
model
isol
cluster
unweight
pair
group
method
arithmet
averag
similar
sab
pair
isol
b
calcul
construct
dendrogram
isol
consid
strain
sab
relat
close
relat
variant
sab
respect
distinct
strain
sab
result
thirtyon
cluster
relat
close
relat
strain
identifi
twelv
small
cluster
ident
strain
identifi
occur
patient
control
strain
three
cluster
isol
ward
time
strain
nine
cluster
distribut
whole
hospit
patient
infect
implant
pacemak
central
venou
cathet
prosthet
valv
significantli
higher
temperatur
lower
platelet
count
control
c
vs
c
vs
gl
respect
p
biofilm
form
pathogen
isol
conclus
small
cluster
epidermidi
strain
isol
patient
control
well
thu
distinct
strain
caus
bacteraemia
infect
identifi
resist
profil
biofilmposit
strain
staphylococcu
epidermidi
isol
blood
cultur
v
f
ruzicka
r
tejkalova
votava
brno
cz
object
biofilm
format
surfac
medic
devic
repres
seriou
problem
magnifi
increas
use
prosthet
devic
biofilmform
bacteria
difficult
erad
antibiot
often
caus
chronic
infect
determin
minimum
inhibitori
concentr
mic
base
activ
antimicrobi
agent
plancton
bacteria
convent
use
antibiot
suscept
test
biofilm
phenotyp
differ
suscept
profil
minimum
biofilm
erad
concentr
mbec
measur
biofilm
grown
peg
polystyren
plate
aim
studi
determin
resist
profil
blood
cultureisol
biofilmposit
genotyp
phenotyp
method
method
staphylococcu
epidermidi
strain
repeatedli
isol
blood
cultur
use
studi
isol
icaposit
show
phenotyp
abil
form
biofilm
control
five
icaneg
biofilmneg
strain
use
antibiot
test
plate
polystyren
peg
fit
standard
microtitr
plate
use
peg
plate
coat
polyl
llysin
transfer
microtitr
plate
fresh
overnight
cultur
staphylococc
strain
enabl
primari
adhes
quantif
attach
cell
sonif
use
h
biofilm
format
plate
transfer
microtitr
plate
contain
logarithm
dilut
antibiot
penicillin
oxacillin
chloramphenicol
tetracyclin
cotrimoxazol
erythromycin
clindamycin
ciprofloxacin
gentamicin
teicoplanin
vancomycin
overnight
cultiv
plate
transfer
colorimetr
medium
indic
metabol
activ
surviv
cell
chang
medium
detect
spectrophotometr
mbec
determin
minim
concentr
antibiot
erad
bacteria
inhibit
metabol
activ
result
conclus
test
strain
show
drastic
higher
resist
abovement
antibiot
test
biofilm
form
antibiot
exceed
maxim
concentr
achiev
human
plasma
explain
treatment
infect
normal
dosag
antibiot
often
fail
patient
method
conduct
retrospect
studi
period
two
orthopaedictraumatolog
unit
inclus
criteria
patient
articular
sign
fistula
posit
pure
cultur
lugdunensi
articular
fluid
surgic
sampl
first
identtif
criteria
lugdunensi
ornithin
l
lpyrrolidonyl
arylamidas
catalaseposit
test
negativecoagulas
test
full
identif
assess
api
staph
galleri
bio
criteria
favour
outcom
lack
pain
disabl
local
inflammatori
sign
result
studi
includ
patient
male
seven
femal
mean
age
year
seven
patient
comorbid
factor
histori
cancer
three
rheumatoid
arthriti
one
rheumatoid
spondyl
one
diabet
mellitu
two
fifteen
bone
joint
foreign
bodi
joint
prosthesi
nine
hip
five
knee
four
osteosynthesi
six
mean
time
surgic
oper
lugdunensi
identif
week
mean
time
clinic
sign
lugdunensi
identif
week
twelv
patient
local
inflammatori
sign
four
fever
case
pu
andor
macroscop
inflammatori
sign
note
surgeon
oper
strain
lugdunensi
suscept
oxacillin
six
one
respect
resist
penicillin
fluoroquinolon
howev
resist
phosphomycin
patient
receiv
antibiot
combin
case
mean
period
week
quinolon
nine
oxacillin
rifampin
fusid
acid
clindamycin
pristinamycin
miscellan
three
patient
two
also
surgic
treatment
mean
followup
time
month
favour
clinic
cours
lugdunensi
infect
observ
case
except
two
patient
surgic
treatment
conclus
lugdunensi
emerg
pathogen
associ
infect
orthopaed
devic
inflammatori
sign
macroscop
aspect
similar
describ
aureu
infect
pathogen
treatment
infect
must
associ
surgeri
gener
antibiotherapi
object
multiresist
enterobact
aerogen
mrea
major
nosocomi
pathogen
associ
epidem
sever
countri
includ
belgium
object
studi
assess
clinic
therapeut
aspect
outcom
mrea
infect
academ
hospit
method
retrospect
review
medic
file
patient
pt
posit
cultur
mrea
period
select
infect
accord
cdc
criteria
antimicrobi
suscept
determin
standard
disc
diffus
extendedspectrum
blactamas
esbl
screen
perform
doubledisc
potenti
test
isol
consid
multiresist
resist
third
gener
cephalosporin
fluoroquinolon
andor
aminoglycosid
result
mrea
isol
total
hospitalis
respons
infect
among
studi
episod
foci
infect
urinari
respiratori
abdomin
soft
tissu
eight
blood
three
central
venou
cathet
two
bone
one
infect
polymicrobi
case
associ
bacteraemia
total
episod
complic
sepsi
sever
sepsi
septic
shock
pt
urinari
infect
ui
sign
sepsi
contrast
pt
pneumonia
periton
four
six
respect
esbl
product
identifi
strain
appropri
treatment
consist
meropenem
temocillin
given
ui
cefepim
combin
aminoglycosid
episod
clinic
outcom
favour
case
patient
die
due
infect
highest
mortal
rate
found
patient
periton
catheterrel
infect
pneumonia
lowest
rate
found
patient
urinari
infect
multivari
analysi
outlin
sepsi
factor
statist
associ
increas
risk
mortal
microbiolog
erad
obtain
temocillin
uncompl
urinari
infect
favour
clinic
outcom
case
microbiolog
erad
conclus
nonurinari
mrea
infect
associ
sever
initi
clinic
present
nonneglig
mortal
given
favour
clinic
outcom
temocillin
could
use
select
patient
uncompl
urinari
tract
infect
purpos
establish
incid
esblproduc
enterobacteri
strain
isol
cardiovascular
devic
cd
insert
patient
intens
care
unit
institut
heart
diseas
cc
iliescu
correl
esbl
product
virul
factor
plasmidi
profil
strain
method
antibiot
suscept
determin
disc
diffus
doubl
discdiffus
esbl
phenotyp
detect
vitro
studi
adher
invas
capac
hela
cell
investig
gentamycinprotect
assay
adher
inert
substrat
evalu
slime
test
virul
factor
kanagawa
sheep
erythrocyt
haemolysin
dnase
lipas
lecitinas
amylas
gelatinas
mucinas
caseinas
congo
red
test
test
specif
media
plasmid
dna
isol
alkalin
lysi
method
result
studi
enterobacteri
strain
place
second
place
aetiolog
infect
cd
insert
patient
staphylococci
incid
main
antibiot
marker
aminopenicillin
third
gener
cephalosporin
aminoglycosid
fluoroquinolon
esbl
screen
test
posit
strain
multiresist
featur
associ
product
enzymat
virul
factor
prove
poor
test
strain
exchang
adhes
inert
cellular
substrat
prove
gener
featur
esblproduc
enterobacteri
strain
plasmid
dna
analysi
reveal
presenc
variabl
number
plasmid
rang
kbp
kbp
strain
conclus
isol
enterobacteri
strain
prove
multipl
drug
resist
great
concern
fact
third
gener
cephalosporin
resist
esblproduct
highli
preval
strain
suggest
emerg
nosocomi
infect
blactamas
produc
strain
genet
determin
great
major
case
nonplasmidi
resist
blactam
probabl
accompani
chang
bacteri
wall
structur
promot
adhesin
express
object
aim
studi
determin
incid
urinari
pathogen
antimicrobi
resist
detect
esblproduc
strain
necessari
guid
antibacteri
therapi
select
method
total
urin
sampl
examin
laboratori
northern
greec
auto
system
dade
behr
use
identifi
bacteria
isol
evalu
suscept
common
antibiot
disc
ceftazidim
lg
ceftazidimeclavulan
lg
cefotaxim
lg
cefotaximeclavulan
lg
use
determin
presenc
esbl
product
among
e
coli
klebsiella
spp
result
interpret
accord
nccl
guidelin
result
total
urin
cultur
posit
frequent
isol
pathogen
e
coli
proteu
spp
klebsiella
spp
pseudomona
spp
enterococcu
spp
enterobact
spp
acinetobact
spp
citrobact
spp
serratia
staph
aureu
staph
epidermidi
staph
saprophyticu
con
fungu
incid
esbl
produc
strain
among
isol
e
coli
klebsiella
spp
respect
resist
rate
e
coli
proteu
spp
klebsiella
spp
antimicrobi
agent
follow
amoxicillinclavulan
cefuroxim
ceftazidim
ciprofloxacin
trimethorpimsulphamethoxazol
amikasin
resist
pseudomona
spp
amikasin
ceftazidim
cefotaxim
cefipim
ciprofloxacin
imipenem
piperacillintazobactam
enterococcu
spp
resist
ciprofloxacin
strain
resist
vancomycin
teicoplanin
observ
conclus
expect
preval
urin
pathogen
e
coli
observ
acinetobact
enterobact
sensit
ampicillinsulbactam
amoxicillinclavulan
ceftazidim
effici
pseudomona
spp
cefotaxim
cefipim
rate
esbl
produc
strain
e
coli
klebsiella
spp
similar
studi
report
countri
strain
show
decreas
suscept
nonlactam
antibiot
compar
nonesbl
produc
strain
object
aim
studi
analyz
epidemiolog
clinic
characterist
patient
extendedspectrum
blactamaseproduc
klebsiella
pneumonia
kp
esbl
bacteraemia
method
studi
period
cover
ten
month
april
januari
retrospect
studi
record
patient
kp
esbl
detect
blood
specimen
incub
autom
system
bactalert
bio
merieux
identif
suscept
perform
vitek
system
bio
merieux
discdiffus
method
accord
nccl
standard
molecular
studi
isol
done
use
adsrrsfingerprint
result
kp
esbl
recov
blood
patient
earlier
colonis
kp
esbl
neonat
femal
mean
gestat
age
week
mean
birth
weight
g
deliveri
cesarean
section
mean
min
apgar
score
neonat
mechan
ventil
necessari
ventil
longer
day
neonat
parenter
nutrit
begin
life
mean
hospit
stay
day
bacteraemia
occur
day
life
compar
infect
colonis
neonat
n
found
higher
gestat
age
week
higher
birth
weight
g
higher
min
apgar
score
shorter
hospit
stay
day
colonis
patient
colonis
neonat
mechan
ventil
howev
analys
popul
ventil
day
molecular
studi
asdsrrsfingerprint
confirm
one
genotyp
respons
outbreak
conclus
detect
outbreak
kp
esbl
bacteraemia
affect
immatur
neonat
risk
factor
adsrrsfingerprint
new
type
method
prove
use
determin
strain
respons
infect
klebsiella
differ
perinat
intens
care
unit
picu
hungari
ib
damjanova
th
j
jakab
budapest
hun
object
molecular
phenotyp
esblproduc
k
pneumonia
k
oxytoca
strain
seven
picu
outbreak
five
hungarian
counti
hospit
method
confirm
esbl
product
etest
doubledisc
diffus
agar
dilut
method
accord
nccl
pcr
analysi
blactamas
detect
use
specif
primer
phage
type
resist
transfer
plasmid
profil
analysi
genom
fingerprint
ericpcr
pfge
result
isol
multidrugresist
still
suscept
ciprofloxacin
isol
belong
six
differ
phage
type
typabl
ericpcr
perform
strain
found
five
major
erictyp
nine
subtyp
pfge
analysi
reveal
seven
differ
genet
clone
homolog
level
isol
harbour
plasmid
rang
mda
plasmid
profil
sequenc
analysi
shv
pcr
product
show
present
two
outbreak
clone
five
outbreak
clone
two
isol
carri
transfer
plasmid
conclus
result
show
preval
esbl
produc
klebsiella
hungarian
picu
work
also
confirm
ericpcr
combin
phage
type
plasmid
profil
analysi
pfge
effect
tool
investig
epidemiolog
esblproduc
k
pneumonia
k
oxytoca
strain
adhes
invas
human
epitheli
cell
esbl
nonesblproduc
klebsiella
pneumonia
strain
h
sahli
r
podschun
schutt
u
ullmann
kiel
object
extend
spectrum
blactams
esbl
produc
klebsiella
pneumonia
strain
suggest
possess
higher
pathogen
potenti
nonesblproduc
strain
mainli
virtu
higher
abil
adher
human
epitheli
cell
resist
bactericid
activ
serum
phagocytosi
polymorph
nuclear
leucocyt
adhes
invas
epitheli
cell
consid
major
virul
factor
bacteria
prerequisit
infecti
process
sought
compar
abil
esbl
nonesblproduc
klebsiella
pneumonia
isol
adher
invad
human
epitheli
cell
method
invas
human
ileocec
bladder
lung
epitheli
cell
esblproduc
nonesblproduc
klebsiella
pneumonia
strain
test
use
imipenem
kill
assay
total
esblproduc
nonesblproduc
klebsiella
pneumonia
strain
test
six
esblproduc
strain
bear
esblcod
plasmid
retest
adhes
invas
abil
elimin
rplasmid
result
signific
differ
could
shown
abil
esblproduc
strain
nonesblproduc
invad
ileocaec
ae
inoculum
vs
ae
bladder
ae
vs
ae
lung
epitheli
cell
ae
vs
ae
p
likewis
adhes
esbl
nonesblproduc
isol
cell
differ
significantli
ae
ae
p
plasmid
cure
influenc
abil
strain
adher
invad
cell
six
plasmidcur
deriv
retain
adhes
invas
potenti
epitheli
cell
ae
ae
p
conclus
result
indic
esblcod
plasmid
contribut
sadhes
invas
potenti
klebsiella
pneumonia
isol
multiresist
strain
klebsiella
oxytoca
neonat
intens
care
unit
colon
infect
j
jursa
kordek
giedryskalemba
szczecin
pl
introduct
exist
mdr
strain
gram
rod
creat
seriou
epidemiolog
danger
therapeut
problem
newborn
infect
import
differenti
colon
infect
object
aim
studi
analysi
occur
esbl
antibiot
suscept
klebsiella
oxytoca
k
ox
isol
newborn
determin
genet
related
strain
differenti
colonis
infect
case
newborn
k
ox
isol
materi
method
total
k
ox
isol
newborn
hospitalis
nicu
b
octob
test
antibiot
suscept
nccl
dd
test
detect
esbl
molecular
type
k
ox
isol
use
pfge
xba
case
newborn
mdr
k
ox
analys
attent
paid
apg
scale
hbd
birth
weight
clinic
state
hospitalis
durat
day
hospitalis
k
ox
isol
treatment
potenti
coexist
diseas
result
strain
k
ox
produc
esbl
sensit
amoxclav
acid
aminoglicosid
carbapenem
analysi
band
pattern
isol
divid
two
type
three
newborn
isol
septemb
b
octob
isol
one
newborn
differ
time
analys
newborn
group
four
colonis
without
symptom
nine
case
infect
found
colonis
newborn
k
ox
isol
fifth
day
hospitalis
ampicillin
meropenem
administr
prophylaxi
two
case
low
weight
infect
newborn
k
ox
isol
day
hospitalis
ampicillin
amikacin
meropenem
administr
characterist
infect
newborn
one
born
good
condit
proper
weight
diarrhoea
symptom
eight
prematur
birth
one
born
good
condit
weight
g
develop
nec
seven
born
medium
sever
manifest
appear
pneumonia
mening
sepsi
one
die
durat
hospitalis
day
conclus
esbl
k
oxz
belong
two
genet
type
isol
type
differ
newborn
month
spread
bacterium
clone
depart
colonis
develop
case
healthi
newborn
infect
develop
case
newborn
low
weight
sever
medium
condit
often
long
hospitalis
yuce
erdenizmenli
n
yapar
senger
izmir
tr
object
investig
antimicrobi
resist
gramneg
rod
caus
bloodstream
infect
bsi
icu
univers
hospit
turkey
method
studi
includ
pseudomona
aeruginosa
acinetobact
spp
klebsiella
pneumonia
escherichia
coli
isol
blood
sampl
patient
bloodstream
infect
period
antibiot
suscept
extendedspectrum
blactamas
esbl
product
determin
etest
ab
biodisc
use
muellerhinton
agar
oxoid
accord
nccl
recommend
result
antibiot
resist
rate
esbl
product
strain
present
tabl
conclus
among
microorgan
caus
bsi
multidrug
resist
acinetobact
spp
lead
pathogen
regard
strain
carbapenem
cefepim
identifi
effect
antimicrobi
agent
littl
known
preval
incid
ht
intassoci
resist
enterobacteriacea
nonoutbreak
period
intens
care
unit
icu
method
period
patient
pt
admit
two
icu
screen
rectal
colonis
enterobacteriacea
reduc
suscept
cephalosporin
ersc
mean
rectal
swab
taken
admiss
twice
weekli
thereaft
cultur
agar
cefpodoxim
isol
iso
identifi
use
vitek
two
iso
speciespt
select
suscept
test
intspecif
pcr
aflp
genotyp
int
characteris
cspcr
rflp
dna
sequenc
demograph
data
antibiot
use
collect
result
total
pt
admit
icu
colonis
ersc
total
pt
colonis
admiss
acquir
colonis
icu
total
iso
select
iso
pt
carri
least
one
int
daili
endem
preval
int
rang
multivari
analysi
reveal
risk
factor
acquisit
intposit
isol
characteris
reveal
three
group
contain
major
intposit
iso
two
group
found
e
coli
iso
collect
first
group
compris
iso
carri
two
int
aadb
gene
second
group
compris
four
iso
carri
int
dfria
gene
third
group
compris
eight
e
cloaca
iso
one
k
oxytoca
iso
one
k
pneumonia
iso
carri
intcontain
aadb
gene
iso
carri
ident
int
except
part
aflp
cluster
ht
complet
intcarri
organ
ie
crosstransmiss
identifi
four
time
two
time
icu
ht
int
suspect
two
patient
colonis
genet
differ
iso
e
coli
tranfer
int
e
cloaca
koxytoca
isol
within
pt
identifi
nineteen
pt
treat
icu
infect
pneumonia
includ
five
ventilatorassoci
pneumonia
intraabdomin
nine
urinari
five
catheterrel
infect
five
other
five
ten
pt
bacteraem
twentyseven
infect
previous
treat
antibiot
colistin
use
median
dosag
rang
million
unit
daili
median
day
day
case
anoth
antibiot
ad
despit
vitro
resist
meropenem
eight
standard
dose
six
doubl
dose
ceftazidim
continu
infus
cefepim
three
aztreonam
one
fourteen
episod
benefit
concomit
drainag
cathet
remov
good
clinic
outcom
achiev
patient
seventeen
patient
die
median
day
colistin
treatment
rang
day
probabl
relat
infect
microbiolog
erad
obtain
eight
pt
treat
least
day
signific
side
effect
report
eight
patient
alter
renal
function
doubl
serum
creatinin
seven
pt
renal
function
return
near
baselin
survivor
myoclonia
due
excess
dose
one
pt
conclus
retrospect
data
suggest
iv
colistin
could
repres
valuabl
therapeut
option
treatment
infect
caus
multiresist
gramneg
bacilli
sinc
toler
drug
appear
good
higher
dose
may
consid
improv
outcom
show
domin
enzym
marcescen
popul
conclus
serratia
marcescen
seem
endem
pathogen
set
respons
numer
infect
incid
esblproduc
isol
decreas
time
probabl
due
strict
implement
infect
control
measur
ctxm
phenotyp
predomin
among
esbl
aim
present
work
investig
use
molecular
type
method
two
put
epidem
cluster
newborn
crossinfect
due
marcescen
k
pneumonia
respect
order
establish
clonal
relationship
among
isol
identifi
possibl
sourc
mode
transmiss
method
period
newborn
intens
care
unit
either
infect
colonis
marcescen
k
pneumonia
three
four
prematur
neonat
among
patient
yield
invas
infect
repetit
posit
blood
cultur
associ
two
case
k
pneumonia
one
case
marcescen
anoth
fatal
case
microorgan
nurs
environ
check
microbiolog
studi
antibiogram
result
two
molecular
type
method
autom
riboprint
ericpcr
bacteraem
colonis
isol
newborn
patient
elsewher
hospit
time
period
compar
order
investig
epidemiolog
cluster
result
total
marcescen
isol
includ
newborn
eight
patient
hospit
k
pneumonia
strain
newborn
examin
initi
analysi
perform
identif
first
nine
newborn
contamin
marcescen
establish
clonal
relationship
among
isol
includ
two
bacteraem
strain
second
analysi
reveal
one
differ
pattern
three
marcescen
strain
success
isol
six
genotyp
unrel
newborn
isol
found
eight
strain
examin
patient
three
k
pneumonia
bacteraem
strain
result
genet
relat
among
unrel
colonis
isol
marcescen
isol
among
differ
molecular
pattern
show
ident
antibiogram
focal
sourc
microorgan
identifi
respect
pfge
profil
integron
contain
order
gene
cassett
within
integron
genet
context
integron
analys
combin
pcr
base
approach
includ
amplif
use
primer
anchor
conserv
sequenc
cs
togeth
random
primer
design
amplifi
upstream
downstream
sequenc
ii
pcr
amplif
use
primer
design
tnpr
tnpa
sequenc
iii
primer
design
amplifi
insert
site
integron
autom
bactalert
vitek
system
use
result
bsi
rate
stabl
admiss
habsi
rate
decreas
adm
p
rate
cabsi
increas
adm
p
patient
immunocompromis
gramneg
bacilli
involv
bsi
period
neither
incid
gramposit
cocci
fungi
augment
unusu
bacteria
mainli
maltophilia
emerg
ca
habsi
presenc
central
venou
cathet
cabsi
increas
ca
oxacillinr
aureu
detect
patient
link
healthcar
system
inadequ
treatment
habsi
frequent
bsi
better
outcom
women
ca
differ
bsi
mortal
appropri
antimicrobi
agent
atm
introduc
second
day
third
fifth
day
bsi
initi
appropri
atm
fifth
day
better
outcom
mortal
fifth
day
mortal
mortal
lower
vs
cabsi
vs
habsi
vs
inhospit
mortal
also
decreas
cabsi
vs
habsi
vs
among
adequ
treat
bsi
outcom
improv
among
inadequ
treat
howev
outcom
similar
decad
first
studi
nosocomi
infect
found
patient
second
patient
third
studi
patient
fourth
patient
fifth
seven
patient
overal
preval
hai
five
studi
respect
first
studi
among
hai
urinarytract
infect
lower
respiratorytract
infect
six
surgic
site
infect
two
second
studi
urinarytract
infect
four
lower
respiratorytract
infect
surgic
site
infect
five
bloodstream
infect
four
third
studi
urinarytract
infect
six
lower
respiratorytract
infect
three
surgic
site
infect
three
bloodstream
infect
one
fourth
studi
urinarytract
infect
seven
lower
respiratorytract
infect
five
upper
respiratorytract
infect
four
surgic
site
infect
three
two
fifth
studi
urinarystract
infect
four
lower
respiratorytract
infect
three
infect
risk
far
higher
birth
weight
g
gestat
age
week
crib
rel
risk
multipli
first
microorgan
respons
bacteriaemia
staphylococcu
epidermidi
devic
central
vascular
cathet
use
rr
ni
multipli
one
possibl
death
note
crib
clinic
risk
index
babi
rr
rel
risk
computeris
system
administr
data
nosocomi
infect
monitor
saia
l
timillero
p
mantoan
b
allegranzi
g
pellizz
p
spolaor
padua
castelfranco
veneto
vicenza
verona
object
assess
accuraci
computeris
system
csi
link
data
hospit
discharg
form
hdf
microbiolog
report
monitor
nosocomi
infect
ni
veneto
region
northern
itali
method
within
frame
region
project
ni
surveil
control
set
data
base
appli
linkag
hdf
microbiolog
report
patient
pt
discharg
region
hospit
select
list
cm
diagnosi
proxi
ni
urinari
tract
uti
wound
infect
ssi
pneumonia
pneu
bloodstream
infect
bsi
list
microorgan
isol
urin
blood
wound
swab
respiratori
sampl
commonli
recognis
nosocomi
pathogen
three
group
discharg
pt
event
proxi
ni
could
identifi
one
group
diagnosi
second
nosocomi
isol
third
diagnosi
nosocomi
isol
sampl
control
group
pt
group
randomli
select
medic
record
reviewd
ni
accord
cdc
definitionsth
posit
predict
valu
ppv
csi
identifi
ni
event
compar
ni
detect
control
group
true
ni
calcul
result
three
region
hospit
vicenza
verona
treviso
analys
discharg
pt
pt
day
overal
csi
identifi
event
proxi
ni
pt
rate
control
group
cdc
criteria
ni
met
case
ppv
csi
ppv
pneu
bsi
uti
ssi
respect
microbiolog
record
highest
ppv
comparison
cm
appli
ppv
estim
obtain
control
group
hdf
adjust
rate
ni
proxi
detect
csi
patient
day
conclus
csi
base
linkag
current
avail
inform
administr
record
abl
produc
adequ
evalu
ni
epidemiolog
comparison
data
obtain
retrospect
review
medic
record
method
could
conveni
term
cost
spare
compar
activ
surveil
ni
easili
appli
larg
scale
allow
continu
monitor
ni
region
level
use
comparison
control
programm
among
differ
hospit
object
describ
collect
analysi
use
cumul
microbi
identif
antimicrobi
suscept
data
hospit
method
local
develop
data
manag
system
use
analys
cumul
microbiolog
test
data
patient
demograph
inform
specimen
inform
test
result
export
laboratori
inform
system
analysi
softwar
detect
duplic
isol
base
patient
name
identif
number
organ
identif
suscept
pattern
isol
screen
specimen
exclud
result
list
identif
antibiot
suscept
test
result
gener
month
speci
present
regardless
number
isol
specif
subset
tabul
differ
patient
group
eg
inpati
outpati
specif
ward
intens
care
unit
specimen
type
blood
urin
special
patient
group
cystic
fibrosi
semiautomat
detect
deviat
sd
use
surveil
isol
resist
frequenc
applic
monthli
list
patient
bacteraemia
daili
list
patient
resist
highli
transmiss
microorganism
expert
system
detect
patient
possibl
nosocomi
infect
cumul
antimicrobi
suscept
data
relev
speci
present
tabular
form
separ
tabl
made
specif
subset
need
graph
made
follow
accumul
data
sever
year
data
use
updat
empir
therapi
scheme
conclus
cumul
identif
antimicrobi
suscept
report
give
use
inform
obtain
consist
matter
help
surveil
nosocomi
pathogen
resist
pattern
also
qualiti
asses
laboratori
select
empir
therapi
access
clear
present
cumul
microbiolog
data
convinc
healthcar
profession
compli
prudent
use
antibiot
hygien
precaut
introduct
surgic
site
infect
associ
consider
morbiditiy
addit
healthcar
cost
aris
lengthi
hospitalis
patient
accord
german
infect
protect
act
implement
januari
hospit
ambulatori
surgeri
institut
requir
assess
document
nosocomi
infect
data
must
avail
health
organis
demand
method
report
new
surveil
modul
ambukiss
design
assess
document
surgic
site
infect
ambulatori
surgeri
object
creat
refer
databas
institut
object
investig
antibiot
resist
pattern
nosocomi
bacteria
accord
meropenem
yearli
suscept
test
inform
collect
mystic
programm
outcom
resist
follow
year
method
resist
pattern
total
bacteria
gramneg
gramposit
meropenem
imipenem
ceftazidim
cefotaxim
cefepim
piperacillintazobactam
ciprofloxacin
tobramycin
investig
use
etest
extendedspectrum
blactamas
esbl
product
determin
use
ceftazidim
ceftazidimeclavulan
acid
etest
strip
result
meropenem
effect
antibiot
gramneg
organ
follow
imipenem
piperacillintazobactam
activ
antibiot
gramposit
bacteria
imipenem
follow
piperacillintazobactam
meropenem
rate
product
esbl
escherichia
coli
klebsiella
pneumonia
serratia
marcescen
respect
esbl
product
increas
year
respect
esbl
produc
isol
sensit
meropenem
sensit
imipenem
ampc
blactamas
produc
enterobact
spp
citrobact
spp
marcescen
sensit
meropenem
imipenem
ciprofloxacin
multidrug
resist
mdr
rate
acinetobact
spp
pseudomona
aeruginosa
isol
conclus
entir
world
resist
antibiot
seriou
problem
countri
solv
problem
depend
primarili
prevent
develop
resist
birth
asphyxia
elbw
gestat
age
equal
week
perinat
risk
factor
case
note
eightytwo
per
cent
infant
mechan
ventil
receiv
parenter
nutrit
develop
septicaemia
underw
vessel
catheter
result
common
bacteria
isol
blood
meticillinresist
staphylococcu
epidermidi
multidrugresist
klebsiella
pneumonia
staphylococc
strain
pseudomona
aeruginosa
other
gramneg
bacteria
enterococcu
candida
c
sake
c
albican
found
typic
clinic
symptom
compris
pneumonia
shock
gastrointestin
disord
includ
nec
purul
mening
dic
syndrom
metabol
acidosi
increas
crp
level
hyper
hypoglycaemia
frequent
biochem
disord
thrombocytopenia
stab
cell
note
despit
intens
antibiot
therapi
base
antibiogram
prematur
infant
die
mean
birthweight
ae
g
aetiolog
septicaemia
infant
die
gramposit
case
gramneg
candida
two
case
sever
brain
injuri
bronchopulmonari
dysplasia
main
caus
death
conclus
multidrugresist
klebsiella
pneumonia
methycillinresist
staphylococcu
epidermidi
potenti
import
pathogen
aetiolog
first
incid
lateonset
septicaemia
prematur
infant
elbw
birth
asphyxia
sever
chronic
lung
diseas
factor
bad
prognosi
lo
prematur
infant
antimicrobi
resist
pattern
bacteria
isol
intens
care
unit
infect
bayram
balci
gaziantep
tr
object
hospitalacquir
infect
especi
among
intens
care
unit
icu
patient
increas
rate
mortal
morbid
also
lead
higher
treatment
cost
grow
antimicrobi
resist
studi
perform
januari
januari
aetiolog
agent
icu
infect
resist
pattern
variou
antimicrobi
evalu
method
clinic
specimen
suspect
site
infect
icu
patient
cultur
onto
sheep
blood
agar
eosinmethyleneblu
agar
sabouraud
dextros
agar
identif
antimicrobi
sensit
bacteri
pathogen
perform
sceptor
system
becton
dickinson
usa
result
specimen
belong
patient
pathogen
isol
identifi
four
major
infect
site
repres
report
infect
lower
respiratorytract
infect
frequent
follow
urinarytract
infect
bloodstream
infect
surgicalsit
infect
commonli
identifi
microorgan
follow
pseudomona
aeruginosa
candida
speci
staphylococcu
aureu
among
gramneg
microorgan
p
aeruginosa
mostli
resist
third
gener
cephalosporin
baumannii
resist
case
piperacillin
ceftazidim
ceftriaxon
coagulaseposit
staphylococci
mostli
resist
penicillin
ampicillin
wherea
coagulaseneg
staphylococci
resist
methicillin
case
resist
ampicillin
tetracyclin
conclus
reduc
emerg
spread
antimicrobialresist
pathogen
icu
monitor
optimis
antimicrobi
use
consid
care
assess
incid
ssi
italian
surgic
unit
inhospit
stay
discharg
identifi
associ
risk
factor
method
onemonth
prospect
nation
multicent
surveil
studi
patient
undergo
select
intervent
thirtyday
postdischarg
surveil
telephon
call
surgicaloutpati
card
conduct
data
surgic
intervent
surgic
unit
collect
intervent
includ
gastric
surgeri
colon
surgeri
cholecystectomi
hernia
repair
vascular
surgeri
hysterectomi
mastectomi
caesarean
section
ssi
defin
accord
criteria
develop
center
diseas
control
prevent
atlanta
multivari
analysi
risk
factor
ssi
perform
result
global
ssi
attack
rate
confid
interv
occur
clean
surgeri
clean
contamin
surgeri
contamin
surgeri
dirti
surgeri
rate
ssi
gener
surgeri
obstetr
gynaecolog
ssi
rate
accord
infect
risk
index
ri
respect
patient
activ
followedup
discharg
ssi
identifi
prior
discharg
postdischarg
multivari
analysi
variabl
independ
associ
risk
ssi
class
intervent
iri
presenc
surgic
drainag
sepsi
half
case
open
surgic
drainag
use
final
one
third
patient
length
surgic
prophylaxi
longer
h
conclus
studi
show
infect
detect
discharg
thu
effect
postdischarg
followup
programm
essenti
reliabl
assess
ssi
studi
ssi
incid
rate
higher
report
european
studi
includ
postdischarg
surveil
final
studi
show
better
polici
regard
use
surgic
drainag
antibiot
prophylaxi
need
work
support
ministri
health
fund
ricerca
finalizzata
ircc
itali
last
multicentr
postop
studi
surgic
patient
date
back
show
ni
rate
surgic
site
infect
ssi
overal
rate
princip
aim
studi
updat
ni
rate
surgic
ward
method
studi
carri
april
may
gener
surgeri
belong
wide
hospit
round
itali
oper
patient
survey
surgeon
hospit
stay
day
oper
diagnosi
ni
defin
accord
cdc
criteria
discharg
patient
receiv
questionnair
regist
onset
ni
symptom
follow
time
frame
statist
analysi
descript
ni
incid
rate
calcul
number
patient
ni
number
ni
everi
oper
patient
ssi
rate
calcul
nni
method
result
patient
male
perform
oper
nni
index
ni
onset
patient
total
ni
ssi
urinari
common
infect
among
ssi
respect
superfici
deep
incision
organspac
site
patient
organspac
ssi
osssi
requir
new
oper
die
averag
postop
hospit
stay
averag
onset
ssi
respect
day
oper
day
patient
pre
postdischarg
ssi
fiftyf
ssi
diagnos
discharg
superfici
incis
postdischarg
questionnair
given
patient
among
repli
ssi
symptom
report
agreement
diagnosi
ssi
made
surgeon
presenc
ssi
symptom
report
patient
conclus
studi
allow
updat
incid
ssi
rate
italian
gener
surgeri
stratifi
rate
nni
method
confirm
risk
mortal
ssi
patient
especi
osssi
ni
target
special
control
program
surgeri
although
postdischarg
surveil
fundament
estim
correctli
ssi
frequenc
method
postdischarg
questionnair
seem
mislead
experi
number
cholecystectomi
nni
risk
categori
respect
five
ssi
belong
nni
risk
categori
one
nni
risk
categori
accord
cdc
definit
two
superfici
incision
two
deepincision
two
organspac
infect
polymicrobi
infect
two
case
microorgan
isol
similar
laparoscop
open
approach
enterobacteriacea
three
p
aeruginosa
three
commonli
microorgan
isol
conclus
although
use
laparoscop
cholecystectomi
incorpor
nni
riskindex
ssi
rate
follow
cholecystectomi
also
stratifi
type
techniqu
evalu
result
conclus
compar
data
nni
report
hospit
rate
nni
nni
lower
percentil
nni
higher
percentil
staphylococci
common
pathogen
recov
major
minor
infect
import
monitor
surgic
care
patient
extens
use
antistaphylococc
antimicrobi
clinic
practic
result
total
patient
oper
period
found
nosocomi
infect
patient
surgic
wound
infect
pneumonia
bacteraemiasepticaemia
urinarytract
infect
patient
nosocomi
infect
mean
day
rang
extra
hospitalis
mortal
rate
discus
length
oper
time
emerg
night
shift
oper
dirtycontamin
contamin
wound
diabet
mellitu
malign
addit
diseas
risk
factor
associ
nosocomi
infect
nation
hospit
infect
surveil
system
kiss
germani
periprosthet
infect
predominantli
due
bacteri
contamin
foreign
materi
time
implant
period
implant
clinic
manifest
periprosthet
infect
may
last
longer
hospitalis
period
patient
accord
cdc
ssi
definit
year
report
assess
infect
rate
extend
postdischarg
followup
addit
predischarg
surveil
materi
method
total
orthopaed
patient
evalu
underw
hrpo
n
primari
n
revis
ssi
record
accord
kisscriteria
hospitalis
period
patient
without
predischarg
ssi
contact
postal
questionnair
month
follow
oper
nonrespond
remind
month
questionnair
analys
case
report
ssi
inform
gain
clinician
gp
data
standardis
stratifi
infect
rate
calcul
result
respons
rate
postal
questionnair
survey
first
contact
remind
total
ssi
notic
record
predischarg
surveil
distribut
among
type
n
n
n
ssi
defin
cdc
criteria
four
case
ssi
found
postdischarg
questionnair
belong
type
ssi
need
reoper
time
infecti
diseas
public
health
issu
surveil
studi
incid
hivposit
patient
lowrisk
group
communityacquir
pulmonari
tuberculosi
introduct
jaipur
india
consid
low
preval
state
hiv
epidem
hivaid
therefor
thrust
area
governmentimpl
public
health
initi
howev
hiv
posit
seen
spread
hitherto
low
risk
group
commun
alarm
rate
warrant
immedi
energet
effort
arrest
epidem
object
establish
incid
hiv
posit
patient
suffer
pulmonari
tuberculosi
hospitalis
civil
hospit
jaipur
india
therebi
highlight
alarm
rate
spread
hiv
epidem
low
risk
group
use
baselin
data
upscal
govern
polici
initi
toward
public
awar
campaign
prevent
measur
care
support
hivposit
popul
method
total
hospitalis
patient
civil
tb
hospit
random
sampl
identifi
target
group
screen
period
month
hiv
use
elisa
method
serum
result
total
serum
sampl
screen
sampl
found
posit
retes
differ
kit
confirm
posit
conclus
mark
increas
hiv
posit
per
figur
low
risk
group
popul
suffer
communityacquir
tb
infect
caus
concern
data
studi
discuss
depart
health
govern
rajasthan
lead
upscal
prevent
initi
discuss
western
greec
examin
complet
notif
studi
demonstr
signific
inaccuraci
insuffici
obligatori
tb
monitor
system
greec
order
improv
accuraci
notif
system
reason
underreport
proper
sincer
cooper
physician
health
centr
hospit
requir
effect
diseas
control
prevent
greec
countri
high
proport
immigr
refuge
come
region
high
tb
incid
achiev
wellorganis
surveil
tuberculosi
local
region
nation
level
order
evalu
plan
programm
target
resourc
develop
appropri
polici
object
brucellosi
system
seriou
infect
may
affect
mani
system
bodi
case
human
brucellosi
occur
peopl
directli
expos
infect
anim
excreta
product
abort
infect
carcass
unpasteuris
milk
process
dairi
food
infect
anim
diseas
close
relat
certain
occup
group
abattoir
worker
farm
worker
veterinarian
meatpack
employe
erzurum
present
studi
conduct
known
endem
area
brucellosi
sinc
economi
mainli
depend
agricultur
livestock
regard
aim
investig
seropreval
brucella
antibodi
risk
group
work
district
method
blood
sampl
collect
person
belong
four
differ
risk
group
consist
veterinarian
butcher
abattoir
worker
farm
worker
addit
serum
sampl
normal
popul
includ
control
sampl
questionnair
concern
age
gender
length
employ
educ
level
protect
precaut
work
avail
administ
individu
risk
group
sera
obtain
risk
control
group
analys
standard
tube
agglutin
test
stat
use
b
abortu
antigen
provid
pendik
veterinarian
research
institut
istanbulturkey
sera
titr
equal
accept
posit
data
result
laboratori
test
analys
use
softwar
spss
result
screen
serum
specimen
risk
group
control
group
stat
gave
posit
result
four
respect
differ
risk
control
group
found
signific
p
seroposit
rate
veterinarian
butcher
abattoir
worker
farm
worker
differ
seroposit
rate
obtain
occup
group
signific
howev
seroposit
associ
demograph
characterist
individu
conclus
result
present
studi
indic
seropreval
brucellosi
higher
certain
occup
group
concern
aninm
husbandri
compar
normal
popul
mainli
due
greater
exposur
infect
livestock
excreta
august
peak
children
parent
also
third
age
retir
peopl
conclus
light
vast
rang
infect
import
worldwid
distribut
possibl
sourc
countri
epidat
monitor
crucial
relev
protect
public
health
mean
earli
warn
system
although
secondari
case
import
infect
regularli
report
far
import
pathogen
differ
biolog
characterist
identifi
respect
nation
refer
laboratori
must
circul
among
czech
popul
suffici
protect
specif
immun
mechan
acut
respiratori
infect
ari
frequent
human
diseas
consider
health
econom
impact
influenza
morbid
monitor
programm
start
czech
republ
agespecif
incid
ari
incid
complic
monitor
weekli
sinc
nowaday
system
cover
million
popul
half
czech
popul
attempt
improv
healthcar
inform
system
substanti
chang
made
ari
report
system
start
season
district
public
health
servic
enter
data
collabor
gener
practition
paediatrician
central
sql
databas
use
secur
protocol
http
basic
data
process
autom
use
statist
model
earli
detect
unusu
increas
rate
indic
monitor
base
gener
linear
model
left
censor
data
direct
standard
weight
size
monitor
popul
also
use
accord
european
commiss
decis
case
definit
report
communic
diseas
commun
network
one
chang
made
system
start
januari
clinic
data
incid
influenzalik
ill
ili
within
popul
age
group
ari
year
also
collect
virolog
surveil
perform
nation
refer
laboratori
nrl
influenza
nrl
noninfluenza
respiratori
virus
data
morbid
epidemiolog
surveil
integr
virolog
surveil
approv
advanc
assess
result
present
weekli
basi
comprehens
output
intern
centr
eiss
flunet
provid
nrl
influenza
conclus
ariili
report
system
czech
republ
modern
effici
tool
surveil
base
collect
high
qualiti
data
sinc
use
internetbas
platform
easili
access
provid
time
inform
conorii
present
subject
u
su
r
p
ns
r
typhi
present
u
su
r
p
ns
strain
past
infect
common
r
u
p
su
p
rr
older
age
associ
past
infecion
r
conorii
p
r
typhi
p
p
gender
contact
anim
travel
rural
area
outdoor
activ
associ
past
infect
rickettsia
rel
risk
past
infect
r
typhi
insect
bite
month
previou
blood
extract
conclus
result
confirm
presenc
widespread
past
infect
r
typhi
strain
peopl
rural
urban
area
south
spain
object
aim
studi
analys
dynam
nasopharyng
carriag
haemophilu
influenza
asymptomat
children
sampl
twice
year
use
phenotyp
molecular
method
method
total
children
orphanag
dcc
examin
twice
year
first
winter
spring
clinic
data
inform
antibiot
treatment
within
period
sampl
collect
questionnair
nasopharyng
swab
process
h
influenza
identifi
convent
microbiolog
method
mic
antimicrobi
determin
agardilut
method
h
influenza
isol
test
presenc
capsul
gene
serolog
type
pcr
pulsedfield
gel
electrophoresi
pfge
smai
restrict
fragment
bacteri
chromosom
use
determin
related
among
h
influenza
isol
result
altogeth
h
influenza
isol
identifi
dcc
singl
case
three
differ
strain
obtain
child
investig
children
colonis
h
influenza
winter
spring
twentyfour
children
colonis
h
influenza
winter
spring
two
colon
strain
second
sampl
first
one
case
h
influenza
isol
two
differ
point
year
child
unrel
particular
group
strain
often
isol
sever
children
isol
h
influenza
three
produc
capsul
capsular
strain
belong
serotyp
b
hib
almost
isol
h
influenza
fulli
suscept
antimicrobi
test
conclus
colonis
nasopharynx
h
influenza
repres
dynam
process
bacteria
acquir
elimin
reacquir
period
month
longterm
colonis
month
involv
two
investig
children
small
close
commun
dcc
place
high
percentag
nasopharyng
carrier
h
influenza
creat
high
risk
clonal
spread
potenti
pathogen
mani
communityacquir
urinarytract
infect
uti
caus
e
coli
bacteria
one
common
bacteri
infect
human
symptomat
uti
manifest
two
syndrom
one
acut
pyelonephr
gener
perceiv
kidney
infect
second
cystiti
gener
perceiv
bladder
infect
recent
defin
categori
potenti
diarrheagen
e
coli
celldetach
strain
origin
defin
capac
detach
tissu
cultur
cell
solid
support
adher
assay
howev
epidemiolog
studi
found
strain
realli
associ
diarrhoea
signific
remain
unknown
report
describ
identif
urinari
e
coli
strain
isol
patient
uti
capabl
detach
cell
monolay
characteris
strain
detail
serotyp
reveal
strain
belong
serotyp
associ
extraintestin
diseas
preval
serogroup
fifteen
e
coli
isol
uti
abil
detach
cell
adher
assay
cultur
supernat
celldetach
bacteria
concentr
caus
detach
effect
contain
sever
secret
protein
two
identifi
sat
secret
autotransport
toxin
haemolysin
protein
band
appear
gel
sdspage
electrophoresi
supernat
promin
consist
secret
protein
appar
molecular
mass
kda
western
blot
analysi
show
protein
recognis
secretori
immunoglobulin
siga
antibodi
isol
milk
mexican
women
strong
siga
respons
secret
protein
obtain
studi
indic
antigen
stimul
intestin
urinarytract
respons
may
elicit
protect
immun
uropathogen
diseas
object
half
centuri
decreas
morbid
mortal
resurg
persist
seriou
group
streptococc
ga
infect
note
sinc
howev
limit
popul
base
prospect
epidemiolog
studi
method
prospect
nationwid
laboratorybas
surveil
invas
ga
infect
formal
organis
region
public
health
laboratori
nation
coverag
netherland
may
result
may
may
patient
invas
ga
diseas
identifi
isol
predominantli
obtain
blood
clear
season
pattern
preponder
case
occur
late
winter
spring
incid
vari
person
year
per
person
year
frequent
identifi
mtype
annual
rel
contribut
type
show
high
degre
variat
explain
local
outbreak
decad
surveil
rel
proport
year
agegroup
increas
gradual
conclus
populationbas
surveil
provid
data
monitor
incid
trend
identifi
import
virul
strain
greek
pregnant
women
maraki
dialyna
e
nioti
gavrilidi
tselenti
heraklion
gr
group
b
streptococcu
gb
lead
caus
sever
infect
neonat
high
mortal
rate
neonat
born
mother
colonis
deliveri
gb
risk
develop
infect
object
aim
studi
determin
preval
gb
carriag
among
pregnant
greek
women
patient
method
studi
colonis
gb
conduct
consecut
pregnant
women
week
gestat
swab
place
ml
select
broth
antibiot
h
incub
subcultur
onto
colistinnalidix
acid
cna
agar
identif
made
convent
microbiolog
method
posit
agglutin
test
gb
isol
underw
antibiot
suscept
test
discdiffus
method
follow
recommend
nccl
result
total
women
age
year
recruit
thirtysix
colonis
gb
isol
penicillinsuscept
resist
erythromycin
clindamycin
detect
respect
conclus
antepartum
screen
gb
colonis
maternalintrapartum
chemoprophylaxi
antibiot
posit
case
appear
effect
approach
order
prevent
transmiss
gb
newborn
reduc
risk
earlyonset
diseas
toxoplasma
gondii
among
women
reproduct
age
region
thrace
greec
object
purpos
studi
evalu
serolog
analysi
immun
rubella
cytomegaloviru
cmv
gondii
popul
pregnant
nonpregn
women
reproduct
age
region
thrace
greec
within
period
method
februari
februari
sera
women
test
detect
specif
rubella
cmv
gondii
antibodi
three
group
women
group
greek
orthodox
women
group
b
greek
moslem
women
group
c
immigr
greek
origin
former
soviet
union
test
detect
level
igg
igm
antibodi
perform
meia
msetholog
axsym
abbott
result
group
women
found
posit
rubella
igg
cmv
igg
gondii
igg
group
b
rubella
igg
cmv
igg
gondii
igg
group
c
women
found
posit
rubella
igg
cmv
igg
eight
gondii
igg
also
measur
seroposit
rate
igm
antibodi
marker
acut
infect
rubella
cmv
gondii
seroposit
rate
rubella
igm
group
group
b
group
c
cmv
igm
group
group
b
group
c
gondii
group
group
b
group
c
conclus
studi
show
signific
preval
rubella
igg
group
c
low
rate
found
group
b
despit
fact
routin
rubella
vaccin
programm
total
women
immun
rubella
ii
total
women
higher
risk
acquir
gondii
infect
pregnanc
inde
larg
number
unprotect
women
iii
total
women
found
posit
cmv
igg
women
neg
iv
overal
seroposit
rate
rubella
cmv
gondii
studi
larger
popul
size
may
need
order
determin
seropreval
virus
gondii
immigr
import
women
check
prior
plan
pregnanc
especi
certain
minor
might
difficulti
attend
exist
vaccin
programm
chicken
dress
commerci
process
plant
market
studi
aim
evalu
level
bacteria
contamin
chicken
carcass
supermarket
method
total
refriger
sampl
collect
supermarket
winter
summer
bacteri
analysi
achiev
qualit
quantit
qualit
serial
dilut
perform
nutrient
broth
g
chicken
skin
place
use
salin
dilut
plate
use
plate
count
agar
plate
incub
c
h
later
determin
level
contamin
term
number
coloni
form
unit
cfu
ml
sampl
quantit
interest
isol
salmonella
spp
staphylococuss
aureu
subcultur
perform
selenit
broth
nutrient
broth
xld
agar
mannitol
salt
agar
msa
respect
plate
incub
c
overnight
gramstain
done
cruickshank
presumpt
gramneg
salmonella
isol
confirm
oxidas
api
test
gramposit
staphylococuss
aureu
isol
test
catalas
test
dnase
test
confirm
coagulas
test
isol
test
resist
variou
antibioticsm
bauer
result
qualit
winter
sampl
bacteri
load
insignific
accept
approach
state
spoilag
respect
contrarili
summer
collect
reveal
sampl
bacteri
load
insignific
accept
approach
spoilag
respect
level
spoilag
higher
summer
oppos
winter
quantit
salmonella
arizona
isol
winter
summer
respect
staphylococuss
aureu
isol
winter
summer
respect
multipl
antibiot
resist
mar
observ
salmonella
staphylococcu
isol
conclus
preced
background
conclud
chicken
free
bacteria
contamin
render
unhealthi
human
consumpt
proper
handl
preserv
measur
implement
n
saltoglu
tasova
midikli
inal
r
burgut
ndar
adana
tr
object
object
studi
determin
prognost
factor
relat
death
adult
tetanu
method
total
tetanu
patient
femal
male
admit
infecti
diseas
depart
cukurova
univers
hospit
januari
juli
investig
follow
day
surviv
analyt
techniqu
chisquar
test
need
fisher
exact
test
use
associ
mortal
categor
variabl
gender
incub
period
tetanu
type
etc
evalu
prognost
valu
score
scheme
trend
test
cochran
armitag
employ
addit
fatal
rate
among
tetanu
patient
examin
multivari
logist
regress
model
includ
variabl
incub
period
symptom
simultan
result
mean
age
year
patient
came
rural
area
case
minor
trauma
deep
injuri
mean
incub
period
day
mortal
high
due
cardiac
respiratori
failur
complic
mortal
relat
length
incub
period
case
incub
period
day
less
mortal
rate
p
mortal
significantli
associ
gener
tetanu
p
fever
c
tachycardia
beatsmin
p
postop
tetanu
p
absenc
posttraumat
tetanu
vaccin
p
patient
given
tetanu
human
immun
globulin
tetanu
antiserum
p
show
similar
outcom
patient
given
penicillin
similar
mortal
rate
patient
given
metronidazol
p
conclus
fatal
rate
higher
patient
sever
tetanu
patient
moder
diseas
binari
logist
model
reveal
exist
tachycardia
year
age
simultan
signific
prognost
risk
factor
relat
mortal
tetanu
patient
qualiti
life
tickborn
enceph
v
chmelik
p
petr
slamova
p
filipova
l
houserova
chrdle
h
kalova
cesk
budejovic
cz
object
south
bohemia
larges
natur
focu
tickborn
enceph
hereinaft
tbe
czech
republ
infecti
depart
cesk
budejovic
hospit
tbe
viru
frequent
proven
pathogen
neuroinfect
recent
year
hospitalis
annuali
patient
clinic
csf
serolog
proven
tbe
convalesc
period
patient
long
unpleas
object
studi
measur
qualiti
life
convalesc
period
method
diagnos
tbe
total
patient
children
adult
offer
fill
questionnair
mean
month
rang
month
discharg
repli
one
sent
fulli
complet
questionnair
total
patient
male
femal
age
ae
year
includ
analysi
patient
encephalit
cours
diseas
respond
often
compar
patient
mening
respond
encephalit
cours
tbe
respond
stratifi
sex
encephalit
vs
meningit
cours
diseas
result
compar
control
generalpopulationbas
oxford
sampl
result
tbe
patient
manifest
wors
result
p
next
segment
test
twosid
test
physic
function
role
limitationphys
role
limitationemot
social
function
pain
mental
health
gener
health
percept
vital
significantli
affect
women
compar
men
significantli
wors
result
p
physic
function
role
limitationphys
role
limitationemot
social
function
pain
mental
health
vital
differ
gener
health
percept
signific
postencephalit
patient
compar
mening
significantli
wors
result
conclus
tickborn
enceph
affect
patient
qualiti
life
month
qualiti
life
women
compar
men
significantli
affect
medic
outcom
trust
boston
usa
health
servic
research
unit
oxford
great
britain
czech
version
zdravotn
socialni
fakulta
jihoceska
univerzita
v
cbudejovicich
escherichia
coli
inocul
hamburg
bactericid
effect
short
time
exposur
escherichia
coli
inocul
beef
hamburg
studi
vitro
hamburg
made
minc
bovin
meat
weigh
g
contamin
e
coli
inoculum
concentr
cfug
subsequ
cook
domest
microwav
oven
sharp
mhz
hamburg
cook
viabl
count
select
media
perform
follow
standard
microbiolog
procedur
time
temperatur
reciproc
viabl
count
record
surviv
rate
assess
exposur
microwav
radiat
hamburg
look
well
cook
howev
e
coli
viabl
cell
recov
concentr
level
cfug
microwav
cook
mean
final
temperatur
c
mean
final
concentr
e
coli
viabl
cell
reduc
cfug
complet
destruct
e
coli
cell
accomplish
exposur
microwav
radiat
mean
final
temperatur
c
result
indic
short
time
exposur
microwav
heat
insuffici
complet
decontamin
beef
burger
potenti
contamin
e
coli
safeti
food
cook
fast
question
object
listeria
monocytogen
intracellular
ubiquit
organ
affect
patient
decreas
cellmedi
immun
elderli
transplant
recipi
cancer
patient
dialysi
patient
patient
diabet
mellitu
hiv
infect
women
particular
risk
pregnanc
cellmedi
immun
slightli
decreas
pregnanc
describ
case
listeriosi
occur
elderli
adult
bari
south
itali
method
strain
l
monocytogen
isol
accord
standard
protocol
variou
clinic
sampl
data
regard
serotyp
antibiot
resist
clinic
inform
analys
softwar
epiinfo
result
march
april
case
human
listeriosi
report
region
refer
centr
pathogen
enterobacteria
seven
strain
l
monocytogen
isol
blood
cultur
three
cerebrospin
fluid
cultur
fetomatern
infect
two
case
stillbirth
one
case
spontan
abort
septicaemia
adult
two
case
elderli
one
case
frequent
follow
central
nervou
system
infect
adult
four
case
seventi
per
cent
patient
present
current
condit
favour
trigger
diseas
predomin
serovar
b
frequent
follow
serovar
preval
antibiot
resist
lower
conclus
number
case
listeriosi
itali
grew
dramat
period
observ
period
also
franc
observ
epidem
cluster
case
notifi
region
refer
centr
pathogen
enterobacteria
april
activ
surveil
invas
listeriosi
carri
may
combin
increas
regulatori
activ
implement
haccp
programm
specif
reccomend
immunocompromis
host
pregnant
women
avoid
foodborn
listeriosi
object
microbiolog
survey
ltcf
perform
aim
determin
preval
pathogen
colonis
elderli
resid
method
total
ltcf
randomli
select
public
sanit
list
attic
provinc
urin
u
nasopharyng
n
wound
w
sampl
collect
resid
ltcf
chose
randomli
exist
elderli
popul
minimum
resid
cultur
suscept
test
carri
inform
collect
facil
resid
demograph
data
result
resid
mean
age
year
preval
resid
indwel
bladder
cathet
rang
mean
total
patient
receiv
system
antibiot
preced
month
lead
prescrib
antibiot
class
quinolon
cephalosporin
mean
preval
rate
recent
previou
day
hospitalis
poor
function
statu
usag
feed
tube
respect
total
specimen
u
n
w
collect
bacteria
isol
preval
rate
lead
isol
escherichia
coli
found
staphylococcu
aureu
proteu
mirabili
klebsiella
pneumonia
providencia
stuartii
morganella
morganii
pseudomona
aeruginosa
enterococci
speci
bacteria
found
gramneg
isol
account
gramposit
among
u
isol
enterobacteriacea
eb
predomin
n
pathogen
w
isol
frequent
aureu
respect
proteu
mirabili
respect
conclus
gramneg
bacteria
predomin
bacteri
flora
greek
ltcf
ii
high
rate
ns
colonis
gnb
aureu
import
must
consid
especi
case
respiratori
infect
iii
antibiot
usag
extrem
high
emphasi
must
laid
antimicrobi
use
manag
greek
ltcf
burkholderia
cepacia
qualiti
control
w
ebner
e
meyer
c
schulzhuotari
g
zilow
dettenkof
u
frank
freiburg
object
investig
microbiolog
detect
burkholderia
cepacia
blood
compon
qualiti
control
method
blood
compon
contamin
b
cepacia
found
microbiolog
qualiti
control
freiburg
univers
hospit
blood
bank
juli
record
procedur
employ
produc
blood
compon
analys
individu
step
qualiti
control
investig
one
entail
inocul
blood
cultur
bottl
sampl
blood
compon
disinfect
investig
includ
use
decontamin
rubber
stopper
belong
blood
cultur
bottl
result
burkholderia
cepacia
found
three
sampl
thrombocyt
erythrocyt
concentr
apheresi
plasma
investig
microbiolog
qualiti
control
septic
reaction
associ
transfus
report
patient
last
month
second
microbiolog
control
affect
blood
compon
neg
mistak
could
found
regard
process
storag
blood
compon
analysi
qualiti
control
procedur
reveal
disinfect
base
quaternari
ammonium
compound
qac
use
disinfect
rubber
stopper
blood
cultur
bottl
disinfect
prepar
concentr
tap
water
accord
manufactur
instruct
b
cepacia
found
sampl
taken
disinfect
four
isol
disinfect
blood
compon
found
ident
biochem
reaction
resist
pattern
genotyp
done
conclus
germani
leucocytedeplet
blood
compon
reduc
risk
cjk
transmiss
requir
law
sinc
octob
howev
increas
risk
bacteri
contamin
blood
product
case
prove
pseudocontamin
due
use
contamin
disinfect
qualiti
control
case
report
demonstr
ensur
qualit
valid
result
obtain
adher
high
standard
hygien
qualiti
control
procedur
import
alcoholbas
disinfect
use
disinfect
rubber
stopper
blood
cultur
bottl
qacbas
disinfect
efficaci
part
spectrum
gramneg
therefor
inadequ
introduct
alcoholbas
prepar
case
b
cepacia
contamin
found
proteolit
lipolit
activ
pseudomona
strain
isol
raw
milk
g
uraz
b
dadakoglu
z
ankara
tr
research
aim
determin
pseudomona
type
isol
raw
milk
indic
proteolyt
lipolyt
activ
accordingli
purpos
name
work
bacteria
isol
piec
raw
milk
collect
place
afterward
use
calcium
cazeinat
agar
cca
feed
place
proteolyt
tyrin
agar
tba
feed
place
lipolyt
activ
work
isol
made
isol
sampl
name
aeromona
hydrophila
pseudomona
six
yersinia
one
alcaligen
two
proteu
two
providencia
one
serratia
speci
name
per
cent
pseudomona
indic
pseudomona
aeruginosa
pseudomona
aurefacien
three
pseudomona
cepacia
four
pseudomona
mallei
pseudomona
pseudoalcaligen
five
pseudomona
pseudomallei
one
pseudomona
fluorescen
biovar
ii
iii
iv
v
pseudomona
stutzeri
one
pseudomona
picketii
two
vs
pseudomona
viridiflava
one
number
speci
indic
proteolyt
lipolyt
activitiy
pseudomona
aeroginosa
number
speci
proteolyt
lipolyt
activitiy
five
pseudomona
alcaligen
number
speci
proteolyt
lipolyt
activitiy
three
pseudomona
aurefacien
number
speci
proteolyt
activitiy
two
number
speci
lipolyt
activitiy
three
pseudomona
cepacia
number
speci
proteolyt
lipolyt
activitiy
one
pseudomona
mallei
number
speci
proteolyt
lipolyt
activitiy
five
pseudomona
pseudoalcaligen
number
speci
proteolyt
activitiy
one
pseudomona
putida
number
speci
proteolyt
lipolyt
activitiy
three
pseudomona
mendocina
number
speci
proteolyt
lipolyt
activitiy
one
pseudomona
pseudomallei
number
speci
proteolyt
activitiy
seven
number
speci
lipolyt
activitiy
eight
pseudomona
fluorescen
biovar
ii
iii
iv
v
number
speci
lipolyt
activitiy
one
pseudomona
stutzeri
number
speci
proteolyt
activitiy
one
number
speci
lipolyt
activitiy
two
pseudomona
picketii
number
speci
proteolyt
lipolyt
activitiy
one
pseudomona
viridiflava
endocard
due
enterococcu
faecali
risk
factor
outcom
case
nation
survey
noskovicova
v
hricak
v
krcmeri
bratislava
sk
object
investig
risk
factor
therapi
outcom
nativ
valv
endocard
due
enterococcu
faecali
e
faecali
slovak
republ
method
case
nativ
valveinfect
endocard
e
faecali
origin
prospect
evalu
use
protocol
submit
medic
depart
slovakia
case
prosthet
endocard
includ
major
minor
criteria
duke
endocard
servic
record
definit
endocard
definit
possibl
univari
analysi
risk
factor
outcom
compar
case
enterococc
endocard
case
endocard
nation
survey
result
among
case
caus
e
faecali
third
common
pathogen
staphylococcu
aureu
commonli
observ
risk
factor
rheumat
fever
eight
case
gastrointestin
neoplasia
gin
four
surgeri
five
diabet
three
case
dialysi
iv
drug
use
record
one
case
mitral
valv
infect
aortic
valv
pulmon
valv
one
patient
two
case
probabl
definit
endocard
case
variou
predispos
heart
condit
present
fever
emboli
immunolog
phenomena
major
two
minor
echocardiograph
find
patient
treat
appropri
mortal
attribut
e
faecali
endocard
isol
e
faecali
case
suscept
vancomycin
also
suscept
ampicillin
gentamicin
nine
patient
underw
valv
replac
surgeri
one
die
four
death
due
infect
heart
failur
cn
emboli
three
treat
inappropri
gin
p
age
year
p
relat
enterococc
endocard
conclus
two
risk
factor
gin
age
year
relat
e
faecali
endocard
ii
mortal
attribut
e
faecali
endocard
lower
studi
iii
good
suscept
ampicillin
gentamicin
also
differ
report
iv
high
suscept
antienterococc
antibiot
earli
surgic
therapi
pt
possibl
explan
good
outcom
case
e
faecali
endocard
describ
kap
sti
immigr
femal
sex
worker
northern
itali
method
prospect
studi
use
questionnair
administ
train
health
oper
fsw
work
street
questionnair
seven
compon
demograph
social
knowledg
sti
hiv
gynaecolog
obstetr
histori
sexual
histori
histori
prostitut
sexual
behaviour
access
public
health
servic
result
august
octob
fsw
answer
questionnair
thirti
africa
illeg
immigr
year
old
europ
sinc
year
less
thirtythre
declar
clientsnight
report
rape
rubberi
awar
hiv
infect
almost
unawar
chlamydia
trichomona
infect
thirtyon
never
done
hiv
test
paptest
never
done
proport
sexual
act
client
protect
condom
vagin
oral
anal
intercours
client
reportedli
request
sexual
intercours
without
condom
women
lubric
use
women
use
inappropri
substanc
previou
month
women
report
least
one
condom
ruptur
broken
slip
etc
time
condom
ruptur
perform
vagin
douch
urin
none
adopt
measur
prevent
pregnanc
sti
thirti
femal
steadi
boyfriend
use
condom
twentyeight
report
least
one
abort
one
almost
never
attend
public
health
servic
prostitut
would
attend
sti
servic
specif
devot
immigr
fsw
conclus
survey
suggest
immigr
fsw
limit
access
prevent
cur
health
servic
rare
hiv
test
expos
signific
infect
risk
due
condom
misus
ruptur
target
intervent
aim
chang
highrisk
behaviour
object
describ
epidemiolog
circumst
clinic
sign
associ
b
cereu
isol
state
pathogen
role
posttraumat
infect
propos
guidelin
treatment
prevent
method
conduct
retrospect
studi
base
b
cereu
isol
patient
orthopaed
traumatolog
unit
toulous
univers
hospit
southern
franc
patient
select
studi
present
clinic
sign
compat
joint
bone
softtissu
infect
includ
fever
local
inflamm
purul
discharg
wound
dehisc
necrosi
collect
data
type
accid
b
cereu
isol
local
sampl
taken
oper
room
wound
open
fractur
oper
site
result
sixtythre
patient
includ
studi
male
femal
averag
age
year
distribut
case
studi
period
homogen
patient
victim
accid
road
accid
industri
agricultur
accid
sport
accid
patient
open
fractur
almost
twothird
patient
present
fever
time
b
cereu
isol
none
present
sever
sepsi
cultur
polymicrobi
case
e
cloaca
frequent
associ
bacterium
isol
b
cereu
patient
three
receiv
antibiot
amoxiclav
aminoglycosid
strain
resist
penicillin
amoxiclav
cephalosporin
suscept
quinolon
aminoglycosid
macrolid
clindamycin
pristinamycin
imipenem
treatment
includ
fluoroquinolon
case
miscellan
vitro
activ
agent
case
heal
wound
obtain
case
seven
patient
two
treat
antibiot
amput
despit
aggress
surgic
treatment
object
aflatoxin
toxic
mold
metabolit
produc
toxigen
strain
aspergillu
speci
import
role
occurr
number
human
diseas
liver
cancer
chronic
hepat
cirrhosi
anim
eat
food
stuff
contain
aflatoxin
toxin
metabolit
excret
aflatoxin
milk
aflatoxin
resist
thermal
inactiv
destroy
complet
pasteuris
autoclav
varieti
food
process
procedur
aim
studi
determin
quantiti
aflatoxin
pasteuris
milk
sampl
shiraz
method
total
pasteuris
milk
sampl
differ
supermarket
shiraz
collect
month
aprilseptemb
centrifug
milk
sampl
upper
cream
layer
complet
remov
lower
phase
analys
enzym
immunoassay
quantit
analysi
aflatoxin
result
aflatoxin
found
milk
sampl
examin
sampl
higher
maximum
toler
limit
ppb
accept
european
union
compar
studi
turkish
milk
higher
contamin
p
brazil
find
albania
contamin
less
result
p
conclus
consequ
subject
seriou
problem
public
health
especi
infant
children
consum
product
therefor
milk
dairi
product
inspect
routin
aflatoxin
contamin
achiev
low
level
aflatoxin
milk
dairi
cow
feed
kept
away
fungal
contamin
much
possibl
fungal
contamin
chees
factori
iran
object
hygien
product
prevent
kind
contamin
one
import
principl
produc
chees
studi
carri
uf
chees
factori
tone
daili
product
follow
goal
rate
fungal
contamin
ii
type
fungal
contamin
iii
sourc
contamin
iv
suggest
effect
method
prevent
fungal
contamin
method
estim
preval
chees
contamin
ci
sampl
select
cultur
day
sampl
repeat
three
time
warm
cold
season
fungu
identifi
studi
characterist
coloni
stain
microscop
structur
determin
sourc
contamin
product
line
also
examin
follow
point
raw
milk
ii
milk
pass
second
bactofug
iii
milk
pass
pasteuris
iv
condens
pasteuris
milk
v
cultur
reservoir
result
plate
waxi
paper
aluminum
foil
addit
use
chees
product
examin
possibl
contamin
air
contamin
differ
part
factori
investig
precipit
filtrat
overal
rate
chees
fungal
contamin
three
period
respect
averag
preval
type
contamin
penicillium
spp
rate
follow
niger
cladosporium
fusarium
alternaria
paecilomyc
fungi
observ
case
raw
milk
factori
contamin
rate
reach
zero
pasteuris
rate
contamin
addit
follow
rennet
antifoam
antisept
thermophil
mesophil
salt
plate
paper
aluminum
foil
water
show
fungal
contamin
rate
respect
air
contamin
penicillium
spp
conclus
spite
multifactori
sourc
contamin
factori
air
import
factor
air
contamin
penicillium
spp
conclud
penicillium
spp
preval
type
chees
fungal
contamin
sinc
use
chemic
dairi
product
prohibit
suggest
utilis
physic
method
fit
orthokeratolog
contact
lens
mv
boost
p
cho
v
chui
hong
kong
hk
object
wear
contact
lens
overnight
report
significantli
increas
risk
ocular
infect
studi
aim
determin
normal
ocular
flora
overnight
orthokeratolog
orthok
patient
level
contamin
lens
len
case
accessori
correl
complianc
contamin
method
lower
conjunctiva
new
patient
swab
two
occas
cultur
normal
eye
flora
commenc
orthok
len
wear
six
followup
visit
specimen
collect
cultur
perform
swab
len
case
suction
holder
isol
fulli
identifi
patient
interview
len
care
fourth
followup
visit
patient
contamin
pseudomona
aeruginosa
consider
number
nonnorm
flora
organ
indic
break
complianc
warn
increas
risk
infect
import
good
len
care
reinforc
result
cultur
patient
len
use
yield
normal
eye
flora
yield
normal
flora
len
wear
staphylococcu
aureu
isol
two
patient
len
wear
one
len
wear
potenti
pathogen
isol
low
number
five
patient
one
occas
len
use
present
subsequ
sampl
consid
transient
investig
len
organ
yield
normal
flora
organ
subject
occas
tap
water
organ
occasion
isol
lens
two
patient
patient
one
isol
potenti
pathogen
four
patient
len
contamin
organ
contamin
len
case
suction
holder
seven
subject
contamin
three
organ
found
either
len
case
follow
interview
subject
judg
good
complianc
eight
patient
report
poor
complianc
contamin
len
accessori
one
occas
reeduc
improv
observ
conclus
use
orthok
lens
result
chang
level
content
normal
flora
failur
regularli
replac
len
case
disinfect
len
case
weekli
common
error
correl
presenc
potenti
ocular
pathogen
one
except
patient
report
good
complianc
minim
contamin
eye
lens
accessori
intervent
improv
complianc
elimin
contamin
confirm
need
reinforc
len
care
procedur
aim
studi
evalu
util
bartel
elisa
legionella
urinari
antigen
triniti
biotech
detect
legionella
water
sampl
comparison
convent
method
materi
method
sampl
atcc
strain
l
pneumophila
serogroup
l
pneumophila
serogroup
l
bozemanii
l
longbeacha
nine
wild
type
strain
use
spike
water
sampl
final
concentr
legionella
per
millilitr
lower
detect
limit
test
refer
strain
assess
serial
dilut
water
sampl
cfu
ml
sampl
b
addit
spike
water
sampl
differ
tap
water
sampl
run
sampl
treatment
one
litr
water
sampl
filter
mm
mcm
millipor
membran
filter
filter
place
test
tube
contain
ml
distil
water
afterward
sampl
sonic
min
cultur
identif
tap
water
sampl
cultur
heat
treatment
acid
treatment
select
bcyeagar
identif
isol
done
biochem
test
immunofluoresc
method
result
legionella
antigen
detect
filter
spike
sampl
except
l
bozemanii
l
longbeacha
water
sampl
spike
wild
strain
lpneumophila
solubl
antigen
detect
case
lower
detect
limit
detect
solubl
l
pneumophila
serogroup
antigen
cfuml
sonic
spike
water
sampl
increas
sensit
techniqu
tap
water
sampl
l
pneumophila
isol
cultur
water
sampl
test
bartel
elisa
posit
three
case
howev
could
rule
possibl
three
sampl
actual
true
posit
conclus
bartel
elisa
rapid
use
method
detect
l
pneumophila
water
sampl
ii
addit
bartel
elisa
capabl
detect
l
pneumophila
serogroup
iii
test
use
rapid
screen
method
detect
legionella
combin
cultur
anaerob
bacteraemia
still
rare
entiti
last
decad
describ
increasingli
adult
haematooncolog
neutropen
patient
fusobacterium
nucleatum
anaerob
gramneg
rod
part
normal
flora
mouth
intestin
tract
period
identifi
episod
bacteraemia
due
f
nucleatum
eight
patient
age
year
diagnosi
aml
md
children
febril
neutropen
granulocyt
cellsml
time
bloodcultur
got
posit
two
patient
undergon
bonemarrow
transplant
shortli
onset
bacteraemia
day
six
eight
children
mucos
possibl
sourc
bacteraemia
one
case
f
nucleatum
readili
grew
anaerob
cultur
one
case
growth
fail
f
nucleatum
identifi
rrna
pcr
follow
sequenc
analysi
directli
bloodcultur
bottl
patient
treat
either
ceftazidim
plu
metronidazol
meropenem
day
patient
recov
one
child
three
recurr
bacteraemia
due
f
nucleatum
endocard
rule
transthorac
echocardiographi
portacath
remov
anoth
persist
focu
abscess
infect
thrombu
found
suscept
data
avail
seven
isol
strain
suscept
metronidazol
amoxiclav
clindamycin
f
nucleatum
rare
caus
bacteraemia
neutropen
paediatr
patient
molecular
diagnost
method
help
identifi
strain
grow
convent
media
method
variou
clinic
sampl
blood
urin
faec
materi
respiratori
tract
materi
examin
isol
bacteri
strain
identifi
biomerieux
test
antibiot
suscept
examin
atb
test
biomerieux
disc
diffus
method
nccl
result
period
compar
total
number
isol
strain
blood
signific
chang
percentag
gramneg
gramposit
isol
blood
respect
notic
among
bacteri
strain
isol
materi
gramposit
gramneg
group
gramposit
strain
n
coagulaseneg
staphylococci
cn
streptococci
oral
enterococci
domin
respect
group
gramneg
strain
n
mainli
escherichia
coli
nonfer
rod
p
aeruginosa
exclud
klebsiella
enterobact
result
antibiot
suscept
follow
group
gramposit
bacteria
glycopeptideresist
strain
found
mr
methicillin
resist
staphylococcu
strain
among
cn
among
aureu
increas
antibiot
resist
gramneg
rod
especi
among
e
coli
amoxicillinclavulan
acid
p
aeruginosa
netilmicin
ceftazidim
nonfer
rod
ceftazidim
piperacillin
observ
gramneg
rod
highli
suscept
imipenem
meropenem
piperacillintazobactam
ciprofloxacin
ceftazidim
among
carbapenemresist
strain
mainli
nonfer
rod
p
aeruginosa
inclus
conclus
rise
trend
observ
number
gramneg
isol
blood
antibiot
resist
gramneg
rod
empir
therapi
piperacillin
tazobactam
plu
amikacin
children
cancer
treat
haematolog
clinic
seem
optim
option
monitor
antibiot
suscept
bacteri
strain
still
requir
evalu
incid
nosocomi
infect
ni
patient
haematolog
malign
suffer
sever
immunosuppress
gener
refer
data
method
surveil
nosocomi
bloodstream
infect
bsi
pneumonia
patient
undergo
bone
marrow
transplant
bmt
peripher
blood
stemcel
transplant
pbsct
multicentr
studi
start
within
framework
kiss
german
hospit
infect
surveil
system
allow
particip
limit
resourc
onkokiss
project
focus
bsi
pneumonia
neutropenia
use
cdc
definit
modifi
criteria
neutropen
patient
neutropenia
wbc
power
per
liter
result
first
period
patient
neutropen
day
investig
particip
hospit
undergon
allogen
autolog
bmt
pbsct
mean
length
neutropenia
day
total
bloodstream
infect
case
pneumonia
identifi
sitespecif
incid
densiti
pool
mean
bsi
case
pneumonia
per
neutropen
day
respect
main
pathogen
associ
bsi
coagulaseneg
staphylococci
follow
streptococci
conclus
surveil
ni
key
element
infect
control
especi
critic
ill
patient
undergo
bmt
pbsct
first
time
onkokiss
project
provid
refer
data
http
wwwnrzhygiened
thu
serv
improv
qualiti
care
provid
bmt
pbsct
patient
nocardiosi
trend
teach
hospit
studi
r
matulionyt
p
rohner
uckay
lew
k
bouchuiguiwaf
j
garbino
geneva
ch
background
nocardiosi
infrequ
sever
infect
especi
profoundli
immunocompromis
patient
howev
clinic
experi
remain
rather
limit
object
object
establish
trend
nocardia
infect
type
antibiot
treatment
outcom
patient
method
retrospect
chart
review
undertaken
hospitalis
patient
geneva
univers
hospit
patient
nocardia
sp
isol
includ
studi
result
nocardia
sp
obtain
patient
male
median
age
year
sixteen
patient
one
underli
condit
solid
organ
malign
patient
chronic
lung
diseas
hiv
diabet
mellitu
organ
transplant
immunosuppress
therapi
lymphopenia
other
median
time
symptom
onset
nocardiosi
diagnosi
day
rang
pulmonari
tuberculosi
tbc
common
initi
diagnosi
nocardiosi
site
infect
lung
case
central
nervou
system
cn
skin
dissemin
n
asteroid
complex
spp
isol
case
vitro
test
perform
strain
resist
detect
imipenem
amikacin
treatment
given
patient
consist
trimethoprimsulfamethoxazol
tmpsmx
case
imipenem
sulfadiazin
ciprofloxacin
improv
observ
patient
one
patient
relaps
one
patient
pulmonari
nocardiosi
complic
cn
involv
three
patient
die
one
treat
sinc
diagnosi
attribut
tbc
two
patient
treatment
start
day
onset
clinic
symptom
oral
tmpsmx
sulfadiazin
conclus
nocardiosi
sever
infect
mainli
affect
profoundli
immunocompromis
patient
differenti
diagnosi
especi
tbc
often
delay
time
diagnosi
worsen
outcom
effort
rapid
diagnost
techniqu
applic
pcr
made
tmtsmx
common
prescrib
treatment
howev
oral
form
suffici
effici
two
case
sever
infect
object
well
document
nonthyphoid
salmonella
nt
infect
occur
frequent
cancer
patient
howev
unclear
whether
due
increas
suscept
de
novo
exogen
salmonella
infect
due
cancer
chemotherapi
induc
reactiv
asymptomat
salmonella
stool
carriag
method
retrospect
analysi
swiss
tertiari
care
centr
medic
record
patient
posit
clinic
sampl
nonthyphoid
salmonella
nononcolog
patient
case
meet
criteria
reactiv
nt
see
exclud
medlin
search
languag
also
perform
identifi
potenti
case
casedefinit
reactiv
nt
patient
asymptomat
admiss
hospit
symptom
consist
salmonellosi
h
hospit
admiss
symptom
aris
antineoplast
chemotherapi
evid
nosocomi
acquisit
result
posit
specimen
nt
identifi
patient
five
specimen
cancer
patient
ill
compat
reactiv
diseas
follow
administr
chemotherapi
medlin
search
yield
four
case
met
criteria
nine
case
five
women
median
age
year
rang
year
five
patient
diarrhoea
one
salmonelluria
three
patient
literatur
bacteraemia
two
patient
asymptomat
stool
colonis
document
prior
reactiv
diseas
patient
success
treat
antibiot
even
chemotherapi
continu
eight
patient
salmonella
relaps
despit
addit
chemotherapi
cycl
five
patient
conclus
asymptomat
salmonella
carrier
malign
neoplasm
unawar
condit
may
develop
symptomat
salmonellosi
trigger
gastrointestin
mucos
damag
immunosuppress
associ
chemotherapi
current
guidelin
recommend
bacteri
stool
analysi
three
day
hospitalis
patient
year
age
signific
comorbid
hiv
infect
neutropenia
howev
reactiv
nt
occur
patient
year
old
absenc
neutropenia
stool
cultur
obtain
cancer
patient
signific
chemotherapi
associ
diarrhoea
even
hospitalis
day
background
pulmonari
infect
major
caus
morbid
mortal
transplant
organ
recipi
purpos
establish
risk
factor
mortal
solid
organ
transplant
recipi
new
onset
pulmonari
infiltr
pi
method
prospect
evalu
solid
organ
transplant
recipi
pi
februari
decemb
patient
underw
diagnost
protocol
includ
obtain
two
sampl
blood
cultur
spontan
induc
sputu
specimen
bronchoaspir
patient
mechan
ventil
sampl
blood
urin
antigen
test
case
diffus
bilater
pi
without
clinic
radiolog
improv
day
treatment
underw
invas
evalu
includ
fiberopt
bronchoscopi
protectedspecimen
brush
psb
bronchial
aspir
bronchoalveolar
lavag
bal
result
includ
patient
men
women
mean
age
ae
year
rang
type
transplant
kidney
kidney
pancrea
liver
cardiac
frequent
diagnos
bacteri
pneumonia
mrsa
pneumonia
case
p
aeruginosa
pneumonia
case
pulmonari
aspergillosi
case
associ
mrsa
cmv
pneumocysti
carinii
candida
albican
scedosporium
prolifican
stenotrophomona
maltophila
pulmonari
oedema
case
case
found
etiolog
diagnosi
mortal
patient
four
without
diagnosi
variabl
associ
great
risk
factor
mortal
mechan
ventil
rr
ci
p
fungal
infect
rr
ci
p
icu
admiss
rr
ci
p
conclus
presenc
pi
solid
organ
transplant
patient
associ
high
mortal
import
risk
factor
mortal
need
mechan
ventil
experi
bacteri
pneumonia
frequent
diagnosi
follow
pulmonari
aspergillosi
fogueda
p
oz
c
rodriguez
mj
dominguez
r
are
j
palomo
e
verd
e
bouza
madrid
e
background
bk
viru
bkv
polyomaviru
caus
emerg
infecti
diseas
particularli
troublesom
kidney
transplant
recipi
bkv
remain
latent
urinari
tract
gener
popul
may
reactiv
immunosuppress
bkv
viruria
preval
renal
allograft
recipi
bk
viremia
relat
nephropathi
graft
loss
renal
transplant
recipi
nevertheless
preval
viral
agent
solid
organ
transplant
group
sot
cardiac
liver
well
establish
object
determin
preval
bkv
infect
diseas
type
sot
recipi
centr
method
seventyseven
consecut
sot
recipi
studi
renal
cardiac
liver
transplant
recipi
sampl
obtain
mean
day
transplant
rang
day
presenc
bkvdna
initi
screen
nestedpcr
urin
plasma
pcr
perform
patient
posit
urin
pcr
preestablish
clinic
protocol
fulfil
day
sampl
obtain
transplant
procedur
immunosuppress
standard
result
polyomaviru
bk
found
urin
sampl
preval
viruria
renal
transplant
cardiac
transplant
liver
transplant
one
patient
bkv
viremia
renal
transplant
recipi
lost
first
kidney
transplant
due
bkvassoci
nephropathi
poor
renal
function
month
second
transplant
conclus
studi
confirm
urinari
shed
bk
viru
common
type
solid
organ
transplant
recipi
time
abl
find
bkv
diseas
kidney
transplant
recipi
relaps
earli
transplant
caus
loss
first
graft
studi
need
understand
natur
histori
primari
infect
reactiv
bk
viru
sot
relat
graft
function
introduct
despit
major
advanc
diagnosi
manag
pneumocysti
carinii
pneumonia
pcp
sever
complic
immunocompromis
patient
analys
outcom
patient
pcp
posit
bronchoalveolar
lavag
bal
patient
method
retrospect
analys
medic
record
patient
posit
bal
cultur
admit
tertiari
intens
care
depart
januari
septemb
demograph
clinic
microbiolog
data
collect
result
studi
period
patient
pcp
confirm
clinic
radiolog
microbiolog
data
five
patient
acquir
immunodefici
syndrom
sever
immunocompromis
state
twelv
patient
sever
respiratori
failur
pao
fio
ratio
mmhg
among
nine
receiv
invas
mechan
ventil
rest
patient
manag
noninvas
mechan
ventil
degre
sever
calcul
apach
ii
score
ae
length
stay
icu
day
three
patient
receiv
prophylact
antibiot
therapi
time
bal
perform
overal
mortal
rate
intub
patient
mortal
nonintub
patient
p
signific
differ
icu
inhospit
mortal
patient
pcp
associ
hiv
infect
compar
immunocompromis
state
vs
vs
respect
risk
factor
death
need
mechan
ventil
p
prophylact
antibiot
therapi
p
conclus
pcp
associ
high
mortal
rate
immunocompromis
patient
critic
ill
patient
requir
invas
mechan
ventil
prophylact
antibiotherapi
wors
outcom
method
evalu
retrospect
patient
treat
turku
univers
central
hospit
posit
result
pccpcrassay
balfluid
specimen
patient
identifi
microbiolog
registr
system
clinic
symptom
radiolog
sign
pulmonari
infect
result
diagnost
test
pcc
antimicrobi
chemotherapi
patient
outcom
analys
patient
stratifi
four
group
accord
confirm
diagnosi
pneumocysti
carinii
pneumonia
pcp
definit
probabl
possibl
nonprob
clinic
radiolog
find
respons
specif
pcp
therapi
use
stratif
result
altogeth
patient
bal
sampl
test
period
patient
least
one
posit
result
pcrassay
major
patient
immunocompromis
immunofluoresc
test
concomitantli
posit
pcr
patient
test
methenamin
silver
stain
mss
respect
eightythre
per
cent
patient
posit
test
patient
posit
mss
concomitantli
posit
pcrassay
patient
posit
pcrassay
triad
typic
symptom
pcp
dri
cough
short
breath
fever
bilater
interstiti
pulmonari
infiltr
diagnosi
pcp
consid
definit
probabl
patient
patient
posit
pcr
assay
patient
diagnosi
pcp
consid
nonprob
seventynin
per
cent
patient
posit
pcr
assay
patient
definit
probabl
diagnosi
pcp
receiv
appropri
antimicrobi
treatment
pcc
mortal
patient
definit
probabl
diagnosi
pcp
seventyf
per
cent
patient
whose
diagnosi
consid
nonprob
receiv
treatment
pcp
one
patient
die
invas
aspergillosi
conclus
posit
pccpcrassay
bal
specimen
correl
poorli
clinic
diseas
diagnost
method
pcrassay
use
supplementari
test
immununofluoresc
test
methenamin
silver
stain
object
bacteri
infect
seem
import
cirrhot
patient
varic
bleed
aim
studi
find
preval
bacteri
infect
cirrhot
admit
hospit
varic
bleed
comparison
patient
liver
cirrhosi
admit
reason
materi
method
bacteriolog
investig
urin
stool
throat
smear
haemocultur
ascit
investig
cirrhot
patient
admit
hospit
varic
bleed
cirrhot
admit
reason
result
differ
bacteriolog
find
patient
without
varic
bleed
bacteri
infect
significantli
frequent
cirrhot
patient
bleed
posit
patient
comparison
patient
without
bleed
posit
patient
bacteri
sepsi
frequent
group
patient
varic
bleed
patient
vs
group
patient
without
bleed
also
differ
bacteri
colonis
proxim
part
gastrointestin
tract
patient
bleed
colonis
gramneg
bacteria
patient
without
bleed
colonis
conclus
bacteri
infect
frequent
cirrhot
patient
admit
varic
bleed
comparison
patient
liver
cirrhosi
admit
reason
also
colonis
proxim
part
gastrointestin
tract
gramneg
bacteria
frequent
group
patient
bleed
sampl
patient
liver
cirrhosi
without
bleed
studi
support
grant
agenc
ministri
health
czech
republ
object
determin
risk
factor
evalu
microbiolog
spectrum
diabet
foot
infect
method
studi
consecut
diabet
patient
foot
ulcer
men
women
group
patient
match
sex
age
year
diabet
durat
year
two
diabet
casecontrol
without
foot
ulcer
group
b
patient
regularli
followedup
period
depart
mean
age
year
group
year
group
b
mean
durat
diabet
year
year
group
b
respect
two
group
compar
bodi
mass
index
bmi
mean
glycosyl
haemoglobin
concentr
serum
lipid
total
cholesterol
hdl
triglycerid
hypertens
smoke
pack
year
angiopathi
neuropathi
sampl
cultur
taken
ulcer
exclud
necrot
materi
result
mean
bmi
group
group
b
p
ns
group
patient
insulin
antidiabet
oral
agent
group
b
patient
insulin
antidiabet
agent
mean
glycosyl
haemoglobin
concentr
g
dl
group
gdl
p
mean
serum
cholesterol
level
mgdl
group
mean
hdl
level
mgdl
mgdl
group
b
mean
hdl
level
mg
dl
p
ns
mean
serum
triglycerid
mgdl
group
mgdl
group
b
p
ns
eightyseven
microorgan
isol
aerob
gramposit
gramneg
four
anaerob
common
pathogen
staph
aureu
methicillinsuscept
methicillinresist
proteu
sp
coagulaseneg
staphylococci
pseudomona
sp
mean
number
microorgan
per
patient
statist
signific
differ
aforement
risk
factor
identifi
among
patient
monomicrobi
polymicrobi
infect
rate
antimicrobi
resist
low
studi
group
includ
outpati
previous
treat
antibiot
conclus
poor
diabet
control
main
risk
factor
develop
diabet
foot
infect
diabet
foot
infect
polymicrobi
gramneg
isol
particularli
enterobacteriaca
predomin
studi
group
object
unusu
case
actinomyc
neuii
isol
foot
necrot
ulcer
diabet
end
stage
renal
diseas
esrd
patient
continu
ambulatori
periton
dialysi
capd
present
method
specimen
ulcer
surgic
debrid
cultur
day
admiss
onto
appropri
media
also
direct
smear
gram
stain
examin
identif
microorgan
perform
standard
method
api
coryn
biomerieux
suscept
test
perform
disc
diffus
method
etest
case
report
woman
esrd
came
hospit
fever
c
pain
oedemat
necrot
ulcer
small
finger
foot
suffer
also
diabet
complic
retinopathi
nephropathi
coronari
arteri
diseas
hypertens
generalis
peripher
arteriopathi
start
capd
year
ago
month
later
present
fungu
peritoni
admiss
treat
metronidazol
mg
iv
ciprofloxacin
mg
iv
togeth
surgic
debrid
wbc
count
blood
neutrophil
esr
mmh
abund
leucocyt
gram
small
rob
seen
direct
smear
gram
stain
neuii
ssp
neuii
isol
cultur
sampl
growth
better
anaerob
condit
strain
resist
cinolon
aminoglycosid
suscept
penicillin
g
cefaclor
cefotaxim
erythromycin
clindamycin
vancomycin
teicoplanin
hospitalis
antimicrobi
treatment
chang
clyndamicin
mg
iv
administ
day
worsen
local
inflamm
find
amput
small
finger
decid
concomit
teicoplanin
mg
iv
day
next
day
h
im
administr
followup
cultur
isol
neuii
conclus
neuii
unusu
caus
sever
ulcer
abscess
immunocompromis
diabet
patient
antibiot
treatment
seldom
success
without
surgic
clean
amput
coryneform
isol
identifi
either
grown
pure
cultur
coexist
microorgan
serum
peripher
blood
mononuclear
cell
infecti
burden
correl
inflamm
atherosclerosi
haemodialysi
patient
g
tsirpanli
chatzipanagiot
ioannidi
f
boufid
moutafi
lagourani
p
tseke
c
nicola
athen
gr
infecti
agent
may
implic
inflammatori
atherosclerot
process
specif
microorgan
also
infecti
burden
defin
number
pathogen
patient
expos
associ
atherosclerosi
studi
infecti
burden
determin
directli
identif
viabl
pathogen
peripher
blood
mononuclear
cell
pbmc
indirectli
serum
antibodi
detect
correl
inflammatori
atherosclerot
statu
haemodialysi
hd
patient
popul
high
risk
cardiovascular
diseas
viabl
form
four
microorgan
chlamydia
pneumonia
herp
viru
ii
cytomegaloviru
identifi
patient
pbmc
cell
cultur
subsequ
polymeras
chain
reaction
serum
igg
pathogen
helicobact
pylori
also
determin
inflamm
assess
creactiv
protein
crp
serum
amyloid
saa
three
pro
one
antiinflammatori
cytokin
four
adhes
molecul
measur
atherosclerosi
defin
score
system
use
medic
histori
data
number
viabl
pathogen
identifi
pbmc
hd
patient
includ
studi
one
two
three
one
patient
number
igg
antibodi
determin
one
patient
two
three
four
seroposit
nt
significantli
differ
patient
without
respect
viabl
pathogen
identifi
pbmc
atherosclerosi
present
patient
crp
saa
well
increas
patient
neither
inflammatori
index
atherosclerosi
significantli
differ
patient
higher
number
viabl
pathogen
detect
pbmc
higher
number
antibodi
direct
infecti
burden
determin
number
viabl
pathogen
pbmc
nt
coincid
serum
igg
detect
infecti
burden
although
inflamm
correl
atherosclerosi
neither
pbmc
serum
infecti
burden
associ
two
entiti
inflam
atherosclerot
hd
patient
k
j
pragu
cz
background
caus
kaposi
sarcoma
lymphoprolif
disord
immunodefici
individu
western
central
european
countri
seropreval
infect
low
increas
seropreval
occasion
occurr
kaposi
sarcoma
describ
solid
organ
transplant
recipi
aim
studi
evalu
risk
infect
haematopoiet
stem
cell
transplant
hsct
recipi
method
seropreval
retrospect
studi
adult
allogen
hsct
recipi
antibodi
lytic
antigen
detect
pretranspl
late
posttranspl
sera
use
indirect
immunofluoresc
test
nest
pcr
use
detect
presenc
viral
dna
consecut
peripher
blood
sampl
patient
seroconvers
transplant
result
seropreval
rate
transplant
respect
two
patient
seroposit
transplant
test
neg
antibodi
posttransplant
period
two
patient
show
seroconvers
hsc
transplant
exhibit
intermitt
presenc
viral
dna
peripher
blood
conclus
hsct
recipi
signific
risk
infect
allogen
hsct
recipi
may
lose
seroposit
transplant
activ
infect
posttransplant
period
two
hsct
recipi
associ
neither
high
viral
load
peripher
blood
signific
sign
clinic
ill
one
patient
reactiv
infect
associ
activ
cmv
infect
gvhd
acquir
shapiro
syndrom
recurr
hypothermia
due
human
herpesviru
stem
cell
transplant
l
arenilla
f
grau
smithson
r
palmero
rovira
barcelona
e
introduct
human
human
pathogen
emerg
clinic
signific
although
overt
clinic
diseas
infrequ
adult
reactiv
immunosuppress
describ
patient
develop
enceph
characteris
recurr
episod
hypothermia
associ
extrem
hyperhidrosi
cord
blood
stem
cell
transplant
clinic
featur
resembl
describ
shapiro
plum
patient
agenesia
corpu
callosum
usual
respond
treatment
clonidin
alfa
agonist
antivir
treatment
foscarnet
associ
clonidin
start
resolut
symptom
achiev
case
report
patient
man
receiv
cord
blood
stem
cell
transplant
treatment
philadelphia
chromosomeposit
acut
lymphoblast
leukaemia
condit
perform
cyclophosphamid
total
bodi
irradi
antithymocit
globulin
prophylaxi
graftversushost
diseas
consist
cyclosporin
prednison
prophylaxi
infect
carri
aerosolis
pentamidin
oral
acyclovir
unspecif
gamma
globulin
day
patient
develop
episod
hypothermia
profus
sweat
shiver
well
confus
abdomin
pain
routin
blood
analysi
reveal
abnorm
except
sever
hyponatremia
na
meql
hypoosmolar
high
cyclosporin
concentr
magnet
reson
brain
show
bilater
lesion
involv
amygdala
hippocampu
corpu
callosum
present
electroencephalogram
show
diffus
slow
wave
lumbar
punctur
demonstr
mononuclear
pleocytosi
cellsul
high
protein
level
mgdl
normal
glucos
level
mgdl
viral
studi
neg
except
dna
isol
cerebrospin
fluid
pcr
diagnosi
enceph
foscarnet
start
symptom
patient
similar
shapiro
syndrom
clonidin
ad
foscarnet
combin
therapi
initi
control
cerebrospin
fluid
dna
pcr
neg
remiss
symptom
observ
five
month
transplant
patient
die
autopsi
demonstr
presenc
infect
cell
hippocampu
object
cytomegaloviru
cmv
infect
seriou
complic
solidorgan
recipi
phosphotransferas
dna
polymeras
gene
mutat
confer
ganciclovir
gcv
resist
studi
document
case
dissemin
gcvresist
cmv
infect
heart
transplant
recipi
associ
risk
factor
viral
monitor
process
method
viral
load
retrospect
monitor
realtim
quantit
amplif
bp
viral
glycoprotein
b
gpb
gene
fragment
peripher
blood
extract
dna
use
lightcycl
instrument
roch
molecular
biochem
dna
quantif
perform
serial
dilut
plasmid
standard
pdrive
qiagen
pcr
clone
contain
primerspan
region
gpb
gene
plasmid
standard
dna
concentr
calibr
spectrophotometri
nm
cmv
antigenemia
prospect
perform
least
week
peripher
mononuclear
cell
extens
detect
fluoresc
monoclon
antibodi
biorad
differ
clinic
sampl
inocul
diploid
human
fibroblast
incub
week
co
enrich
atmospher
c
examin
twice
week
specif
cytopath
effect
phenotyp
genotyp
antivir
suscept
studi
perform
plaqu
reduct
assay
inocul
plaqu
increas
concentr
gcv
lm
respect
sequenc
gene
abi
prism
dna
sequenc
appli
biosystem
respect
result
higher
plasmat
viral
load
antigenemia
valu
correl
viral
syndrom
set
end
gcv
treatment
viral
load
antigenemia
becom
neg
foscarnet
treatment
implement
cmv
strain
isol
cell
cultur
blood
gastric
biopsi
sampl
viral
strain
present
mutat
gene
gcv
lm
creutzfeldtjakob
diseas
cjd
common
fatal
transmiss
neurodegen
diseas
import
group
human
prion
diseas
effect
therapi
avail
cjd
occur
sporad
caus
unknown
genet
cjdspecif
mutat
prion
gene
iatrogen
caus
transmiss
infecti
agent
contamin
tissu
instrument
first
iatrogen
cjd
report
caus
corneal
transplant
subsequ
experiment
studi
demonstr
infect
cornea
anim
inocul
cjd
agent
present
specif
method
definit
diagnosi
cjd
intra
vitam
therefor
asymptomat
carrier
cjdspecif
mutat
exclud
tissu
donat
slovakia
characteris
except
high
percentag
genet
cjd
patient
cjdspecif
mutat
genet
cjd
risk
group
repres
asymptomat
carrier
mutat
longterm
observ
carrier
found
develop
diseas
experi
well
increas
number
corneal
transplant
initi
introduct
prevent
genet
test
corneal
donor
test
start
april
sinc
donor
test
dna
isol
peripher
blood
mutat
polymorph
codon
prion
gene
indic
suscept
iatrogen
cjd
test
donor
sinc
donor
randomli
arisen
group
repres
gener
popul
result
polymorph
correl
data
normal
control
obtain
distribut
codon
polymorph
demonstr
major
donor
homozygot
either
methionin
valin
indic
high
suscept
cjd
data
agreement
preponder
heterozygot
report
previous
author
observ
us
obtain
significantli
smaller
test
group
present
result
suggest
urgent
need
reevalu
gener
accept
indic
genet
suscept
prion
diseas
concern
test
genet
cjd
risk
unexpectedli
two
dna
examin
posit
mutat
carrier
cjdspecif
mutat
present
rel
small
group
donor
justifi
prevent
measur
introduc
exclus
slovakia
object
polyomaviru
found
human
tumour
normal
tissu
bone
marrow
transplant
patient
polyomavirus
particularli
bkv
associ
postengraft
haemorrhag
cystiti
recent
coinfect
bkv
observ
kidney
transplant
adult
nephropathi
paediatr
patient
distinct
strain
occasion
detect
transplant
kidney
suggest
human
kidney
could
reservoir
polyomavirus
host
immunosuppress
may
favour
viral
replic
studi
aim
investig
presenc
children
underw
allogen
bmt
whether
infect
correl
clinic
event
method
period
patient
underw
allogen
bmt
paediatr
hospit
burlogarofolo
triest
dna
pbmc
urin
sediment
cell
supernat
analys
pcr
hcmv
av
bkv
jcv
dna
filter
hybridis
carri
sampl
direct
sequenc
done
two
patient
result
footprint
detect
blood
seven
patient
pcr
five
patient
infect
transient
unrel
clinic
relev
condit
contrari
two
patient
develop
sever
form
haemorrhag
cystiti
reveal
blood
urin
posit
found
start
onset
hc
frequent
followup
mean
time
day
direct
sequenc
tagnc
termin
regulatori
region
indic
two
virus
relat
archetyp
strain
conclus
studi
infect
found
seven
children
undergon
bmt
two
later
develop
sever
postengraft
hc
exclud
vertic
transmiss
contamin
transfus
stem
cell
blood
transfus
receiv
one
patient
past
invas
procedur
may
possibl
rout
infect
howev
explan
remain
mere
hypothet
sinc
epidemiolog
human
larg
unknown
conclus
studi
point
may
infect
children
suggest
possibl
role
addit
bkv
av
aetiolog
sever
hc
bmt
deserv
evalu
presenc
specif
antibodi
chlamydia
n
n
method
igm
igg
iga
antibodi
common
lp
antigen
chlamydia
detect
elisa
speciesspecif
antibodi
major
outer
membran
protein
momp
elementari
bodi
igm
igg
antibodi
detect
mif
find
antichlamydi
antibodi
sera
classifi
follow
categori
igg
anamnest
respons
igg
iga
suspect
chronic
infect
igm
igg
iga
igm
iga
suspect
reactiv
result
substanti
differ
ms
patient
healthi
control
found
antibodi
respons
detect
elisa
method
antibodi
momp
antigen
mainli
chlamydophila
pneumoniaespecif
find
antibodi
chlamydia
trachomati
chlamydia
psittaci
neglig
ms
patient
control
proport
anamnest
respons
momp
nearli
ident
ms
patient
control
hand
sign
chronic
infect
activ
found
ms
patient
none
control
subject
anamnest
antibodi
igg
detect
ms
patient
control
sign
activ
infect
found
ill
subject
healthi
control
csf
specif
antibodi
chlamydia
detect
elisa
mif
well
antibodi
found
rare
case
exceed
ms
control
subject
conclus
serolog
method
use
similar
proport
anamnest
antibodi
chlamydophila
pneumonia
found
ms
patient
healthi
control
sign
activ
chlamydi
infect
significantli
frequent
patient
analysi
result
lead
suggest
chlamydia
infect
probabl
play
import
role
trigger
autoimmun
process
ms
frequent
activ
may
result
immunosuppress
therapi
object
infect
remain
frequent
caus
morbid
mortal
neutropen
cancer
patient
examin
characterist
febril
neutropen
cancer
patient
predictor
treatment
success
tertiari
care
univers
hospit
turkey
januari
decemb
method
medic
chart
patient
analys
retrospect
febril
attack
categoris
microbiolog
clinic
document
infect
fever
unknown
origin
fuo
result
treatment
group
success
success
modif
treatmentfailur
particular
patient
experienc
one
febril
neutropen
attack
hospitalis
first
attack
includ
analysi
result
patient
male
mean
age
ae
year
underli
diseas
haematolog
malign
infect
clinic
document
cd
patient
microbiolog
document
md
aetiolog
fever
undetect
patient
multivari
logist
regress
analysi
vancomycin
use
signific
predictor
treatment
success
patient
fuo
like
success
outcom
compar
md
infect
result
indic
therapi
success
common
case
fuo
compar
cd
md
infect
indic
need
extens
care
latter
group
particularli
fever
resolv
day
success
rate
higher
patient
receiv
vancomycin
cours
treatment
compar
use
yet
find
justifi
empir
use
drug
sinc
patient
receiv
vancomycin
upon
document
gramposit
infect
backgroundobject
varieti
organ
isol
febril
neutropen
patient
fnp
warrant
empir
antimicrobi
therapi
broad
enough
cover
clinic
signific
gram
posit
neg
bacteria
adult
lowrisk
subset
patient
current
idsa
guidelin
includ
option
give
ciprofloxacin
c
amoxicillinclavulan
ac
jointli
sever
featur
fluoroquinolon
levofloxacin
l
make
attract
potenti
monotherapi
altern
combin
regimen
spectrum
encompass
implic
pathogen
serum
tissu
level
achiev
mg
dose
exceed
pd
target
bacteria
administ
oral
daili
extens
reassur
toler
safeti
profil
report
two
pilot
studi
use
l
manag
fnp
method
talcott
iv
outpati
randomis
receiv
c
mg
h
plu
ac
mg
po
h
follow
least
one
iv
dose
ceftriaxon
ctx
gm
amikacin
ak
mgkg
l
mg
po
qd
poster
present
icid
sever
ill
inpati
randomis
cefepim
cp
g
iv
h
l
mg
iv
qd
fever
defervesc
primari
endpoint
trial
secondari
endpoint
includ
safeti
toler
microbiolog
erad
result
outpati
studi
total
defervesc
ltreat
patient
n
compar
comparatortr
patient
n
clinic
cure
rate
post
therapi
inpati
studi
ltreat
patient
n
comparatortr
patient
n
advers
event
compar
arm
studi
none
consid
drugrel
conclus
limit
data
suggest
l
mg
ivpo
qd
may
offer
safe
effect
conveni
new
option
antimicrobi
manag
febril
neutropenia
sinc
fluoroquinolon
agent
cidal
concentrationdepend
manner
higher
dose
thought
possibl
capabl
retard
emerg
resist
recent
pd
studi
vitro
lend
experiment
support
hypothesi
give
one
reason
consid
higher
dose
l
set
febril
neutropenia
base
result
propos
addit
fullscal
studi
l
mg
qd
fnp
suggest
carri
regular
mainten
check
air
filter
ventil
unit
aircondit
system
togeth
introduct
code
conduct
hospit
personnel
design
reduc
product
dissemin
airborn
particl
within
area
reserv
treatment
immunodepress
patient
suffici
ensur
level
airborn
hyphomycet
fall
within
limit
propos
fundament
overhaul
ventil
system
would
seem
therefor
requir
along
wider
diffus
establish
code
conduct
among
hospit
personnel
latter
end
monitor
programm
also
set
assess
extent
hospit
staff
follow
recommend
procedur
conclus
observ
far
e
coli
pig
switzerland
e
coli
pig
cattl
poultri
germani
present
studi
first
identifi
human
isol
addit
show
gene
spread
among
human
anim
also
sweden
result
impli
possibl
spread
resist
element
pig
human
origin
preval
new
gene
import
investig
genet
context
might
provid
clue
emerg
new
resist
gene
old
antibiot
sulfonamid
method
sixteen
antibioticresist
salmonella
strain
recov
faec
travel
develop
area
presenc
class
integron
determin
pcr
specif
primer
amplifi
product
recov
sequenc
order
establish
gene
carri
sequenc
compar
present
genebank
analysi
plasmid
well
conjug
perform
integronborn
isol
addit
suscept
gentamicin
gentamicin
sisomicin
neomycin
dibekacin
kanamycin
tobramycin
amikacin
netilmicin
apramycin
dactimicin
spectinomycin
streptomycin
lividomycin
butyrosin
establish
isol
carri
aac
result
four
isol
present
least
one
class
integron
contain
antibioticresist
gene
three
strain
present
singl
integron
contain
aadb
plu
gene
plu
aac
ilik
plu
gene
remain
strain
carri
two
integron
contain
gene
respect
one
strain
carri
plasmid
posit
conjug
obtain
either
remain
isol
homolog
dna
amino
acid
sequenc
aac
ilik
enzym
aac
enzym
respect
antibioticsuscept
differ
aminoglycosid
strain
show
resist
decreas
suscept
gentamicin
gentamicin
dactimicin
sisomicin
accord
presenc
aac
resist
streptomycin
spectinomycin
also
shown
probabl
due
presenc
gene
conclus
high
frequenc
class
integron
detect
antibioticresist
salmonella
isol
caus
travel
diarrhoea
integron
present
high
variabl
resist
gene
mainli
associ
aminoglycosid
antibiot
line
novel
aac
encod
gene
carri
integron
identifi
et
al
gyras
mutat
observ
isol
gyra
gyrb
addit
qrdr
parc
mutat
twothird
isol
present
studi
search
addit
pare
mutat
isol
mutat
outsid
qrdr
isol
lack
qrdr
mutat
harbour
high
level
resist
ciprofloxacin
method
pcr
amplif
sequenc
qrdr
pare
appli
strain
isol
pitiesalpetrier
pari
three
strain
isol
tuni
suscept
ciprofloxacin
mic
mgl
strain
without
mutat
pare
qrdr
end
region
pare
gyrb
also
amplifi
sequenc
result
pare
mutat
observ
isol
either
qrdr
eight
strain
outsid
qrdr
two
strain
isol
share
gyra
mutat
mutat
qrdr
gyrb
qrdr
parc
ciprofloxacin
mic
mgl
three
strain
high
level
resist
ciprofloxacin
one
gyra
mutat
mutat
observ
pare
entir
gyrb
lead
hypothesi
anoth
addit
mechan
resist
multipl
efflux
pump
enhanc
conclus
pare
mutat
observ
p
aeruginosa
isol
high
level
ciprofloxacin
resist
mic
mgl
addit
gyras
mutat
gyra
gyrb
absenc
parc
mutat
p
aeruginosa
isol
least
two
topoisomeras
mutat
harbour
ciprofloxacin
mic
mgl
wherea
isol
ciprofloxacin
mic
mgl
harbour
one
gyra
mutat
method
isol
test
ctz
imp
mer
without
serineblactamas
inhibitor
brl
pump
inhibitor
reserpin
agar
dilut
betalactamas
activ
imipenem
meropenem
evalu
use
standard
spectroscop
techniqu
number
betalactamas
first
evalu
use
isoelectr
focus
ief
experi
pcr
reaction
undertaken
identifi
blactamas
gene
present
strain
omp
profil
strain
determin
protein
decreas
express
submit
ntermin
sequenc
four
suscept
isol
recov
medic
site
period
use
neg
control
result
isol
show
mic
mgl
ctz
mgl
imp
mgl
mer
signific
differ
mic
inhibitor
observ
ief
experi
show
isol
possess
two
four
differ
blactamas
result
cluster
isol
three
differ
group
accord
betalactamas
profil
isol
pi
ii
pi
iii
pi
one
strain
group
submit
pcr
custom
primer
blatem
blacmi
blactxm
blage
blakcp
blaimia
blaoxa
blashv
blactamas
gene
sequenc
analys
amplicon
confirm
presenc
gene
conclus
decreas
suscept
carbapenem
argentinean
acinetobact
spp
isol
due
decreas
express
porin
associ
hyperexpress
betalactamas
normal
low
affin
carbapenem
low
level
vitro
resist
carbapenem
may
jeopardis
treatment
infect
caus
pathogen
object
due
recent
advanc
genom
sequenc
project
metallobetalactamas
mbl
homologu
found
widespread
microbi
genom
also
present
higher
organ
protein
share
signific
structur
similar
mbl
defin
mbl
superfamili
exhibit
varieti
function
aryland
alkylsulfatas
cyclas
glyoxalas
etc
genom
novosphingobium
aromaticivoran
bacterium
present
notabl
biotechnolog
interest
abil
produc
glycosphingolipid
degrad
aromat
hydrocarbon
open
read
frame
orf
detect
encod
protein
share
ident
subclass
mbl
work
demonstr
actual
encod
mbl
investig
function
properti
enzym
name
method
n
aromaticivoran
smcc
grown
miner
medium
c
betalactamas
activ
assay
spectrophotometr
orf
clone
transcript
control
promot
express
vector
obtain
plasmid
recombin
plasmid
transform
escherichia
coli
evalu
betalactamas
product
result
crude
extract
n
aromaticivoran
prepar
cell
grown
liquid
medium
exhibit
hydrolyt
activ
imipenem
sp
act
nmolminmg
protein
inhibit
incub
presenc
mm
edta
orf
encod
put
protein
residu
clone
express
vector
express
orf
e
coli
led
product
edtainhibit
imipenemas
activ
sp
act
nmolminmg
protein
compar
subclass
enzym
exhibit
highest
ident
thinb
respect
notabl
longer
ntermin
domain
addit
residu
comparison
truncat
gene
start
altern
atg
codon
locat
bp
downstream
clone
vectorhost
system
yield
betalactamas
activ
enzym
subject
function
characteris
spain
microdilut
assay
nccl
guidelin
use
determin
mic
cefoxitin
fox
cefotaxim
ctx
ceftazidim
caz
cefepim
fep
cefpirom
cpm
alon
combin
fix
concentr
mgl
two
inhibitor
serin
betalactamas
brl
clavulan
acid
clv
isoelectr
point
pi
inhibit
profil
betalactamas
clv
cloxacillin
clx
determin
isoelectr
focus
hydrolysi
cephaloridin
cfl
determin
spectrophotometri
use
indic
ampc
product
mutat
promot
attenu
ampc
determin
direct
nucleotid
sequenc
pcr
product
gener
use
primer
specif
region
ampc
result
mic
mgl
cpm
affect
presenc
brl
mic
fox
ctx
fep
decreas
fox
ctx
fep
brl
contrast
mic
cephalosporin
reduc
clv
band
betalactamas
pi
inhibit
cloxacillin
clv
observ
hydrolysi
cfl
nmolesmg
protein
promot
ampc
show
five
point
mutat
posit
c
g
c
g
c
delet
nucleotid
posit
contain
dyad
symmetri
region
ampc
attenu
also
observ
evalu
mechan
decreas
suscept
cefepim
fep
clinic
isol
enterobact
aerogen
ea
method
three
consecut
isol
cultur
bronchial
aspir
patient
evalu
identif
perform
vitek
system
clonal
relationship
among
isol
determin
reppcr
mic
fep
cefotaxim
ctx
cefoxitin
fox
ceftazidim
caz
determin
microdilut
nccl
alon
andor
combin
mgl
clavulan
cv
brl
brl
gl
cloxacillin
cx
product
esbl
detect
disc
diffus
nccl
etest
ctctcv
czczcv
isoelectr
point
pi
inhibit
profil
betalactamas
bl
cv
cx
determin
isoelectr
focus
hydrolysi
cephaloridin
cf
fep
determin
spectrophotometri
presenc
temand
shvtype
esbl
gene
assess
pcr
amprampc
gene
sequenc
outer
membran
protein
omp
studi
sdspage
result
three
isol
show
ident
reppcr
pattern
three
isol
resist
mic
mgl
fox
ctx
caz
mic
fep
mic
ctx
fep
reduc
brl
cx
cv
affect
mic
ctx
fep
esbl
detect
amplif
temor
shvtype
gene
observ
three
isol
show
pattern
bl
pi
inhibit
cx
cv
hydrolysi
nmolesmg
cf
fp
sequenc
amprampc
gene
ident
e
aerogen
strain
deposit
genebank
access
howev
point
mutat
posit
ampc
caus
chang
val
glu
three
omp
kda
observ
three
isol
express
kdaomp
reduc
conclus
decreas
suscept
fep
relat
reduc
express
omp
kda
wherea
resist
fep
associ
hyperproduct
ampc
analysi
mutat
pbp
gene
penicillinnonsuscept
pneumococci
turkey
bicmen
z
gulay
izmir
tr
object
investig
alter
gene
caus
penicillin
resist
streptococcu
pneumonia
isol
turkey
method
pbp
sequenc
analysi
total
pneumonia
high
level
penr
low
level
peni
penicillin
resist
penicillin
suscept
isol
perform
use
abi
prism
big
dye
termin
cycl
sequenc
readi
reaction
kit
sequenc
compar
nucleotid
amino
acid
sequenc
pen
isol
peni
penr
strain
provid
genbank
use
clustal
x
program
ka
ks
kak
valu
transit
transvers
ratio
determin
mega
version
result
compar
sequenc
nucleotid
peptid
sequenc
penir
isol
contain
diverg
respect
phylogenet
tree
construct
accord
pbp
sequenc
seen
turkish
isol
cluster
togeth
high
bootstrap
valu
separ
branch
apart
genbank
sequenc
common
alter
sequenc
isol
mutat
activ
site
stmk
motif
block
also
detect
isol
mutat
found
sequenc
penir
isol
respect
isol
also
possess
svestk
block
aminoacid
instead
qlqpt
sequenc
analysi
gene
reveal
alter
stmk
motif
isol
three
isol
also
chang
locat
near
ksg
box
moreov
segment
nucleotid
diverg
homologu
show
similar
sequenc
miti
conclus
first
studi
analys
alter
pbp
sequenc
pneumococci
isol
turkey
report
previous
emerg
penicillin
resist
pneumonai
consequ
alter
three
major
pbp
object
sinc
suscept
pneumonia
telithromycin
tel
track
protekt
global
surveil
programm
strain
show
phenotyp
resist
tel
undergon
molecular
analysi
determin
underli
resist
mechan
method
pneumonia
isol
number
collect
three
consecut
respiratori
season
patient
communityacquir
respiratori
tract
infect
countri
tel
mic
determin
central
use
nccl
microbroth
dilut
method
interpret
use
nccl
breakpoint
resist
mgl
approv
nccl
sast
januari
multilocu
sequenc
type
pulsedfield
gel
electrophoresi
serotyp
perform
telresist
telr
isol
full
erm
b
gene
includ
promot
control
peptid
region
copi
rrna
gene
amplifi
sequenc
result
tel
show
potent
antipneumococc
activ
evid
increas
tel
mic
time
mode
mic
mgl
mgl
respect
year
among
erm
b
posit
strain
n
tel
mode
mgl
mgl
respect
telr
isol
identifi
two
year
two
year
six
year
mic
mgl
mic
mg
l
test
posit
erm
b
gene
neg
rrna
mutat
associ
mlsb
resist
five
telr
isol
basepair
chang
ta
ag
site
start
erm
b
three
telr
isol
basepair
delet
erm
b
promot
region
result
remov
site
fusion
remnant
control
peptid
erm
b
gene
result
format
new
protein
amino
acid
longer
control
express
erm
b
mutat
identifi
remain
two
telr
isol
evid
reproduc
clonal
spread
telr
isol
centr
conclus
tel
demonstr
potent
vitro
activ
pneumonia
shift
suscept
antibacteri
note
studi
period
resist
tel
rare
low
level
occur
evid
clonal
spread
mutat
describ
thought
result
increas
constitut
express
erm
b
gene
howev
possibl
yet
determin
apr
use
human
plasmidmedi
apramycin
resist
aprr
detect
human
isol
salmonella
klebsiella
escherichia
coli
aim
studi
assess
cost
carriag
aprr
plasmid
determin
transfer
frequenc
method
weekli
faecal
sampl
collect
month
birth
calv
treat
aminoglycosid
aprr
e
coli
select
tbx
agar
contain
mg
l
apr
mic
determin
follow
bsac
guidelin
plasmid
transfer
frequenc
measur
e
coli
strain
endpoint
method
ratio
transconjug
donor
growth
rate
plasmidcarri
plasmidfre
strain
measur
minim
media
mm
luria
broth
lb
serial
dilut
result
aprr
e
coli
found
six
calv
aprr
e
coli
crossresist
tobramycin
gentamicin
netilmicin
presenc
aprr
e
coli
unrel
calf
age
p
sampl
date
p
aprr
confer
three
conjug
plasmid
transfer
high
frequenc
approxim
td
ml
per
cell
also
carri
tetracyclin
streptomycin
resist
analysi
varianc
growth
rate
plasmidcarri
plasmidfre
e
coli
demonstr
signific
differ
growth
rate
either
mm
lb
measur
serial
dilut
p
ttest
reveal
growth
rate
differ
significantli
plasmidcarri
plasmidfre
e
coli
strain
grown
direct
competit
p
plasmid
segreg
discount
mixedeffect
model
chang
cell
number
time
reveal
signific
differ
recoveri
plasmidcarri
plasmidfre
cell
p
conclus
aprr
plasmid
high
transfer
frequenc
detect
commens
e
coli
despit
aminoglycosid
usag
presenc
aprr
plasmid
confer
crossresist
medic
import
drug
appar
lack
fit
cost
associ
carriag
pose
sever
implic
transmiss
resist
determin
clinic
bacteria
highlevel
gentamicin
resist
hlgr
well
recognis
enterococci
due
presenc
bifunct
enzym
aac
ieaph
ia
hand
highlevel
gentamicin
resist
bovi
report
object
studi
determin
preval
hlgr
blood
cultur
isol
bovi
year
investig
mechan
resist
isol
method
total
undupl
isol
bovi
collect
princ
wale
hospit
hong
kong
bovi
isol
identifi
speci
level
api
strept
system
antimicrobi
suscept
test
perform
standard
agar
dilut
method
accord
nccl
guidelin
standard
disc
diffus
test
use
gentamicin
mg
disc
also
perform
tabl
standard
disc
diffus
test
use
gentamicin
mg
disc
perform
seven
isol
zone
diamet
mm
among
isol
aac
ieaph
ia
gene
detect
seven
isol
exhibit
hlgr
isol
harbour
gene
conclus
first
report
highlevel
gentamicin
resist
bovi
rapid
emerg
hlgr
sinc
year
isol
hlgr
alarm
like
mechan
due
bifunct
enzym
aac
ieaph
ia
routin
screen
hlgr
recommend
clinic
signific
blood
cultur
isol
order
avoid
inadvert
use
short
cours
combin
therapi
penicillin
gentamicin
may
lead
treatment
failur
endocard
unnecessari
usag
gentamicin
drug
potenti
toxic
aim
work
characteris
metallo
blactamas
mbl
determin
present
gramneg
rod
belong
cdc
group
ii
b
isol
sputum
patient
haematolog
unit
hospit
ferrarotto
catania
itali
strain
grow
macconkey
agar
c
ureas
indol
oxidaseposit
abl
hydrolys
gelatin
resist
imipenem
meropenem
ceftazidim
suscept
piperacillintazobactam
diffus
dilut
suscept
test
method
mbl
product
test
spectrophotometr
method
genom
dna
analys
southern
blot
use
sever
metalloblactamas
probe
includ
pcr
experi
perform
ng
genom
dna
use
follow
primer
indfor
atgaaaaaaagaattcagttcttta
indrev
ttattttttgttaagaagttcaaga
amplicon
gener
pcr
directli
sequenc
strand
use
abi
prism
dna
sequenc
deduc
amino
acid
sequenc
protein
compar
natur
ind
blactamas
report
genbank
amplicon
clone
pgemt
easi
vector
blactamas
express
escherichia
coli
result
mbl
activ
detect
crude
extract
isol
southern
blot
assay
perform
sever
metalloblactamas
probe
reveal
strongest
hybridis
signal
probe
pcr
analysi
use
ind
primer
yield
amplicon
bp
encod
ind
variant
differ
amino
acid
residu
conclus
new
ind
mbl
variant
identifi
cdc
group
ii
b
clinic
isol
present
report
point
presenc
mbl
gene
clinic
isol
group
bacteria
mbl
product
mechan
carbapenem
resist
similar
isol
clinic
escherichia
coli
strain
portug
ferreira
e
ferreira
gemvsa
lisbon
p
object
part
antimicrobi
resist
surveil
program
evalu
preval
mechan
betalactam
resist
e
coli
portug
mainli
attribut
betalactamas
product
method
undupl
strain
number
urin
collect
consecut
hospit
three
public
health
laboratori
month
disc
diffus
select
amoxicillin
resist
amxr
strain
mic
amxr
e
coli
strain
determin
antibiot
agar
dilut
isoelectr
focus
use
characteris
betalactamas
extend
spectrum
betalactamas
esbl
select
synergi
clavulan
multiplexpcr
method
identifi
sequenc
result
among
e
coli
amxr
amxr
strain
suscept
imipenem
resist
amxclavulan
piperacillintazobactam
mecillinam
cefuroxim
cefotaxim
ceftriaxon
respect
resist
ceftazidim
aztreonam
amxr
strain
account
hospit
commun
acquir
infect
respect
detect
higher
preval
amxr
urinari
tract
infect
patient
icu
surgeri
outpati
fortysix
amxr
plu
cefoxitin
suscept
strain
show
synergi
cl
amxr
plu
cefoxitin
resist
strain
synergi
account
molecular
plu
phenotyp
method
show
betalactam
resist
e
coli
mainli
due
product
ampc
oxa
esbl
temderiv
irt
betalactamas
conclus
studi
show
high
preval
betalactam
resist
e
coli
strain
nosocomi
origin
portug
also
highlight
import
ration
use
famili
antibiot
need
continu
surveil
infect
control
programm
infect
caus
c
krusei
purportedli
increas
recent
year
inher
resist
agent
fluconazol
well
known
main
resist
mechan
fluconazol
diminish
sensit
target
enzym
cytochrom
sterol
ldemethylas
inhibit
azol
agent
accord
studi
use
limit
number
strain
altern
mechan
resist
could
base
activ
efflux
pump
aim
studi
know
possibl
contribut
efflux
pump
confer
resist
fluconazol
larg
studi
c
krusei
isol
method
obtain
c
krusei
strain
differ
sourc
urin
mucou
membran
genit
respiratori
cathet
steril
fluid
wound
atcc
strain
activ
efflux
pump
check
use
inhibitor
cccp
carbonyl
cyanid
could
decreas
minimum
inhibitori
concentr
mic
resist
correl
mechan
establish
concentr
mgml
cccp
verifi
kill
yeast
suscept
pattern
isol
six
antifung
drug
amphotericin
b
fluconazol
itraconazol
ketoconazol
flucytosin
voriconazol
determin
accord
nccl
protocol
modif
sensititr
yeast
one
test
strain
ad
cccp
rpmi
medium
result
rang
drug
ident
cccp
treatment
amphotericin
b
mgml
tabl
two
clinic
isol
imipenem
mic
declin
fold
respect
atcc
strain
show
declin
betalactam
affect
lesser
degre
fold
omp
analysi
reveal
overexpress
band
kd
two
clinic
isol
higher
mic
ertapenem
imipenem
sequenc
protein
progress
conclus
found
phenotyp
evid
efflux
mechan
affect
carbapenem
suscept
strain
imipenem
seem
affect
overexpress
kd
omp
organ
higher
ertapenem
mic
may
efflux
pump
streptococcu
pneumonia
finland
special
refer
telithromycin
resist
rantala
p
huovinen
j
jalava
finnish
studi
group
antimicrobi
resist
object
aim
studi
follow
develop
macrolid
resist
especi
telithromycin
resist
streptococcu
pneumonia
finland
investig
genet
mechan
macrolid
resist
materi
method
pneumonia
strain
number
collect
fire
laboratori
repres
whole
countri
strain
isol
noninvas
n
invas
n
infect
mininum
inhibitori
concentr
mic
macrolid
erythromycin
azithromycin
spiramycin
telithromycin
clindamycin
test
use
agar
plate
dilut
techniqu
presenc
resist
gene
mef
e
erm
b
erm
tr
test
multiplexpcr
method
strain
erythromycin
mic
equal
higher
mcgml
result
pneumococc
strain
n
resist
erythromycin
r
mic
equal
higher
mcg
ml
five
strain
intermedi
suscept
resist
azithromycin
clindamycin
seven
per
cent
pneumococci
n
reduc
suscept
telithromycin
mic
equal
higher
mcgml
genotyp
test
strain
mef
ae
common
genotyp
strain
posit
n
strain
harbour
erm
b
gene
n
erm
tr
found
one
strain
doubl
mechan
mef
ae
erm
b
detect
strain
pcr
result
neg
test
strain
n
strain
reduc
suscept
telithromycin
also
resist
mechan
genom
mef
ae
n
erm
b
n
doublemechan
n
conclus
resist
macrolidelincosamid
widespread
increas
among
pneumococci
finland
macrolid
resist
pneumococci
mef
ae
seem
still
common
mechan
finland
although
erm
b
also
frequent
present
interest
find
unexpectedli
high
proport
pneumococci
reduc
suscept
telithromycin
escherichia
coli
background
bacteri
resist
antibiot
biocid
preval
problem
may
exacerb
commonplac
often
unnecessari
inclus
biocid
domest
product
object
studi
investig
potenti
adapt
resist
escherichia
coli
commonli
employ
antibacteri
agent
order
identifi
mechan
underli
resist
obtain
method
e
coli
strain
serial
expos
subinhibitori
concentr
erythromycin
eri
benzalkonium
chlorid
bkc
chlorohexidin
chx
triclosan
tln
follow
passag
mic
antibacteri
adapt
resist
record
adapt
resist
readili
promot
follow
two
subinhibitori
exposur
permeabl
chang
outer
membran
includ
lp
cell
surfac
charg
hydrophob
presenc
activ
efflux
investig
possibl
resist
strategi
outer
membran
lp
profil
analys
sdspage
visualis
coomassi
blue
silver
stain
respect
cell
surfac
charg
hydrophob
investig
employ
microelectrophoresi
microbi
adhes
hydrocarbon
math
assay
efflux
activ
examin
compar
level
resist
preand
postadapt
strain
presenc
efflux
inhibitor
reserpin
addit
fabi
gene
pre
postadapt
sequenc
compar
order
investig
presenc
possibl
mutat
confer
increas
resist
result
examin
outer
membran
lp
reveal
signific
chang
preand
postadapt
strain
correl
cell
surfac
charg
hydrophob
howev
hydrophob
cell
increas
cell
passag
becam
adapt
resist
esbl
produc
bacteria
compris
one
seriou
resist
problem
hospit
especi
nosocomi
infect
new
esbl
emerg
rapidli
overus
antibiot
new
shvderiv
extendedspectrum
betalactamas
temporarili
design
confer
highlevel
resist
ceftazidim
cefotaxim
identifi
islandwid
surveil
escherichia
coli
tsari
resist
ampicillin
cephalothin
cephaloridin
cefpodoxim
ceftazidim
sensit
cefoxitin
ceftriaxon
cefotaxim
imipenem
firstgener
cephem
cefazolin
isol
urin
patient
treat
betalactam
antibiot
resist
betalactam
transfer
conjug
e
coli
tsari
e
coli
transfer
plasmid
kbp
pi
enzym
ceftazidim
resist
gene
clone
transfer
plasmid
sequenc
gene
determin
open
read
frame
gene
found
consist
base
genbank
access
number
comparison
shv
betalactamas
suggest
substitut
arginin
import
substrat
specif
characteris
enzym
molecular
biolog
enzymolog
method
provid
us
inform
extens
substrat
specif
threedimension
model
enzym
provid
critic
inform
model
develop
new
antibiot
futur
major
symptom
product
cough
vespertin
fever
radiolog
imag
pulmonari
tuberculosi
extens
rel
examin
cultur
verifi
patient
lowensteinjensen
media
posit
sensibl
mbbact
system
sensibl
elev
p
detect
time
mbbact
system
ae
day
lj
media
ae
day
p
conclus
mbbact
system
higher
recoveri
rate
lower
detect
time
lowensteinjensen
media
could
appli
routin
method
detect
tuberculosi
mycobacterium
tuberculosi
mycobacteri
speci
use
cultur
supplement
szpinda
olsen
tonjum
oslo
n
object
rapid
detect
growth
mycobacteri
speci
suscept
test
liquid
media
greatli
reduc
time
overal
process
cultureposit
sampl
complet
procedur
also
reduc
effort
invest
cultur
neg
sampl
detect
minim
growth
earli
stage
combin
use
nucleic
acidbas
test
mycobacteri
speci
identif
drug
suscept
marker
provid
uniqu
opportun
rapid
diagnost
howev
time
requir
growth
less
optim
media
still
limit
factor
perform
cultur
system
aim
improv
sensit
reduc
time
detect
mycobacteria
clinic
specimen
method
clinic
sampl
investig
presenc
mycobacteria
cultiv
cultur
system
bactec
mgit
system
employ
middlebrook
medium
fluoresc
indic
growth
detect
sampl
cultiv
regular
bbltm
middlebrook
medium
without
addit
cultur
supplement
among
cultur
supplement
ad
bovin
serum
albumin
hemin
greek
woman
present
gradual
increas
swell
left
pg
month
durat
otherwis
well
given
sever
cours
differ
antibiot
underw
evacu
punctur
improv
two
discharg
sinus
overli
skin
reddish
normal
temperatur
left
cervic
lymphadenopathi
present
laboratori
investig
show
mild
lymphocytopenia
tuberculin
test
weal
mm
stain
acidfast
bacilli
afb
cultur
discharg
neg
chest
radiograph
normal
contrast
enhanc
ct
show
enlarg
left
pg
fill
defect
mass
extend
parapharyng
region
histopatholog
examin
reveal
florid
granulomat
process
area
necrosi
stain
afb
neg
tissu
cultur
mycobacteria
paraffin
section
pcr
posit
mycobacterium
tuberculosi
complex
tb
parot
diagnos
afterward
threedrug
antitubercul
regimen
start
third
month
therapi
show
progress
improv
discuss
tb
parot
usual
suspect
possibl
caus
parotid
tumour
may
clinic
clue
import
clinician
opportun
review
case
suspicion
tuberculosi
aris
opportun
provid
pcr
rapid
within
hour
sensit
techniqu
detect
mycobacteri
dna
formalinfix
paraffinembed
tissu
store
even
year
recent
year
cutan
tuberculosi
ctb
atyp
clinic
appear
becom
common
develop
countri
often
confus
granulomat
dermatosi
diagnosi
ctb
remain
troublesom
difficulti
detect
mycobacteria
skin
lesion
convent
laboratori
method
lupu
vulgari
lv
commonest
form
ctb
affect
earlob
well
part
bodi
articl
present
male
patient
lv
left
earlob
initi
period
pyodermia
misdiagnosi
patient
treat
superflu
antibiot
four
year
elsewher
definit
diagnosi
diseas
confirm
polymeras
chain
reaction
pcr
mycobacteria
could
seen
isol
stain
smear
convent
radiometr
cultur
method
skin
biopsi
specimen
lesion
treat
success
antitubercul
chemotherapi
atbc
pcr
reliabl
rapid
method
establish
confirm
diagnosi
ctb
seen
patient
object
tradit
recommend
incub
time
specimen
submit
mycobacteriolog
laboratori
eight
week
today
introduct
liquid
media
laboratori
routin
time
detect
mycobacteria
could
reduc
aim
studi
analys
reduct
incub
time
week
evalu
impact
number
mycobacteria
recov
method
studi
mycobacteria
strain
isol
period
specimen
decontamin
standard
procedur
inocul
onto
liquid
media
mgit
solid
media
lowensteinjensen
pyruv
ljp
incub
time
mgit
ljp
week
week
respect
growth
rate
onefold
hour
mgit
onefold
week
ljp
result
studi
period
recov
mycobacteria
mycobacterium
tuberculosi
complex
mtb
mycobacterium
avium
complex
mac
nontubercul
mycobacteria
ntm
recov
ljp
day
although
also
grew
mgit
incub
time
day
therefor
strain
grew
ljp
day
mycobacteria
group
follow
mac
mtb
ntm
review
total
specimen
patient
mycobacteria
case
mycobacteria
isol
specimen
result
diagnosi
could
made
patient
realtim
assay
amplifi
region
mycobacteri
rdna
use
primer
bind
site
conserv
member
tuberculosi
complex
gener
specif
amplicon
detect
duallabel
fluorogen
probe
addit
realtim
assay
contain
second
heterolog
pcr
system
detect
socal
intern
control
use
control
dna
purif
procedur
well
exist
possibl
pcr
inhibitor
assess
usabl
realtim
assay
clinic
diagnost
tuberculosi
cultur
posit
cultur
neg
sputum
sampl
examin
result
realtim
pcr
assay
detect
member
tuberculosi
complex
analyt
sensit
bacteri
genom
per
pcr
specif
high
sinc
neither
atyp
mycobacteria
sever
bacteria
test
gener
signal
abi
prism
sd
instrument
examin
sputum
sampl
show
realtim
pcr
assay
exhibit
specif
sensit
smear
posit
smear
neg
sampl
compar
result
cultur
one
per
cent
sampl
show
inhibit
conclus
describ
realtim
assay
sensit
highli
specif
tool
detect
member
tuberculosi
complex
integr
intern
control
allow
exclus
fals
neg
result
due
purif
loss
inhibit
pcr
mycobacterium
tuberculosi
purifi
protein
peptid
current
evalu
antigen
immun
diagnosi
tb
set
elispot
assay
ifngamma
whose
novelti
consist
two
multiepitop
peptid
protein
select
comput
analysi
allow
discrimin
latent
activ
tb
monitor
efficaci
antitb
therapi
vincenti
et
al
mol
med
carrara
et
al
clin
infec
di
press
import
find
new
strategi
increas
sensit
diagnost
assay
thu
object
studi
assess
perform
assay
base
elispot
technic
assay
use
immunolog
laboratori
elisa
cell
cultur
supernat
elisa
plasma
whole
blood
cultur
prolifer
assay
evalu
thymidin
incorpor
intracellular
cytokin
stain
evalu
fac
pbmc
whole
blood
patient
activ
tb
microbiolog
confirm
posit
cultur
biolog
fluid
andor
pcr
biopsi
specimen
seed
presenc
absenc
protein
select
peptid
ppd
recal
antigen
mitogen
control
result
obtain
within
one
day
elisa
plasma
fac
analysi
within
day
elispot
day
prolifer
assay
elisa
cell
supernat
found
sensit
elispot
assay
significantli
higher
compar
prolifer
assay
p
elisa
cell
cultur
supernat
fac
analysi
although
statist
signific
howev
similar
sensit
found
result
obtain
elispot
assay
elisa
plasma
whole
blood
cultur
hand
fac
analysi
allow
identif
singl
cell
involv
mycobacterium
tuberculosisspecif
respons
conclus
immunediagnost
assay
base
respons
select
peptid
obtain
elispot
elisa
perform
plasma
whole
blood
compar
wherea
suboptim
sensit
found
prolifer
assay
fac
analysi
elisa
cell
cultur
supernat
formalinfix
clinic
specimen
cultur
mycobacterium
spp
imposs
pcr
provid
rapid
sensit
altern
diagnost
method
detect
mycobacterium
tuberculosi
nontubercul
mycobacteria
clinic
sampl
evalu
use
rrna
pcr
combin
revers
line
blot
retrospect
detect
non
tubercul
mycobacteria
lymph
node
biopsi
granuloma
found
microscop
accord
nationwid
patholog
anatom
autom
archiv
palga
pcr
result
compar
previou
clinic
cultur
avail
mycobacteri
dna
shown
materi
tuberculosi
found
seven
time
sampl
contain
fortuitum
time
avium
respect
clinic
cultur
two
patient
show
tuberculosi
three
sampl
contain
mycobacteri
dna
show
reactiv
genu
probe
one
specif
speci
probe
determin
sequenc
analysi
conclud
although
sensit
lower
rrna
pcr
also
applic
retrospect
detect
mycobacterium
spp
formalinfix
paraffinembed
archiv
specimen
lymph
node
biopsi
analys
includ
variou
strain
could
determin
previous
rrna
gene
sequenc
compar
public
ridom
databas
mycobacteria
avail
internet
result
sequenc
analysi
excel
match
revers
line
blot
biochem
method
cross
reactiv
revers
line
blot
could
explain
probe
strain
sequenc
homolog
one
strain
previous
consid
tuberculosi
mistak
correctli
identifi
mycobacterium
holsaticum
conclud
sequenc
analysi
mycobacteria
reliabl
techniqu
applic
routin
use
laboratori
hcw
work
hospit
invit
particip
studi
logist
regress
perform
multivari
analysi
result
particip
twostep
tst
posit
fifti
hcw
tst
neg
third
tst
tst
convers
rate
mean
age
convers
detect
hcw
femal
univari
analysi
number
bcg
scar
work
intern
medicin
followup
tb
patient
within
last
year
age
year
found
significantli
associ
outcom
p
tst
convers
rate
higher
among
hcw
work
durat
year
p
annual
incom
p
although
statist
signific
howev
convers
rate
associ
public
transport
hospit
p
entertain
crowd
set
hospit
p
none
subject
histori
tb
famili
none
tst
convert
subject
histori
contact
tb
patient
outsid
hospit
none
bcg
vaccin
within
year
multivari
analysi
hcw
follow
tb
patient
last
year
found
higher
risk
tst
convers
ci
p
although
hcw
declar
compli
protect
measur
everi
extra
bcg
vaccin
detect
physic
examin
five
time
increas
tst
convers
rate
detect
ci
p
tst
convert
hcw
screen
chest
xray
chest
xray
one
hcw
cavit
detect
computeris
tomographi
support
diagnosi
acidfast
bacteria
sputum
investig
three
time
bacteria
detect
sampl
treat
month
object
mycobacterium
kansasii
mk
identifi
agent
diseas
worldwid
howev
incid
vari
significantli
area
area
nowaday
avail
data
mk
infect
spain
object
studi
establish
frequenc
geograph
distribut
mk
infect
spain
studi
relationship
sever
demograph
characterist
know
distribut
differ
subtyp
mk
isol
spain
method
retrospect
year
prospect
year
surveil
patient
infect
mk
autonom
commun
spain
carri
case
mk
infect
identifi
microbiolog
laboratori
refer
hospit
gemka
demograph
clinic
microbiolog
data
record
standardis
questionnair
clinic
signific
isol
ascertain
accord
american
thorac
societi
criteria
genet
characteris
subspeci
level
mk
isol
one
per
patient
perform
pcrrflp
analysi
gene
result
total
case
identifi
studi
period
autonom
commun
euskadi
n
catalunya
n
madrid
n
n
n
valencia
n
asturia
n
n
navarra
n
n
n
canaria
n
cantabria
n
galicia
n
extremadura
n
murcia
n
castillala
mancha
n
mean
age
year
male
hivinfect
patient
younger
noninfect
one
mean
age
vs
year
p
clinic
mk
diseas
detect
hivinfect
noninfect
patient
respect
pulmonari
involv
observ
case
seventyfour
mk
isol
analys
differ
geograph
area
subtyp
conclus
mk
pathogen
frequent
mycobacteria
isol
sever
geograph
region
spain
especi
dens
popul
area
subtyp
seem
frequent
subtyp
isol
man
present
abdomin
pain
diarrhoea
dysphonia
disphagia
weight
loss
symptom
colonoscop
find
inflammatori
bowel
diseas
refer
clinic
infect
crohn
diseas
furthermor
given
medic
treatment
accord
diagnosi
consist
corticosteroid
plan
investig
tuberculosi
patient
whose
complaint
increas
despit
steroid
therapi
diagnosi
colonoscopi
perform
first
multipl
ulcer
seen
cecum
transvers
colon
ascend
colon
ileocec
valv
infiltr
regard
diffus
involv
crohn
diseas
upper
gi
endoscopi
perform
order
see
oral
caviti
oesophagu
stomach
duodenum
result
oesophagu
found
normal
edema
epiglott
area
pangastr
observ
colon
biopsi
indic
granuloma
posit
acidfast
bacilli
acidfast
bacilli
also
posit
sputum
addit
chest
xray
thorax
ct
show
bilater
infiltr
pulmonari
apic
pcr
test
mycobacterium
tuberculosi
posit
biopsi
sputum
stool
accord
diagnosi
dissemin
tuberculosi
antitubercul
therapi
inh
rifampin
pyrazinamid
streptomycin
start
good
respons
observ
end
two
week
later
diagnosi
absolut
confirm
cultur
tuberculosi
ad
differenti
diagnosi
patient
suspect
crohn
diseas
particularli
start
immunosuppress
therapi
object
current
guidelin
recommend
screen
blood
unit
larg
number
pathogen
exclus
nontreponem
bacteri
mycobacteri
organ
base
assumpt
bacteri
infect
healthi
donor
unlik
asymptomat
present
studi
describ
identif
mucogenicum
contamin
blood
unit
immunocompromis
patient
method
sampl
blood
unit
incub
upon
detect
bacteri
growth
posit
sampl
inocul
blood
agar
dna
extract
bacteri
coloni
fragment
encompass
gene
pcramplifi
subsequ
digest
bsteii
haeiii
endonucleas
bacteri
dna
also
pcramplifi
use
primer
pair
specif
conserv
region
rrna
nucleotid
sequenc
result
amplicon
establish
analys
use
blast
softwar
result
femal
patient
acut
myelogen
leukaemia
develop
sever
rigor
follow
transfus
blood
unit
cultur
obtain
blood
unit
grew
gramposit
weakli
acid
fast
rod
identifi
base
morpholog
criteria
nocardia
sp
howev
pcrrflp
analysi
reveal
restrict
pattern
compat
atyp
mycobacteria
ident
contamin
ultim
establish
mucogenicum
base
blast
analysi
bacteri
rrna
sequenc
conclus
mycobacteria
capac
grow
regular
blood
agar
instead
tradit
eggbas
agar
fact
recent
demonstr
experiment
jcm
may
lead
misidentif
grow
pathogen
accordingli
mycobacterium
speci
isol
present
studi
initi
categoris
nocardia
sp
recognis
mucogenicum
follow
molecular
type
present
case
suggest
need
assess
valu
largescal
routin
screen
blood
product
bacteri
mycobacteri
contamin
especi
transfus
immunocompromis
patient
hospit
archiv
survey
retrospect
case
mening
classifi
tubercul
year
studi
data
collect
regard
histori
clinic
laboratori
radiolog
find
therapi
outcom
result
fiftyeight
case
identifi
male
femal
year
old
mean
age
xsd
year
twentyfour
patient
admit
stage
stage
ii
stage
iii
symptom
appear
median
day
admiss
diagnosi
patient
definit
mycobacterium
tuberculosi
cultur
csf
rest
patient
fulfil
follow
criteria
diagnosi
tubercul
mening
long
period
symptom
admiss
high
csf
protein
level
low
csf
glucos
level
favour
respons
antitubercul
therapi
durat
hospitalis
day
csf
find
admiss
xsd
cell
mm
protein
mgdl
csf
glucoseblood
glucos
mgdl
lactat
mgdl
mortal
rate
patient
perman
sequela
ct
mri
patient
show
patient
hydrocephalu
five
mening
enhanc
three
infarct
two
tb
spondyl
one
intradur
tuberculoma
spinal
cord
two
brain
tuberculoma
patient
normal
imag
morbid
mortal
rate
higher
patient
year
old
patient
admit
stage
ii
iii
patient
year
old
admit
frequent
late
stage
younger
one
conclus
tubercul
mening
still
remain
seriou
diseas
high
incid
mortal
morbid
especi
among
elder
peopl
late
stage
concern
extrapulmonari
bodi
site
particular
pleural
fluid
urin
blood
bone
marrow
smaller
number
ascet
fluid
cerebrospin
fluid
pericardi
periton
fluid
pu
biopsi
lymph
node
skin
tissu
specimen
process
nalcnaoh
method
recommend
cdc
stain
cultur
parallel
wensteinjensen
medium
autom
bactec
mgit
system
radiometr
bactec
system
isol
identifi
accuprob
test
gene
probe
inc
classic
biochem
criteria
result
laboratori
test
mycobacteri
infect
posit
extrapulmonari
specimen
specif
grew
tuberculosi
avium
regard
tuberculosi
isol
deriv
pleural
fluid
urin
lymph
node
pu
tissu
biopsi
cerebrospin
fluid
ascet
fluid
blood
bone
marrow
upper
respiratori
tract
bone
biopsi
pericardi
fluid
genit
tract
one
skin
biopsi
concern
avium
isol
recov
blood
bone
marrow
lymph
node
pleural
fluid
pu
specimen
one
stool
specimen
conclus
incid
extrapulmonari
tuberculosi
detect
tuberculosi
recov
vast
varieti
clinic
sourc
avium
recov
mainli
blood
bone
marrow
specimen
hivinfect
patient
lymph
node
young
children
introduct
tuberculosi
cervic
lymph
node
unusu
even
develop
countri
area
also
common
site
present
nonhodgkin
lymphoma
nevertheless
concurr
diseas
lymph
node
extrem
rare
case
report
seventyyearold
woman
italian
origin
admit
institut
due
unfavour
evolut
cervic
lymphadenopathi
thought
tubercul
origin
seriou
medic
problem
refer
famili
histori
pulmonari
tuberculosi
present
six
month
admiss
bilater
cervic
mass
first
develop
three
month
later
biopsi
left
side
reveal
tissu
patholog
compat
tb
acidfast
bacilli
visibl
ziehlneelsen
stain
pcr
posit
tuberculosi
complex
standard
threedrug
antitubercul
regimen
initi
drug
suscept
test
follow
identif
resist
prove
evid
pulmonari
diseas
haematolog
biochem
profil
normal
despit
strict
adher
treatment
node
enlarg
appear
new
mass
occur
smear
cultur
fine
needl
aspir
turn
neg
obstruct
phenomena
due
compress
trachea
ensu
complet
excis
involv
node
perform
diagnosi
diffus
larg
bcell
nhl
establish
basi
morpholog
immunophenotyp
featur
chemotherapi
chop
follow
massiv
relaps
cervic
mass
week
later
patient
die
discuss
although
except
believ
coexist
nhl
tb
random
sever
studi
propos
tb
could
predispos
factor
nhl
also
enough
evid
nhl
may
caus
tb
reactiv
increas
level
produc
neoplast
bcell
inabl
tcell
malign
lymph
node
express
helper
function
may
respons
mechan
tb
hiv
rate
odessa
ukrain
dramat
rise
last
decad
f
drobniewski
v
nikolayevskyy
bazhora
asmolov
balabanova
servetski
london
uk
odessa
ukr
infect
hiv
continu
escal
across
countri
former
soviet
union
includ
ukrain
less
hiv
case
diagnos
annual
june
case
offici
record
case
total
occur
previou
month
unfortun
rate
tuberculosi
also
increas
parallel
nation
rate
hiv
tb
hiv
tb
coinfect
underestim
real
situat
odessa
ukrain
report
higher
rate
hiv
diseas
rest
countri
may
repres
increas
role
heterosexu
transmiss
part
effect
strategi
prevent
coalesc
two
outbreak
need
detail
epidemiolog
hiv
tb
region
well
nation
includ
anonym
link
unlink
hiv
seropreval
studi
gener
popul
riskgroup
drug
resist
survey
tb
patient
behaviour
modif
campaign
appropri
educ
deliv
profession
peergroup
harm
intervent
strategi
includ
condom
provis
interrupt
mothertochild
transmiss
needl
exchang
improv
tb
diagnosi
case
manag
instituteeffect
mechan
limit
tb
transmiss
within
institut
hospit
prison
particularli
hivposit
patient
van
der
spoel
van
dijk
mn
jans
van
rensburg
bloemfontein
za
object
genotyp
mycobacterium
tuberculosi
tb
strain
vari
geograph
area
eg
wbeij
strain
report
caus
diseas
outbreak
asia
across
africa
unit
state
haarlem
strain
well
report
recent
report
strain
far
found
south
africa
south
africa
epidemiolog
studi
limit
western
cape
mpumalanga
provinc
aim
studi
determin
tuberculosi
diseas
dynam
semirur
popul
central
free
state
provinc
south
africa
method
type
done
accord
intern
approv
method
use
tb
strain
isol
smear
posit
patient
attend
nine
clinic
three
region
free
state
provinc
period
three
year
result
fingerprint
perform
strain
almost
patient
men
age
group
age
group
year
seventi
two
percent
male
repres
cluster
small
cluster
strain
found
one
cluster
six
consist
strain
four
band
two
strain
subdivid
use
spoligotyp
cluster
strain
newli
diagnos
previous
treat
tb
patient
contact
could
establish
member
two
cluster
anoth
cluster
contain
strain
patient
clinic
suggest
interperson
transmiss
recent
transmiss
rate
calcul
strain
similar
wbeij
famili
found
strain
common
western
cape
one
strain
found
belong
newli
describ
cape
town
resist
cluster
conclus
evid
molecular
epidemiolog
tuberculosi
free
state
differ
rest
countri
bigger
famili
group
evid
similar
index
studi
could
confirm
opinion
transmiss
rate
might
higher
calcul
differ
fact
wbeij
strain
found
could
due
high
unemploy
therefor
low
migrat
patient
studi
area
find
studi
indic
need
continu
resist
monitor
molecular
epidemiolog
surveil
activ
contact
trace
part
free
state
tuberculosi
control
program
method
patient
isol
nprgm
select
retrospect
studi
record
mycobacteriolog
laboratori
june
decemb
clinic
chart
review
accord
predefin
protocol
clinic
signific
evalu
accord
accept
criteria
result
nprgm
identifi
patient
patient
mycobacteri
isol
seven
patient
hospit
patient
select
studi
review
case
isol
consid
clinic
signific
two
case
consid
doubt
respiratori
isol
consid
signific
eleven
isol
identifi
mycobacterium
chelona
two
fortuitum
two
abscessu
two
peregrinum
seven
patient
skin
soft
tissu
infect
three
dissemin
infect
two
case
osteomyelti
periton
capd
diabet
foot
infect
one
case
urinari
tract
infect
arthriti
diarrhoea
conjunct
surgic
site
infect
antimicrobi
select
therapi
perform
accord
individualis
suscept
test
surgeri
remov
foreign
bodi
sequestra
perform
bodi
present
one
patient
cure
one
case
treat
antitubercul
drug
despit
identif
suscept
studi
isol
persist
sever
month
conclus
nprgm
caus
clinic
syndrom
one
third
case
mainli
isol
nonrespiratori
sourc
media
therapi
select
antibiot
surgeri
need
lead
cure
patient
found
locat
vertebr
knee
seven
hip
five
wrist
five
elbow
three
six
locat
five
case
diseas
affect
two
joint
previou
pulmonari
tuberculosi
contact
transmiss
import
predispos
factor
patient
immigr
two
patient
hiv
pain
main
clinic
present
follow
fever
one
case
hip
prosthesi
present
strain
isol
also
tuberculin
test
reaction
posit
patient
case
acidfast
strain
posit
least
one
sampl
strain
suscept
firstlin
drug
except
bovi
pyrazinamid
three
patient
die
diseas
tuberculosi
nine
patient
residu
abnorm
patient
treat
antitubercul
drug
also
requir
surgeri
four
case
men
isol
rapidli
grow
mycobacteria
rgm
three
case
two
chelona
one
abscessu
isol
consid
signific
one
joint
two
bone
repres
osteoarticular
infect
due
mycobacteria
three
patient
cure
proper
chemotherapi
surgeri
conclus
osteoarticular
tuberculosi
still
import
form
extrapulmonari
tuberculosi
differ
risk
factor
form
diseas
outcom
tubercul
diseas
good
case
residu
abnorm
appear
almost
one
quarter
patient
osteoarticular
mycobacteriosi
hospit
caus
rgm
case
proper
chemotherapi
remov
foreign
bodi
necrot
tissu
necessari
good
evolut
patient
object
mycobacterium
malmoens
slowgrow
nonphotochromogen
mycobacterium
recognis
nontubercul
pathogen
northern
northwestern
europ
recent
isol
clinic
sampl
area
caus
pulmonari
extrapulmonari
diseas
also
dissemin
infect
object
present
two
case
malmoens
lymphaden
two
immunocompet
children
spain
first
document
case
extrapulmonari
infect
malmoens
countri
case
report
method
two
patient
eightyearold
boy
twoyearold
girl
refer
evalu
enlarg
painless
superfici
lymph
node
cervic
area
one
fine
needl
aspir
biopsi
perform
case
establish
diagnosi
specimen
decontamin
seed
onto
wensteinjensen
slant
liquid
system
bact
alert
r
mp
inc
durham
result
microscop
examin
specimen
yield
acidfast
bacilli
case
cultur
liquid
medium
show
growth
mycobacteria
day
first
case
day
second
primari
cultur
wensteinjensen
remain
neg
day
cultur
confirm
slowgrow
mycobacteria
nonphotochromogen
malmoens
identifi
polymeras
chain
reaction
restrict
enzym
pattern
analysi
pra
analysi
gene
conclus
unilater
cervic
lymphaden
frequent
extrapulmonari
infect
due
malmoens
predominantli
affect
children
ensur
sensit
primari
isol
malmoens
crucial
care
choos
cultur
media
condit
new
clinic
isol
differ
countri
isol
environ
question
fact
malmoens
exclus
limit
specif
zone
probabl
malmoens
present
mani
geograph
area
may
colonis
caus
infect
human
anim
want
draw
attent
microbiologist
clinician
emerg
pathogen
ad
list
nontubercul
mycobacteria
respons
diseas
immunocompet
patient
object
describ
epidemiolog
clinic
featur
outcom
adult
central
nervou
system
tuberculosi
patient
method
perform
retrospect
studi
case
central
nervou
tuberculosi
hospitalis
depart
period
result
total
patient
femal
male
includ
mean
age
year
age
rang
year
patient
histori
tuberculosi
clinic
symptom
sign
admiss
fever
headach
neck
stiff
compat
tubercul
mening
alter
conscious
focal
neurolog
sign
present
patient
paraplegia
hemiplegia
present
patient
extraneurolog
tuberculosi
associ
spinal
fluid
admiss
clear
patient
case
cell
count
result
cellsmm
predominantli
lymphocyt
case
low
level
glucos
seen
patient
wherea
elev
protein
gl
observ
patient
five
case
without
mening
spinal
fluid
normal
mycobacterium
tuberculosi
isol
cerebrospin
fluid
patient
abnorm
chest
xray
found
patient
cranial
ct
scan
mri
show
hydrocephalu
case
tuberculoma
case
leptomening
case
infarct
case
abcess
case
five
case
tuberculoma
abcess
associ
hydrocephalu
without
mening
patient
treat
antitubercul
drug
steroid
overal
mortal
perman
neurolog
sequela
seen
patient
conclus
tuberculosi
central
nervou
system
continu
import
problem
develop
countri
includ
tunisia
diseas
still
sever
mortal
morbid
remain
high
earli
diagnosi
consid
improv
prognosi
background
tuberculosi
long
surveil
histori
czech
republ
howev
past
year
experienc
import
chang
epidemiolog
tuberculosi
well
implement
improv
notif
approach
object
aim
work
present
new
featur
notif
tuberculosi
czech
republ
summaris
chang
epidemiolog
tuberculosi
evid
routin
surveil
method
notif
tuberculosi
done
two
independ
system
regist
tuberculosi
inform
system
bacillari
tuberculosi
first
one
regist
tuberculosi
base
obligatori
report
physician
second
one
isbt
base
laboratori
report
collect
posit
laboratori
find
notifi
compulsori
basi
also
isbt
control
nation
refer
laboratori
mycobacteria
niph
system
serv
sourc
microbiolog
inform
valid
devic
regist
tuberculosi
laboratoryproven
tuberculosi
case
studi
data
last
five
year
result
averag
yearli
burden
request
investig
posit
approxim
major
request
therapi
check
contact
investig
sinc
observ
steadi
decreas
tb
preval
age
structur
patient
remain
almost
unchang
increas
men
late
product
age
five
time
higher
women
group
trend
open
tuberculosi
preval
decreas
slower
total
figur
substanti
geograph
differ
pragu
west
bohemia
eastern
region
preval
case
mdr
tuberculosi
fluctuat
around
show
trend
yet
new
case
tuberculosi
diagnos
among
legal
migrant
immigr
increas
tendenc
mainli
young
peopl
infect
mdr
strain
conclus
surveil
tuberculosi
gain
import
chang
pattern
case
increas
import
foreignborn
person
threat
mdr
tb
partli
import
abroad
czech
republ
low
incid
countri
technic
mean
increas
import
improv
surveil
method
bandarabba
iran
p
davoodian
j
zerang
darvishkhah
bandarabba
ir
object
prison
highrisk
group
tb
infect
diseas
preval
tb
prison
higher
commun
time
ppd
convers
prison
bandarabba
studi
research
method
carri
descript
research
bandarabba
prison
six
month
select
prison
one
year
convict
quarantin
first
step
ppd
test
prison
select
prison
ppd
test
less
mm
month
repeat
ppd
test
prison
neg
ppd
test
could
carri
ppd
test
prison
variou
reason
result
observ
case
ppd
convers
durat
case
remain
neg
ppd
minimum
age
prison
maximum
year
minimum
ppd
convers
mm
maximum
mm
maximum
ppd
convers
observ
iv
drug
abus
among
age
group
conclus
high
preval
ppd
convers
research
indic
high
contamin
rate
tb
prison
prevent
tb
propos
start
inh
prophylaxi
prison
month
convict
ppd
convers
object
five
million
peopl
infect
mycobacterium
lepra
global
due
high
socioeconom
standard
howev
leprosi
becom
rare
western
world
object
describ
clinic
manifest
leprosi
pregnanc
otherwis
healthi
southeastasian
woman
present
rash
itch
arthralgia
univers
hospit
frankfurtmain
germani
initi
patient
receiv
prednison
reactiv
arthriti
subsequ
treat
dapson
rifampin
clofazimin
method
clinic
isol
detect
skin
biopsi
stain
acidfast
bacilli
amplifi
pcr
mycobacteria
spp
genet
identif
achiev
specif
pcr
tuberculosi
complex
lepra
specimen
inocul
liquid
solid
mycobacteri
cultur
media
result
microscopi
skin
smear
reveal
multibacillari
diseas
variant
microorgan
arrang
like
cigar
pcr
mycobacteria
spp
reveal
weak
signal
could
identifi
posit
result
pcr
specif
lepra
pcr
reaction
specif
tuberculosi
complex
remain
neg
isol
noncultivat
week
incub
conclus
present
case
pregnancyinduc
immunosuppress
led
manifest
previous
subclin
lepra
infect
stain
acidfast
bacilli
perform
patient
skin
lesion
travel
histori
tropic
countri
laboratori
diagnosi
larg
made
applic
molecular
techniqu
infect
tissu
tasova
sarpel
inal
n
saltoglu
b
kurtaran
sanli
adana
tr
object
evalu
featur
tubercul
tb
spondyl
case
cukurova
region
turkey
method
twenti
patient
pt
tb
spondyl
follow
januari
august
evalu
tuberculin
brucella
agglut
test
made
diagnosi
spondyl
made
follow
criteria
isol
mycobacterium
tuberculosi
show
asidoresist
basil
ehrlichziehlneelsen
specimen
obtain
site
spinal
involv
sputum
b
clinic
evid
diseas
c
histopatholog
examin
radiolog
find
plain
radiographi
computeris
tomographi
magnet
reson
imag
mri
patient
follow
least
month
result
patient
male
mean
age
mean
time
onset
symptom
time
diagnosi
month
min
monthsmax
year
tuberculosi
dissemin
eight
patient
frequent
constitut
complaint
back
pain
n
weight
loss
n
paresi
n
night
sweat
n
physic
find
determin
follow
tender
vertebra
region
n
fever
n
tender
sacriliac
joint
n
tuberculin
test
posit
five
patient
elev
erythrocyt
sediment
rate
mmhr
patient
increas
crp
level
mgl
patient
detect
chest
graphi
six
patient
abnorm
five
patient
involv
limit
one
vertebra
thoracolumbar
vertebra
affect
n
follow
lumbar
spine
n
thorac
spine
n
tuberculosi
isol
site
infect
seven
patient
two
strain
resist
soniasid
histopatholog
examin
reveal
caseat
granulomat
necrosi
frequent
mri
find
compress
n
psoa
abscess
n
paravertebr
tissu
inflamm
n
epidur
abscess
n
patient
given
four
drug
antituberculosi
treatment
least
nine
month
one
patient
die
sepsi
therapi
end
therapi
patient
remain
sequela
seven
mild
moder
three
sever
followup
period
nt
relaps
conclus
half
patient
remain
sequela
patient
dissemin
diseas
earli
diagnosi
prevent
complic
tubercul
spondyl
consid
patient
back
pain
region
greek
patient
immigr
patient
newli
diagnos
pulmonari
tb
among
immigr
repatri
greek
eastern
european
countri
foreign
countri
tuberculosi
strain
identifi
accuprob
test
gene
probe
inc
classic
biochem
criteria
suscept
test
strain
perform
method
proport
wensteinjensen
medium
use
radiometr
bactec
system
autom
bactec
mgit
system
bactec
sire
becton
dickinson
result
inh
monoresist
rate
greek
foreign
repatri
greek
patient
rif
monoresist
rate
greek
foreign
repatri
greek
patient
multidrug
resist
rate
greek
foreign
repatri
greek
patient
comparison
monoresist
rate
begin
end
studi
period
show
twofold
increas
inh
greek
repatri
greek
patient
foreign
show
slight
decreas
multidrug
resist
rate
eightfold
increas
greek
patient
twelvefold
increas
repatri
greek
twofold
increas
foreign
conclus
last
period
three
group
patient
studi
quit
low
incid
rif
mono
resist
detect
contrast
high
incid
inh
monoresist
multidrug
resist
particular
data
alert
use
reliabl
timeconsum
method
evalu
suscept
rate
antitubercul
agent
object
prepar
dissemin
inventori
european
train
nosocomi
infect
control
establish
european
core
standard
curriculum
valid
dg
sanco
fund
helic
hospit
infect
link
infect
control
surveil
educ
work
parti
compris
peopl
charg
train
programm
method
eighteen
expert
nomin
countri
repres
helic
advisori
board
questionnair
design
pilot
two
three
volunt
countri
sent
rest
group
indic
deadlin
email
use
exchang
questionnair
data
view
lichart
qualit
score
use
throughout
project
excel
tm
use
data
entri
instanc
analys
respons
infect
control
nurs
icn
doctorepidemiologist
icd
train
requir
cours
explor
four
syllabu
templat
use
develop
audit
tool
assess
content
current
cours
proof
principl
result
group
happi
use
uk
syllabu
develop
multidisciplinari
group
basi
core
curriculum
questionnair
design
variou
requir
icn
icd
current
cours
run
countri
agre
inventori
establish
countri
differ
train
scheme
accredit
requir
amount
time
avail
expect
lectur
distanc
owntim
learn
accredit
infect
control
nurs
doctor
implement
mani
countri
consid
rest
nine
favour
problemsolv
test
written
examin
like
project
howev
method
less
popular
templat
audit
tool
well
receiv
core
compet
initi
consid
futur
could
help
rationalis
cours
major
stumbl
block
identifi
sourc
fund
possibl
intern
activ
fellow
could
travel
centr
train
reflect
conclus
consider
progress
made
agre
syllabu
content
infect
control
cours
real
progress
eu
qualif
central
fund
identifi
thu
far
earli
use
appropri
empir
antibiot
nosocomi
infect
reduc
mortal
morbid
length
hospit
stay
obviou
benefit
patient
physician
payor
intent
academi
infect
manag
aim
commun
new
treatment
paradigm
healthcar
profession
worldwid
method
faculti
multidisciplinari
expert
infect
manag
defin
set
core
principl
devis
educ
materi
introduc
multidisciplinari
audienc
almost
deleg
three
intern
nation
aim
educ
meet
educ
materi
avail
via
dedic
freeaccess
websit
http
wwwinfectionacademyorg
result
aim
websit
provid
educ
involv
manag
seriou
nosocomi
infect
healthcar
profession
regist
user
websit
materi
download
edit
use
nation
region
institut
meet
selfguid
learn
patient
case
studi
form
slide
present
interact
key
question
workmat
major
featur
websit
almost
attende
first
two
meet
n
thought
educ
standard
materi
good
excel
summari
key
public
support
aim
principl
also
avail
topic
includ
clinic
manag
antibiot
resist
pharmacokineticpharmacodynam
principl
pharmacoeconom
consider
infect
manag
websit
also
provid
forum
ask
member
faculti
specif
question
manag
nosocomi
infect
conclus
aim
websit
provid
continu
educ
resourc
healthcar
profession
access
latest
materi
support
concept
use
appropri
antibiot
earli
nosocomi
infect
result
hospit
infect
control
ic
committe
present
includ
mainli
microbiologist
clinician
infect
control
nurs
icn
infect
control
doctor
icd
pharmacist
chief
execut
one
icn
specif
train
infect
control
present
centr
wherea
one
special
train
icd
link
nurs
system
present
hospitalwid
highrisk
unit
centr
icp
annual
objectivesprogress
report
develop
review
senior
manag
hand
hygien
hh
health
worker
hcw
promot
educ
centr
written
guidelin
updat
yr
centr
guidelin
recommend
wear
glove
contact
bodi
fluid
washingdisinfect
hand
remov
glove
use
alcoholbas
solut
andor
medicatedantisept
soap
decontamin
nonsoil
hand
educ
session
hcw
ic
practic
report
hospit
mainli
target
qualifi
nurs
junior
medic
staff
clean
staff
observationfeedback
hh
practic
perform
centr
audit
ic
protocol
ic
team
provid
regular
report
ic
committe
centr
epidemiolog
report
preval
patient
infect
multiresist
alert
organ
publish
particip
conclus
result
indic
wide
variat
icp
amongst
european
hospit
promot
hh
techniqu
well
develop
audit
ic
polici
feedback
surveil
data
limit
need
defin
minimum
core
element
effect
icp
strengthen
resourc
harmonis
implement
result
hospit
laboratori
provid
ao
detect
report
infect
control
team
follow
organ
methicillin
resist
aureu
mrsa
glycopeptid
resist
enterococci
gre
third
gener
cephalosporin
resist
k
pneumonia
carbapenem
resist
baumannii
crab
c
difficil
cdiff
gentamicin
resist
p
aeruginosa
mrsa
activ
screen
carrier
perform
patient
hospit
health
care
worker
hcw
screen
ao
perform
hospit
depend
organ
contact
precaut
use
care
mrsa
patient
major
centr
glove
gown
precaut
use
ao
fewer
centr
gre
glove
gown
glove
gown
crab
glove
gown
cdiff
glove
gown
addit
placement
colonis
patient
singl
room
vari
organ
mrsa
crab
mrsa
patient
centr
complet
measur
use
mask
mupirocin
decolonis
patient
cohort
care
conclus
major
european
hospit
particip
arpac
survey
implement
laboratorybas
surveil
antimicrobi
resist
ao
local
ao
control
polici
includ
varieti
special
barrier
precaut
care
colonis
patient
mrsa
frequent
target
ao
determin
broad
divers
control
programm
requir
studi
object
accord
recent
studi
data
concern
chemoprophylaxi
colorect
surgeri
chang
prospect
studi
present
experi
issu
one
two
dose
ticarcillineclavoulan
acid
chemoprophylaxi
colectomi
necess
administ
postop
chemoprophylact
agent
analys
far
concern
avoid
surgic
site
infect
method
decemb
decemb
patient
men
women
mean
age
year
respect
underw
colectomi
due
malign
patient
benign
diseas
six
patient
nineteen
deem
highrisk
patient
due
coexist
diseas
cardiac
diseas
diabet
mellitu
respiratori
diseas
renal
insuffici
hepat
insuffici
obes
cortison
therapi
patient
divid
two
group
random
group
one
dose
ticarcillineclavoulan
acid
administ
intraop
group
b
two
dose
antibiot
administ
first
one
intraop
second
postop
thereaft
patient
clinic
laboratori
monitor
surgic
site
infect
result
surgic
site
infect
develop
six
patient
studi
four
patient
two
group
suffer
wound
suppur
two
intraabdomin
abscess
format
equal
present
group
cultur
isol
escherichia
coli
five
patient
enterococci
four
treatment
consist
wound
drainag
system
antibacteri
agent
case
wound
suppur
case
intraabdomin
infect
administr
two
antimicrobi
imipenem
perform
patient
cure
mean
hospitalis
day
conclus
review
materi
appear
benefit
aris
administ
addit
postop
antimicrobi
prophylaxi
colorect
surgeri
statist
insignific
nevertheless
number
patient
studi
still
small
would
unsaf
extract
conclus
dervisogl
k
kanellakopoul
pini
n
galanaki
pierakaki
p
giannakaki
p
dasiou
c
iordan
liveran
h
giamarel
pireu
athen
gr
object
intraabdomin
abscess
result
elect
cholecystectomi
due
spill
stone
bile
infest
bacteria
cefuroxim
consid
appropri
agent
given
chemoprophylaxi
elect
cholecystectomi
nevertheless
enterococci
infest
bile
sensit
ampicillin
sulbactam
rather
cefuroxim
even
though
enterococci
lethal
implic
intraabdomin
sepsi
need
antienterococc
prophylaxi
studi
yet
method
period
extend
juli
decemb
patient
male
femal
mean
age
year
respect
underw
elect
cholecystectomi
eightynin
deem
highrisk
patient
cultur
gallbladd
bile
mucosa
taken
patient
cefuroxim
g
ampicillinsulbactam
g
administ
intraop
random
patient
clinic
laboratori
monitor
postop
infect
surgic
site
result
fortytwo
patient
reveal
posit
cultur
specif
cultur
result
follow
enterococci
isol
patient
escherichia
coli
klebsiella
four
staphylococcu
epidermidi
three
citrobact
three
enterobact
cloaca
three
streptococci
two
citrobact
freundi
two
bacteroid
fragili
two
pseudomona
one
enterobact
aerogenu
one
acinetobact
one
among
patient
reveal
neg
cultur
two
suffer
steril
collect
wound
one
present
postop
day
wound
suppur
cn
isol
pu
cultur
patient
microb
isol
gall
bladder
bile
cultur
one
develop
wound
infect
e
coli
klebsiella
patient
reveal
bacteria
bile
mucos
cultur
one
suffer
postop
suppur
wound
cn
isol
pu
two
patient
hospitalis
icu
due
respiratori
insuffici
mortal
rate
nil
mean
hospitalis
mean
postop
hospitalis
day
respect
conclus
chemoprophylaxi
result
group
nevertheless
antienterococc
prophylaxi
consid
far
enterococcu
isol
great
number
patient
posit
cultur
ceftriaxon
vs
antibiot
surgic
prophylaxi
esposito
noviello
vanasia
p
venturino
napl
object
investig
possibl
differ
prophylaxi
ceftriaxon
compar
antimicrobi
agent
surgicalsit
infect
ssi
remot
infect
respiratori
rti
urinari
tract
infect
uti
method
efficaci
ceftriaxon
cro
compar
antibiot
periop
prophylaxi
local
ssi
remot
rti
uti
infect
metaanalysi
randomis
control
trial
publish
analysi
base
conting
tabl
classif
treatment
number
infect
obtain
individu
studi
global
estim
effect
treatment
obtain
weight
mean
log
odd
ratio
accord
mantelhaenszel
associ
confid
interv
ci
calcul
perform
use
sa
chisquar
test
perform
result
evalu
perform
studi
total
patient
four
hundr
six
patient
cro
group
compar
group
develop
ssi
log
odd
ratio
ci
p
rti
observ
patient
cro
group
patient
compar
group
log
odd
ratio
ci
p
uti
report
cro
prophylax
patient
compar
patient
prophylax
drug
log
odd
ratio
ci
p
overal
clean
surgeri
patient
develop
ssi
cro
compar
group
respect
log
odd
ratio
ci
p
rti
prevent
patient
cro
group
compar
group
p
clean
surgeri
cro
group
vs
compar
group
p
result
observ
clean
surgeri
evid
statist
signific
superior
cro
prevent
uti
insurg
log
ci
p
shown
cleancontamin
surgeri
fact
patient
cro
group
vs
patient
compar
group
develop
uti
log
ci
p
advers
event
observ
similar
proport
cro
prophylaxi
compar
group
durat
prophylaxi
influenc
outcom
infect
conclus
metaanalysi
show
cro
statist
superior
antibiot
prevent
local
remot
postop
infect
object
cdc
recommend
repres
standard
antimicrobi
prophylaxi
cleanclean
contamin
surgeri
first
second
gener
cephalosporin
indic
aim
studi
monitor
antimicrobi
prophylaxi
italian
gener
surgeri
ward
penicillin
routin
use
method
studi
carri
april
may
gener
surgeri
perform
larg
hospit
round
itali
oper
patient
survey
surgeon
hospit
stay
day
oper
nosocomi
infect
ni
diagnosi
pattern
antimicrobi
prophylaxi
time
durat
type
collect
electron
case
report
form
result
surgic
procedur
number
perform
nni
risk
index
clean
prosthesi
cleancontamin
oper
repres
colcestectomia
herniorrhaphi
colon
surgeri
appendectomi
among
oper
patient
clean
elect
clean
contamin
contamin
surgeri
receiv
antimicrobi
prophylaxi
clean
intervent
amoxocillinclavulan
follow
ceftizoxima
ampicillinsulbactam
prescrib
antibiot
one
antibiot
use
patient
prophylaxi
treatment
given
day
surgeri
treat
patient
case
induct
intervent
respect
patient
treat
cephalosporin
higher
risk
develop
ni
rr
ci
respect
patient
treat
penicillin
two
group
compar
age
sex
nni
risk
index
howev
major
herniorrhaphi
mastectomi
repres
penicillin
group
respect
cefalosporin
separ
analysi
herniorrhaphi
patient
confirm
increment
rr
patient
treat
cephalosporin
conclus
high
use
antibiot
observ
clean
surgeri
particularli
high
use
penicillinprotect
document
class
surgeri
rational
antibiot
treatment
clean
nonprosthet
surgeri
controversi
determin
whether
unknown
origin
bacteraemia
uob
independ
risk
factor
mortal
critic
ill
patient
bloodstream
infect
materi
method
clinic
signific
bacteraemia
intens
care
unit
teach
hospit
evalu
clinic
microbiolog
characterist
assess
risk
factor
hospit
mortal
multivari
logist
regress
spss
packag
result
eightyf
episod
bacteraemia
critic
ill
patient
unknown
origin
eightysix
percent
episod
uob
hospit
acquir
mean
age
patient
uob
ae
year
factor
associ
uob
nosocomi
origin
p
nonsever
sepsi
p
aetiolog
uob
cn
acinetobact
baumannii
staphylococcu
aureu
enterococcu
spp
pseudomona
aeruginosa
escherichia
coli
other
preval
cn
higher
episod
uob
p
preval
baumannii
e
coli
lower
uob
known
origin
bacteraemia
p
p
global
relat
death
rate
uob
episod
known
origin
respect
p
p
factor
associ
global
mortal
episod
bacteraemia
sever
sepsi
septic
shock
nosocomi
origin
septic
shock
associ
relat
mortal
uob
conclus
contrari
previou
report
unknown
sourc
bacteraemia
independ
associ
fatal
outcom
critic
ill
patient
background
previous
report
nonsignific
attribut
mortal
rate
nosocomi
candidemia
intens
care
unit
icu
patient
remain
uncertain
whether
candidemia
involv
candida
nonalbican
spp
associ
wors
outcom
comparison
candida
albican
candidemia
particular
patient
popul
method
retrospect
studi
attribut
mortal
c
albican
c
nonalbican
candidemia
investig
compar
icu
patient
two
independ
match
cohort
studi
perform
match
base
sever
underli
diseas
acut
ill
apach
ii
score
admiss
diagnosi
length
icu
stay
prior
onset
candidemia
expect
mortal
deriv
apach
ii
match
procedur
result
equal
prognosi
case
control
subject
attribut
mortal
determin
subtract
hospit
mortal
rate
control
candidem
case
result
studi
period
icu
admiss
complic
microbiolog
document
candidemia
admiss
fiftyon
episod
caus
c
albican
c
nonalbican
spp
c
glabrata
c
parapsilosi
c
krusei
c
tropicali
c
albican
match
cohort
studi
attribut
mortal
found
ci
mortal
rate
case
control
respect
p
c
nonalbican
match
cohort
studi
attribut
mortal
found
ci
mortal
rate
case
control
p
attribut
mortal
rate
statist
signific
consequ
differ
also
signific
conclus
differ
attribut
mortal
candidemia
involv
c
albican
vs
c
nonalbican
spp
observ
cohort
icu
patient
object
acinetobact
baumannii
name
methicillinresist
staphylococcu
aureu
gramneg
pathogen
special
steadi
rise
number
isol
report
mani
intens
care
unit
outbreak
aim
studi
identifi
independ
risk
factor
develop
acinetobact
baumannii
hospitalacquir
bacteraemia
abb
materi
method
studi
nosocomi
bacteraemia
medicalsurg
intens
care
unit
teach
hospit
sevenyear
period
analys
predispos
factor
develop
abb
appropri
clinic
epidemiolog
variabl
record
clinic
chart
use
stepwis
logist
regress
analysi
determin
independ
predictor
abb
spss
softwar
use
data
analysi
result
fiftynin
nosocomi
bacteraemia
due
acinetobact
baumannii
mean
age
patient
abb
ae
year
relat
menwomen
princip
origin
abb
respiratori
cathet
unknown
polymycrobi
bacteraemia
identifi
episod
abb
septic
shock
present
mean
length
stay
hospit
day
mean
day
hospitalis
onset
bacteraemia
ae
among
strain
identifi
multidrugresist
imipenemresist
global
relat
mortal
rate
abb
respect
risk
factor
abb
mechan
ventil
ic
p
respiratori
sourc
infect
ic
p
previou
use
cephalosporin
ic
p
wherea
less
ten
day
hospitalis
onset
bacteraemia
ic
p
presenc
cardiac
comorbid
ic
p
prevent
factor
multivari
analysi
conclus
day
hospitalis
use
mechan
ventil
pneumonia
sourc
bacteraemia
previou
use
cephalosporin
must
consid
risk
factor
develop
abb
period
combin
ceftazidim
gday
amikacin
gday
use
empir
antibacteri
therapi
vap
june
octob
ii
period
cefepim
gday
singledrug
therapi
nine
hundr
thirtyseven
strain
differ
pathogen
vap
studi
antibiot
resist
p
aeruginosa
enterobacteriaca
wide
spread
caus
agent
vap
correspondingli
studi
materi
obtain
bal
sensit
pathogen
test
antibiot
determin
discdiffus
method
result
total
consumpt
amikacin
ceftazidim
cefepim
icu
depart
first
period
g
second
period
consumpt
cefepim
g
amikacin
ceftazidim
exclud
conclus
exclus
ceftazidim
amikacin
month
result
decreas
resist
p
aeruginosa
ceftazidim
possibl
overcom
high
level
resist
amikacin
period
reveal
increas
resist
cefepim
despit
wide
use
month
object
knowledg
attitud
behaviour
health
care
worker
concern
infect
control
import
determin
level
hospit
hygien
also
reflect
success
infect
control
organis
institut
much
known
infect
control
indonesia
therefor
studi
investig
knowledg
attitud
selfreport
behaviour
health
care
worker
two
indonesian
teach
hospit
mean
inquiri
method
questionnair
carri
amongst
healthcar
worker
depart
intern
medicin
surgeri
paediatr
obstetr
gynaecolog
icu
goal
questionnair
explain
anonym
analysi
result
guarante
particip
particip
complet
questionnair
session
one
research
infect
control
nurs
present
check
whether
work
individu
answer
question
result
repres
sampl
doctor
nurs
assistantnurs
involv
depart
hospit
n
complet
questionnair
answer
show
hospit
minor
personnel
vaccin
hepat
b
although
major
experienc
needl
stick
accid
report
knowledg
bloodborn
diseas
small
clear
guidelin
handl
needl
stick
accid
place
infect
control
organis
matter
enough
hand
wash
point
inconsist
knowledg
attitud
behaviour
concern
role
hand
infect
control
suppli
person
protect
equip
glove
mask
gown
insuffici
distinct
steril
nonsteril
glove
clear
limit
knowledg
wound
care
care
patient
urinari
cathet
conclus
questionnair
show
deficit
knowledg
regard
infect
control
gener
specif
regard
hand
hygien
safe
blood
handl
person
protect
equip
surgic
procedur
admit
risk
area
near
work
carri
data
collect
process
infecti
diseas
id
team
basic
data
obtain
incom
censu
microbiolog
result
antimicrobi
prescript
seriat
visit
id
consult
use
sourc
case
detect
cdc
criteria
definit
ni
use
microbiolog
air
qualiti
check
hepa
protect
area
everi
month
monthli
nonprotect
area
sampl
problem
detect
adequ
correct
measur
taken
result
global
incid
rate
weekli
incid
ni
oscil
urinari
tract
infect
frequent
increas
respiratori
surgic
infect
observ
epidem
outbreak
aspergillosi
filament
fungi
legionellosi
detect
patient
bone
marrow
transplant
heart
transplant
admit
haematolog
cardiolog
servic
increas
rate
invas
aspergillosi
compar
previou
year
medic
day
bed
unit
mu
subject
standardis
screen
programm
fourmonth
period
aim
examin
environment
organ
ward
compar
bacteri
resist
associ
antimicrobi
usag
ward
method
handtouch
site
door
handl
comput
keyboard
site
floor
sink
screen
use
commerci
dipslid
organ
quantit
qualit
assess
subject
antimicrobi
suscept
test
antibiot
consumpt
data
obtain
previou
year
unit
express
defin
daili
dose
ddd
patientday
result
amount
ident
organ
ward
similar
differ
ward
regard
microbi
densiti
certain
site
nearli
staphylococci
recov
oppos
gramneg
bacilli
antibiot
resist
significantli
associ
individu
ward
particularli
staphylococci
p
also
coliform
p
gramneg
organ
p
despit
fewer
number
itu
consum
ddd
patientday
six
time
su
mu
associ
made
betalactam
consumpt
methicillin
resist
aminoglycosid
consumpt
gentamicin
resist
conclus
antibacteri
resist
signific
differ
environment
bacteria
differ
ward
appear
reflect
prescrib
pressur
place
ward
dirtiest
ward
visual
su
least
heavi
microbi
growth
handtouch
site
least
number
resist
bacteria
itu
appear
much
cleaner
demonstr
higher
proport
heavili
contamin
handtouch
site
multipl
resist
bacteria
thu
visual
inspect
ward
may
provid
reliabl
guid
potenti
risk
infect
environ
find
implic
local
antibiot
polici
infect
control
clean
schedul
object
mani
branch
medicin
microbiolog
clean
air
signific
condit
either
microbi
pollut
infect
reduct
ie
oper
place
medic
staff
infect
method
mfi
method
multifunct
ion
air
clean
genano
oy
finland
examin
use
nanobio
devic
point
air
decontamin
effici
test
devic
work
paramet
clean
capac
h
air
flow
veloc
ms
microbiolog
puriti
exhaust
air
measur
two
method
appli
qualit
quantit
test
de
vill
biotechnolog
microbio
devic
contact
plate
method
oxoid
test
bacteri
fungal
type
atcc
collect
rockvil
usa
quantit
test
microbi
suspens
aerosol
use
densiti
cfu
ml
asept
condit
result
microbiolog
puriti
air
pass
air
clean
mfi
devic
determin
remov
destroy
bacteria
fungi
air
highli
effect
toward
wide
spectrum
microb
germicid
effect
ceilingand
wallmount
ultraviolet
c
uvc
light
nm
isol
unit
neg
pressur
pascal
examin
compar
disinfect
chloramin
enddisinfect
patient
stay
microbi
sampl
taken
surfac
disinfect
uvc
min
chloramin
h
exposur
use
standard
contact
plate
cm
uvcdistribut
isol
unit
monitor
posit
output
floor
vari
wm
averag
aesd
ae
wm
patient
room
ae
wm
sluic
ae
wm
bath
decontamin
room
place
valu
vari
wm
unit
uvcdisinfect
min
correspond
dose
rang
jm
shadow
area
jm
highest
expos
site
accord
publish
uvcdosimetri
surviv
bacteria
bacteri
spore
reduc
dose
rang
jm
jm
respect
thu
uvc
dose
use
studi
high
enough
inactiv
bacteri
organ
includ
spore
even
surfac
directli
expos
uvc
uvcdisinfect
significantli
reduc
bacteria
surfac
directli
indirectli
expos
uvc
low
number
c
cfuplat
chloramin
disinfect
c
cfuplat
alon
p
p
respect
sinc
clean
disinfect
may
risk
staff
isol
unit
disinfect
uvcor
chemic
alway
perform
first
presenc
complet
shadow
area
isol
unit
bed
rail
locker
mattress
etc
still
need
disinfect
chemic
clean
therefor
uvc
may
use
alon
good
addit
chemic
disinfect
lower
biolog
burden
infecti
agent
isol
unit
highrisk
infecti
patient
object
qualiti
control
qc
program
intern
literatur
infect
relat
highrisk
flexibl
gastrointestin
endoscop
fe
especi
night
prolifer
microorgan
fe
channel
patient
infect
risk
use
numberbetween
gtype
statist
control
chart
associ
statist
method
identifi
unstabl
fe
reprocess
procedur
method
use
microbi
count
cfu
flush
water
water
channel
endoscopi
qc
program
clean
critic
highrisk
fe
defin
gcontrol
card
figur
xaxi
repres
consecut
number
critic
highrisk
fe
yaxi
number
clean
fe
everi
critic
highrisk
fe
center
line
clwd
illustr
expect
qualiti
reprocess
fe
defin
concret
type
washerdisinfector
wd
clmc
line
show
expect
qualiti
reprocess
fe
use
manual
clean
mc
fe
prolifer
microorgan
storag
thirteen
endoscopi
unit
eight
hospit
copenhagen
hospit
corpor
h
copenhagen
counti
ka
particip
program
clwd
determin
three
differ
wd
clmc
previou
experi
gcontrol
chart
produc
endoscopi
unit
allow
control
evalu
relat
occurr
critic
highrisk
fe
result
qc
sampl
fe
evalu
present
data
gcontrol
chart
period
depart
use
three
olympu
etd
wd
show
develop
control
situat
fe
reprocess
went
control
control
consecut
control
point
clwd
clmc
occasion
observ
highrisk
fe
last
two
year
control
situat
detect
eight
consecut
control
point
consecut
control
point
fall
clwd
clmc
conclus
gcontrol
chart
found
valuabl
statist
tool
allow
identif
control
procedur
reprocess
fe
data
show
control
manual
clean
give
earli
sign
wd
need
repair
bad
condit
replac
gcontrol
chart
great
improv
previous
use
pcontrol
chart
prevent
spread
legionella
hospit
ward
measur
adopt
polyclin
bologna
g
finzi
p
cacciari
n
manoni
n
alvaro
l
mavilla
bologna
aim
legionella
repres
seriou
problem
old
hospit
year
expand
size
result
ad
plumb
system
origin
build
policlinico
sorsolamalpighi
highli
specialis
ward
treatment
patient
particularli
vulner
infect
transplant
cancer
patient
part
plumb
network
year
old
comprehens
radic
overhaul
plumb
system
order
erad
legionella
complet
realist
goal
target
set
hospit
prevent
highrisk
patient
expos
infect
method
filter
fit
tap
shower
head
room
highrisk
patient
follow
sector
haematolog
oncolog
paediatr
oncohaematolog
nephrolog
surgeri
transplant
patient
monitor
programm
set
assess
effici
measur
februari
singl
sampl
taken
interv
year
howev
method
lowlevel
intermitt
contamin
outlet
filter
instal
could
identifi
evalu
plumb
system
risk
distort
fals
neg
result
reason
new
monitor
programm
set
march
involv
take
regular
sampl
everi
outlet
inspect
result
year
outlet
protect
filter
shown
legionella
contamin
one
except
level
contamin
found
within
rang
vigil
recommend
exist
regul
contrast
inspect
shower
head
tap
fit
filter
given
neg
result
sampl
recent
outlet
also
monitor
repeat
sampl
avoid
fals
neg
result
lowlevel
intermitt
contamin
outlet
fit
filter
found
uncontamin
even
subject
type
inspect
except
one
outlet
present
room
kept
shut
sever
day
found
contamin
two
instanc
conclus
data
monitor
carri
indic
fit
water
outlet
filter
effect
way
avoid
legionella
contamin
long
certain
basic
requir
met
filter
must
instal
correct
posit
plumb
system
must
undergo
period
mainten
replac
object
nosocomi
origin
legionellosi
must
confirm
molecular
type
legionella
strain
isol
patient
hospit
water
suppli
studi
use
pulsedfield
gel
electrophoresi
pfge
random
amplifi
polymorph
dna
pcr
rapdpcr
type
legionella
strain
isol
four
patient
acquir
legionellosi
four
differ
hospit
relat
hospit
environment
strain
method
l
pneumophila
serogroup
isol
first
patient
male
year
immunosuppress
l
pneumophila
relat
hospit
water
l
pneumophila
serogroup
isol
second
patient
male
year
cardiopat
l
pneumophila
respect
hospit
water
l
bozemanii
isol
third
patient
femal
year
immunosuppress
autoimmun
diseas
l
pneumophila
l
bozemanii
relat
hospit
water
last
case
l
pneumophila
sero
group
isol
patient
femal
year
immunosuppress
l
pneumophila
serogroup
legionella
spp
hospit
environ
strain
patient
relat
hospit
water
suppli
type
pfge
dna
cleav
sfii
noti
perform
agaros
gel
chef
dr
iii
amplif
rapdpcr
perform
two
primer
use
readytogo
rapd
analysi
bead
visual
stain
ethidium
bromid
electrophoresi
polyacrylamid
gel
genephor
system
result
four
case
strain
patient
relat
hospit
environment
isol
show
genom
profil
pfge
rapdpcr
differ
pattern
found
unrel
strain
conclus
molecular
type
demonstr
strain
patient
hospit
hot
water
genet
indistinguish
show
hospit
water
sourc
infect
nosocomi
origin
would
probabl
unrecogn
without
molecular
techniqu
use
epidemiolog
marker
experi
chlorin
dioxyd
water
treatment
system
control
legionella
hospit
hot
water
suppli
g
mascart
doyen
k
de
cuyper
brussel
b
object
evalu
efficac
chlorin
dioxyd
system
reduc
signific
amount
legionella
present
hot
water
suppli
method
evalu
amount
legionella
hot
water
suppli
chlorin
dioxyd
system
market
gulldag
instal
octob
system
includ
three
compon
one
pump
inject
reaction
chamber
aquou
stabilis
solut
chlorin
dioxyd
activ
one
pump
inject
reaction
chamber
activ
activ
reaction
chamber
activ
product
inject
entranc
hot
water
suppli
control
amount
legionella
differ
place
suppli
decemb
march
also
investig
risk
corros
water
pipe
place
small
piec
steel
steel
zinc
point
inject
clo
anoth
point
inject
result
pretreat
measur
reveal
juli
presenc
legionella
water
sampl
nine
water
sampl
number
legionella
ufcl
mean
number
legionella
sampl
ufcl
seven
control
made
octob
instal
clo
system
march
period
necessari
see
efficac
decemb
two
nine
sampl
posit
cful
march
three
sampl
posit
one
sampl
cful
mean
number
cful
concern
corros
steel
piec
loss
weight
day
mg
initi
weight
g
without
mg
initi
weight
g
clo
steel
plu
zinc
loss
weight
mg
initi
weight
g
without
clo
clo
initi
weight
g
conclus
result
structur
water
pipe
network
presenc
biofilm
appear
clo
effect
decreas
legionella
level
year
moreov
adjunct
clo
increas
risk
corros
karpanen
worthington
p
lambert
elliott
birmingham
uk
object
assess
antimicrobi
efficaci
novel
triclosan
hand
prepar
thp
clinic
set
determin
sustain
antimicrobi
activ
thp
adopt
part
routin
hand
hygien
determin
effect
repeat
hand
wash
soap
water
sustain
antimicrobi
activ
thp
method
control
randomis
prospect
open
trial
undertaken
one
hundr
two
health
care
worker
hcw
recruit
acut
surgic
ward
critic
care
unit
radiolog
depart
base
univers
hospit
birmingham
nh
trust
uk
baselin
level
microorgan
hand
hcw
determin
standard
microbiolog
techniqu
fiftytwo
hcw
appli
thp
recommend
manufactur
fifti
hcw
appli
thp
serv
control
assess
immedi
antimicrobi
efficaci
thp
hand
sampl
microorgan
one
minut
follow
applic
hcw
continu
normal
clinic
practic
hand
sampl
microorgan
h
determin
sustain
antimicrobi
activ
thp
data
regard
frequenc
hand
wash
durat
glove
worn
investig
also
obtain
alcohol
hand
rub
medic
soap
wash
exclud
assess
thp
result
signific
reduct
mean
bacteri
count
studi
group
compar
control
min
h
h
follow
applic
thp
p
respect
signific
differ
group
number
time
hand
wash
soap
water
p
h
object
nosocomi
infect
one
import
problem
caus
mortal
hospit
around
world
problem
emphasis
oper
room
staff
deal
aim
studi
determin
rate
infect
among
oper
room
staff
yazd
univers
hospit
yazd
citi
iran
method
one
hundr
thirtyfour
person
oper
team
staff
men
women
includ
surgeon
nurs
student
involv
crosssect
studi
follow
swap
hand
betadin
scrub
four
part
hand
sampl
cultur
use
standard
method
detect
possibl
bacteria
detect
bacteria
diagnos
use
relat
biochem
test
simultan
demograph
statu
age
sex
period
scrub
time
case
record
separ
special
form
result
speci
detect
staphylococci
coagulas
posit
coagulas
neg
person
nail
infect
cstaph
cstaph
staff
palm
infect
cstaph
cstaph
hand
staph
infect
cand
cstaph
staff
wrist
infect
staph
cwa
detect
staff
wrist
infect
among
men
found
significantli
women
staff
scrub
hand
min
studi
popul
carri
coloni
bacteria
conclus
present
studi
show
men
careless
infect
scrub
nosocomi
infect
found
domin
among
oper
room
staff
nail
significantli
carri
infect
agent
may
suggest
least
min
scrub
recognis
minimis
infect
evalu
prevent
method
bloodborn
pathogen
among
health
care
worker
tatsiopoulo
k
mandrav
imprisimi
polit
alexioudaniel
thessaloniki
gr
object
estim
risk
evalu
condit
exposur
bloodborn
pathogen
among
health
care
worker
hcw
conduct
comparison
present
past
data
hospit
method
data
collect
use
questionnair
includ
characterist
worker
type
occup
exposur
immun
statu
expos
worker
infect
sourc
patient
follow
serolog
test
worker
eight
hundr
eight
incid
enrol
januari
decemb
data
compar
data
collect
similar
cohort
previou
period
result
notic
increas
absolut
number
report
incid
vs
nurs
appear
highest
injuri
rate
per
year
among
hcw
vs
lack
attent
remain
main
caus
incid
vs
worker
short
work
experi
year
primarili
affect
p
result
indic
seriou
increas
rate
incid
resheat
use
needl
vs
taken
consider
appropri
adjust
relev
hospit
polici
interestingli
studi
demonstr
decreas
rate
incid
involv
hbsag
antihcv
patient
vs
respect
period
none
report
incid
progress
seroconvers
hcw
immun
statu
blood
born
pathogen
estim
find
line
previou
survey
conclus
awar
hcw
regard
earli
report
incid
observ
effort
infect
control
committe
need
intens
order
identifi
unsaf
practic
provid
adequ
prevent
measur
ventilatorassoci
pneumonia
evalu
patient
ventilatorassoci
pneumonia
erbay
h
bodur
e
akinci
n
balaban
olpan
ankara
tr
object
determin
epidemiolog
ventil
associ
pneumonia
vap
examin
characterist
outcom
patient
vap
method
patient
diagnosi
vap
surgic
medic
intens
care
unit
icu
enrol
studi
follow
prospect
diagnosi
vap
base
posit
quantit
cultur
deep
endotrach
aspir
cfu
ml
new
increas
purul
sputum
chest
radiograph
show
new
progress
infiltr
demograph
detail
apach
ii
score
length
icu
stay
length
mechan
ventil
surgeri
comorbid
nutrit
statu
isol
microorgan
suscept
result
record
individu
form
result
studi
period
vap
diagnos
patient
male
mean
age
ae
reason
icu
admiss
respiratori
failur
trauma
postop
care
cardiopulmonari
arrest
reason
respect
mean
durat
icu
stay
ae
day
mean
durat
mechan
ventil
ae
day
comorbid
obtain
seven
patient
apach
ii
score
patient
six
patient
vap
occur
ae
day
mechan
ventil
acinetobact
spp
frequent
identifi
pathogen
found
nine
episod
follow
pseudomona
aeruginosa
klebsiella
pneumonia
methicillin
resist
staphylococcu
aureu
overal
mortal
rate
seven
die
patient
pneumonia
direct
reason
death
risk
factor
lead
death
vap
patient
longer
icu
stay
ae
ae
day
respect
p
longer
ventil
time
ae
ae
day
respect
p
statist
signific
differ
found
apach
ii
score
patient
die
vap
surviv
three
seven
patient
die
vap
infect
acinetobact
spp
resist
antibiot
conclus
ventilatorassoci
pneumonia
import
complic
mechan
ventil
among
icu
patient
prevent
measur
nosocomi
infect
appropri
antibiot
treatment
may
import
step
reduc
mortal
vap
background
ventilatorassoci
pneumonia
vap
caus
pseudomona
aeruginosa
pa
sever
complic
high
mortal
vitro
data
shown
major
pa
isol
develop
stabl
resist
exposur
serial
passag
contain
antibiot
object
investig
whether
antibiot
therapi
vap
determin
select
antibiot
resist
pa
vivo
determin
whether
chang
pa
strain
antibiot
therapi
method
prospect
cohort
studi
start
septemb
diagnosi
vap
requir
posit
quantit
cultur
bal
new
persist
infiltr
chest
xray
follow
hyperhypopirexia
leucocytosi
purul
bronchial
secret
onset
h
start
mechan
ventil
mv
chest
x
ray
haemochrom
sap
ii
minib
obtain
start
therapi
everi
h
genotyp
perform
autom
laser
fluoresc
analysi
digit
fingerprint
data
result
twentysix
patient
fulfil
diagnost
criteria
vap
within
first
year
studi
eleven
patient
pa
vap
enrol
serial
bal
major
patient
male
mean
sd
age
year
nineti
per
cent
patient
receiv
antibiot
within
day
vap
diagnos
day
mv
enrol
resist
antibiot
detect
strain
patient
present
leucocytosi
mean
six
patient
neg
cultur
minib
obtain
h
therapi
remain
pa
still
isol
compar
patient
neg
bal
h
posit
bal
excess
mortal
vs
p
higher
leucocytosi
vs
p
radiolog
pictur
mean
sap
ii
chang
significantli
h
two
patient
develop
resist
piperacillintazobactam
imipenem
day
therapi
respect
patientuniqu
isol
pa
genet
differ
serial
isol
patient
ident
conclus
stepwis
select
resist
observ
vivo
antibiot
therapi
vap
mortal
rate
significantli
higher
patient
pa
still
isol
h
preliminari
data
suggest
minib
h
therapi
may
use
control
antimicrobi
suscept
isol
reduc
mortal
method
total
isol
quantit
bal
cultur
analys
observ
cohort
septemb
march
one
intens
care
unit
univers
teach
hospit
preliminari
final
coloni
count
isol
categoris
either
growth
insignific
cfuml
signific
cfuml
vap
diagnos
basi
posit
quantit
cultur
sensit
specif
posit
predict
valu
neg
predict
valu
preliminari
result
estim
concurr
antibiot
therapi
record
growth
insignific
growth
detect
preliminari
result
result
preliminari
coloni
count
report
isol
growth
insignific
growth
signific
growth
overal
preliminari
result
sensit
specif
posit
predict
valu
neg
predict
valu
preliminari
bal
cultur
result
accur
predict
presenc
absenc
vap
bal
perform
isol
growth
preliminari
final
greater
reliabl
predict
absenc
vap
isol
insignific
growth
preliminari
final
wherea
differ
note
fals
neg
antibiot
insignific
growth
group
conclus
preliminari
bal
cultur
result
signific
growth
highli
predict
similar
final
result
wherea
result
insignific
growth
less
reliabl
data
isol
signific
growth
clinic
import
antibiot
adapt
appropri
discontinu
respect
obtain
final
result
object
compar
impact
outcom
earli
day
mechan
ventil
vs
late
day
mechan
ventil
modif
accord
bronchoalveolar
lavag
bal
cultur
result
initi
inappropri
antibiot
therapi
patient
ventil
associ
pneumonia
vap
method
total
subject
male
femal
median
age
year
rang
diagnos
vap
quantit
cultur
result
bal
receiv
initi
inappropri
antibiot
treatment
enrol
initi
antibiot
inappropri
least
one
develop
microorgan
resist
administ
antibiot
modifi
accord
bal
cultur
result
becam
avail
paramet
record
includ
time
modif
earli
vs
late
accord
vap
episod
develop
outcom
result
inappropri
initi
antibiot
therapi
modifi
earli
late
crude
mortal
crude
mortal
case
earli
modif
inappropri
treatment
four
case
late
modif
apach
ii
score
p
pseudomona
spp
p
develop
differ
significantli
two
group
earli
late
modif
initi
inappropri
treatment
conclus
data
favour
outcom
patient
vap
observ
initi
inappropri
empir
antibiot
therapi
modifi
accord
bal
cultur
result
earli
day
mechan
ventil
late
day
mechan
ventil
deescal
therapi
base
use
initi
larg
spectrum
first
hand
therapi
reassess
microbiolog
data
becom
avail
order
reduc
narrow
spectrum
therapi
method
total
subject
clinic
evid
vap
randomli
assign
two
group
b
group
n
malesfemal
median
age
year
rang
year
quantit
cultur
qc
bal
taken
wherea
group
b
n
malesfemal
median
age
year
rang
year
qc
tta
initi
antibiot
therapi
modifi
light
cultur
result
either
stop
inappropri
least
one
strain
resist
administ
antibiot
chang
anoth
narrow
spectrum
outcom
term
crude
mortal
rate
assess
group
result
patient
diagnos
develop
vap
group
b
respect
signific
differ
age
p
apach
ii
score
p
durat
mechan
ventil
sampl
taken
p
contribut
medic
vs
surgic
patient
x
p
detect
group
b
bal
tta
qc
result
permit
deescal
group
b
respect
wherea
therapi
remain
unchang
overal
mortal
group
b
x
p
crude
mortal
deescal
appli
group
b
respect
x
p
therapi
remain
unchang
p
conclus
data
vap
patient
favour
outcom
deescal
appli
light
qc
bal
rather
tta
result
vap
episod
attribut
one
pathogen
episod
multipl
pathogen
episod
total
microorgan
develop
quantit
cultur
bal
pa
vap
attribut
pa
otpa
flora
pa
exclus
flora
includ
pa
among
strain
episod
median
valu
apch
ii
score
vap
episod
due
pa
due
otpa
flora
ae
ae
respect
p
crude
mortal
vap
due
pa
otpa
respect
p
median
durat
ventil
develop
vap
pa
otpa
day
respect
p
durat
mechan
discharg
intens
care
vap
pa
otpa
ae
ae
respect
p
conclus
data
differ
detect
vap
pa
vap
otpa
flora
term
durat
mechan
ventil
outcom
introduct
increas
number
recent
report
suggest
van
suboptim
treatment
gisa
infect
studi
look
mortal
icu
patient
aureu
vap
mssa
mrsa
gisa
method
extract
follow
inform
prospect
record
databas
outcomerea
demograph
characterist
admiss
categori
sever
ill
admiss
use
simplifi
acut
physiolog
score
sap
ii
hospit
mortal
vap
diagnos
use
protect
specimen
brush
bronchoalveolar
lavag
sampl
van
monitor
patient
pt
cox
model
timedepend
covari
use
measur
impact
aureu
vap
hospit
mortal
result
van
administ
continu
infus
use
alon
combin
fosfomycin
fucid
acid
synercid
gisa
vap
adjust
sap
ii
categori
admiss
medic
vs
surgic
mrsa
pneumonia
ci
p
gisa
pneumonia
ci
p
associ
increas
risk
mortal
compar
mssa
pneumonia
pt
patient
surgic
icu
sicu
bed
medic
icu
micu
nine
bed
burn
unit
seven
bed
includ
patient
older
year
age
includ
data
collect
includ
physic
examin
find
apach
ii
score
admiss
onset
np
conscious
risk
factor
intub
mv
nasotrach
aspir
presenc
nasogastr
tube
enter
nutrit
tracheotomi
prior
surgeri
immunosuppress
prior
antimicrobi
antacid
histamin
type
blocker
therapi
clinic
outcom
length
stay
icu
hospit
np
defin
accord
center
diseas
control
cdc
criteria
one
hundr
sixti
three
patient
admit
icu
period
bacteriolog
histolog
evid
pneumonia
use
control
group
result
overal
patient
develop
np
n
patient
np
ventilatorassoci
pneumonia
vap
one
hundr
sixtythre
patient
admit
icu
period
bacteriolog
histolog
evid
pneumonia
use
control
group
coma
copd
hypoalbuminaemia
mechan
ventil
mv
tracheotomi
presenc
nasogastr
tube
nasogastr
aspir
previou
treatment
broad
spectrum
antibiot
found
independ
risk
factor
crude
attribut
mortal
respect
mortal
rate
five
time
greater
case
ci
mean
length
stay
icu
hospit
case
longer
control
group
p
conclus
patient
requir
mv
high
frequenc
np
np
associ
poor
prognosi
increas
length
icu
hospit
stay
enterococcu
faecali
streptococcu
viridan
enterobact
cloaca
escherichia
coli
four
case
balcultur
polymicrobi
patient
neg
primari
balfluid
cultur
develop
vap
hospitalis
organ
isol
balfluid
vap
patient
p
aeruginosa
k
pneumonia
stenotrophomona
maltophilia
e
cloaca
marcescen
acinetobact
e
coli
enterococcu
mrsa
seven
cultur
polymicrobi
four
patient
develop
two
episod
vap
caus
differ
pathogen
respiratori
treatment
organ
isol
balfluid
throat
andor
rectum
swab
vappati
major
klebsiella
pseudomona
isol
obtain
bal
differ
patient
ident
pfge
pattern
isol
enterobact
stenotrophomona
differ
pfge
type
confirm
five
case
vap
caus
microorgan
k
pneumonia
p
aeruginosa
present
time
admiss
remain
vap
due
nosocomi
flora
object
ventil
associ
pneumonia
vap
import
caus
mortal
throughout
world
aim
studi
investig
antibacteri
resist
gram
neg
basilli
isol
respiratori
sampl
patient
vap
method
studi
includ
pseudomona
aeruginosa
acinetobact
spp
klebsiella
pneumonia
five
escherichia
coli
isol
tracheal
aspir
bronchoalveolar
lavag
sampl
patient
vap
antibiot
suscept
extendedspectrum
betalactamas
produc
esbl
determin
etest
ab
biodisk
use
muellerhinton
agar
oxoid
accord
nccl
recommend
result
antibiot
resist
strain
present
tabl
esbl
product
ratio
k
pneumonia
strain
produc
none
e
coli
strain
conclus
studi
common
gram
neg
bacilli
caus
lower
respiratori
tract
infect
p
aeruginosa
acinetobact
spp
notic
resist
mani
antimicrobi
includ
carbapenem
howev
regard
strain
carbapenem
cefepim
identifi
effect
antimicrobi
agent
method
evalu
pt
men
women
mean
age
ae
year
mean
durat
hospitalis
ae
day
caus
surgic
intervent
follow
acut
abdomen
pt
ileu
pt
open
lung
biopsi
pt
abdomin
ca
eight
pt
traumat
haemothorax
pneumothorax
six
pt
pneumonectomi
six
pt
ruptur
concav
viscera
four
pt
aortal
abdomin
aneurysm
four
pt
miscellan
six
pt
result
total
mortal
twelv
pt
develop
nosocomi
pneumonia
posit
cultur
endobronchi
secret
first
h
hospitalis
increas
care
unit
eight
staphyl
aureu
four
pseud
aeruginosa
pt
pneumonia
occur
later
caus
microorgan
isol
cultur
endobronchi
secret
third
day
hospitalis
increas
care
unit
eight
aureu
four
acinetobact
sp
p
aeruginosa
subgroup
pt
earlyonset
pneumonia
first
day
mortal
subgroup
lateonset
pneumonia
third
day
mortal
statist
differ
detect
apach
ii
score
two
subgroup
ae
ae
respect
correl
found
mortal
age
sex
caus
surgic
intervent
conclus
find
indic
postsurg
pt
requir
increas
care
develop
pneumonia
first
day
hospitalis
increas
care
unit
indic
colonis
preexist
infect
possibl
unidentifi
relat
sever
prognosi
method
identif
isol
bacteria
perform
classic
method
suscept
antibiot
test
kirbybau
method
accord
nccl
criteria
suscept
ciprofloxacin
cip
imipenem
imp
amikacin
ceftazidim
caz
cefepim
fep
examin
doubledisk
synergi
test
use
detect
extendedspectrum
betalactamas
esbl
product
result
first
day
admiss
strain
esblproduc
k
pneumonia
resist
suscept
cip
imp
isol
oropharynx
icu
patient
infecti
involv
respiratori
tract
eighti
per
cent
patient
stay
hospit
day
demonstr
mucou
membran
colonis
addit
pyoverdinproduc
strain
p
aeruginosa
resist
cip
imp
suscept
caz
fep
start
tenth
day
patient
stay
icu
microbi
spectrum
oropharynx
present
p
aeruginosa
associ
k
pneumonia
acinetobact
spp
enterococcu
spp
similar
associ
found
process
microbiolog
studi
bronchoalveolar
lavag
fluid
patient
develop
ventilatorassoci
bronchopulmonari
infecti
complic
conclus
thu
studi
rate
colonis
bacteri
spectrum
characterist
oropharynx
show
bronchopulmonari
infecti
complic
ventil
multipl
sever
trauma
patient
may
due
aspir
hospit
strain
colonis
oropharynx
earli
follow
patient
admiss
hospit
result
thirtyon
blood
cultur
posit
maltophilia
constitut
blood
cultur
posit
gramneg
organ
bacteraemia
episod
hospitalacquir
twentytwo
patient
underli
ill
twenti
patient
receiv
antibiot
therapi
within
previou
week
septicaemia
pneumonia
due
maltophilia
bacteraemia
common
clinic
diagnos
ciprofloxacin
trimethoprimsulfamethoxazol
combin
withwithout
aminoglycosid
common
select
antibiot
treatment
maltophilia
infect
one
child
die
acut
maltophilia
bacteraemia
episod
antibiot
suscept
maltophilia
strain
variou
antibiot
follow
penicillin
g
ampicillin
ampicillinsulbactam
amoxicillinclavulan
piperacillin
ticarcillinclavulan
cephalothin
cefuroxim
cefixim
ceftriaxon
ceftazidim
cefotaxim
cefoperazon
cefoperazonesulbactam
cefepim
aztreonam
meropenem
ciprofloxacin
ofloxacin
amikacin
gentamicin
netilmicin
tobramycin
chloramphenicol
doxycyclin
trimethoprimsulfamethoxazol
ciprofloxacin
suscept
determin
agar
dilut
method
conclus
studi
demonstr
although
maltophilia
bacteraemia
rare
children
antibiot
resist
import
problem
strain
tetracyclin
trimethoprimsulfamethoxazol
fluoroquinolon
effect
agent
maltophilia
strain
isol
blood
cultur
children
hospit
howev
ciprofloxacin
suscept
determin
dilut
method
prompt
administr
appropri
antibiot
improv
prognosi
maltophilia
bacteraemia
object
maltophilia
import
emerg
nosocomi
pathogen
isol
gener
highli
resist
betalactam
macrolid
aminoglycosid
fluoroquinolon
tetracyclin
chloramphenicol
threat
maltophilia
come
multidrug
resist
abil
form
biofilm
colonis
surfac
medic
devic
abil
produc
virul
factor
report
preliminari
analysi
genom
sequenc
clinic
maltophilia
isol
bristol
uk
method
maltophilia
isol
rrna
subgroup
type
strain
isol
bacteraemia
oncolog
patient
genom
dna
produc
ctab
method
shear
ligat
clone
vector
shotgun
sequenc
perform
raw
sequenc
data
assembl
contig
contig
search
use
tblastn
homologu
databas
sequenc
result
current
read
total
mb
raw
sequenc
perform
give
theoret
coverag
genom
current
contig
contig
kb
total
size
mb
blast
analysi
reveal
six
operon
homolog
known
tripartit
multidrug
efflux
pump
smedef
smeabc
homologu
pseudomona
aeruginosa
mexcd
mexef
acinetobact
baumanii
adeabc
homologu
xanthomona
campestri
rpf
cluster
involv
quorum
sens
virul
factor
product
locat
system
uniqu
member
xanthomona
group
includ
maltophilia
produc
quorumsens
signal
homoserin
lacton
number
put
virul
factor
gene
locat
conclus
determin
maltophilia
genom
sequenc
allow
knockout
mutagenesi
determin
gene
import
multidrug
resist
biofilm
format
virul
factor
product
togeth
give
bacterium
potenti
futur
threat
clinic
set
haemolyt
activ
examin
sheep
blood
agar
elastas
product
elastintrishydrochlorid
agar
incub
bacteria
h
c
suscept
bactericid
activ
serum
examin
determin
surviv
rate
h
normal
human
serum
induct
respiratori
burst
gaug
phagocytosi
bacteria
neutrophil
measur
luminolenhanc
chemiluminesc
test
result
product
elastas
detect
frequent
among
maltophilia
isol
among
p
aeruginosa
strain
haemolyt
activ
could
observ
speci
similar
frequenc
vs
stenotrophomona
maltophilia
isol
found
significantli
less
often
serum
resist
p
aeruginosa
strain
contrast
level
respiratori
burst
induct
neutrophil
maltophilia
isol
significantli
higher
observ
p
aeruginosa
strain
p
conclus
result
show
except
serum
resist
properti
abil
clinic
maltophilia
isol
express
charact
regard
pathogen
factor
similar
haemolysin
elastas
express
even
higher
stimul
neutrophil
p
aeruginosa
indic
pathogen
potenti
maltophilia
posit
bc
bacteria
identifi
autom
method
bactec
vitek
strain
genotyp
rapd
use
eric
primer
case
patient
bc
posit
p
putida
first
eight
case
tumour
carri
central
venou
cathet
cvc
therefor
heparin
lock
solut
suspect
prefil
heparin
syring
recent
bought
new
cater
patient
charg
heparin
lock
sinc
day
first
case
receiv
carri
cvc
call
cathet
drawn
bc
irrespect
signssymptom
blood
draw
longterm
cvc
lock
amicacin
heparin
oral
ciprofloxacin
start
patient
posit
bc
longterm
cvc
treat
iv
local
lock
antimicrobi
agent
shortterm
n
cvc
remov
promptli
result
p
putida
isol
one
three
valid
lot
heparin
lock
syring
use
bc
patient
total
patient
charg
heparin
syring
thirti
nonsymptomat
patient
cvc
call
attend
seven
chill
fever
cvc
manipul
fourteen
nonsymptomat
symptomat
patient
p
putida
isol
eleven
patient
bc
drawn
cvc
venipunctur
seven
posit
bc
cvc
five
symptomat
four
posit
bc
site
three
symptomat
bc
patient
also
yield
stenotrophomona
maltophilia
five
longterm
cvc
remov
genotyp
p
putida
patient
show
three
differ
band
pattern
two
also
found
heparin
isol
present
moment
object
bacteria
burkholderia
cepacia
complex
bcc
import
pathogen
cystic
fibrosi
cf
patient
pt
bcc
compris
least
nine
speci
genomovar
aim
studi
assess
epidemiolog
bcc
recov
pt
attend
cf
centr
gaslini
children
hospit
genova
itali
method
total
bcc
isol
recov
pt
regular
follow
studi
period
genomovar
isol
determin
rflp
analysi
reca
gene
confirm
pcr
reca
genomovarspecif
primer
strain
type
rapd
analysi
clinic
cours
pt
infect
differ
speci
determin
compar
infect
p
aeruginosa
prior
bcc
acquisit
chang
lung
function
bodi
weight
bcc
postacquisit
period
mortal
longterm
period
result
burkholderia
cenocepacia
genomovar
iii
predomin
speci
recov
cf
pt
infect
bcc
genoa
centr
eight
speci
compris
bcc
isol
belong
bc
genomovar
b
stabili
b
pyrrocinia
found
four
reca
lineag
b
cenocepacia
pt
harbour
iiib
strain
patienttopati
spread
bcc
among
cf
pt
mostli
associ
b
cenocepacia
strain
particular
iiia
iiid
reca
lineag
mortal
significantli
higher
pt
infect
bcc
noninfect
pt
death
associ
presenc
b
cenocepacia
within
b
cenocepacia
infect
epidem
strain
belong
lineag
iiia
iiid
associ
higher
mortal
lineag
iiib
strain
signific
differ
lung
function
bodi
weight
mortal
rate
observ
pt
infect
epidem
strain
belong
either
b
cenocepacia
iiia
b
cenocepacia
iiid
conclus
studi
confirm
preval
b
cenocepacia
among
bccinfect
cf
pt
high
percentag
mortal
associ
speci
major
role
epidem
strain
belong
recent
identifi
reca
lineag
iiid
spread
bcc
infect
among
cf
pt
recognis
first
time
start
open
multicentr
prospect
studi
pegyl
pegifn
rbv
coinfect
patient
undergo
antiretrovir
treatment
method
inclus
criteria
absenc
antiretrovir
treatment
art
week
cell
count
hivrna
copiesml
biopsyproven
chronic
c
hepat
patient
treat
pegifn
lg
subcutan
weekli
rbv
mg
po
daili
week
hivrna
hcvrna
cell
count
alt
level
monitor
result
octob
patient
median
age
year
start
treatment
hcv
genotyp
found
patient
week
respect
patient
virolog
respons
hcvrna
copiesml
patient
biochem
respons
signific
decreas
median
cell
count
baselin
hivrna
chang
significantli
five
patient
discontinu
treatment
advers
effect
conclus
virolog
respons
obtain
patient
data
indic
administr
pegifn
ribavirin
may
effect
coinfect
patient
treatment
hcv
infect
without
concomit
art
may
offer
advantag
avoid
hepatotox
antiretrovir
drug
immun
restor
syndrom
potenti
complic
treatment
moreov
cell
count
associ
good
immun
system
activ
limit
studi
high
preval
hcv
genotyp
known
associ
better
respons
rather
genotyp
ribavirin
combin
treatment
special
categori
chronic
hepat
c
patient
exus
intraven
administ
narcot
substanc
c
drakouli
e
stavropoul
e
nikitidi
nikola
c
malli
e
katsador
minadaki
piraeu
gr
purpos
evalu
complianc
respons
pegifn
alpha
ribavirin
combin
treatment
special
categori
chronic
hepat
c
patient
ex
user
intraven
administ
narcot
substanc
materi
method
sixtytwo
patient
stop
use
addict
substanc
month
initi
combin
treatment
pegifn
alpha
studi
among
men
five
women
averag
age
year
old
result
regard
categori
patient
complianc
treatment
poor
patient
fulli
compli
treatment
patient
partli
compli
return
second
biopsi
pcr
test
patient
follow
treatment
recommend
two
treatmentabid
patient
interrupt
seriou
sideeffect
sever
weight
loss
peroni
nerv
paresi
svr
treatmentabid
patient
assess
conclus
intraven
narcot
substanc
user
abid
recommend
treatment
limit
extent
respond
combin
pegifn
alpha
ribavirin
treatment
great
extent
greater
extent
respons
attribut
patient
young
age
well
prevail
genotyp
ribavirin
endotheli
cell
inflammatori
integrin
stress
marker
advanc
chronic
hepat
c
korzh
fedotova
v
nemtsova
kharkov
ukr
object
individu
chronic
hepat
c
chc
progress
cirrhosi
hepat
cancer
individu
advanc
chc
coagulopath
manifest
fibrinolysi
coagulopathi
consequ
hepatocyt
dysfunct
fibrinolysi
repres
respons
local
endotheli
cell
injuri
interferon
ribavirin
decreas
necroinflamm
chronic
hepat
c
without
virolog
clearanc
aim
studi
evalu
effect
combin
therapi
interferon
ribavirin
endotheli
cell
inflammatori
integrin
measur
endotheli
stress
method
immedi
prior
treatment
individu
advanc
chc
plasma
level
tissu
factor
tf
thrombomodulin
tm
solubl
solubl
solubl
lselectin
slselectin
prothrombin
time
activ
partial
thromboplastin
time
determin
paramet
assay
week
result
tf
tm
level
high
baselin
consist
vascular
endotheli
stress
respons
similarli
well
lselectin
level
increas
week
therapi
mark
reduct
tm
lesser
degre
tf
lselectin
level
observ
reduct
persist
week
chang
measur
fibrinolysi
plasminogen
activ
total
tissu
factor
pathway
inhibitor
ttfpi
activ
tissu
factor
pathway
inhibitor
tfpia
ddimer
dd
fibrinogen
level
occur
conclus
base
upon
data
conclud
combin
therapi
interferon
ribavirin
correct
coagulopathi
seen
advanc
chc
reduc
endotheli
cell
injuri
andor
stress
evidenc
tf
tm
level
plasma
chang
coagul
occur
without
induc
propag
vascular
thrombosi
influenc
therapi
endotheli
cell
protein
patient
chronic
hepat
c
object
hepat
c
viru
hcv
infect
hepatocyt
util
hepatocyt
replic
mani
hepatocyt
activ
shift
nativ
state
one
reflect
liver
cell
stress
thrombomodulin
tissu
factor
endotheli
cell
protein
express
result
tissu
injuri
stress
aim
studi
determin
effect
interleukin
il
administr
level
thrombomodulin
tissu
factor
patient
hcvrelat
liver
diseas
method
fortythre
patient
chronic
hepat
c
fail
antivir
therapi
enrol
treatment
regimen
sq
given
daili
thrice
weekli
liver
biopsi
perform
therapi
level
thrombomodulin
tissu
factor
plasma
hepatocyt
cytosol
evalu
result
led
signific
improv
serum
alt
mean
alt
day
ae
vs
month
ae
p
hepat
inflamm
score
decreas
least
two
patient
mean
decreas
ae
ae
p
show
reduct
fibrosi
score
mean
chang
ae
ae
p
caus
decreas
thrombomodulin
level
plasma
cytosol
p
chang
parallel
improv
alt
level
tissu
factor
plasma
cytosol
vari
minim
baselin
therapi
conclus
therapi
appear
decreas
diseas
activ
patient
hcvrelat
liver
diseas
thrombomodulin
may
uniqu
marker
cellular
endotheli
stress
present
individu
chronic
hepat
c
marker
might
use
clinic
cours
chronic
hepat
c
mean
gaug
tissu
respons
therapi
object
thrombosi
small
intrahepat
vein
suggest
trigger
liver
tissu
remodel
suggest
quantifi
measur
plasma
marker
von
willebrand
factor
thrombomodulin
solubl
adhes
molecul
hypothes
may
exist
correl
plasma
level
von
willebrand
factor
thrombomodulin
tissu
plasminogen
activ
antigen
tpaag
marker
endotheli
cell
dysfunct
serum
concentr
solubl
adhes
molecul
monocyt
chemoattract
patient
chronic
hepat
c
method
patient
n
chronic
hepat
c
without
malign
histori
venou
thrombosi
antiviralimmunosuppress
therapi
within
last
month
match
control
n
includ
evalu
possibl
influenc
acut
phase
reaction
reinvestig
perform
month
result
concentr
von
willebrand
factor
thrombomodulin
tpaag
plasma
significantli
higher
patient
chronic
hepat
c
compar
healthi
subject
p
p
p
respect
still
statist
signific
month
also
adjust
establish
risk
factor
patient
also
significantli
higher
concentr
solubl
vascular
cell
adhes
compar
healthi
control
p
comparison
strong
correl
concentr
solubl
intercellular
adhes
von
willebrand
factor
patient
chronic
hepat
c
r
p
concentr
thrombomodulin
r
p
tpaag
r
p
furthermor
neg
correl
observ
concentr
thrombomodulin
cell
surfac
express
monocyt
granulocyt
peripher
circul
p
case
conclus
strong
correl
marker
endotheli
dysfunct
solubl
adhes
molecul
patient
chronic
hepat
c
strengthen
view
ongo
stress
endotheli
cell
present
patient
may
play
pathophysiolog
role
progress
diseas
role
antibodi
protein
hepat
c
viru
hcv
igm
antibodi
hcv
predict
factor
treatment
interferon
alpha
patient
chronic
hepat
c
object
antibodi
protein
hepat
c
viru
hcv
igm
antibodi
hcv
antihcv
igm
studi
predictor
respons
therapi
interferon
alpha
patient
chronic
hepat
c
live
gomel
region
affect
chernobyl
catastroph
method
studi
carri
patient
chronic
hepat
c
treat
interferon
alpha
gomel
region
antibodi
antihcv
igm
studi
cours
treatment
mean
elisa
test
posit
antihcv
igm
posit
sera
sampl
virolog
respons
undetect
hcvrna
serum
evalu
month
treatment
virolog
respons
detect
patient
nonrespons
patient
result
cours
treatment
reveal
respond
vs
nonrespond
chisquar
p
antihcv
igm
respond
vs
nonrespond
chisquar
p
conclus
antibodi
antihcv
igm
reveal
significantli
frequent
nonrespond
alphainterferon
therapi
antihcv
igm
show
predict
valu
respons
interferon
therapi
chronic
hepat
c
aim
studi
evalu
correl
quantit
total
hepat
c
viru
core
antigen
hcvrna
level
patient
treat
pegyl
pegifn
plu
ribavirin
combin
therapi
method
total
patient
age
year
infect
genotyp
enrol
prospect
studi
patient
antihcv
posit
pretreat
viral
load
bdna
bayer
diagnost
uiml
histolog
confirm
chronic
hepat
abnorm
activ
aminotransferas
last
least
month
start
therapi
patient
treat
pegifn
plu
ribavirin
month
genotyp
month
genotyp
hcvrna
detect
cutoff
uiml
copiesml
month
defin
earli
respons
er
month
end
treatment
respons
etr
genotyp
genotyp
respect
total
hcv
core
ag
quantif
hcvrna
viral
load
assess
baselin
month
total
hcv
core
ag
quantif
assess
use
ortho
trackc
assay
orthoclin
diagnost
raritan
nj
usa
hcvrna
assess
use
quantiplex
brach
dna
bdna
assay
bayer
diagnost
emmeryvil
ca
usa
assay
perform
accord
manufactur
instruct
result
month
patient
neg
hcvrna
hcvag
posit
two
hcvrna
posit
hcvag
neg
one
hcvrna
neg
hcvag
posit
pgml
month
neg
hcvrna
hcvag
nine
posit
one
hcvrna
posit
hcvag
neg
conclus
hcvag
test
show
strong
correl
hcvrna
level
percentag
concord
rang
although
wealth
inform
numer
assay
hcv
rna
detect
serum
plasma
realtim
pcr
yet
appli
viral
load
measur
method
develop
singl
step
real
time
rtpcr
protocol
accur
quantit
hcv
rna
plasma
sampl
use
lightcycl
dual
hybridis
probe
technolog
hcv
rna
quantif
clinic
sampl
base
amplif
one
iuml
rna
refer
standard
accurun
bbi
compar
previous
quantifi
standard
curv
result
interassay
coeffici
variat
standard
deviat
refer
standard
respect
period
month
total
plasma
sampl
test
hcv
rna
quantifi
sampl
level
vari
iuml
amplicon
remov
lightcycl
glass
capillari
purifi
probe
use
autom
sequenc
analysi
visibl
genet
bayer
diagn
genotyp
assess
hcv
posit
sampl
major
type
genotyp
also
identifi
melt
temperatur
probe
obtain
genotyp
compar
temperatur
calcul
sequenc
analysi
amplifi
target
verifi
feasibl
hcv
genotyp
real
time
pcr
conclus
new
hcv
quantif
method
seem
rapid
accur
reproduc
abl
quantit
hcv
genotyp
hcv
type
melt
temperatur
studi
optimis
tatsiopoulo
k
mandrav
papadopoul
alexioudaniel
thessalonica
gr
object
genotyp
distribut
hepat
c
viru
differ
group
patient
hepat
c
correl
age
viru
load
way
contamin
method
one
hundr
sixti
patient
hcv
infectionbefor
commenc
therapi
admit
ahepa
univers
hospit
januari
decemb
hcvrna
presenc
assess
revers
transcriptionpcr
hcv
monitor
caroch
revers
hybridis
test
amplif
use
genotyp
innolipa
innogenet
result
thirtyfour
patient
multitransfus
present
end
stage
renal
diseas
esrd
hemodialysi
patient
hiv
coinfect
intraven
drug
user
ivdu
sporad
case
sc
hepat
c
unknown
sourc
infect
sc
sampl
distribut
four
group
accord
age
year
common
genotyp
group
patient
follow
genotyp
genotyp
less
common
case
genotyp
case
genotyp
high
level
viraemia
copiesml
observ
sampl
follow
distribut
genotyp
genotyp
genotyp
lowest
viraemia
observ
subtyp
genotyp
genotyp
observ
patient
older
year
genotyp
frequent
patient
younger
year
conclus
genotyp
common
group
patient
particular
patient
older
year
associ
higher
level
viru
load
comparison
subtyp
genotyp
observ
includ
genotyp
tma
isotherm
autocatalyt
target
amplif
method
sensit
potenti
detect
low
viraemia
approxim
iuml
hcv
rna
genotyp
carri
short
h
pcr
procedur
tma
product
pcrtma
product
use
hcv
genotyp
carri
revers
hybridis
test
lipa
hcv
genotyp
assay
lipa
versant
viral
load
hcv
rna
posit
sera
quantifi
bdna
assay
hcv
rna
assay
bdna
versant
result
among
ivdu
antibodi
hcv
anti
hcv
activ
viraemia
hcv
rna
posit
serum
distribut
hcv
genotyp
case
one
eight
case
three
case
conclus
group
ivdu
preval
hcv
infect
high
predomin
genotyp
viral
load
among
hcv
rna
posit
patient
iuml
wherea
none
evid
mix
hcv
infect
object
studi
determin
genotyp
variat
among
drug
user
flander
relat
genotyp
distribut
characterist
popul
method
hcvrna
quantif
genotyp
perform
store
sampl
antihcv
posit
inject
noninject
drug
user
standardis
interview
provid
inform
sociodemograph
statu
drugrel
sexual
risk
behaviour
avail
drug
user
result
hcvrna
present
sampl
genotyp
could
determin
case
genotyp
predomin
follow
genotyp
genotyp
genotyp
univari
analysi
hcv
genotyp
relat
geograph
region
histori
idu
number
sexual
partner
last
year
tattoo
presenc
antihbc
multivati
analysi
histori
inject
drug
use
idu
confirm
statist
signific
predictor
infect
genotyp
predictor
infect
genotyp
found
presenc
antihbc
antibodi
histori
inject
drug
use
tattoo
emerg
statist
signific
predictor
infect
genotyp
conclus
preval
hcvrna
among
antihcv
posit
drug
user
consider
higher
expect
chronic
rate
furthermor
distribut
hcv
genotyp
idu
differ
significantli
distribut
among
nonidu
genotyp
predomin
among
former
genotyp
among
latter
final
result
studi
suggest
role
tattoo
practic
spread
hcv
among
drug
user
ai
aller
l
calbo
jl
de
francisco
jc
alado
c
de
miguel
jerez
de
la
frontera
e
object
aim
studi
evalu
immunoenzymat
antigen
detect
earli
diagnosi
hepat
c
viru
hcv
infect
dialysi
patient
patient
method
use
enzymelink
immunosorb
assay
ortho
hcv
elisa
test
system
orthoclin
diagnost
detect
antibodi
hcv
patient
chronic
renal
failur
treat
haemodialysi
depart
hospit
total
hcv
core
antigen
determin
immunoassay
trackc
ortho
total
hcv
antigen
assay
orthoclin
diagnost
compar
measur
obtain
coba
amplicor
hcv
test
version
coba
amplicor
coba
amplicor
monitor
hcv
roch
molecular
system
assay
perform
accord
manufactur
instruct
cutoff
valu
hcv
antigen
pgml
cutoff
valu
coba
amplicor
hcv
test
uiml
amplicor
hcv
monitor
test
uiml
result
patient
anti
hcv
antibodyposit
show
global
correl
hcv
core
antigen
amplicor
hcv
test
tabl
patient
anti
hcv
antibodyneg
show
global
correl
tabl
conclus
good
correl
hcvpcr
hcv
core
antigen
assay
new
use
test
earli
detect
hcv
infect
studi
group
antihcvv
alt
hcvrna
hcv
viral
load
hcv
genotyp
viraem
determin
women
first
pregnanc
previou
histori
intraven
drug
addict
ivdu
haemotransfus
patient
partner
investig
clinic
evalu
serum
level
alt
perform
determin
perform
gestat
deliveri
month
hiv
hbv
coinfect
present
case
two
case
tripl
infect
hcv
genotyp
determin
virem
pregnant
women
indetermin
one
account
respect
alt
level
uln
initi
third
trimest
month
deliveri
sexual
partner
investig
check
antihcvv
heroin
abus
blood
transfus
health
care
employ
unknown
sourc
respons
hcv
infect
result
male
partner
check
hcvviti
among
partner
ivdu
report
haemotransfus
four
report
risk
factor
discuss
high
rate
antihcvv
observ
group
regular
sexual
partner
antihcvv
pregnant
women
hundr
fortythre
antihcvv
men
ivdu
receiv
transfus
suggest
greatest
risk
factor
hcv
infect
relat
presenc
bloodborn
risk
factor
make
difficult
distinguish
contribut
sexual
activ
risk
hcv
transmiss
sariola
p
koskela
p
finn
k
melen
riikonen
julkunen
western
countri
incid
hepat
c
viru
hcv
infect
steadili
increas
especi
among
young
adult
thu
like
increas
preval
hcv
infect
also
found
pregnant
women
assess
frequenc
hcv
infect
metropolitan
area
helsinki
select
antihcv
antibodi
test
carri
pregnant
women
year
altogeth
mother
identifi
among
mother
frequenc
antihcv
posit
rose
earli
mother
knew
seroposit
wherea
end
followup
period
almost
mother
knew
hcv
infect
alreadi
pregnanc
intraven
drug
abus
major
risk
factor
case
contract
diseas
mother
chronic
hcv
infect
well
control
popul
mean
serum
alanin
aminotransferas
alt
valu
decreas
toward
end
pregnanc
howev
antihcv
ab
posit
mother
develop
intrahepat
cholestasi
odd
ratio
characteris
itch
elev
serum
bile
acid
level
correspond
valu
control
pregnanc
antihcv
ab
posit
mother
younger
deliv
earlier
gave
birth
babi
smaller
birth
weight
compar
control
deliveri
comprehens
view
problem
hcv
infect
pregnanc
randomli
select
serum
specimen
finnish
matern
cohort
test
serum
specimen
test
select
cohort
preval
steadili
role
metropolitan
area
helsinki
preval
higher
respect
studi
indic
increas
problem
hcv
infect
pregnant
women
finland
although
women
cope
well
diseas
pregnanc
subpopul
mother
develop
cholestasi
liver
statu
thu
followedup
care
test
mother
serum
antihcv
antibodi
recommend
z
mohtasham
amiri
rezvani
jafari
shakib
r
jafari
shakib
h
asadi
nejad
rasht
ir
object
hepat
c
viru
hcv
lead
caus
liver
failur
liver
transplant
adult
identifi
risk
factor
hcv
infect
includ
intraven
iv
drug
use
exposur
infect
blood
product
intranas
drug
use
highrisk
sexual
activ
multipl
sexual
partner
histori
sexual
transmit
diseas
std
tattoo
skin
pierc
purpos
studi
determin
preval
hcv
highrisk
behaviour
drug
addict
inmat
method
conduct
crosssect
preval
studi
hcv
infect
drug
addict
inmat
admit
prison
guilan
provinc
north
iran
septemb
octob
subject
ask
question
regard
behaviour
might
put
risk
acquir
hcv
blood
drawn
hcv
antibodi
test
use
enzymelink
immunosorb
assay
elisa
posit
sampl
recheck
western
blot
result
four
hundr
fifti
inmat
particip
seropreval
studi
mean
age
respond
ae
sd
rang
year
durat
addict
ae
sd
year
treacl
addict
heroin
addict
cannabi
addict
other
addict
one
substanc
hcv
risk
behaviour
common
popul
intraven
drug
use
intranas
drug
use
tattoo
two
hundr
two
studi
subject
hcv
antibodi
posit
hcvposit
statu
significantli
associ
histori
intraven
drug
use
tattoo
durat
addict
durat
stay
prison
bodi
pierc
conclus
infect
hepat
c
endem
iranian
prison
better
access
harm
reduct
strategi
need
environ
futur
studi
address
need
target
hcv
screen
educ
prison
inmat
regard
risk
hcv
k
koncova
j
kazar
bratislava
sk
object
liver
diseas
caus
hepat
c
viru
hcv
pose
seriou
public
health
problem
hcv
present
group
highli
variabl
strain
due
variabl
nucleotid
sequenc
viru
isol
indic
effect
therapi
hcv
infect
import
determin
presenc
activ
viru
patient
bodi
also
specifi
hcv
genotyp
object
studi
determin
incid
hcv
genotyp
patient
includ
therapeut
process
slovak
republ
method
altogeth
patient
chosen
studi
base
hcv
rna
posit
serum
detect
pcr
method
coba
amplicor
version
test
roch
specif
genotyp
andor
subtyp
amplicon
determin
hybridis
specif
probe
genotyp
test
innolipa
hcv
ii
innogenet
result
sera
test
hcv
genotyp
found
case
genotyp
case
four
posit
case
genotyp
could
determin
detail
analysi
reveal
subtyp
subtyp
five
case
case
belong
genotyp
indetermin
subtyp
genotyp
subtyp
subtyp
age
distribut
group
patient
older
year
genotyp
highli
predomin
case
wherea
genotyp
occur
four
case
one
case
genotyp
could
determin
contrast
group
patient
younger
year
genotyp
prevail
case
follow
case
genotyp
indetermin
genotyp
conclus
studi
follow
genotyp
difficult
treat
common
slovak
republ
howev
younger
popul
year
higher
incid
drug
addict
genotyp
prevail
infect
hcv
import
caus
viral
hepat
number
graviti
complic
addit
possibl
effect
treatment
studi
epidemiolog
characterist
infect
hcv
area
peopl
detect
carrier
preval
inhabit
averag
age
year
old
rang
correspond
major
men
averag
age
year
old
lower
women
global
genotyp
distribut
show
group
frequent
follow
although
genotyp
chang
base
paramet
like
coinfect
hiv
among
hiv
frequent
follow
etc
side
among
popul
hiv
frequent
follow
etc
genotyp
proport
far
global
distribut
sex
emphasis
predomin
genotyp
women
men
follow
similar
number
show
signific
differ
genotyp
relat
sex
sinc
detect
women
men
four
posit
percentag
next
group
relat
rout
infect
parenter
one
frequent
mainli
hiv
ad
whose
rout
could
sexual
addit
previou
one
rest
transmiss
rout
inferior
studi
year
sinc
infect
acquir
observ
nohiv
group
incid
vari
wherea
hiv
decreas
result
observ
exist
high
preval
hcv
sanitari
area
fundament
men
relat
infect
hiv
half
case
mainli
parenter
acquisit
tendenc
diminut
hiv
carrier
show
great
predomin
genotyp
vari
differ
popul
result
hcvgenotyp
patient
male
femal
age
vari
year
old
age
rang
year
old
year
old
year
old
distribut
genotyp
follow
two
sampl
nontyp
method
use
sent
sequenc
conclus
hcv
subtyp
preval
follow
subtyp
popul
studi
hcv
infect
preval
among
older
patient
year
old
gender
found
signific
factor
incub
h
c
stain
monoclon
antibodi
mop
c
trachomati
microtrak
ireland
use
direct
immunofluoresc
assay
result
studi
period
clinic
sampl
studi
urethr
sampl
male
c
trachomati
isol
sampl
femal
sampl
endocerv
obtain
gener
popul
five
posit
c
trachomati
group
prostitut
group
case
infect
c
trachomati
detect
p
sampl
studi
posit
c
trachomati
preval
infect
c
trachomati
last
year
geograph
area
balear
island
spain
follow
men
women
men
women
men
women
conclus
stabl
preval
infect
c
trachomati
observ
gener
popul
recent
year
posit
percentag
men
statist
higher
p
detect
women
highrisk
group
prostitut
preval
detect
valu
much
higher
p
gener
popul
similar
detect
men
clinic
diagnosi
urethr
aim
determin
whether
serolog
evid
ct
pregnanc
risk
factor
preterm
deliveri
week
gestat
total
women
found
seroposit
igg
antibodi
ct
similar
seroneg
women
respect
matern
age
histori
preterm
birth
obstetr
medic
problem
smoke
statu
histori
drug
abus
educ
statu
psychosoci
stressor
seroposit
women
significantli
like
seroneg
women
preterm
birth
vs
p
posit
predict
valu
seroposit
result
preterm
birth
five
neg
predict
valu
seroneg
result
preterm
birth
six
conclus
women
serolog
evid
ct
may
risk
preterm
birth
studi
requir
determin
whether
serolog
test
ct
routin
part
prenat
care
patient
address
patient
depart
unit
physician
differ
militari
region
univers
militari
hospit
specialist
question
clinic
exam
made
specimen
execut
laboratori
direct
optic
microscopi
exam
perform
immedi
specimen
afterward
isol
specif
medium
neisseria
gonorrhoea
gc
agar
polyvitex
identifi
nh
galleri
biomerieux
search
betalactamas
ngpp
strain
cefinas
test
biomerieux
suscept
antibiot
strain
n
gonorrhoea
test
agar
diffus
method
accord
nccl
research
c
trachomati
perform
dif
direct
immunofluoresc
monoclon
antibodi
elisa
antigen
mycoplasma
isol
specif
medium
mycoplasma
duo
biorad
mycoplasma
ist
biomerieux
aetiolog
agent
isol
identifi
accord
classic
method
result
urethr
specimen
analys
laboratori
posit
neg
repartit
aetiolog
agent
case
c
trachomati
case
n
gonorrhoea
case
ureaplasma
urealyticum
etc
mean
ngpp
incid
observ
crescent
evolut
incid
year
observ
also
resist
neisseria
gonorrhoea
cotrimoxazol
tetracyclin
conclus
result
show
c
trachomati
took
place
n
gonorrhoea
first
aetiolog
agent
urethr
countri
besid
observ
decreas
undetermin
aetiolog
urethr
rate
probabl
due
better
diagnost
therapeut
take
charg
diseas
result
strategi
adopt
sinc
militari
medium
background
chlamydia
trachomati
ct
neisseria
gonorrhoea
gc
easili
transmit
high
asymptomat
infect
rate
women
men
diagnost
treatment
goal
screen
sexual
activ
men
women
use
noninvas
sampl
test
sensit
specif
assay
method
total
women
eight
geograph
divers
preval
site
northern
america
enrol
consent
collect
two
cervic
swab
cs
one
cliniciancollect
vagin
swab
cv
patient
also
selfcollect
first
catch
urin
fcu
vagin
swab
pv
follow
simpl
set
illustr
instruct
sampl
test
ct
gc
aptima
combo
assay
aptima
ct
aptima
gc
assay
genprob
incorpor
pend
fda
clearanc
one
cs
fcu
test
bd
probetec
assay
becton
dickenson
vagin
swab
selfcollect
women
complet
questionnair
determin
eas
difficulti
collect
procedur
prefer
compar
biolog
behaviour
factor
result
preval
ct
gc
equal
determin
pv
cv
yield
equal
number
posit
patient
cs
fcu
assay
fcu
report
vagin
swab
selfcollect
easi
prefer
pv
pelvic
examin
urin
collect
pv
avail
investig
sexual
transmit
infect
sti
indic
would
get
test
often
factor
age
educ
english
second
languag
past
experi
sti
influenc
indic
prefer
conclus
data
indic
pv
test
ct
gc
aptima
assay
would
enabl
women
choos
noninvas
specimen
facilit
implement
screen
programm
object
observ
variat
gene
target
neisseria
gonorrhoea
molecular
type
method
appli
opatyp
recent
develop
sequencebas
method
ngmast
isol
sexual
contact
within
known
transmiss
chain
assess
level
discrimin
concord
afford
method
method
ngmast
involv
sequenc
intern
fragment
bp
two
highli
polymorph
loci
por
tbpb
encod
outer
membran
protein
porin
compon
transferringbind
protein
respect
uniqu
sequenc
por
tbpb
assign
allel
number
provid
gonococc
isol
two
digit
allel
profil
uniqu
allel
profil
assign
sequenc
type
st
ngmast
result
compar
opatyp
result
transmiss
chain
construct
identifi
sexual
contact
mutual
name
interview
result
total
transmiss
chain
identifi
compris
pair
chain
three
two
chain
five
one
chain
four
seven
eight
individu
isol
individu
avail
studi
chain
known
part
two
larger
cluster
ngmast
identifi
st
among
isol
patient
transmiss
chain
compar
opatyp
chain
st
opatyp
total
concord
two
chain
predominantli
concord
except
two
isol
differ
st
sexual
contact
singl
nonsynonym
substitut
por
chain
opatyp
differ
direct
contact
wherea
st
remain
consist
three
chain
opatyp
st
differ
sexual
contact
suggest
transmiss
multipl
strain
conclus
result
indic
sequenc
por
tbpb
gene
fragment
provid
somewhat
less
discrimin
analys
famili
opagen
former
procedur
simpler
produc
unambigu
data
ngmast
opatyp
highli
discriminatori
type
method
ngmast
identifi
larger
cluster
indistinguish
isol
wherea
opatyp
give
finer
discrimin
within
chain
may
often
result
isol
sexual
contact
appear
distinct
specimen
origin
cultur
select
agar
plate
oxoid
uk
identif
base
gramstain
posit
oxidas
reaction
follow
confirm
accuprob
n
gonorrhoea
idenf
test
genprob
inc
usa
micvalu
determin
use
agar
dilut
method
nccl
penicillin
tetracyclin
ceftriaxon
ciprofloxacin
betalactamas
test
use
nitrocefin
disc
method
ab
biodisk
solna
sweden
result
eleven
five
strain
cultur
year
respect
resist
rate
penicillin
tetracyclin
ceftriaxon
ciprofloxacin
vari
annual
year
highest
number
ciprofloxacinresist
isol
detect
ciprofloxacinresist
strain
period
n
resist
intermedi
penicillin
betalactamas
posit
five
neg
tetracyclin
seven
show
slightli
elev
micvalu
ceftriaxon
mcgml
accord
nccl
guidelin
interpret
nonsuscept
first
ciprofloxacinresist
isol
cultur
decemb
probabl
import
thailand
due
rapid
increas
ciprofloxacinresist
strain
ceftriaxon
replac
fluiroquinolon
drug
choic
novemb
ciprofloxacinresist
isol
found
contact
trace
interview
patient
unsuccess
molecular
type
conduct
analys
similar
n
gonorrhoeaestrain
conclus
observ
emphasis
import
continu
surveil
antimicrobi
suscept
n
gonorrhoea
isol
guid
treatment
therefor
cultur
remain
basic
laboratori
method
diagnosi
diseas
aim
studi
characteris
defin
pattern
mutat
gyra
parc
gene
gonococc
isol
method
suscept
test
perform
etest
method
follow
manufactur
procedur
cipr
strain
differenti
accord
serovar
pulsedfield
gel
electrophoresi
pfge
profil
mutat
two
target
gene
identifi
pcr
direct
sequenc
amplifi
product
result
april
novemb
isol
strain
cipr
n
gonorrhoea
mic
rang
mcgml
six
isol
patient
previou
ciprofloxacin
therapi
ten
also
penicillin
resist
mic
mcgml
cipr
strain
except
two
belong
serovar
ib
remain
crossreact
iaib
three
differ
unrel
pfge
profil
identifi
dna
sequenc
show
common
mutat
amino
acid
substitut
phe
gli
ala
gyra
asn
asn
arg
ly
parc
mutat
pro
found
one
strain
parc
gene
conclus
resist
present
among
differ
type
strain
suggest
incid
cipr
strain
itali
exclus
due
appear
singl
clone
crossresist
ciprofloxacin
structur
unrel
penicillin
observ
alreadi
describ
strain
harbour
mutat
gyra
gene
ciprofloxacin
recommend
first
line
therapi
gonorrhoea
emerg
signific
resist
taken
account
therapeut
choic
background
neisseria
gonorrhoea
adept
develop
mechan
resist
antimicrobi
agent
continu
need
inform
antimicrobi
suscept
pattern
describ
suscept
n
gonorrhoea
isol
five
antibiot
main
group
use
treatment
gonorrhoea
russia
ciprofloxacin
penicillin
ceftriaxon
erythromycin
tetracyclin
method
isol
n
gonorrhoea
obtain
mail
patient
acut
urethr
visit
three
sexual
transmit
diseas
clinic
moscow
decemb
may
suscept
antibiot
determin
agar
dilut
method
use
gcii
agar
base
isovitalex
supplement
twofold
dilut
antibiot
accord
nccl
qualiti
control
use
n
gonorrhoea
atcc
betalactamas
product
test
use
nitrocefin
disk
cefinas
bbl
microbiolog
system
result
one
strain
n
gonorrhoea
blactamas
posit
though
isol
sensit
penicillin
lgml
resist
tetracyclin
slightli
lower
strain
sensit
strain
intermedi
resist
mic
lgml
activ
ceftriaxon
lgml
n
gonorrhoea
isol
suscept
unexpect
result
detect
high
level
resist
fluoroquinolon
isol
resist
lgml
strain
suscept
erythromycin
intermedi
resist
lgml
conclus
studi
indic
high
level
resist
penicillin
probabl
relat
chromosom
resist
fluoroquinolon
resist
neisseria
gonorrhoea
emerg
russia
ceftriaxon
erythromycin
activ
drug
ureaplasma
urealyticum
isol
male
patient
urethr
sever
antibiot
includ
telithromycin
aydin
kbasmaci
n
z
akta
object
despit
report
antibiot
resist
neisseria
gonorrhoea
ureaplasma
urealyticum
world
studi
antibiot
suscept
pathogen
turkey
goal
studi
determin
antibiot
suscept
n
gonorrhoea
u
urealyticum
strain
isol
istanbul
method
mic
telithromycin
azithromycin
clarithromycin
erythromycin
gemifloxacin
moxifloxacin
levofloxacin
ciprofloxacin
ofloxacin
norfloxacin
doxycyclin
tetracyclin
n
gonorrhoea
u
urealyticum
strain
isol
caus
urethr
determin
compar
addit
activ
penicillin
ceftriaxon
n
gonorrhoea
strain
explor
result
suscept
rate
penicillin
tetracyclin
n
gonorrhoea
strain
respect
gonococc
strain
suscept
ceftriaxon
low
mic
mgml
quinolon
resist
detect
singl
strain
n
gonorrhoea
ciprofloxacin
activ
quinolon
n
gonorrhoea
mgml
gemifloxacin
moxifloxacin
activ
u
urealyticum
mgml
quinoloneresist
n
gonorrhoea
strain
mic
mgml
telithromycin
highli
activ
n
gonorrhoea
u
urealyticum
strain
mgml
mgml
respect
conclus
due
low
suscept
rate
tetracyclin
penicillin
option
empir
treatment
n
gonorrhoea
infect
still
resist
intermedi
suscept
even
decreas
suscept
ceftriaxon
among
gonococci
ceftriaxon
continu
first
choic
antibiot
treatment
gonococc
urethr
coinfect
due
n
gonorrhoea
u
urealyticum
ketolid
telithromycin
may
use
treatment
altern
accord
vitro
result
find
support
clinic
studi
within
quinolon
ciprofloxacin
still
effect
n
gonorrhoea
mycoplasma
homini
among
immigr
prostitut
nonselect
patient
noviello
v
cuniato
f
bellitti
e
nocera
esposito
napl
object
ureaplasma
urealyticum
mycoplasma
homini
frequent
isol
urogenit
tract
associ
differ
clinic
syndrom
assum
particular
epidemiolog
import
prostitut
due
possibl
sexual
transmiss
evalu
u
urealyticum
homini
preval
possibl
relationship
behaviour
risk
factor
prospect
studi
carri
immigr
prostitut
subsaharian
area
nonselect
patient
clinic
sign
urogenit
infect
patient
method
immigr
prostitut
averag
age
year
nonselect
patient
resid
napl
averag
age
year
underw
microbiolog
investig
detect
possibl
presenc
mycoplasm
endocerv
swab
possibl
associ
bacteri
pathogen
mycoplasma
identif
coloni
count
vitro
suscept
test
erythromycin
e
josamycin
tetracyclin
doxiciclin
ofloxacin
ofx
perform
mean
mycoplasma
ist
kit
identif
microorgan
base
morpholog
featur
biochem
test
api
system
result
overal
posit
sampl
uccml
detect
immigr
prostitut
nonselect
patient
respect
u
urealyticum
isol
immigr
prostitut
nonselect
patient
contemporari
detect
u
urealyticum
homini
note
seven
immigr
prostitut
three
nonselect
patient
associ
mycoplasm
gardnerella
vaginali
observ
immigr
prostitut
nonselect
patient
immigr
prostitut
group
detect
mycoplasm
relat
number
daili
sexual
partner
condom
use
number
partner
result
posit
respect
condom
usenot
use
posit
suscept
pattern
mycoplasm
rang
e
ofx
drug
conclus
incid
mycoplasm
immigr
prostitut
higher
nonselect
patient
correl
number
welldefin
risk
factor
rate
resist
convent
drug
remain
low
noviello
v
cuniato
f
bellitti
e
nocera
esposito
napl
object
immigr
reach
big
proport
western
countri
poor
econom
social
condit
immigr
togeth
difficulti
access
healthcar
institut
proper
sanitari
inform
constitut
enorm
risk
acquir
andor
transmit
sexual
transmit
diseas
within
project
aim
make
easi
immigr
access
social
sanitari
facil
educ
sanitari
prevent
intervent
carri
epidemiolog
survey
among
immigr
evalu
incid
main
sexual
transmit
diseas
order
realis
proper
educ
program
direct
sexual
transmit
diseas
prevent
major
prematur
deliveri
particularli
end
hbd
bacteri
infect
fetal
egg
involv
prematur
deliveri
prematur
fetal
membran
break
frequent
connect
bacteri
vaginosi
uti
gonococc
streptococc
cervic
infect
howev
role
infect
caus
chlamydia
mycoplasma
ureaplasma
trichomona
candida
fulli
understood
recent
mycoplasma
ureaplasma
isol
vagin
potenti
pathogen
respons
prematur
deliveri
object
aim
work
epidemiolog
microbiolog
clinic
characterist
infect
connect
prematur
deliveri
prematur
fetal
membran
break
method
eightyseven
pregnant
patient
prematur
deliveri
symptom
preterm
ruptur
oocyst
membran
examin
cervic
swab
taken
cultur
identif
perform
standard
method
isol
identif
mycoplasma
mycoplasma
duo
test
agar
biomerieux
use
one
isol
studi
resist
antibiot
test
nevertheless
resist
one
antibiot
quit
frequent
especi
genit
mycoplasma
present
frequenc
acquir
resist
justifi
modif
usual
treatment
genit
mycoplasma
infect
result
label
chromosom
dna
use
random
hexam
hybridis
dna
microarray
least
paraluiscuniculi
gene
show
significantli
lower
signal
compar
signal
pallidum
ssp
pallidum
gene
cluster
least
five
chromosom
region
vicin
tpr
region
code
hypothet
protein
unknown
function
pcr
amplif
subsequ
restrict
analysi
paraluiscuniculi
pallidum
ssp
pallidum
genom
reveal
differ
nine
bamh
target
site
four
deletionsinsert
paraluiscuniculi
chromosom
among
gene
test
realtim
rtpcr
show
signific
differ
gene
express
gener
gene
encod
protein
involv
electron
transport
less
express
paraluiscuniculi
higher
express
observ
gene
encod
tpr
protein
sequenc
kb
paraluiscuniculi
genom
short
region
dispers
throughout
chromosom
reveal
averag
one
nucleotid
chang
per
bp
conclus
observ
differ
genom
content
composit
provid
insight
differ
pathogen
potenti
treponem
help
defin
genet
basi
syphili
syphili
infecti
diseas
sexual
transmit
obligatori
declar
whose
pathogen
agent
treponema
pallidum
appear
clinic
success
phase
treponema
highlight
direct
indirect
method
exist
quiet
clinic
phase
diagnosi
current
possibl
test
serolog
one
major
difficulti
track
syphili
constitut
accus
psychiatr
caus
carri
research
neurosyphili
systemat
inde
associ
neurolog
syndrom
abl
lead
complet
physic
forfeitur
drive
psychiatr
syndrom
true
irrat
state
work
concern
serum
lcr
spinal
punctur
come
patient
address
psychiatr
hospit
razi
januari
decemb
serolog
syphili
neurosyphili
half
patient
age
rang
year
unmarri
without
job
syphilit
serolog
compris
time
two
reaction
agglutin
vdrl
coal
specif
passiv
haemagglutin
tpha
result
show
preval
diseas
syphilit
serum
neurolog
man
conform
literatur
preval
serum
syphili
higher
age
break
rang
year
count
year
neurosyphili
declar
patient
unmarri
reflexion
great
freedom
manner
without
job
better
social
integr
could
make
regress
diseas
notic
preval
decreas
syphilit
serolog
pass
year
itali
hav
infect
declin
last
decad
improv
socialeconom
hygien
condit
leav
grow
percentag
young
adult
unprotect
hav
infect
vaccin
protect
travel
direct
toward
highli
endem
countri
becom
rel
common
practic
protect
great
major
hav
infect
acquir
oral
rout
report
nation
case
seieva
report
young
unprotect
msm
hav
must
consid
sexual
transmit
diseas
need
hav
vaccin
within
risk
group
must
evalu
potenti
sever
evolut
diseas
adult
high
preval
ttv
infect
recent
report
among
blood
donor
patient
liver
diseas
howev
gbvchgv
diseas
potenti
ttv
princip
mode
transmiss
unclear
assess
possibl
sexual
transmiss
ttv
examin
preval
ttv
viraemia
among
femal
sexual
worker
warsaw
demonstr
exposur
rout
subject
simultan
examin
infect
associ
risk
behaviour
hbv
hcv
hgvgbvc
method
presenc
hbv
hcv
hgv
ttv
analys
plasma
sampl
commerci
sex
worker
csw
uninfect
csw
blood
donor
preval
hbv
hcv
hgv
ttv
estim
basi
polymeras
chain
reaction
pcr
result
preval
hbv
blood
donor
neg
csw
csw
preval
hcv
blood
donor
neg
csw
csw
preval
hgv
group
respect
preval
ttv
exposur
std
clinic
statist
signific
higher
comparison
subject
std
vs
without
std
preval
ttv
hivneg
csw
vs
basi
pcr
result
statist
signific
higher
preval
hepat
b
viru
hepat
c
viru
hgvgbvc
exposur
std
clinic
compar
group
never
receiv
treatment
std
patient
divid
three
rel
equal
group
number
group
without
signific
patholog
chang
group
b
cervic
dysplasia
differ
stage
group
c
cervic
carcinoma
confirm
cytolog
colposcop
result
signific
risk
occurr
cervic
dysplasia
carcinoma
associ
initi
sexual
activ
year
age
one
pregnancyabort
year
age
three
sexual
partner
lifetim
previou
sexual
transmit
diseas
use
empir
local
contracept
eg
vitamin
c
quinin
year
low
socioeconom
statu
smoke
cigarett
per
day
moment
diagnosi
preval
infecti
factor
higher
group
b
c
group
trichomona
vaginali
group
b
group
c
compar
group
candida
albican
group
b
group
c
compar
group
gramneg
gramposit
cocci
group
b
group
c
group
enterobacteriacea
group
b
group
c
group
coccobacilli
group
b
group
c
group
conclus
carcinogenesi
uterin
cervix
multifactori
process
involv
differ
factor
intric
condit
factor
determin
socal
sexual
pollut
regard
ambient
sexual
habit
contamin
bacteri
viral
parasit
germ
primari
prophylaxi
cervic
carcinoma
conceiv
without
take
consider
factor
diagnost
method
antibiot
suscept
direct
suscept
test
posit
bac
alert
blood
cultur
disk
diffus
preliminari
bacteri
identif
mansoor
e
deberg
p
ninfa
c
leroy
baudour
b
object
procedur
describ
nccl
suscept
test
requir
subcultur
broth
agar
media
result
avail
clinician
h
posit
blood
cultur
outcom
patient
septicaemia
depend
earli
treatment
appropri
antimicrobi
agent
studi
evalu
suscept
result
obtain
use
bacteri
pellet
preliminari
classif
bacteria
base
tube
coagulas
tct
cytochrom
oxidas
test
cot
result
cot
tct
test
obtain
min
h
respect
help
choic
antibiot
method
bacteri
pellet
obtain
centrifug
aliquot
cultur
broth
serum
separ
tube
bacteria
collect
gel
cotton
swab
suspens
equival
mc
farland
mcf
made
coloni
count
perform
order
ascertain
proper
coloni
densiti
use
suscept
test
done
three
inocula
directli
one
drop
broth
nonstandardis
inoculum
nsi
mueller
hinton
agar
oxacillin
screen
vancomycin
screen
plate
tct
cot
test
perform
bacteri
pellet
obtain
centrifug
total
signific
posit
blood
cultur
investig
isol
per
patient
gramneg
antimicrobi
agentorgan
combinationsaaoc
gramposit
aaoc
isol
analys
score
system
adopt
analysi
discrep
point
major
error
fals
suscept
vme
point
major
error
fals
resist
mae
point
minor
error
mie
point
error
object
aim
evalu
accuraci
direct
inocul
card
posit
blood
cultur
bottl
achiev
rapid
bacteri
identif
id
antibiot
suscept
test
ast
method
posit
bactalert
blood
cultur
sampl
includ
direct
inocul
bacteri
suspens
vitek
id
ast
card
made
differenti
centrifug
blood
cultur
type
vitek
id
ast
card
inocul
gramneg
staphylococci
streptococci
enterococci
select
accord
morpholog
organ
direct
gramstain
result
rapid
method
compar
routin
method
base
api
identif
system
ast
kirbybau
disc
diffus
method
accord
nccl
guidelin
result
total
clinic
relev
isol
investig
overal
correctli
identifi
speci
level
sixtythre
strain
could
identifi
due
variou
reason
haemolysi
insuffici
bacteri
pellet
residu
trace
charcoal
strain
misidentifi
rapid
method
prove
mostli
accur
id
enterobacteriacea
eb
enterococci
gramneg
nonferment
gnnf
streptococci
staphylococci
correct
id
direct
suscept
perform
strain
eb
gnnf
staphylococci
includ
antibioticisol
combin
gave
overal
essenti
agreement
discord
correspond
minor
error
major
r
routin
test
major
error
r
routin
test
found
organismantibiot
combin
respect
rate
agreement
rapid
convent
method
rang
depend
antibiot
cluster
discord
specif
antibioticisol
combin
report
time
direct
test
suscept
antibiot
blood
cultur
isol
system
rang
h
conclus
direct
inocul
directli
applic
routin
method
id
ast
eb
enterococci
gnnf
staphylococci
streptococci
compar
convent
method
requir
day
method
make
sameday
report
possibl
may
thu
permit
better
patient
manag
antibiot
suscept
test
pathogen
isol
icu
use
uroquick
system
roveta
f
cavallini
marches
ea
debbia
genoa
object
uroquick
automat
instrument
wide
use
screen
bacteriuria
previous
employ
detect
antibiot
resist
wellcharacteris
bacteri
strain
j
chemoth
press
uropathogen
studi
pathogen
isol
icu
great
italian
hospit
period
septembernovemb
examin
employ
kirbybau
techniqu
antibiot
suscept
test
usual
system
compar
new
rapid
uroquick
method
method
antibiot
appropri
concentr
introduc
vial
contain
ml
muellerhinton
mh
broth
ml
broth
contain
cellsml
strain
test
ad
vial
contain
antimicrobi
molecul
even
drugfre
vial
control
h
incub
gramneg
gramposit
strain
respect
instrument
print
result
growth
growth
curv
like
control
repres
suscept
resist
strain
respect
gram
neg
strain
test
ciprofloxacin
gramneg
strain
test
gramposit
agreement
two
method
gramneg
sxt
ctx
cip
gm
cro
caz
ipm
cxm
amc
tzp
atm
gramposit
lzd
cm
ipm
va
cip
ra
te
sxt
e
oxa
p
gm
pathogen
conclus
major
pathogen
staphylococci
enterococci
enterobacteriacea
agreement
uroquick
system
kirbybau
method
alway
basi
present
find
rapid
method
appear
use
sever
nosocomi
infect
rapid
detect
h
antibiot
suscept
allow
direct
treatment
reduc
empir
therapi
diffus
resist
pathogen
ac
strain
bias
toward
resist
variou
antimicrobi
agent
identif
antimicrobi
suscept
test
run
three
system
simultan
suscept
interpret
made
expert
system
use
comparison
refer
identif
api
pcr
suscept
discrep
assess
agar
dilut
mic
determin
nccl
method
result
accuraci
identif
speci
level
ph
compar
refer
identif
respect
sa
cn
en
nf
sa
major
minor
discrep
suscept
categoris
system
organismag
combin
test
cn
major
minor
discrep
organismag
combin
test
discrep
common
oxacillin
staphylococci
fewer
discrep
ph
either
ph
en
major
minor
discrep
suscept
categoris
among
organismag
combin
test
nf
major
minor
discrep
suscept
among
organismag
combin
test
conclus
identif
system
gener
reliabl
sa
en
nf
although
report
strain
pseudomona
spp
acinetobact
spp
nonferment
identif
cn
speci
level
less
reliabl
particularli
system
collect
includ
high
proport
resist
organ
good
agreement
suscept
categoris
system
sa
less
organ
detect
extendedspectrum
betalactamas
esbl
clinic
strain
k
pneumonia
e
coli
object
aim
studi
compar
effect
two
disc
method
etest
appli
detect
esbl
method
test
clinic
strain
e
coli
strain
k
pneumonia
strain
examin
use
follow
test
doubledisc
synergi
test
ddst
accord
jarlier
cefotaxim
ceftazidim
aztreonam
clavulan
acid
disc
test
accord
appleton
cefpodoxim
cefpodoxim
clavulan
acid
also
etest
cefotaxim
cefotaxim
clavulan
acid
ceftazidim
ceftazidim
clavulan
acid
result
case
k
pneumonia
activ
esbl
detect
among
strain
jarlier
test
appleton
test
etest
among
e
coli
four
strain
found
esblposit
jarlier
test
howev
three
strain
esblposit
appleton
test
etest
use
conclus
esbl
must
routin
detect
clinic
strain
e
coli
k
pneumonia
method
use
detect
esbl
k
pneumonia
strain
equal
effect
two
test
appleton
test
etest
found
use
detect
esbl
e
coli
strain
sensit
costeffect
differ
phenotyp
method
detect
confirm
extendedspectrum
betalactamas
includ
inexpens
novel
method
r
colodn
n
keller
b
chazan
r
raz
afula
tel
hashom
il
object
evalu
sensit
costeffect
extendedspectrum
betalactamas
esbl
detect
confirm
method
countri
includ
inexpens
modif
origin
jarlier
method
method
sensit
costeffect
singl
disk
diffus
test
sddt
inhibitor
potenti
doubl
disk
ipdd
etest
evalu
collect
esblposit
organ
isol
israel
includ
e
coli
klebsiella
spp
proteu
spp
enterobact
spp
addit
aproxim
test
modif
origin
jarlier
method
use
first
secondgener
cephalosporin
evalu
result
sensit
differ
method
vari
sddt
ceftazidim
etest
cefotaxim
alon
sever
combin
test
reach
sensit
conclus
ipdd
use
cefotaxim
ceftazidim
ceftazidim
cefpodoxim
prove
best
option
countri
term
sensit
costeffect
howev
cephalotin
cefuroxim
inexpens
method
use
first
screen
esbl
accept
result
object
carbapenem
resist
mediat
acquir
metalloblactamas
mbl
imp
vim
type
increas
sever
countri
particularli
among
pseudomona
aeruginosa
clinic
isol
limit
use
betalactam
purpos
studi
evalu
perform
etest
mbl
phenotyp
test
commonli
use
detect
metalloblactamas
p
aeruginosa
region
highpreval
mblproduc
pseudomonad
method
eightyeight
clinic
isol
p
aeruginosa
resist
imipenem
meropenem
isol
year
separ
patient
univers
hospit
thessali
includ
studi
suscept
isol
variou
antibiot
includ
carbapenem
examin
disk
diffus
method
detect
gene
blaimp
blavim
code
mbl
describ
mediterranean
region
perform
polymeras
chain
reaction
pcr
use
consensu
primer
gene
final
isol
test
etest
mbl
strip
accord
manufactur
ab
biodisk
solna
sweden
result
fiftyf
isol
show
posit
result
presenc
blavim
pcr
blaimp
gene
detect
isol
test
etest
mbl
indic
mbl
product
edta
potenti
imipenem
activ
time
two
blavim
posit
isol
posit
addit
isol
neg
pcr
reaction
two
isol
etest
mbl
neg
pcr
gave
specif
pcr
product
isol
exhibit
mic
carbapenem
mg
l
imipenemimipenem
plu
edta
ratio
carri
blavim
cgene
discrep
observ
isol
carbapenem
mic
mgl
conclus
etest
mbl
strip
quick
easi
method
perform
routin
clinic
laboratori
discrep
detect
lowlevel
carbapenemresist
isol
suggest
case
use
method
may
requir
use
addit
assay
pcr
casfm
franc
publish
ast
standard
interpret
vitro
suscept
result
standard
also
includ
relev
therapi
warn
guidelin
interpret
intrins
suscept
resist
crossresist
appropri
inform
commun
assist
clinician
select
optim
therapi
patient
streptococc
infect
bdxpert
system
develop
bd
phoenix
tm
system
bd
epicent
tm
interpret
ast
test
result
commun
appropri
comment
recommend
nccl
sfm
studi
evalu
function
expert
rule
creat
specif
interpret
ast
result
str
method
comment
list
nccl
casfm
report
convert
expert
rule
use
bdxpert
system
special
rule
creat
detect
follow
resist
marker
highlevel
penicillin
resist
hlpsp
lowlevel
penicillin
resist
llpsp
pneumonia
sp
induc
mlsb
efflux
meff
constitut
mlsb
mlsb
resist
highlevel
streptomycin
hlsr
gentamicin
kanamycin
hlkr
action
associ
messag
implement
specifi
standard
document
total
challeng
strain
possess
resist
mechan
select
base
previous
determin
genotyp
phenotyp
characterist
evalu
effect
bdxpert
rule
report
review
least
two
human
expert
accuraci
action
messag
result
mic
valu
interpret
correctli
accord
breakpoint
respect
standard
evalu
sp
isol
use
nccl
sfm
criteria
demonstr
correct
detect
hlpsp
llpsp
meff
mlsb
sfm
criteria
appli
hlsr
hlkr
also
detect
strain
pyogen
strain
test
meff
mlsb
phenotyp
detect
three
strain
expert
messag
identifi
intrins
resist
commun
appropri
therapeut
warn
consist
ast
result
speci
conclus
bdxpert
system
reliabl
detect
report
resist
marker
str
special
messag
includ
therapi
warn
intrins
resistancesuscept
crossresist
use
commun
time
accur
inform
clinician
proper
antimicrobi
therapi
conclus
falseposit
result
studi
indic
fep
ae
ca
use
cautious
esbl
detect
ec
kl
furthermor
fep
ae
ca
reliabl
detect
like
esbl
especi
mb
test
fep
ae
ca
use
esbl
detect
en
coproduc
ampc
betalactamas
confirm
panel
enterobacteriaceaeproduc
extendedspectrum
betalactamas
e
cercenado
n
j
garciamartinez
e
bouza
madrid
e
object
increas
emerg
enterobacteriaceaeproduc
extendedspectrumbetalactamas
esbl
caus
concern
detect
import
laboratori
evalu
microscan
esbl
plu
confirm
panel
dade
behr
sacramento
ca
usa
detect
enterobacteriaceaeproduc
esbl
speci
method
twohundr
strain
studi
isol
patient
institut
belong
welldefin
previous
publish
collect
entrobacteriacea
differ
resist
mechan
three
control
strain
e
coli
atcc
k
pneumonia
atcc
p
aeruginosa
atcc
total
isol
produc
esbl
compris
strain
target
nccl
esbl
test
e
coli
k
oxytoca
k
pneumonia
nontarget
strain
salmonella
spp
p
mirabili
marcescen
enterobact
spp
c
freundii
addit
test
ampchyperproduc
ampch
e
coli
k
oxytoca
two
ampch
e
cloaca
suscept
test
perform
broth
microdilut
method
follow
manufactur
instruct
read
perform
visual
h
incub
c
result
sensit
specif
microscan
panel
target
bacteria
respect
sensit
specif
nontarget
bacteria
respect
eighteen
strain
classifi
incorrectli
isol
k
oxytoca
ampch
e
coli
misidentifi
esbl
produc
seven
esblposit
isol
detect
e
coli
strain
k
pneumonia
salmonella
spp
c
freundii
e
cloaca
marcescen
seven
strain
synergi
effect
clavulan
acid
observ
doubledisk
synergi
test
use
cefepim
disk
chromosom
ampcproduc
microorgan
might
produc
high
level
ampc
addit
esbl
mic
cefoxitin
mgl
remain
esblproduc
show
either
high
low
ceftazidim
cefotaxim
mic
conclus
microscan
esbl
plu
confirm
panel
show
excel
perform
detect
target
microorgan
although
misidentif
nonesbl
produc
esbl
produc
frequent
k
oxytoca
addit
cefepim
clavulan
acid
panel
may
significantli
improv
detect
esblproduc
strain
object
evalu
countrywid
level
profici
italian
laboratori
detect
betalactam
resist
phenotyp
includ
mediat
extendedspectrum
betalactamas
esbl
wellcharacteris
isol
enterobacteriacea
method
june
clinic
microbiolog
laboratori
locat
differ
italian
region
enter
nationwid
profici
studi
particip
laboratori
receiv
five
wellcharacteris
strain
enterobacteriacea
produc
esbl
klebsiella
klebsiella
proteu
escherichia
k
two
hyperproduc
chromosom
enzym
ampchyperproduc
e
coli
k
oxytoca
addit
three
refer
strain
e
coli
atcc
e
coli
atcc
pseudomona
aeruginosa
atcc
also
provid
blind
intern
qualiti
control
laboratori
request
use
routin
method
identif
suscept
test
ast
expect
result
establish
two
independ
refer
laboratori
accord
nccl
guidelin
result
identif
speci
genu
level
correctli
report
case
respect
perform
ast
differ
depend
speci
type
esbl
produc
approxim
laboratori
fail
appli
nccl
rule
klebsiella
spp
produc
shvtype
esbl
case
major
error
mostli
relat
cefotaxim
ceftriaxon
cefepim
higher
rate
failur
occur
detect
esbl
phenotyp
e
coli
p
mirabili
two
strain
incorrectli
report
suscept
ceftazidim
case
respect
contrari
isol
hyperproduc
chromosom
enzym
correctli
report
frequent
although
esblmedi
resist
mechan
erron
report
case
notabl
centr
use
confirmatori
test
esbl
product
conclus
detect
esbl
still
problem
clinic
laboratori
laboratori
method
ast
appear
perform
better
well
known
enzym
involv
wherea
fail
report
resist
face
emerg
enzym
eg
ctxmtype
organ
well
recognis
esblproduc
current
intern
guidelin
eg
p
mirabili
object
aim
studi
compar
differ
phenotyp
method
detect
methicillinresist
staphylococcu
aureu
appear
methicillin
suscept
vitek
carri
meca
gene
method
novemb
june
strain
mrsa
detect
multiplex
pcr
analysi
nuca
meca
rrna
gene
among
strain
appear
methicillin
suscept
vitek
suscept
card
compar
discdiffus
method
use
oxacillin
mg
casfm
breakpoint
cefoxitin
mg
inhibit
diamet
mm
ii
agar
dilut
mic
iii
atb
staph
system
iv
standard
etest
procedur
popul
analysi
profil
method
use
detect
heteroresist
level
result
methicillin
resist
demonstr
among
strain
use
agar
dilut
mic
strain
disk
diffus
method
use
oxacillin
disk
strain
use
standard
etest
strain
use
atb
staph
system
strain
discdiffus
method
use
cefoxitin
disk
popul
analysi
profil
method
demonstr
extrem
heteroresist
among
strain
test
compat
tomasz
class
nativ
popul
class
conclus
data
suggest
mrsa
strain
undetect
vitek
could
classifi
heteroresist
mrsa
pcr
detect
meca
gene
repres
gold
standard
methicillinresist
diagnosi
though
cefoxitin
disk
diffus
actual
consid
accur
phenotyp
method
detect
methicillin
resist
among
aureu
howev
clinic
relev
heteroresist
strain
remain
evalu
wenger
nahimana
g
prodhom
j
bill
k
jaton
lausann
ch
object
test
nonselect
clinic
strain
staphylococci
oxacillin
ox
suscept
instrument
kirbybau
kb
devis
strategi
solv
discrep
method
month
august
clinic
signific
staphylococci
isol
laboratori
except
blood
cultur
isol
test
simultan
ast
card
ox
disc
diffus
use
nccl
guid
line
interpret
criteria
discrep
three
test
ox
calcul
mic
oxmic
growth
presenc
mgl
ox
nacl
oxst
disc
diffus
oxkb
resolv
follow
complementari
test
induc
meca
gene
pcr
identif
speci
level
coagulaseneg
staphylococci
cn
result
aureu
sa
mrsa
cn
mrse
test
bacteri
suspens
could
prepar
primari
plate
sa
cn
two
strain
need
repetit
mix
inoculum
sa
eight
cn
capiti
epidermidi
lugdunensi
saprophyticu
need
complementari
test
meca
gene
neg
epidermidi
strain
posit
sa
four
fals
mrsa
flag
advanc
expert
system
discord
oxmic
oxst
eight
cn
five
saprophyticu
fals
mrse
oxmic
oxkb
lugdunensi
oxmic
one
capiti
flag
growth
oxst
well
last
mr
epidermidi
miss
oxkb
thu
routin
set
ppvnpv
detect
methicillin
resist
sa
vs
cn
vs
comparison
figur
kb
vs
conclus
found
strategi
combin
oxkb
induc
detect
best
way
safe
detect
mix
inocula
quickli
solv
either
flag
result
discord
three
test
allow
us
special
improv
specif
methicillin
detect
cn
strain
identifi
biochem
automat
atb
express
system
id
staph
strip
biomerieux
poland
accord
recommend
produc
identif
confirm
slidex
staphkit
biomerieux
poland
methicillin
resist
mr
determin
discdiffus
method
accord
nccl
recommend
use
muellerhinton
agar
biomerieux
poland
mcg
oxacillin
disc
oxoid
ltd
england
atb
express
system
atb
staph
strip
version
accord
recommend
produc
biomerieux
poland
result
total
number
aureu
strain
examin
determin
methicillin
resist
method
mention
case
cultur
strain
consist
result
method
obtain
proper
result
control
strain
achiev
thirti
clinic
strain
aureu
examin
strain
show
methicillin
resist
method
strain
indic
mssa
case
four
strain
result
method
inconsist
conclus
high
consist
result
two
method
discdiffus
atb
staph
version
appli
detect
methicillinresist
aureu
mrsa
strain
reveal
atb
staph
version
test
seem
equal
effici
routin
determin
mrsa
mssa
strain
discdiffus
method
may
use
altern
object
sinc
isol
frequenc
methicillinresist
staphylococcu
aureu
mrsa
switzerland
rise
set
find
screen
method
optim
sensit
mrsa
recoveri
among
protocol
implement
countri
two
method
use
muellerhintonoxacillin
enrich
broth
combin
mannitolsalt
agar
subcultur
mhomsa
mannitolsalt
broth
combin
mannitolsaltoxacillin
agar
msb
mso
frequent
use
major
laboratori
although
method
abl
identifi
mrsa
carrier
investig
abil
identifi
possibl
lower
level
mrsa
carriag
decontamin
patient
carrier
method
compar
two
method
use
clinic
sampl
mrsa
screen
addit
challeng
sensit
vitro
lower
level
mrsa
load
cfu
use
well
characteris
mrsa
strain
differ
incub
period
h
result
clinic
sampl
mhomsa
msbmso
isol
respect
p
howev
vitro
studi
show
load
mrsa
cfu
sensit
mhomsa
msbmso
p
h
incub
h
incub
isol
rate
mhomsa
msbmsa
shorter
incub
time
lower
mrsa
load
result
even
poorer
yield
mhomsa
msbmso
remain
highli
sensit
conclus
method
appear
equal
sensit
appli
clinic
sampl
untreat
mrsa
carrier
low
mrsa
number
shorter
incub
time
howev
msb
mso
significantli
superior
mhomsa
also
found
mrsa
workup
incub
less
tediou
laboratori
msbmso
method
gu
fca
itr
nccl
microdilut
macrodilut
method
amb
rang
mic
modal
mic
valu
within
dilut
three
method
antifung
except
itr
among
seven
isol
known
mechan
resist
azol
correctli
detect
eucast
atb
fungu
method
one
nccl
among
isol
found
resist
suscept
dose
depend
fca
either
one
refer
method
number
minor
major
major
discrep
accordingli
nccl
breakpoint
found
one
method
comparison
two
other
follow
respect
eucast
nccl
atb
fungu
conclus
comparison
nccl
eucast
e
di
atb
fungu
show
good
essenti
agreement
method
antifung
agent
except
itr
atb
fungu
vs
eucast
vrc
eucast
vs
nccl
particular
isol
found
resist
one
refer
method
major
major
discrep
observ
accord
studi
refer
method
atb
fungu
show
similar
perform
result
sabouraud
gentamicin
chloramphenicol
secondgener
select
media
recommend
isol
yeast
mould
clinic
sampl
sabouraud
gentamicin
chloramphenicol
sgc
reformul
order
improv
pigment
mould
fertil
yeast
object
purpos
studi
compar
perform
term
fertil
pigment
select
sgc
method
ninetyseven
microorgan
yeast
mould
bacteria
test
parallel
two
sgc
media
refer
medium
sabouraud
dextros
yeast
mould
trypticas
soya
agar
bacteria
fungi
inocul
use
techniqu
allow
enumer
incub
yeast
incub
day
c
mould
c
andor
c
day
accord
media
packag
insert
inform
bacteria
inocul
semiquantit
cultur
method
loop
incub
day
c
enumer
growth
intens
morpholog
coloni
studi
simultan
media
incub
result
yeast
inocul
grew
refer
medium
enabl
growth
strain
wherea
strain
grew
sgc
h
incub
mould
incub
c
day
strain
show
growth
refer
medium
enabl
growth
strain
correct
morpholog
sgc
nine
strain
show
growth
three
gave
expect
colour
ambient
temperatur
day
strain
grew
refer
medium
sixteen
mould
grew
among
show
expect
pigment
wherea
three
strain
observ
right
aspect
sgc
bacteria
test
strain
grew
sgc
h
respect
conclus
medium
significantli
superior
sgc
growth
mould
yeast
select
bacteria
equival
new
formula
demonstr
good
capac
obtain
coloni
specif
morpholog
import
orient
diagnosi
fungal
infect
oxacillin
suscept
test
oxacillin
agar
screen
method
lgml
oa
oxacillin
cefoxitin
disk
diffus
method
autom
phoenix
system
oxacillin
disk
diffus
determin
two
method
accord
nccl
recommend
oxacillin
lg
c
h
incub
french
casfm
recommend
oxacillin
lg
c
h
incub
oxacillin
cefoxitin
mic
determin
agar
dilut
method
oxacillin
resist
confirm
multiplex
pcr
meca
gene
result
overal
sensit
oxacillin
resist
detect
oa
phoenix
respect
method
fulli
specif
method
show
sensit
epidem
mrsa
contrast
heteromrsa
isol
detect
sensit
oa
phoenix
respect
disk
diffus
method
interpret
h
incub
strain
fals
report
suscept
h
cefoxitin
test
show
mic
lg
ml
agar
dilut
phoenix
system
mrsa
strain
zone
diamet
cefoxitin
mm
disk
diffus
conclus
cefoxitin
test
disk
diffus
phoenix
system
sensit
specif
method
oxacillin
resist
detect
particularli
heteromrsa
strain
autom
system
need
optimis
detect
lowlevel
mrsa
strain
object
laboratori
diagnosi
pertussi
isol
identif
bacteria
hamper
difficulti
test
earli
sampl
taken
acut
phase
diseas
happen
studi
seroconvers
pair
sera
difficult
acut
neg
sampl
quantif
antibodi
pertussi
toxin
pt
singl
serum
sampl
suggest
use
diagnost
approach
pertussi
compar
three
serolog
method
applic
quantif
antibodi
differ
antigen
diagnost
tool
bordetella
pertussi
infect
singl
serum
sampl
method
use
serum
sampl
patient
outbreak
pertussi
vaccin
children
well
control
gener
popul
case
control
age
mean
age
year
respect
receiv
number
dose
respect
type
vaccin
whole
cellular
vaccin
sampl
test
three
commerci
method
design
detect
antibodi
mixtur
pt
filament
haemagglutinin
fha
mardx
unit
state
igg
whole
cell
antigen
serion
germani
igg
iga
pt
fha
separ
determin
pertusscan
sweden
diagnost
cut
assay
establish
result
accord
cut
provid
manufactur
sensit
rang
igatp
pertusscan
serion
mardx
specif
vari
serion
mardx
determin
pertusscan
modifi
cut
valu
figur
strongli
improv
sensit
specif
valu
serion
unit
correspond
valu
mardx
assay
ratio
sampl
absorbancecut
best
figur
pertusscan
sensit
specif
igg
haf
pt
ratio
sampl
absorbancecut
conclus
use
commerci
avail
serolog
method
test
singl
serum
sampl
seem
use
tool
diagnosi
pertussi
diagnost
condit
assay
establish
applic
commerci
kit
improv
knowledg
real
incid
pertussi
enzym
immunoassay
measur
specif
igg
antibodi
tetanu
toxoid
r
budd
c
budd
f
alcock
r
georg
k
broughton
bradwel
birmingham
london
uk
object
studi
perform
characterist
tetanu
toxoid
igg
eia
investig
method
tetanu
vaccin
utilis
denatur
form
tetanu
toxin
tetanu
toxoid
antibodi
respons
vaccin
measur
enzym
immunoassay
eia
studi
perform
bind
site
ltd
uk
tetanu
toxoid
igg
eia
assess
addit
correl
perform
inhous
eia
respiratori
system
infect
laboratori
central
public
health
lab
london
result
kit
calibr
nibsc
refer
materi
assay
measur
rang
iuml
analyt
sensit
assay
measur
iuml
intraassay
precis
found
less
assay
low
medium
high
level
sampl
time
interassay
precis
shown
less
sampl
measur
three
separ
occas
determin
effect
potenti
interf
substanc
high
low
sampl
assay
without
addit
rang
standard
interfer
substanc
variat
observ
linear
assess
use
three
posit
sampl
comparison
achiev
valu
linear
regress
gave
valu
greater
r
case
correl
perform
inhous
eia
respiratori
system
infect
laboratori
central
public
health
lab
london
use
serum
sampl
linear
regress
show
good
correl
r
use
result
iuml
indic
protect
level
specif
antibodi
overal
correl
two
assay
conclus
result
achiev
studi
bind
site
eia
appear
suitabl
assay
measur
specif
igg
antibodi
tetanu
toxoid
result
also
correl
well
exist
inhous
enzym
immunoassay
studi
perform
characterist
diphtheria
toxoid
igg
enzym
immunoassay
eia
investig
togeth
correl
vca
method
classic
neutralis
antibodi
diphtheria
measur
invitro
toxin
neutralis
assay
vca
diphtheria
vaccin
utilis
denatur
form
diphtheria
toxin
diphtheria
toxoid
antibodi
respons
vaccin
also
measur
eia
studi
new
eia
bind
site
ltd
uk
assess
result
correl
vca
perform
respiratori
system
infect
laboratori
central
public
health
lab
london
result
elisa
kit
calibr
nibsc
refer
materi
assay
measur
rang
iuml
intraassay
precis
found
assay
low
iuml
medium
iuml
high
iuml
level
sampl
time
assay
linear
assess
use
three
posit
sampl
comparison
achiev
expect
valu
linear
regress
gave
valu
greater
r
case
correl
perform
vca
use
serum
sampl
linear
regress
show
excel
correl
r
use
result
iu
ml
indic
minimum
protect
level
specif
antibodi
overal
agreement
two
assay
conclus
result
achiev
studi
bind
site
assay
appear
accur
precis
assay
measur
specif
igg
antibodi
diphtheria
toxoid
could
consid
possibl
altern
vca
signific
advantag
speed
eas
use
adapt
autom
applic
gene
recombin
chromatographi
bioaffin
product
purifi
yersinia
enterocolitica
protein
antigen
use
recombin
yopd
protein
serodiagnosi
enter
ill
reactiv
arthriti
w
rastawicki
r
ski
jagielski
b
kwiatkowska
warsaw
pl
object
yersinia
enterocolitica
caus
varieti
infect
human
includ
enterocol
acut
mesenter
lymphaden
erythema
nodosum
reactiv
arthriti
whole
yersinia
bacteria
purifi
lipopolysaccharid
lp
use
antigen
detect
antibodi
sera
patient
howev
crossreact
elisa
enterocolitica
pathogen
describ
therefor
high
specif
antigen
free
lipopolysaccharid
base
yersinia
outer
membran
protein
yop
adhesin
ail
yada
invasin
myf
need
aim
studi
evalu
use
gene
recombin
techniqu
use
eklic
express
vector
product
yop
call
yopd
evalu
purifi
protein
antigen
serodiagnosi
yersiniosi
method
protein
yopd
enterocolitica
express
escherichia
coli
use
eklic
express
vector
purif
express
enzym
suspens
e
coli
cell
treat
bug
buster
tm
proteinextract
reagent
accomplish
immobilis
metal
ni
affin
column
chromatographi
histrap
igm
igg
iga
class
antibodi
yopd
measur
serum
sampl
collect
patient
suspect
yersiniosi
blood
donor
obtain
result
compar
result
elisa
lp
yop
isol
cultur
enterocolitica
supernat
calcium
defici
condit
antigen
result
case
patient
suspect
clinic
investig
yersiniosi
frequent
posit
result
obtain
igg
class
antibodi
igm
iga
antibodi
detect
serum
sampl
respect
sera
obtain
blood
donor
antibodi
immunoglobulin
class
yopd
antigen
detect
significantli
rare
p
high
specif
good
sensit
display
elisa
yopd
relat
elisa
lp
yop
antigen
iga
igg
frequent
found
sera
adult
person
arthriti
immunoglobulin
sera
children
enter
ill
conclus
recombin
yopd
protein
purifi
chromatographi
bioaffin
may
use
serodiagnosi
yersiniosi
high
specif
antigen
free
yersinia
lipopolysaccharid
abstract
withdrawn
signific
increas
specif
antibodi
titer
pair
sera
accept
serolog
indic
acut
c
pneumonia
infect
microimmunofluoresc
assay
mif
requir
expertis
perform
consid
long
time
gold
standard
method
mif
lead
variabl
result
urg
need
object
test
method
autom
enzymelink
immunosorb
assay
elisa
standardis
allow
defin
antibodi
titer
compar
mif
without
subject
bia
aim
studi
comparison
two
quantit
assay
method
second
gener
elisabas
assay
mif
method
select
serum
sampl
normal
laboratori
routin
patient
c
pneumonia
infect
sera
collect
adult
popul
high
low
respiratori
tract
infect
show
high
serum
level
c
pneumoniaespecif
iga
andor
igg
antibodi
mif
serofia
savyon
il
usa
serum
sampl
appar
healthi
children
without
antibodi
accord
mif
c
pneumonia
c
trachomati
c
psittaci
use
control
group
c
pneumoniaespecif
iga
igg
antibodi
also
determin
two
group
serum
sampl
commerci
quantit
elisa
test
cpquant
eurospit
test
perform
recommend
manufactur
result
concord
result
mif
cp
quant
adult
patient
igg
determin
iga
healthi
children
neg
igg
iga
elisa
test
high
overal
agreement
result
two
differ
method
conclus
result
obtain
elisa
overlap
obtain
tradit
mif
assay
show
elisa
quantit
test
highli
reliabl
addit
rapid
eas
use
possibl
autom
well
easi
analyt
interpret
independ
subject
evalu
oper
import
advantag
elisa
quantit
test
use
altern
clinic
diagnost
test
mif
aim
studi
serolog
method
wide
use
diagnosi
mycoplasma
pneumonia
mp
infect
studi
evalu
avail
commerci
test
studi
commerci
mp
igg
igm
eia
use
pcr
detect
mp
gold
standard
method
twentynin
mp
pcrposit
patient
serum
sampl
includ
two
prospect
studi
acut
lower
respiratori
tract
infect
lrti
control
sera
test
patient
acut
lrti
neg
pcr
ii
patient
microbiolog
document
lrti
mp
without
pcr
exclus
differ
eia
test
platelia
biorad
seromp
savyon
serion
classic
virionserion
biotest
eia
biotest
ridascreen
eia
rbiopharm
anilabsystem
eia
labsystem
novum
eia
novum
diagnostica
diagnosi
eia
mp
product
genzymevirotech
eia
immunowel
eia
genbio
immunocard
eia
meridian
addit
complement
fixat
test
cft
serodiamyco
ii
agglutin
test
fujirebio
includ
result
sensit
igm
eia
rang
first
day
onset
diseas
day
ill
igg
eia
detect
seroconvers
signific
rise
igg
titer
pcrposit
patient
igm
test
best
result
sensit
specif
anilabsystem
eia
diagnosi
eia
serodiamycoii
wherea
igm
test
fail
achiev
satisfactori
result
either
sensit
day
specif
falseposit
eia
igm
result
occur
frequent
control
patient
acut
ebv
infect
sensit
specif
cft
exceed
commerci
igm
test
clinic
timepoint
conclus
evalu
current
avail
serolog
eia
cft
agglutin
test
pneumonia
use
pcr
gold
standard
show
substanti
differ
perform
assay
object
ureaplasma
spp
serotyp
frequent
isol
lower
genit
tract
men
women
relat
advers
pregnanc
outcom
develop
serolog
assay
ureaplasma
spp
antibodi
hamper
low
puriti
antigen
use
assay
difficulti
obtain
larg
quantiti
antigen
aim
present
studi
produc
recombin
antigen
serotyp
develop
serolog
assay
method
multipl
band
antigen
mba
ureaplasma
spp
surfac
express
antigen
one
major
antigen
recognis
infect
present
serotyp
make
suitabl
candid
use
serolog
assay
code
part
mba
gene
serotyp
amplifi
pcr
pcr
product
clone
ligat
ptrchi
topo
plasmid
follow
transform
e
coli
compet
cell
express
antigen
induc
iptg
addit
express
protein
contain
polyhi
tag
purifi
analys
western
blot
assay
wba
use
antipoli
antibodi
elisa
wba
use
serotypespecif
monoclon
antibodi
mab
result
except
serotyp
mba
success
express
serotyp
mba
serotyp
recognis
serotyp
specif
mab
elisa
moreov
preliminari
analysi
elisa
use
human
sera
serotyp
infect
patient
shown
promis
result
background
syphili
remain
signific
caus
morbid
estim
annual
incid
million
new
case
worldwid
serolog
test
play
decis
role
diagnosi
syphili
two
type
serolog
test
use
nontreponem
treponem
test
main
limit
current
treponem
test
use
situat
rapid
diagnosi
requir
account
disadvantag
rapid
recombin
antigen
base
test
recent
introduc
routin
syphili
serolog
object
evalu
new
treponem
test
syphili
fast
diess
diagnostica
senes
itali
rapid
serodiagnosi
syphili
comparison
serolog
test
syphili
fast
test
latex
agglutin
test
base
polystyren
particl
coat
three
immunodomin
protein
treponema
pallidum
molecular
weight
kda
obtain
escherichia
coli
recombin
technolog
patient
method
total
sera
analys
nontreponem
test
rapid
plasma
reagin
test
rpr
combin
two
treponem
test
syphili
fast
mercia
syphili
total
eia
reactiv
specimen
confirm
use
fluoresc
treponem
antibodi
absorpt
test
ftaab
consid
gold
standard
serodiagnosi
syphili
studi
popul
includ
immigr
return
travel
subsaharan
africa
patient
risk
behaviour
sexual
transmit
diseas
hiv
homosexu
bisexu
intraven
drug
user
patient
multipl
sexual
partner
immigr
sex
worker
adopt
children
pregnant
women
patient
neurolog
symptom
genit
cutan
lesion
result
agreement
ftaab
syphili
fast
three
falsereact
three
fals
nonreact
result
ftaab
mercia
syphili
total
eia
eight
fals
nonreact
result
compar
syphili
fast
found
sensit
mercia
syphili
total
eia
detect
syphili
vs
slightli
less
specif
vs
leptospira
genu
spirochet
bacteria
caus
agent
leptospirosi
zoonot
diseas
global
distribut
extens
serovar
divers
attribut
differ
structur
composit
lipopolysaccharid
lp
much
work
focus
role
leptospir
lp
immun
prepar
leptospir
lp
elicit
protect
immun
immun
gener
serovarspecif
among
mani
antigen
isol
pathogen
leptospira
glycolipoprotein
glp
like
involv
pathogenesi
diseas
induc
lymphocyt
monocyt
activ
focu
research
protect
antigen
better
serodiagnost
strategi
shift
toward
conserv
antigen
may
abl
stimul
heterolog
immun
identif
leptospir
antigen
express
infect
potenti
import
implic
develop
new
serodiagnost
immunoprotect
strategi
work
studi
candid
antigen
serodiagnosi
use
elisadotblot
reactiv
sera
patient
leptospirosi
confirm
microscop
agglutin
test
mat
elisadotblot
analysi
perform
use
sera
patient
leptospirosi
sera
patient
diseas
neg
control
glp
identifi
candid
antigen
serodiagnosi
leptospirosi
sevendayold
cultur
leptospira
interrogan
serogroup
icterohaemorrhagia
use
prepar
antigen
serum
sampl
assay
elisadotblot
use
antigen
prepar
microscop
agglutin
test
mat
use
serovar
antigen
prepar
aproxim
lgml
glp
igg
antibodi
nt
show
reactiv
posit
sera
mat
howev
basi
igm
respons
posit
sera
mat
found
react
glp
none
control
posit
preliminari
observ
demonstr
glp
newli
identifi
antigen
recognis
sera
patient
leptospirosi
data
provid
tool
understand
pathogenesi
leptospirosi
identif
candid
antigen
serodiagnosi
immunoprotect
western
blot
method
respect
sensit
specif
j
danka
kucsera
e
orosz
z
budapest
hun
object
human
toxocarosi
caus
larval
stage
differ
toxocara
speci
due
lack
specif
clinic
sign
diagnosi
usual
base
detect
antitoxocar
igg
igg
igm
antibodi
indirect
elisa
western
blot
wb
method
test
utilis
excretorysecretori
es
antigen
obtain
vitro
maintain
cani
larva
homemad
test
differ
laboratori
commerci
elisa
differ
manufactur
vari
procedur
paramet
perform
characterist
caus
difficulti
comparison
interpret
result
object
investig
studi
outcom
test
method
total
serum
sampl
patient
clinic
suspect
toxocara
infect
select
basi
result
obtain
homemad
elisa
test
whole
rang
od
valu
cover
sera
neg
borderlin
weak
strongli
posit
sampl
result
homemad
elisa
compar
two
commerci
elisa
test
eia
cani
igg
testlin
czech
republ
cani
igg
elisa
novatec
germani
wb
method
toxocara
western
blot
igg
ldbio
franc
sensit
specif
elisa
test
comput
relat
wb
result
result
sensit
homemad
testlin
novatec
elisa
specif
respect
distribut
neg
posit
result
significantli
influenc
cutoff
level
given
test
best
fit
semiquantit
result
found
homemad
testlin
elisa
borderlin
neg
close
borderlin
elisa
result
homemad
testlin
novatec
elisa
found
posit
wb
case
respect
conclus
high
proport
wb
posit
patient
negativeelisa
result
suggest
low
level
antibodi
frequent
occur
clinic
sampl
data
underlin
necess
confirm
neg
borderlin
elisa
result
wb
immunoassay
infecti
mononucleosi
epsteinbarr
viru
use
biorad
bioplex
immunoassay
analys
r
bruehl
h
scholz
l
cuadra
f
torr
j
wang
r
kaul
k
yu
p
chen
binder
hercul
usa
object
diagnosi
infecti
mononucleosi
im
clinic
assess
epsteinbarr
viru
ebv
infect
involv
detect
igg
antibodi
three
ebv
antigen
igm
antibodi
ebv
viral
capsid
antigen
vca
nonebv
heterophil
antigen
typic
identif
antibodi
involv
multipl
independ
eia
agglutin
immunoassay
amen
high
throughput
analysi
object
studi
thu
develop
autom
high
throughput
igg
igm
immunoassay
ebv
gener
composit
data
differenti
acut
im
secondari
infect
method
use
biorad
bioplex
immunoassay
analys
autom
high
throughput
multiplex
platform
report
detect
igg
igm
antibodi
ebv
heterophil
antigen
compar
result
gener
commerci
avail
test
assay
employ
array
control
antigenco
fluoromagnet
bead
discret
spectral
address
assign
substrat
result
report
index
valu
rel
fourpoint
calibr
curv
sort
base
fluoresc
emiss
assign
analyt
control
bead
result
concord
test
igg
triniti
tm
eiarev
rel
sensit
specif
valu
vca
earli
diffus
antigen
nuclear
respect
concord
test
vca
heterophil
igm
diasorin
eti
eia
wampol
laboratori
monolatex
r
test
reveal
rel
sensit
specif
valu
respect
conclus
contrast
convent
serolog
test
bioplex
assay
offer
rapid
method
acquir
composit
igg
igm
data
diagnos
acut
im
identifi
ebv
infect
inclus
control
bead
everi
sampl
ensur
reliabl
result
abil
process
primari
sampl
tube
per
hour
access
sampl
continu
offer
signific
advantag
standard
protocol
method
specimen
sensit
evalu
includ
seroconvers
panel
antigen
panel
cellcultur
deriv
divers
group
subtyp
group
isol
test
pgml
ag
sampl
collect
variou
area
word
specif
unselect
hiv
neg
sampl
collect
four
french
laboratori
use
result
detect
ag
murex
axsym
show
best
limit
detect
ag
pgml
irrespect
train
vida
duo
could
detect
pgml
except
subtyp
c
strain
limit
detect
genscreen
plu
pgml
except
subtyp
f
group
vironostika
enzygnost
detect
hiv
strain
pg
seroconvers
panel
axsym
murex
detect
first
posit
bleed
panel
respect
wherea
vida
duo
genscreen
plu
enzygnost
vironostika
genscreen
ortho
detect
first
posit
bleed
panel
respect
improv
reliabl
serodiagnosi
human
deep
candida
infect
western
immunoblot
analysi
evalu
retrospect
studi
method
condit
immunoblot
standardis
sera
differ
five
group
patient
test
group
healthi
blood
donor
n
group
patient
system
candidosi
candida
isol
least
one
blood
cultur
n
group
patient
probabl
proven
candidosi
candida
isol
steril
site
except
blood
cultur
n
group
patient
hospitalis
candida
isol
peripher
site
n
group
patient
without
isol
candida
posit
serolog
routin
techniqu
n
result
standardis
techniqu
lectur
method
defin
exclus
nonspecif
band
patient
group
group
posit
detect
immunoblot
techniqu
detect
group
none
group
condit
patient
group
posit
candida
serolog
routin
diagnosi
detect
immunoblot
analysi
patient
group
liver
transplant
explain
probabl
nonspecif
serolog
reactiv
routin
techniqu
patient
probabl
prove
candidosi
gave
result
significantli
differ
patient
without
candidosi
test
show
good
posit
predict
valu
conclus
find
suggest
western
immunoblot
test
could
use
good
confirmatori
method
detect
candida
antibodi
patient
serum
serolog
diagnosi
african
tick
bite
fever
atbf
spot
fever
group
sfg
rickettsiosi
caus
rickettsia
africa
emerg
health
problem
intern
travel
subsaharan
africa
troublesom
mani
avail
test
either
poor
sensit
poor
specif
method
evalu
sensit
speci
specif
multipleantigen
immunofluoresc
assay
ifa
multipleantigen
western
blot
wb
assay
detect
antibodi
sfg
rickettsia
r
africa
pair
serum
sampl
collect
consecut
patient
atbf
sampl
patient
nonspeciesspecif
antibodi
detect
also
test
crossadsorpt
assay
ca
result
antibodi
sfg
rickettsia
detect
ifa
patient
wb
patient
p
first
week
ill
correspond
estim
four
nine
respect
p
compar
titr
stain
characterist
multipleantigen
ifa
demonstr
specif
antibodi
r
africa
six
ifaposit
patient
wb
detect
reaction
specif
protein
antigen
r
africa
case
seven
patient
nonspeciesspecif
antibodi
detect
wb
ca
demonstr
specif
antibodi
r
africa
conclus
studi
demonstr
wb
significantli
sensit
ifa
diagnos
consecut
case
atbf
also
acut
phase
patient
like
present
speci
specif
wb
may
increas
use
ca
select
case
statu
ifa
consid
serolog
refer
method
diagnosi
atbf
reevalu
valid
evalu
interlaboratori
concord
two
method
specimen
prepar
direct
inocul
phoenix
cultur
suspens
posit
bactec
blood
cultur
vial
compar
routin
phoenix
method
id
ast
method
multicentr
prospect
clinic
trial
parallel
process
clinic
sampl
investig
refer
method
bactec
vial
process
within
h
posit
aerob
facult
anaerob
gramneg
rod
includ
differenti
centrifug
method
diff
bacteria
recuper
two
consecut
centrifug
step
g
supernat
g
gel
separ
method
sst
bacteria
recuper
one
centrifug
step
object
blood
cultur
bc
help
defin
pathogen
resist
spectra
time
benefit
bc
result
manag
individu
patient
therefor
cost
effect
disput
aim
identifi
clinic
organis
factor
associ
neg
bc
result
oblig
pathogen
op
bc
patient
gener
intern
medicin
ward
method
abstract
chart
patient
least
one
bc
blood
volum
per
bc
approxim
ml
drawn
gener
intern
medicin
ward
tertiari
care
hospit
year
retriev
evalu
multipl
logist
regress
follow
factor
associ
bc
neg
op
site
time
bc
draw
presenc
central
venou
cathet
prior
bc
taken
emerg
room
intens
care
unit
antibiot
treatment
prior
day
intraven
antibiot
prior
day
temperatur
valu
c
rise
rise
c
leucocyt
count
valu
rise
rise
creactiv
protein
crp
level
valu
mgl
rise
mgl
gener
special
nurs
categori
vs
prior
order
written
chart
draw
bc
case
fever
also
evalu
number
bc
within
diagnost
episod
de
consecut
bc
singl
patient
taken
day
apart
attribut
de
result
object
medic
center
blood
cultur
drawn
resid
physician
intern
medic
student
blood
cultur
examin
institut
everi
year
sampl
posit
total
blood
cultur
grow
bacteria
consid
contamin
begin
implement
intervent
programm
month
attempt
reduc
contamin
rate
intern
medicin
ward
largest
proport
blood
cultur
taken
method
infecti
diseas
team
conduct
educ
campaign
subject
techniqu
blood
cultur
sampl
six
intern
medicin
ward
resid
intern
student
drew
blood
cultur
ask
sign
full
name
request
accompani
blood
sampl
one
instruct
respons
cultur
result
resid
found
supercontamin
ask
particularli
adher
proper
techniqu
blood
sampl
skin
decontamin
result
march
april
may
blood
sampl
drawn
respect
cultur
intern
medicin
ward
march
intervent
program
began
contamin
rate
april
rate
decreas
diminish
may
disappointingli
unpredict
rate
contamin
increas
soon
intervent
programm
end
compar
result
whole
year
year
prior
intervent
period
year
afterward
found
differ
contamin
rate
respect
conclus
programm
interven
two
level
first
educ
regard
techniqu
draw
blood
cultur
second
tri
make
everi
physician
respons
sampl
effort
reduc
blood
cultur
contamin
rate
effect
period
immedi
follow
intervent
programm
hospit
resid
physician
student
collect
blood
cultur
instead
skill
phlebotomist
continu
effort
need
educ
staff
contamin
four
hospit
unit
correct
sampl
process
train
object
aim
studi
monitor
improv
bc
sampl
necessari
role
train
method
studi
perform
two
phase
base
tqm
train
focuspdca
procedur
first
phase
retrospect
studi
collect
data
bc
contamin
forth
first
month
year
calcul
rate
blood
contamin
four
hospit
unit
icu
nicu
level
nicu
level
ii
pediatr
initi
addit
train
staff
second
phase
collect
blood
contamin
data
forth
second
month
year
train
result
compar
studi
result
bc
contamin
train
show
contamin
nicu
train
train
nicu
ii
train
train
icu
train
pediatr
train
train
also
compris
result
bc
contamin
month
month
four
unit
conclus
cost
relat
falseposit
blood
cultur
result
ie
contamin
associ
higher
charg
iv
antibiot
microbiolog
test
train
cost
effici
rate
contamin
train
decreas
four
hospit
unit
object
intravascular
cathet
indispens
modernday
medic
practic
diagnosi
port
relat
bloodstream
infect
prbi
remain
difficult
without
cathet
remov
clinician
usual
avoid
remov
port
reinsert
new
cathet
carri
substanti
risk
blot
et
al
describ
method
evalu
differenti
time
posit
dtp
determin
continu
blood
cultur
monitor
system
qualit
blood
cultur
drawn
simultan
cathet
peripher
vein
diagnos
cathet
relat
bloodstream
infect
howev
method
valid
longterm
tunnel
cathet
aim
present
studi
ass
valu
dtp
diagnosi
prbi
use
pair
quantit
blood
cultur
standard
criterion
defin
prbi
method
period
june
patient
port
suspect
primari
sourc
fever
studi
prospect
two
qualit
two
quantit
cultur
blood
sampl
simultan
obtain
peripher
vein
port
differ
peripher
port
blood
qualit
cultur
time
detect
min
use
cutoff
point
diagnos
prbi
result
total
episod
occur
patient
studi
period
ten
patient
exclud
studi
diagnos
pocketsit
infect
forti
patient
treat
antibiot
blood
sampl
obtain
episod
prbi
nonprbi
determin
standard
criterion
median
time
posit
blood
sampl
prbi
min
rang
min
significantli
greater
nonprbi
min
rang
min
p
sensit
specif
predict
valu
posit
neg
result
dtp
compar
quantit
cultur
respect
conclus
differenti
time
posit
easi
reliabl
method
diagnos
port
relat
bloodstream
infect
without
remov
cathet
compar
quantit
blood
cultur
diagnostica
gmbh
germani
septic
patient
within
h
admiss
analys
medic
patient
treat
intens
care
unit
six
sepsi
five
sever
sepsi
one
patient
septic
shock
patient
sepsi
pct
level
ngml
n
ngml
n
ngml
n
ngml
n
patient
sever
sepsi
pct
level
ng
ml
n
ngml
n
patient
septic
shock
pct
level
ngml
conclus
measur
plasma
pct
semiquantit
pctq
test
allow
rapid
support
diagnosi
septic
patient
howev
followup
pct
clinic
cours
ill
correl
outcom
still
determin
studi
possibl
discrimin
role
procalcitonin
pct
differenti
acut
fever
bacteri
infect
fever
inflammatori
process
patient
treat
intern
medicin
depart
method
prospect
examin
patient
acut
fever
admit
depart
variabl
record
includ
patient
demograph
princip
diagnosi
pct
creactiv
protein
crp
erythrocyt
sediment
rate
esr
white
blood
cell
count
wbc
measur
blood
sampl
collect
h
presenc
fever
outcom
determin
survivor
nonsurvivor
patient
distinguish
accord
aetiolog
diagnosi
base
clinic
assess
laboratori
result
fever
bacteri
infect
group
fever
inflammatori
process
group
b
among
statist
test
appli
student
ttest
chisquar
abil
pct
predict
patient
bacteri
infect
evalu
perform
receiv
oper
characterist
curv
analys
result
studi
patient
fever
bacteri
infecti
inflammatori
process
mean
plasma
concentr
pct
patient
bacteri
infecti
ngml
aesd
patient
group
b
ngml
aesd
subgroup
analysi
group
show
patient
sepsi
higher
valu
pct
ngml
aesd
compar
patient
bacteri
infect
p
patient
group
expect
higher
valu
esr
p
crp
p
mean
valu
wbc
differ
two
group
percentag
neutrophil
differ
signific
level
p
patient
die
pct
level
higher
ngml
compar
survivor
p
predict
accuraci
bacteri
infecti
express
area
receiv
oper
characterist
curv
pct
ci
esr
ci
crp
ci
conclus
pct
probabl
use
use
tool
initi
work
patient
fever
supplement
biolog
indic
pct
help
make
decis
antibiot
therapi
patient
treat
intern
medicin
depart
object
evalu
diagnost
valu
procalcitonin
pct
detect
osteomyel
om
septic
arthriti
sa
children
method
pct
c
reactiv
protein
crp
erythrocyt
sediment
rate
esr
white
blood
cell
wbc
measur
children
admit
suspicion
osteomyel
septic
arthriti
pct
measur
pctq
kit
pct
immunochromatographi
assay
base
monoclon
polyclon
antibodi
catacalcin
brahm
result
divid
four
categori
normal
nnml
mildli
elev
nnml
high
nnml
high
valu
nnml
diagnosi
om
made
two
follow
diagnost
criteria
presenc
purul
bone
posit
bone
blood
cultur
local
erythema
oedema
posit
imag
studi
either
radiographi
tc
scintigraphi
magnet
reson
imag
result
total
children
evalu
eleven
diagnosi
om
septic
arthriti
diagnos
aspir
sinovi
fluid
six
children
diagnos
soft
tissu
infect
transient
synov
reactiv
arthriti
diagnos
anoth
six
children
three
diagnos
later
juvenil
rheumatoid
arthriti
six
children
anoth
differ
diagnosi
wbc
higher
sa
compar
om
diagnosi
ae
l
ae
l
ae
l
respect
p
esr
admiss
higher
among
children
diagnos
om
compar
sa
diagnosi
ae
vs
ae
vs
ae
crp
admiss
higher
among
children
subsequ
diagnos
sa
compar
om
diagnosi
differ
signific
ae
vs
ae
vs
ae
pct
valu
mildli
elev
six
patient
om
three
children
diagnosi
sa
mildli
elev
valu
among
children
diagnosi
posit
pct
valu
conclus
pct
found
good
tool
diagnosi
osteomyel
septic
arthriti
larger
studi
need
confirm
find
comparison
timetoposit
hubblood
vs
peripheralblood
cultur
use
tool
diagnos
catheterrel
infect
v
mirov
b
tomanov
belgrad
cs
object
evalu
differenti
time
posit
dtp
pair
blood
cultur
drawn
simultan
via
cathet
hub
peripher
venou
site
diagnost
tool
catheterrel
infect
cri
method
period
simultan
hubblood
peripheralblood
cultur
obtain
patient
suspect
cri
record
dtp
hubblood
peripheralblood
cultur
automat
devic
bactalert
system
organon
teknika
detect
blood
cultur
posit
result
microorgan
found
hubblood
peripher
blood
cultur
episod
suspect
cri
associ
bacteraem
cri
dtp
h
wherea
cri
exclud
remain
nine
major
microorgan
involv
bacteraem
cri
candida
spp
coagulaseneg
staphylococci
n
klebsiella
pneumonia
n
acinetobact
spp
n
morganella
morganii
n
staphylococcu
aureu
n
escherichia
coli
n
serratia
spp
n
stenotrophomona
maltophilia
n
enterococcu
spp
n
pseudomona
aeruginosa
n
conclus
result
show
measur
delay
posit
hubblood
peripher
blood
cultur
simpl
use
tool
diagnos
cri
propos
routin
practic
hospit
use
automat
devic
detect
posit
blood
cultur
system
ii
blood
cultur
v
labombardi
fett
kamel
n
sullivan
new
york
sun
prairi
usa
object
seri
studi
conduct
compar
next
gener
blood
cultur
instrument
versatrek
vt
esp
cultur
system
ii
esp
studi
conduct
laboratori
trek
diagnost
system
ts
sun
prairi
wi
usa
st
vincent
hospit
svh
new
york
new
york
usa
method
vt
ml
blood
cultur
bottl
esp
ml
blood
cultur
bottl
seed
suspens
varieti
microorgan
bottl
incub
respect
instrument
compar
time
requir
detect
posit
cultur
qualiti
curv
gener
clinic
trial
conduct
use
specimen
routin
collect
blood
cultur
inpati
svh
result
initi
seed
studi
ts
includ
differ
gram
neg
gram
posit
bacteria
yeast
compar
esp
bottl
redox
vt
bottl
isol
vt
shorter
time
detect
ttd
esp
isol
averag
time
h
result
graph
profil
vt
equal
better
gener
esp
comparison
esp
anaerob
bottl
vt
redox
yield
similar
result
seed
studi
conduct
svh
isol
repres
differ
speci
bacteria
yeast
compar
two
system
speci
seen
faster
ttd
vt
esp
preliminari
data
sampl
ongo
clinic
trial
compar
recoveri
ttd
patient
specimen
shown
vt
least
compar
esp
two
criteria
conclus
seed
clinic
data
demonstr
vt
least
compar
esp
blood
cultur
valid
vt
use
clinic
microbiolog
laboratori
comparison
effect
delay
entri
two
differ
blood
cultur
system
bactec
bactalert
cultur
posit
oa
akan
e
yildiz
ankara
tr
autom
continu
monitor
blood
cultur
system
brought
mani
advantag
laboratori
practic
rapid
detect
agent
labor
reduct
delay
specimen
transport
one
problem
may
effect
cultur
posit
clinic
laboratori
evalu
differ
effect
delay
entri
blood
cultur
system
bactec
bd
bactalert
ba
detect
bacteri
growth
blood
cultur
media
bactec
f
f
bactalert
fa
bactalert
fan
standard
inoculum
cfu
microorgan
frequent
isol
blood
cultur
staphylococcu
aureu
escherichia
coli
enterococcu
faecali
acinetobact
baumannii
haemophilu
influenza
bacteroid
fragili
streptococcu
pneumonia
inocul
blood
cultur
bottl
contain
ml
steril
human
blood
bottl
cultur
use
two
instrument
store
room
temperatur
c
incub
h
five
set
pair
bacteria
studi
temperatur
posit
neg
cultur
day
record
subcultur
perform
none
cultur
fals
neg
first
h
delay
except
two
strain
pneumonia
h
influenza
ba
preincub
c
h
delay
fals
neg
bd
e
coli
baumannii
e
faecali
pneumonia
ba
pneumonia
fals
neg
result
bottl
preincub
c
bd
h
delay
fals
neg
rate
bd
e
coli
b
fragili
e
faecali
pneumonia
baumannii
h
influenza
ba
pneumonia
baumannii
b
fragili
delay
preincub
h
fals
neg
common
bd
especi
storag
c
ba
difficulti
detect
pneumonia
start
h
preincub
failur
detect
microbi
growth
notic
h
system
may
disadvantag
clinic
laboratori
practic
institut
specimen
transport
work
regularli
object
diagnosi
brucellosi
gener
made
standard
tube
agglutin
titr
antibrucella
antibodi
presenc
compat
clinic
sign
symptom
studi
aim
describ
rate
durat
isol
brucella
spp
blood
cultur
use
autom
blood
cultur
system
bactec
method
march
decemb
adult
diagnos
brucellosi
mean
posit
standard
tube
agglutin
cultur
clinic
manifest
blood
cultur
obtain
patient
standard
tube
agglutin
titr
ten
millilitr
blood
inocul
bactec
plu
aerobicf
bottl
incub
bactec
autom
system
bottl
kept
incub
day
subcultur
machin
signalis
growth
blind
subcultur
perform
day
neg
cultur
result
patient
patient
posit
standart
tube
agglutin
bacteremia
posit
result
appear
day
h
mean
earlier
detect
seen
second
day
latest
one
sixth
day
conclus
conclud
autom
bactec
cultur
system
isol
brucella
spp
fast
effici
way
suggest
least
day
case
brusellosi
suspici
modif
gold
standard
method
diagnosi
chlamydia
trachomati
infect
use
peripher
blood
leucocyt
cultur
saralidz
shvelidz
p
gabunia
l
mohchevishvili
e
saralidz
tbilisi
geo
chlamydia
trachomati
common
diseas
among
sexual
transmit
diseas
worldwid
evid
famili
charact
infect
addit
underlin
import
diagnosi
c
trachomati
infect
especi
conceal
latent
form
asymptomat
cours
among
adult
children
well
consid
persist
c
trachomati
infect
organ
know
accur
method
diagnosi
infect
clinic
specimen
site
tissu
cultur
techniqu
employ
cicloheximid
treat
mccoy
cell
call
golden
standard
decid
investig
cytomorpholog
peculiar
c
trachomati
cultur
peripher
blood
leucocyt
patient
urogenit
chlamydiosi
aim
peripher
blood
leucocyt
patient
infect
c
trachomati
infect
studi
use
origin
method
cultur
diagnosi
c
trachomati
confirm
direct
fluorescentantibodi
techniqu
vitro
morpholog
inclus
specif
c
trachomati
reveal
cytoplasm
monocytesmacrophag
segment
neutrophil
even
lymphocyt
especi
among
children
cell
inclus
appear
pasposit
cytochem
stain
glycogen
use
peripher
blood
leucocyt
cultur
enabl
us
diagnos
infect
c
trachomati
first
time
patient
among
two
children
age
year
four
patient
myelodysplast
syndrom
appli
us
estim
immun
reactiv
organ
accord
amount
macrophagelymphocyt
rosett
format
vitro
georgia
patent
n
case
diagnosi
c
trachomati
infect
confirm
direct
indirect
immunofluoresc
assay
accord
studi
macrophagelymphocyt
rosett
format
significantli
decreas
patient
urogenit
chlamydiosi
compos
instead
ae
observ
healthi
donor
point
decreas
function
activ
immunocompet
cell
result
research
show
blood
leucocyt
cultur
method
use
diagnosi
latent
form
chlamydi
infect
estim
efficaci
treatment
immun
reactiv
organ
well
communityacquir
infect
infect
due
abiotrophia
defectiva
granulicatella
adiacen
identif
sequenc
rdna
clinic
manifest
l
senn
k
jaton
wenger
j
bill
calandra
g
prodhom
lausann
ch
background
taxonomi
nutrit
variant
streptococci
nv
recent
modifi
includ
genu
abiotrophia
creat
new
genu
granulicatella
propos
report
clinic
manifest
nv
infect
endocard
septicemia
bacteremia
isol
case
kerat
endophthalm
brain
abscess
iatrogen
mening
osteomyel
also
describ
object
identifi
molecular
tool
nv
strain
isol
clinic
specimen
clinic
laboratori
correl
molecular
identif
clinic
diagnosi
method
strain
nv
isol
five
last
year
blood
cultur
vascular
endograft
specimen
retriev
storag
one
strain
per
patient
identifi
partial
rrna
sequenc
analysi
patient
chart
review
clinic
characterist
report
document
infect
due
nv
result
nv
isol
seven
patient
period
identif
base
partial
rrna
sequenc
analysi
show
two
genogroup
abiotrophia
defectiva
granulicatella
adiacen
clinic
diagnos
three
patient
defectiva
endocard
two
plu
septic
metastat
arthriti
one
aortic
endograft
infect
one
four
patient
g
adiacen
clinic
diagnosi
febril
neutropenia
bacteremia
four
plu
possibl
endocard
one
risk
factor
malign
hemopathi
solid
tumour
conclus
small
seri
g
adiacen
appear
associ
bacteremia
febril
neutropen
patient
contrast
defectiva
observ
nonneutropen
patient
mediterranean
spot
fever
studi
case
e
louro
campo
j
carvalho
r
santo
c
rei
e
almiro
porto
coimbra
p
introduct
mediterranean
spot
fever
also
known
boutonneus
fever
estiv
endem
zoonosi
mediterranean
region
dog
tick
rhipicephalu
sanguineu
accident
transmiss
rickettsia
conorii
men
aim
author
claim
demonstr
distribut
diseas
medicin
depart
period
rel
sex
age
clinic
symptom
resid
job
anim
contact
season
distribut
tach
noir
locat
analyt
alter
complic
treatment
method
retrospect
studi
mediterranean
spot
fever
medicin
iii
depart
coimbra
univers
hospit
result
peak
incid
occur
summer
season
sex
equal
reach
predomin
sixth
seventh
decad
life
tach
noir
observ
patient
main
clinic
manifest
fever
maculopapular
rash
involv
palm
sole
frequent
laboratori
alter
observ
increas
ast
alt
thrombocytopenia
hiponatremia
common
complic
shock
pneumonia
dissemin
intravascular
coagul
ten
patient
posit
serolog
result
r
conorii
treatment
doxycyclin
frequent
adopt
conclus
gener
boutonneus
fever
benign
diseas
progress
sever
ill
shock
pneumonia
lead
signif
increas
mortal
advis
maintain
close
followup
case
object
shewanella
putrefacien
saprophyt
microorgan
distribut
commonli
water
soil
isol
putrefacien
human
clinic
specimen
uncommon
usual
repres
colonis
caus
wide
rang
infect
mild
cellul
life
threaten
septicemia
endocard
describ
scalp
infect
caus
putrefacien
healthi
man
case
man
admit
depart
neurosurgeri
ankara
train
research
hospit
wound
infect
scalp
accident
hit
head
rock
sea
day
trauma
wound
sutur
emerg
room
purul
discharg
develop
day
later
physic
examin
cm
length
superfici
incis
surround
erythema
area
purul
discharg
left
pariet
localis
physic
examin
find
normal
full
blood
count
show
minor
leucocytosi
lesion
debrid
resutur
cultur
taken
lesion
patient
given
empir
antimicrobi
therapi
intraven
cefazolin
gday
protect
dress
affect
region
third
day
admiss
start
therapi
wound
cultur
becam
posit
putrefacien
identif
isol
perform
use
mini
api
instrument
e
biomerieux
sa
marcyietoil
franc
microorgan
sensit
ceftazidim
cefepim
cefoperazon
ciprofloxacin
gentamicin
imipenem
aztreonam
treatment
chang
ciprofloxacin
mg
bid
po
respond
well
treatment
discharg
fifth
day
still
treatment
ciprofloxacin
definit
withdrawn
day
later
ted
viral
infect
iv
high
percentag
aureu
may
repres
colonis
characterist
microbiolog
profil
cervic
sampl
pregnant
women
nonpregn
healthi
young
women
v
kaliterna
n
kucisectep
l
pejkov
e
borzic
z
baris
v
zoran
jelic
split
zagreb
hr
vs
day
absent
favour
respons
rate
shown
tabl
conclus
respons
rate
etp
day
pt
four
time
day
similar
patient
without
abscess
anaerob
bacteria
recov
often
abscess
present
earli
oper
intervent
perform
higher
proport
patient
abscess
object
histori
modern
research
shown
us
loom
crisi
antimicrobi
resist
avoid
control
abil
control
rate
resist
develop
spread
requir
understand
bacteri
adapt
colonis
infect
environment
studi
first
import
step
clarifi
evolutionari
trend
molecular
relationship
strain
commun
associ
bacteria
data
studi
provid
inform
use
develop
viabl
longterm
strategi
treatment
infecti
diseas
object
studi
collect
isol
characteris
sampl
aureu
area
utilis
midshipman
athlet
unit
state
naval
academi
method
environment
sampl
collect
indoor
outdoor
varsiti
intramur
athlet
area
sampl
classifi
sever
step
includ
gross
morpholog
determin
biochem
activ
dna
sequenc
addit
result
obtain
environment
sampl
correl
local
clinic
isol
sequenc
comparison
specif
genom
loci
perform
result
observ
differ
antibiot
sensit
protein
coagulas
product
sampl
indic
presenc
least
three
five
distinct
strain
aureu
three
strain
exhibit
resist
oxacillin
conclus
increas
preval
observ
antibiot
resist
athlet
facil
repres
mani
factor
complic
recent
attempt
model
bacteri
interact
evolut
nonmed
environ
new
genet
inform
effect
evolutionari
trend
analysi
refin
relationship
strain
systemat
surveil
document
environment
factor
weather
frequenc
use
method
clean
ad
model
eventu
control
develop
spread
antimicrobi
resist
method
consecut
adult
patient
typic
erythema
migran
enrol
prospect
studi
earli
lyme
borreliosi
depart
infecti
diseas
ljubljana
patient
receiv
antibiot
first
visit
clinic
evid
dissemin
borrelia
burgdorferi
sl
infect
andor
pregnant
exclud
randomis
receiv
either
azithromycin
mg
bid
first
day
follow
mg
day
follow
day
azt
amoxicillin
mg
tid
first
day
follow
mg
tid
follow
day
amo
basic
epidemiolog
data
obtain
mean
questionnair
serum
igm
igg
antibodi
titr
b
burgdorferi
sl
determin
ifa
without
absorbt
titr
interpret
posit
patient
skin
biopsi
accomplish
prior
institut
antibiot
treatment
specimen
cultur
mkp
medium
result
total
patient
femal
male
age
year
median
includ
studi
patient
evalu
azt
group
patient
amo
group
differ
epidemiolog
pretreat
characterist
present
compar
two
group
median
durat
skin
lesion
institut
treatment
day
azt
group
day
amo
group
p
followup
month
none
patient
develop
major
late
manifest
lyme
borreliosi
six
patient
sever
minor
manifest
appear
two
azt
group
four
includ
amo
group
isol
rate
b
burgdorferi
sl
skin
treatment
vs
p
month
therapi
vs
compar
two
group
three
azt
group
patient
one
patient
amo
group
report
mild
gastrointestin
discomfort
p
conclus
treatment
adult
patient
solitari
erythema
migran
two
differ
antibiot
exhibit
equal
effect
compar
sideeffect
outcom
borreli
infect
year
favour
treatment
group
presenc
periodontopathogen
bacteria
risk
factor
periimplant
microbiolog
test
subgingiv
flora
help
estim
risk
implant
failur
periodont
pathogen
especi
actinobacillu
actinomycetemcomitan
aa
show
high
potenti
transmiss
famili
member
purpos
introduc
transmiss
coupl
implant
examin
presenc
periodontopathogen
bacteria
prior
implant
patient
result
neg
doubl
restor
golden
implant
made
succes
month
suppur
appear
next
implantth
result
microbiolog
cultiv
posit
aa
order
detect
potenti
sourc
infect
collect
four
differ
sampl
husband
made
cultiv
dorsum
tongu
buccal
mucosa
tonsil
pool
sampl
three
teeth
aa
isol
place
except
dorsum
tongu
method
purpos
investig
studi
restrict
endonucleas
analysi
rea
type
present
oral
caviti
posit
subject
studi
possibl
transmiss
aa
within
famili
dna
aa
isol
digest
combin
restrict
endonucleas
psti
bamhi
dna
fragment
separ
agaros
gelelectrophoresi
result
result
show
one
reatyp
present
conclus
elimin
periodont
pathogen
patient
partner
oral
caviti
administ
dental
implant
treatment
may
inhibit
colonis
pathogen
reduc
risk
periimplant
earli
diagnosi
appropri
theurepat
approach
import
prevent
complic
sequel
identif
microorgan
caus
arthriti
constitud
basement
appropri
antimicrobi
threapi
studi
aim
isol
identifi
microorgan
caus
arthriti
specimen
sinovi
fluid
accept
laboratori
method
analys
sinovi
fluid
specimen
sent
sever
ward
identif
infecti
agent
caus
arthriti
may
septemb
materi
stain
either
gram
ehrlichziehl
neelsen
method
specimen
inocul
human
blood
agar
emb
agar
leuwensteinjensen
sabourad
media
also
incub
automatedcalorimetr
bactalert
microbi
detect
system
biomeriux
franc
grow
gramposit
gramneg
bacteria
identifi
use
vitec
api
identif
system
yeast
form
microorgan
identifi
use
germ
tube
test
api
id
c
system
lactophenol
cotton
blue
stain
use
identifi
filament
fungal
element
result
isol
infecti
agent
sinovi
fluid
specimen
sent
laboratori
mean
age
femal
common
profess
farmer
butcher
housew
mean
incub
period
day
case
expos
bacteria
butcher
sick
anim
sixteen
patient
use
antibiot
addmiss
hospit
common
effect
site
lesion
hand
finger
site
arm
eyelid
neck
dissemin
lesion
seen
patient
gram
stain
posit
nine
case
cultur
posit
five
case
bacillu
anthraci
except
one
patient
discharg
treat
penicillin
ciprofloxasin
one
patient
dissemin
lesion
neck
die
although
steroid
use
antibiot
conclus
cutan
anthrax
still
public
health
problem
turkey
cutan
anthrax
consid
patient
painless
ulcer
vesicl
oedema
histori
exposur
anim
anim
product
penicillin
ciprofloxacin
effect
treatment
anthrax
standard
convers
surgic
manag
heterogen
cure
obtain
case
mortal
rate
sequel
essenti
ocular
rare
success
c
could
occur
indic
need
prolong
clinic
radiolog
followup
conclus
adult
sever
c
follow
bacteri
sinus
still
observ
spite
adequ
antibiot
treatment
suscept
pathogen
usual
antibiot
high
morbid
residu
mortal
obtain
complet
disappear
c
unrealist
howev
present
low
rate
expect
maintain
adequ
antibiot
treatment
term
choic
drug
respect
treatment
durat
better
standardis
surgic
manag
warrant
bhaemolyt
streptococci
group
period
hyperendem
danish
region
ejlertsen
k
ekelund
hc
aalborg
copenhagen
dk
object
peak
incid
infect
due
bhaemolyt
streptococci
group
ga
winter
begin
becam
awar
ga
infect
expect
coincid
mani
report
impetigo
gener
practition
gp
order
ascertain
problem
undertook
prospect
survey
ga
infect
februari
march
danish
counti
north
jutland
materi
method
depart
clinic
microbiolog
aalborg
hospit
provid
diagnost
bacteriolog
counti
north
jutland
approxim
inhabit
serv
around
gp
seven
hospit
inform
relat
posit
cultur
obtain
gp
hospit
physician
ttype
done
streptococcu
unit
staten
serum
institut
copenhagen
retrospect
data
retriev
depart
laboratori
inform
system
adbakt
autonik
sweden
result
februarymarch
observ
total
ga
infect
approxim
increas
compar
two
month
averag
month
previou
year
preschool
children
account
age
group
year
young
age
year
second
peak
incid
occur
age
group
year
skin
common
site
infect
follow
middl
ear
throat
perian
streptococc
infect
pasi
came
fourth
line
diagnos
case
pasi
boy
eight
girl
six
adult
children
year
age
predomin
ttype
preval
middl
ear
throat
skin
infect
wherea
preval
pasi
skin
infect
middl
ear
throat
conclus
period
hyperendem
ga
infect
found
two
ttype
predomin
clinic
spectrum
seem
link
particular
ttype
otiti
media
skin
infect
incl
pasi
previous
experienc
commun
outbreak
pasi
pediatr
infect
di
j
current
observ
underlin
pasi
continu
clinic
problem
possibl
link
high
preval
assess
qualiti
record
marker
sepsi
prior
commenc
antimicrobi
therapi
adher
local
antibiot
guidelin
acut
medic
receiv
unit
prior
follow
introduct
sepsi
stamp
clinic
note
method
data
gather
case
note
patient
admit
medic
receiv
unit
receiv
antibiot
within
h
admiss
fix
period
time
winter
studi
repeat
winter
follow
introduct
clinic
stamp
record
marker
sepsi
includ
clerk
sheet
patient
data
collect
second
group
patient
result
compar
presenc
absenc
sepsi
sever
assess
use
score
system
base
relev
clinic
histori
plu
two
follow
one
point
posit
temperatur
c
c
puls
respiratori
rate
white
cell
count
blood
pressur
systol
mmhg
diastol
mmhg
total
score
sepsi
sepsi
evid
organ
dysfunct
eg
confus
hypoxia
sever
sepsi
systol
bp
mmhg
refractori
fluid
replac
septic
shock
appropri
antibiot
prescrib
rout
assess
base
local
antibiot
polici
result
total
patient
includ
initi
studi
far
still
ongo
mean
age
two
group
year
year
respect
male
femal
ratio
record
sepsi
marker
two
group
shown
graph
stamp
fulli
complet
patient
partial
complet
rip
ignor
cover
patient
meet
sepsi
criteria
first
studi
second
patient
prescrib
antibiot
via
intraven
rout
choic
antibiot
accord
local
guidelin
patient
initi
studi
followup
infect
detect
penicillin
allerg
patient
previou
treatment
antibiot
antibiot
blactam
previou
month
suffer
upper
respiratorytract
infect
lf
indic
respiratori
infect
pneumonia
pneumonia
coaf
exacerb
sinus
urinari
tract
infect
abdomin
infect
skin
infect
bacteria
isol
obtain
case
e
coli
seven
case
pseudomona
six
case
pneumonia
five
case
respiratori
insuffici
present
patient
intraven
therapi
initi
follow
mean
time
day
complet
oral
mean
time
ae
day
second
antibiot
associ
case
mainli
blactam
lf
suspend
worsen
sideeffect
resist
total
patient
die
two
need
critic
care
sideeffect
six
patient
suffer
diarrhoea
five
nausea
two
rash
serum
kalium
touch
case
without
clinic
relev
conclus
area
lf
antibiot
use
commonli
respiratori
infect
uniqu
drug
special
use
penicillin
allerg
patient
normal
treatment
start
intraven
way
switch
quickli
treatment
mouth
good
toler
characteris
staphylococcu
xylosu
strain
isol
human
clinic
materi
kuboskova
sedlacek
p
svec
p
petra
brno
pragu
cz
object
staphylococci
common
inhabit
skin
skin
gland
mucou
membran
mammal
bird
certain
staphylococcu
speci
found
aetiolog
agent
varieti
human
anim
infect
well
xylosu
equorum
repres
two
phylogenet
biochem
close
speci
although
xylosu
usual
transient
human
primarili
acquir
domest
anim
product
isol
clinic
materi
mainli
urinarytract
infect
difficult
distinguish
xylosu
equorum
base
biotyp
equorum
isol
anim
sourc
isol
human
clinic
specimen
yet
method
group
presumpt
xylosu
strain
isol
human
clinic
specimen
refer
strain
xylosu
equorum
gallinarum
analys
biochem
test
ribotyp
biochem
properti
test
api
staph
id
staph
kit
convent
test
ribotyp
done
ecori
hindiii
restrict
enzym
probe
complementari
rrna
e
coli
result
phenotyp
data
key
test
correspond
speci
descript
xylosu
except
one
intermedi
strain
xylosuss
equorum
result
obtain
acid
product
differ
xylosu
descript
identif
speci
level
accept
ribotyp
ecori
divid
test
strain
two
group
xylosu
group
smaller
group
suppos
belong
equorum
speci
group
contain
two
refer
strain
four
clinic
isol
group
equorum
clearli
distinguish
also
hindiii
xylosu
group
divid
three
smaller
group
use
hindiii
result
ribotyp
profil
correspond
biochem
characteris
isol
conclus
identifi
xylosu
strain
one
intermedi
strain
xylosuss
equorum
biochem
test
contrari
biotyp
coloni
size
p
agar
ribotyp
use
restrict
enzym
show
four
strain
test
seri
repres
equorum
speci
first
case
occurr
equorum
human
clinic
specimen
ribotyp
ecori
hindiii
show
heterogen
ribotyp
profil
result
impli
method
could
suitabl
intraspeci
characteris
xylosu
equorum
staphylococcu
lugdunensi
overlook
easi
identifi
frequent
caus
abscess
gener
practic
cher
j
prag
viborg
dk
object
staphylococcu
lugdunensi
sl
coagulaseneg
staphylococcu
known
rare
caus
sever
infect
consequ
two
seriou
infect
decid
optimis
identif
sl
make
comprehens
epidemiolog
analysi
sl
infect
viborg
counti
popul
denmark
method
specimen
send
depart
clinic
microbiolog
viborg
counti
juli
decemb
includ
specimen
inocul
columbia
agar
plate
contain
sheep
blood
suspect
staphylococci
identifi
catalas
slide
coagulas
test
coloni
phleomorph
bhaemolysi
examin
characterist
eikenellalik
smell
day
incub
strain
suspect
sl
examin
case
posit
sl
follow
telephon
interview
gener
practition
read
hospit
record
result
cultur
sheep
blood
agar
sl
develop
characterist
smell
second
day
cultur
smell
togeth
bhaemolysi
coloni
phleomorph
help
first
step
screen
presenc
sl
routin
cultur
total
incid
sl
infect
viborg
counti
per
year
sl
infect
three
time
common
gener
practic
hospit
sl
found
microbiolog
examin
abscess
bacteri
growth
gener
practic
patient
otherwis
healthi
patient
need
antibiot
andor
surgic
treatment
infect
abscess
monocultur
localis
infect
seem
age
depend
conclus
calcul
incid
otherwis
healthi
popul
sl
infect
least
life
span
find
probabl
low
estim
sl
import
common
caus
abscess
look
identifi
bacteriolog
examin
furthermor
microbiologist
make
gener
practition
hospit
physician
acquaint
name
patholog
risk
seriou
complic
urin
nine
bone
joint
fluid
nine
surgic
wound
seven
iv
cathet
prosthet
materi
seven
variou
site
seven
lugdunensi
isol
sole
agent
case
three
case
confirm
infect
soft
tissu
abscess
skin
infect
predomin
overal
type
infect
septicaemia
urinarytract
infect
eight
bone
joint
infect
seven
surgic
wound
infect
five
prosthet
materi
infect
five
endocard
one
iv
catheterrel
infect
one
miscellan
five
infect
nosocomi
acquir
case
associ
foreign
devic
mainli
orthopaed
prosthet
materi
nine
case
isol
blactamas
posit
methicillinresist
conclus
lugdunensi
well
recogn
pathogen
superfici
also
deep
seriou
infect
howev
may
difficult
laboratori
establish
relationship
isol
lugdunensi
infect
bacteria
part
normal
human
flora
may
isol
colonis
organ
survey
conduct
evalu
frequenc
true
lugdunensi
infect
clinic
data
collect
analys
aim
preliminari
result
confirm
wide
rang
clinic
pattern
emphasis
predomin
skin
soft
tissu
infect
investig
actual
conduct
review
patient
medic
record
independ
physician
ii
search
virul
factor
strain
collect
staphylococcu
aureu
bacteraemia
bold
p
vernazza
henz
g
eich
object
staphylococcu
aureu
common
import
microorgan
modern
medicin
associ
increas
antibiot
resist
mortal
aureu
bacteraemia
sab
report
high
aim
studi
evalu
manag
outcom
predict
factor
sab
studi
also
investig
impact
introduct
infecti
diseas
id
consult
servic
method
inpati
canton
hospit
st
gallen
episod
sab
april
june
includ
exclus
criteria
polymicrobi
bacteraemia
one
posit
blood
cultur
bottl
without
sign
infect
sab
treat
termin
underli
diseas
patient
record
avail
review
retrospect
patient
record
demograph
data
clinic
cours
infect
underli
condit
focu
sab
treatment
complic
outcom
treatment
consid
adequ
accord
written
guidelin
id
servic
result
among
patient
sab
communityacquir
nosocomi
acquir
cure
die
nine
experienc
relaps
persist
sign
infect
case
outcom
inform
avail
risk
factor
mortal
sepsi
septic
shock
present
p
age
year
p
inadequ
treatment
univari
analysi
inadequ
choic
antibiot
p
inadequ
length
treatment
p
signific
predictor
mortal
introduct
id
consult
servic
proport
patient
inadequ
treatment
significantli
lower
p
despit
improv
manag
mortal
higher
introduct
id
consult
howev
observ
increas
sever
diseas
underli
condit
period
also
increas
cathet
relat
sab
p
conclus
increas
trend
sever
case
sab
observ
time
improv
manag
sab
adequ
select
antibiot
drug
appropri
length
therapi
associ
better
treatment
outcom
introduct
id
consult
servic
staphylococcu
aureu
sepsi
swiss
tertiari
centr
c
kaech
l
elzi
p
sendi
r
frei
u
fluckig
basl
ch
significali
relat
gnb
aetiolog
therefor
case
empir
antimicrobi
treatment
cover
gnb
pvo
diagnos
aetiolog
agent
abl
identifi
reduc
suscept
quinolon
isol
outbreak
korea
lee
kim
c
chang
h
kim
busan
kor
object
infect
salmonella
paratyphi
possess
reduc
suscept
quinolon
may
compromis
effect
ciprofloxacin
therapi
regard
drug
choic
paratyphoid
fever
korea
purpos
studi
examin
antibiot
suscept
characteris
resist
mechan
paratyphi
isol
decreas
suscept
quinolon
isol
outbreak
korea
determin
isol
genet
similar
clonal
method
total
clinic
isol
paratyphi
nine
outbreak
one
control
use
antibiot
suscept
paratyphi
ampicillin
cephalothin
ceftriaxon
gentamicin
tetracyclin
chloramphenicol
nalidix
acid
ofloxacin
ciprofloxacin
moxifloxacin
determin
microdilut
broth
test
mutat
respons
quinolon
resist
gyra
gyrb
parc
pare
gene
paratyphi
investig
use
pcr
amplif
dna
sequenc
quinolon
resist
determin
region
reserpin
known
efflux
pump
inhibitor
use
determin
whether
effluxmedi
mechan
contribut
reduc
suscept
quinolon
pulsedfield
gel
electrophoresi
perform
examin
clonal
related
isol
result
among
seven
patient
three
ciprofloxacin
therapi
show
clinic
respons
requir
retreat
ceftriaxon
four
patient
treat
ceftriaxon
initi
empir
therapi
success
clinic
repons
isol
sensit
ampicillin
cephalothin
ceftriaxon
gentamicin
tetracyclin
chloramphenicol
mic
quinolon
clinic
isol
reduc
suscept
quinolon
exhibit
follow
nalidix
acid
mgl
ofloxacin
mgl
ciprofloxacin
mg
l
moxifloxacin
mgl
sequenc
qrdr
gyra
gene
singl
mutat
posit
tcc
ttc
ser
phe
mutat
found
gyrb
parc
pare
gene
reserpin
effect
mic
ciprofloxacin
nalidix
acid
ofloxacin
moxifloxacin
pfge
analysi
reveal
ident
pattern
isol
conclus
sequenc
qrdr
gyra
paratyphi
strain
reduc
suscept
quinolon
isol
outbreak
singl
mutat
mutat
found
gyrb
parc
pare
gene
recent
isol
rate
salmonella
hadar
place
among
major
foodborn
serotyp
greec
whilst
resist
clinic
import
drug
cefotaxim
ciprofloxacin
resist
rate
drug
includ
tetracyclin
nalidix
acid
high
aim
studi
resist
pattern
genotyp
divers
among
human
anim
isol
serotyp
investig
possibl
relationship
result
chromosom
type
specif
resist
phenotyp
total
two
respect
suscept
antimicrobi
drug
ampicillin
amoxicillinclavulan
acid
amc
ceftazidim
caz
cefotaxim
ctx
amikacin
gentamicin
gm
kanamycin
k
netilmicin
net
streptomycin
tobramycin
tm
chloramphenicol
c
tetracyclin
te
sulphonamid
sss
sulphomethoxazoletrimethoprim
sxt
trimethoprim
tmp
ciprofloxacin
cip
nalidix
acid
na
test
muellerhinton
agar
discdiffus
assay
accord
nccl
guidelin
pfge
xbaidigest
total
dna
perform
tbe
chef
driii
apparatu
result
isol
suscept
caz
ctx
gm
net
tm
cip
resist
rate
drug
rang
c
sss
sxt
tmp
te
resist
nalidix
acid
domin
resist
phenotyp
among
human
isol
nast
amnasteamc
rang
pfgedistinguish
three
type
ac
eight
subtyp
type
major
human
isol
belong
subtyp
predominantli
associ
isol
express
resist
phenotyp
nast
nast
amnasteamc
respect
major
anim
isol
belong
subtyp
belong
isol
resist
phenotyp
nast
knast
respect
conclus
recent
rise
hadar
human
infect
reflect
rise
amongst
poultri
isol
nalidix
acid
resist
hadar
strain
caus
human
gastroenter
indistinguish
pfge
poultri
strain
object
purpos
studi
investig
clinic
laboratori
find
includ
spesif
cultur
c
difficil
toxin
detect
stool
specimen
patient
antibiot
associ
diarrhoea
aad
method
june
decemb
patient
hospitalis
diagnosi
aad
hospit
note
patient
age
gender
histori
antibiot
usag
symptom
physic
find
fever
degre
dehidrat
laboratori
find
therapi
cost
direct
microscop
examin
routin
cultur
stool
specimen
perform
patient
toxin
detect
spesif
cultur
could
perform
patient
detect
toxin
perform
elisa
use
cycloserincefoxitinfructoseagar
isol
c
difficil
result
patient
male
femal
mean
age
ae
year
mean
durat
hospitalis
ae
day
minimum
common
symptom
bloodi
diarrhoea
tenesmu
andor
abdomin
discomfort
vomit
mild
moder
dehidrat
patient
sever
dehydrataion
two
patient
fever
one
patient
main
clinic
find
patient
sever
dehydrat
suffer
colon
cancer
antibiot
therapi
initi
hospit
rest
patient
comorbid
factor
histori
previou
oral
outpati
antibiot
usag
time
interv
antibiot
use
onset
symptom
day
patient
mean
time
ae
day
sulbactam
ampicillin
common
agent
note
neither
toxin
posit
c
difficil
isol
stool
specimen
obtain
also
compar
cost
diagnost
procedur
therapeut
approach
saw
toxin
detect
spesif
cultur
c
difficil
result
increas
euro
cost
per
patient
conclus
studi
observ
patient
aad
diseas
begun
day
antibiot
use
symptom
resolv
within
day
patient
recov
result
toxin
test
stool
cultur
avail
procedur
increas
cost
therapi
method
june
octob
total
stool
rectal
swab
patient
admit
clinic
milad
hospit
sent
microbiolog
laboratori
specimen
examin
microscop
inocul
bacteriolog
cultur
media
isol
enteropathogen
isol
bacteria
confirm
biochem
method
isol
shigella
speci
seotyp
antisera
bahar
afshan
compani
suscept
test
perform
discdiffus
method
recommend
nation
committe
clinic
laboratori
standard
nccl
result
specimen
specimen
yield
shigella
speci
studi
sonnei
preval
serotyp
account
isol
second
preval
serotyp
flexneri
seven
isol
follow
boydii
dysenteria
three
isol
major
patient
children
year
old
mean
age
patient
year
sd
microscop
examin
show
leucocyt
erythrocyt
case
isol
resist
ampicillin
trimethoprimesulphametoxazol
tetracyclin
rate
resist
nadix
acid
ciprofloacin
cefotaxim
ceftrixon
amikacin
respect
conclus
conclud
sonnei
preval
serotyp
isol
hospit
higher
rate
resist
ampicillin
trimethoprimesulphamethoxazol
tetracyclin
among
isol
shigella
serotyp
hospit
cytoleth
distend
toxin
cdt
novel
famili
protein
toxin
interfer
cell
cycl
broad
spectrum
mammalian
cell
produc
multipl
pathogen
studi
use
polymeras
chain
reaction
pcr
target
variou
cdt
allel
among
shiga
toxinproduc
e
coli
stec
human
isol
eaeposit
eaeneg
belong
differ
serotyp
cdt
identifi
strain
belong
serotyp
eaeneg
southern
blot
hybridis
sequenc
analysi
demonstr
stec
serotyp
cdt
locat
chromosom
close
relat
cdtv
stec
h
contrast
stec
cdt
larg
plasmid
ident
cdtiii
necrotoxigen
e
coli
cdti
cdtii
cdtiv
allel
identifi
supernat
cdtposit
stec
progress
distend
subsequ
disintegr
chines
hamster
ovari
cho
cell
cdt
activ
detect
cho
assay
remain
stec
strain
pcrneg
cdti
cdtii
cdtiii
cdtiv
cdtv
suggest
addit
cdt
allel
undetect
pcr
approach
use
occur
among
stec
strain
investig
data
demonstr
two
differ
cdt
allel
differ
genom
locat
encod
biolog
activ
cdt
stec
particular
serotyp
among
eaeneg
stec
cdt
associ
diseas
haemolyt
uraem
syndrom
diarrhea
vs
asymptomat
infect
p
suggest
cdt
might
contribut
pathogen
organ
object
cholera
continu
import
public
health
problem
among
mani
poorer
commun
despit
bacteriolog
epidemiolog
diseas
describ
centuri
ago
order
determin
preval
vibrio
cholera
southeast
iran
studi
perform
method
total
patient
wateri
diarrhoea
refer
hospit
relat
zabol
faculti
medicin
sistanblouchestan
provinc
situat
southeast
iran
year
juli
octob
result
v
cholera
strain
isol
sampl
age
social
econom
strata
affect
twentyseven
per
cent
isol
children
age
year
among
patient
male
femal
case
live
urban
area
total
case
cholera
refer
rural
area
remain
subject
came
neighbour
countri
afghanistan
eightyon
patient
among
afghan
popul
isol
found
v
cholera
ogawa
strain
confirm
v
cholera
inaba
hikojima
serosubtyp
found
investig
patient
total
inpati
remain
outpati
six
patient
die
sever
diseas
sever
dehydr
electrolyt
imbal
conclus
prioriti
cholera
control
remain
public
health
intervent
improv
water
sanit
improv
surveil
access
healthcar
facil
develop
appropri
vaccin
method
fortyf
pup
litter
pointer
breed
affect
sever
respiratori
sign
septicaemia
day
birth
mortal
rate
observ
bitch
healthi
usual
fed
foodstuff
hospit
dine
room
necropsi
organ
anim
display
haemorrhag
lesion
sampl
spleen
liver
kidney
lung
intestin
pup
faecal
pharyng
swab
collect
bitch
cultur
sheep
blood
agar
mcconkey
mcc
agar
brainheart
infus
agar
organ
identifi
commerci
micromethod
system
biochem
test
strain
test
suscept
antimicrob
disc
agar
diffus
method
genotyp
random
amplifi
polymorph
dna
rapd
analysi
result
gram
neg
rod
nonhaemolyt
lactoseposit
mcc
identifi
k
pneumonia
isol
organ
puppi
swab
collect
bitch
isol
exhibit
antibiotyp
resist
ampicillin
amoxicillinclavulan
acid
azlocillin
bacitracin
ciprofloxacin
gentamicin
metronidazol
norfloxacin
cotrimoxazol
sulphonamid
streptomycin
oxacillin
tetracyclin
suscept
imipenem
cefuroxim
strain
isol
lung
liver
pup
faecal
pharyng
swab
bitch
display
rapd
profil
conclus
k
pneumonia
common
pathogen
human
usual
respons
hospitalacquir
infect
dog
k
pneumonia
rare
detect
gener
associ
sever
clinic
sign
dog
fed
foodstuff
hospit
dine
room
canin
isol
might
foodborn
origin
author
hypothesis
k
pneumonia
colonis
oropharynx
bitch
transmit
puppi
birth
subsequ
infect
puppi
develop
sever
fatal
septicaemia
object
increas
fluorquinolon
resist
streptococcu
pneumonia
spn
concurr
treatment
failur
led
concern
activ
class
antimicrobi
analys
vitro
activ
commonli
use
fluoroquinolon
clinic
pneumococc
isol
canada
determin
evolut
resist
agent
method
spn
isol
collect
canadian
bacteri
surveil
network
compris
privat
hospitalaffili
laboratori
across
canada
laboratori
ask
collect
defin
number
consecut
clinic
isol
follow
steril
site
isol
spn
vitro
suscept
test
perform
broth
microdilut
use
nccl
guidelin
resist
ciproflocacin
base
mic
lgml
genet
mutat
parc
gyra
loci
examin
molecular
method
result
total
clinic
isol
includ
patient
age
group
obtain
across
canada
vitro
suscept
data
list
tabl
signific
increas
nonsuscept
fluoroquinolon
except
moxifloxacin
year
p
fewer
isol
nonsuscept
moxifloxacin
ciprofloxacin
levofloxacin
p
year
total
isol
suscept
levofloxacin
suscept
moxifloxacin
sequenc
analysi
parc
gyra
isol
reveal
seven
contain
point
mutat
either
parc
parc
gyra
respect
conclus
oxifloxacin
preferenti
target
gyra
appear
associ
lower
level
vitro
nonsuscept
present
compar
parc
target
agent
increas
nonsuscept
fluoroquinolon
test
moxifloxacin
signific
increas
nonsuscept
find
may
explain
improv
activ
moxifloxacin
isol
parc
mutat
possibl
parc
gyra
doubl
mutat
number
spn
isol
canada
parc
mutat
increas
util
gyra
target
agent
may
becom
increasingli
import
method
fifteen
strain
sp
five
fluoroquinolon
fq
suscept
six
parc
mutant
low
level
fq
resist
four
parc
gyra
mutant
high
level
fq
resist
evalu
bactericid
activ
muellerhinton
broth
supplement
lyse
hors
blood
cultur
inocul
densiti
cfuml
incub
c
examin
viabl
growth
h
exposur
test
antibiot
concentr
simul
cmax
serum
concentr
mxf
gat
gar
lev
mg
lev
mg
adjust
protein
bind
lgml
protein
bind
mxf
gat
gar
lev
taken
pcr
use
amplifi
parc
gyra
mutat
detect
dna
sequenc
result
fluoroquinolon
highli
bactericid
suscept
strain
pneumonia
cmax
concentr
typic
drop
cfu
observ
h
complet
erad
achiev
h
parc
mutant
mxf
gar
consist
achiev
complet
bactericid
erad
h
cmax
h
regrowth
observ
two
six
strain
expos
lev
one
strain
expos
gat
cmax
dna
sequenc
reveal
select
gyra
mutat
strain
regrowth
observ
two
strain
lev
one
strain
lev
high
level
fq
resist
parcgyra
strain
mxf
gar
achiev
log
kill
two
strain
bacteriostat
two
strain
cmax
mxf
gar
bacteriostat
lev
gat
growth
characterist
compar
growth
control
cmax
concentr
conclus
fluoroquinolon
extrem
activ
suscept
pneumonia
superior
kill
kinet
observ
mxf
gat
gar
compar
lev
low
level
parc
fluoroquinolon
resist
pneumonia
mxf
gar
achiev
bactericid
activ
high
level
parc
gyra
fluoroquinolon
resist
pneumonia
compar
vitro
activ
fluoroquinolon
clinic
isol
streptococcu
pneumonia
r
alonso
r
cisterna
vitoriagasteiz
bilbao
e
object
fluoroquinolon
recommend
treatment
communityacquir
pneumonia
increas
multidrug
resist
streptococcu
pneumonia
incid
fluoroquinolon
resist
clinic
isol
pneumonia
rel
low
purpos
studi
determin
local
fluoroquinolon
suscept
pneumonia
method
ninetyf
nondupl
clinic
isol
pneumonia
collect
januari
novemb
basurto
hospit
bilbao
agar
dilut
mic
determin
levofloxacin
lev
sparfloxacin
spx
gatifloxacin
gat
moxifloxacin
mox
gemifloxacin
gem
use
muellerhinton
agar
hors
blood
isol
examin
evid
efflux
mechan
determin
mic
ciprofloxacin
cip
presenc
absenc
reserpin
mgl
result
mic
distribut
mgl
strain
summaris
sparfloxacin
gatifloxacin
moxifloxacin
gemifloxacin
mgl
respect
four
pneumonia
isol
ciprofloxacin
mic
mgl
three
isol
show
fourfold
greater
decreas
ciprofloxacin
mic
presenc
reserpin
fourth
ciprofloxacinresist
isol
uniformli
resist
levofloxacin
sparfloxacin
gatifloxacin
moxifloxacin
gemifloxacin
conclus
overal
data
indic
fluoroquinolon
valuabl
compound
treatment
pneumonia
infect
fluoroquinolon
test
gemifloxacin
activ
agent
relationship
mutant
prevent
concentr
kill
ciprofloxacin
levofloxacin
clinic
isol
pseudomona
aeruginosa
j
blondeau
g
hansen
saskatoon
object
resist
subpopul
recov
larg
suscept
cultur
expos
mic
fluoroquinolon
fq
mutant
prevent
concentr
mpc
repres
threshold
requir
inhibit
resist
firststep
resist
mutant
present
cell
test
test
two
strain
pseudomona
aeruginosa
pa
use
mpcbase
experi
mic
mpc
concentr
determin
kill
pa
ciprofloxacin
c
levofloxacin
l
method
experi
cultur
grown
late
log
phase
centrifug
resuspend
ml
muellerhinton
broth
aliquot
transfer
four
flask
contain
ml
broth
mic
mpc
drug
concentr
growth
sampl
h
drugfre
media
plate
contain
lgml
c
l
result
strain
mic
log
reduct
lr
seen
c
l
h
cultur
demonstr
regrowth
h
log
regrowth
seen
cultur
sampl
h
mutant
growth
observ
four
cultur
time
test
mpc
lr
occur
h
h
h
log
reduct
observ
mutant
growth
seen
c
treat
cultur
beyond
h
mutant
growth
seen
l
h
strain
mic
lr
seen
h
h
growth
reduct
observ
mutant
growth
observ
beyond
cultur
test
mpc
lr
observ
cultur
h
h
lr
observ
mutant
growth
observ
cultur
h
mic
concentr
log
mutant
growth
seen
h
result
observ
acinetobact
spp
one
lvxresist
strain
select
lvx
imi
one
cipresist
strain
select
combin
cip
amk
imi
caz
cpm
frequenc
mutat
higher
antibiot
alon
combin
combin
give
highest
rate
cip
amk
cip
ptz
frequenc
mutat
p
aeruginosa
conclus
use
combin
fluoroquinolon
blactam
amikacin
reduc
risk
vitro
select
resist
p
aeruginosa
acinetobact
spp
collect
cuti
among
isol
collect
uuti
escherichia
coli
common
eb
isol
caus
cuti
show
region
variat
belgium
franc
itali
germani
spain
among
klebsiella
spp
cuti
lev
belgium
franc
germani
itali
spain
lev
activ
pseudomona
aeruginosa
rang
among
isol
cuti
among
isol
uuti
lev
among
eb
isol
collect
bloodstream
infect
rang
among
enterobact
spp
among
proteu
mirabili
lev
show
potent
activ
eb
collect
respiratori
sourc
rang
among
e
coli
among
enterobact
spp
limit
geograph
variat
conclus
overal
lev
activ
eb
test
irrespect
specimen
sourc
longitudin
track
antimicrobi
suscept
initi
global
surveil
import
identifi
chang
trend
help
guid
antimicrobi
use
introduct
ciprofloxacin
usual
perceiv
greatest
activ
pseudomona
aeruginosa
howev
fluoroquinolon
also
possess
vitro
activ
pathogen
levofloxacin
recent
report
least
activ
ciprofloxacin
owe
highlevel
resist
mani
antimicrobi
abil
develop
resist
therapi
exist
therapeut
option
alon
combin
worthi
object
method
purpos
studi
evalu
vitro
activ
differ
fluoroquinolon
ciprofloxacin
levofloxacin
moxifloxacin
p
aeruginosa
isol
compar
synerg
effect
fluorquinolon
combin
potent
antipseudomon
agent
aminoglycosid
ceftazidim
piperacillintazobactam
mic
perform
isol
p
aeruginosa
obtain
clinic
microbiolog
laboratori
hospit
mic
fluorquinolon
determin
etest
synergist
effect
dilut
method
accord
nccl
recommend
resust
find
statist
differ
activ
clinic
isol
p
aeruginosa
among
ciprofloxacin
levofloxacin
strain
show
suscept
ciprofloxacin
vs
levofloxacin
moxifloxacin
less
activ
fluorquinolon
strain
suscept
moxifloxacin
isol
obtain
icu
show
highest
rate
resist
ciprofloxacin
levofloxacin
moxifloxacin
demonstr
equival
synerg
effect
p
aeruginosa
vitro
conclus
signific
differ
found
rate
suscept
p
aeruginosa
ciprofloxacin
levofloxacin
fluorquinolon
moxifloxacin
show
synerg
activ
p
aeruginosa
test
combicn
antipseudomon
agent
hostacka
ciznar
r
melkova
k
krovacek
bratislava
sk
uppsala
object
plesiomona
shigelloid
recognis
one
member
among
expand
group
water
foodborn
pathogen
present
studi
effect
subinhibitori
concentr
submic
mic
five
quinolon
antibiot
enoxacin
ciprofloxacin
norfloxacin
ofloxacin
pefloxacin
two
p
shigelloid
strain
hhuman
wsurfac
water
studi
known
submic
antibiot
kill
bacteria
howev
may
impact
pathogen
potenti
method
properti
associ
put
pathogen
factor
speci
evalu
vitro
use
test
hydrophob
motil
lipas
activ
sensit
hydrogen
peroxid
quorum
sens
result
quinolon
reduc
hydrophob
demonstr
adher
bacteria
xylen
submic
test
strain
h
except
enoxacin
mic
two
submic
mic
strain
w
except
norfloxacin
mic
strain
effect
quinolon
chang
surfac
hydrophob
toward
hydrophil
state
motil
strain
treat
quinolon
major
case
enhanc
ciprofloxacin
norfloxacin
mic
strain
h
norfloxacin
mic
strain
w
reduc
motil
lipolyt
activ
antibiot
treat
strain
slightli
modifi
quinolon
increas
sensit
p
shigelloid
hydrogen
peroxid
except
enoxacin
ofloxacin
submic
strain
h
norfloxacin
submic
ciprofloxacin
one
submic
strain
w
test
strain
possess
short
chain
acyl
homoserin
lacton
ahl
quinolon
evok
product
object
compar
vitro
activ
new
broad
spectrum
levofloxacin
lev
previous
develop
ciprofloxacin
cip
ofloxacin
ofx
quinolon
clinic
isol
nonfer
bacteria
materi
method
total
nonfer
bacteria
p
aeruginosa
baumanii
maltophila
nine
b
cepecia
recov
clinic
isol
januari
januari
studi
isol
identifi
standart
method
kept
frozen
c
use
antibiot
powder
provid
respect
manufactur
cip
bayer
ofx
lev
aventi
mic
determin
agardilut
method
mullerhinton
agar
result
interpret
accord
recommend
nccl
control
strain
p
aeruginosa
atcc
e
coli
atcc
valu
summaris
tabl
result
cip
activ
compound
test
againt
p
aeruginosa
levofloxacin
ofloxacin
show
best
vitro
activ
maltophilia
b
cepecia
also
found
high
mic
valu
quinolon
test
baumanii
conclus
nonferment
usual
resist
accept
dose
mani
antibiot
nosocomi
infect
caus
bacteria
frequent
difficult
treat
accord
result
cip
still
effect
quinolon
p
aeruginosa
levofloxacin
ofloxacin
could
becom
therapeut
option
treat
infect
due
maltophilia
b
cepecia
